<div class="aLF-aPX-aPF-aw9 aLF-aPX-aPF-aPE-auM aLF-aPX-av4-aPV" role="document" tabindex="0" style="margin-top: 56px; margin-bottom: 56px; width: 800px; left: 271px;"><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.vetmed.lsu.edu" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.vetmed.lsu.edu" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.vetmed.lsu.edu&amp;ust=1666162200000000&amp;usg=AOvVaw3wRydcCx_SeQtzsZIiMxid&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 63.7255%; top: 65.1515%; width: 12.5817%; height: 1.13636%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 1 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 26.1438%; height: 2.0202%;">Disease: Anthrax
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 22.3856%; height: 1.26263%;">Classification: ICD-9 022; ICD-10 A22
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.3137%; height: 1.38889%;">Syndromes and synonyms: Charbon, malignant pustule,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 30.2288%; height: 1.38889%;">malignant edema, woolsorter disease, tanner disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.3137%; height: 2.77778%;">Agent: Spores of Bacillus anthracis, a Gram-positive, encapsu-
lated, non-motile rod. The spores are resistant to desiccation,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">extremes of temperature and pH, ultraviolet radiation and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">many disinfectants, and can remain viable for 60 years. It is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 21.732%; height: 1.38889%;">considered a biological warfare agent.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">Reservoir: Soil, animal hair, wool or hides, particularly goat
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">skins contaminated with soil. Spores can germinate outside an
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 21.4052%; height: 1.26263%;">animal under appropriate conditions.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.4771%; height: 1.38889%;">Vector: Tabanid and Stomoxys flies and mosquitoes can
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">transmit, but are not epizootic vectors. Blow-flies can also
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 11.4379%; height: 1.38889%;">spread the bacteria.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.9673%; height: 1.13636%;">Transmission: Contact with infected animal tissue. Cutaneous
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.3137%; height: 2.77778%;">anthrax: direct skin inoculation during processing of contami-
nated animal hides, hair, wool, or animal hide products.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.3137%; height: 1.38889%;">Gastro-intestinal (GI) anthrax: consuming meat from infected
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">livestock. Inhalation anthrax: inhalation of anthrax spores by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.3137%; height: 1.38889%;">tanning/shearing sheep or processing contaminated hair/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">wool or intentional during a bioterrorist attack. Rare in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 33.9869%; height: 2.77778%;">IVDU from contaminated heroin. There is no direct person-
to-person transmission.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">Cycle: Herbivores become infected when they ingest spores
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.3137%; height: 1.38889%;">during grazing on contaminated soil. When the animal dies,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.4771%; height: 1.13636%;">the soil under the carcase is contaminated. Omnivores and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.3137%; height: 1.38889%;">carnivores are infected by feeding on infected prey or carcases.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 25.3268%; height: 1.0101%;">Carnivores and humans are incidental hosts.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">Incubation period: 1–7 days; up to 60 days in case of low
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 7.84314%; height: 1.13636%;">inhaled dose.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">Clinical findings: Depends on portal of entry. The skin lesion
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">is a characteristic black eschar surrounded by edema, usually
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">on the head, forearms or hands, accompanied by malaise and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.4771%; height: 1.38889%;">fever, in 80% of cases resolving spontaneously after 7–10 days,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 34.4771%; height: 1.38889%;">but if left untreated it may evolve into fatal septicemia. GI
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.4771%; height: 1.38889%;">anthrax produces nausea, vomiting, abdominal pain,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 34.4771%; height: 1.26263%;">fever, hematemesis, occasionally bloody diarrhea and often
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 2.77778%;">fatal septicemia and shock. Inhalation anthrax is rapidly pro-
gressive and starts with fever, malaise and mild cough and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">chest pain, evolving to acute respiratory distress, diagnostic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.4771%; height: 2.65152%;">mediastinal widening, cyanosis and shock. Untreated cutane-
ous anthrax has a CFR of 5–20% (&lt;1% with treatment), GI
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">anthrax 25–60%, and inhalation anthrax 100% (75% with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 6.53595%; height: 1.26263%;">treatment).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 27.5253%; width: 34.3137%; height: 1.38889%;">Diagnostic tests: Microscopy (M’Fadyan stain) of lesion;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">bacterial culture of lesion, blood, or respiratory specimen;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.303%; width: 7.51634%; height: 1.13636%;">PCR; ELISA.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">Therapy: Cutaneous anthrax: penicillin, ciprofloxacin or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 42.4837%; height: 2.65152%;">doxycycline po; severe anthrax (GI or inhalation): ciprofloxa- cin iv preferred. Clindamycin can inhibit toxin production.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 2.77778%;">Prevention: Vaccination of livestock and humans with occu-
pational risk in endemic areas. Antibiotic prophylaxis when
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">exposed and vaccination in case of inhalation anthrax. Infected
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">animal carcases should be burned or deeply buried, preferably
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 11.1111%; height: 1.13636%;">at the site of death.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 4.16667%;">Epidemiology: Anthrax has a worldwide distribution. Live-
stock vaccination, antibiotic treatment, and quarantaine regu-
lations lead to a strong decline in anthraxinfections in domestic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">lifestock. Anthrax occurs mainly in rural areas in countries
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">where there is no livestock vaccination and no veterinary
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">control of slaughtered animals.There is a seasonal variation
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">in animal disease with an increase in cases during hot dry
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">weather. Anthrax is an occupational hazard for people who
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">process contaminated animal tissues. GI anthrax occurs when
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">infected tissue is ingested. Of note is the terrorist distribution of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">anthrax powder by mail in the USA in 2001, which killed 5
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.2374%; width: 20.4248%; height: 1.26263%;">people and produced sickness in 17.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 63.8889%; width: 34.1503%; height: 1.26263%;">Map sources: Modified from WHO World Anthrax Data
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">Site, available at: www.vetmed.lsu.edu tropics (accessed
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.5404%; width: 6.20915%; height: 1.26263%;">Jan. 2011).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 69.3182%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.5808%; width: 37.5817%; height: 1.38889%;">Dixon TC, et al. (1999) Anthrax. N Engl J Med 341(11):815–826.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 71.9697%; width: 40.6863%; height: 2.65152%;">Hugh-Jones ME, et al. (2009) The ecology of Bacillus anthracis. Mol Aspects Med 30(6):356–367.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 74.6212%; width: 46.8954%; height: 2.65152%;">Swartz MN (2001) Recognition and management of anthrax – An update. N Engl J Med 345:1621–1626.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 85.1307%; top: 9.21717%; width: 1.79739%; height: 1.0101%;">43
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/ca1f3a31-97ad-406c-9d16-077c6862c0f5" class="aLF-aPX-aPF-aPE-J3" alt="Page 1 of 113" aria-hidden="true" style="opacity: 1;"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 2 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 71.5686%; height: 2.27273%;">Disease: Bartonellosis, Bartonella bacilliformis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 23.366%; height: 1.26263%;">Classification: ICD-9 088.0; ICD-10 A44
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">Syndromes and synonyms: Oroya fever, Carrión disease,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 19.281%; height: 1.38889%;">verruga peruana (Peruvian wart).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 33.9869%; height: 2.77778%;">Agent: Bartonella bacilliformis, a fastidious intracellular Gram-
negative bacterium.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 31.3726%; height: 1.38889%;">Reservoir: Humans are the only known reservoir host.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 34.3137%; height: 1.38889%;">Vector: The sandfly Lutzomyia verrucarum. Preferred habitat:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.3137%; height: 1.38889%;">narrow river gorges at elevations between 500 and 3,200
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 33.0808%; width: 4.57516%; height: 1.0101%;">meters.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">Transmission: By bite of the female sandfly (usually at dusk
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.4771%; height: 1.38889%;">and at sundown, often indoors); rarely by blood transfusion or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">transplacental. There is no direct person-to-person
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 7.84314%; height: 1.13636%;">transmission.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.3137%; height: 1.38889%;">Cycle: Human–sandfly–human. Humans can be bacteremic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">for many months. Period of infectivity in the sandfly is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 6.04575%; height: 1.0101%;">unknown.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.3137%; height: 1.38889%;">Incubation period: 16–22 days, occasionally up to 7 months.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.3137%; height: 1.38889%;">Clinical findings: There are two phases, divided into an acute
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">phase (Oroya fever) followed after at least 2 weeks by a chronic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">phase (verruga peruana). Verruga peruana may occur without
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">an evident acute phase. Oroya fever: fever,myalgia, arthralgia,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">headache, evolving to severe hemolytic anemia, generalized
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 2.77778%;">lymphadenopathy and hepatosplenomegaly; milder symp-
toms in children. The CFR for untreated Oroya fever is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.3137%; height: 1.13636%;">40–88% and for treated disease is 1–9%. Survivors are immune.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.1111%; width: 36.7647%; height: 2.77778%;">Mortality is associated with secondary infections (e.g. Salmo-
nella andToxoplasma). Verruga peruana: painless nodular rash,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">appearing as ‘bleeding warts,’ mainly on extensor surfaces of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.3137%; height: 1.38889%;">the limbs, face, trunk and mucous membranes; may last 3–6
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">months and is rarely fatal; relapses occur. Differences in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">clinical presentation and mortality may be due to strain
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 8.33333%; height: 1.38889%;">heterogeneity.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.4771%; height: 1.26263%;">Diagnostic tests: Giemsa stain of red blood cells or dermal
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 34.3137%; height: 1.38889%;">biopsy; blood culture on special media (results take 3–6
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 13.2353%; height: 1.38889%;">weeks); PCR; serology.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 2.77778%;">Therapy: Oroya fever: penicillin, streptomycin, chloram-
phenicol and tetracyclines are all effective, with ampicillin
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">for secondary infections, but the case may still evolve to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.4771%; height: 1.38889%;">verruga peruana, which is treatable with streptomycin or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">rifampicin. Severe cases: ceftriaxone iv is used and blood
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 2.77778%;">transfusion in case of severe anemia. Verruga peruana: rifam-
picin or streptomycin. B. bacilliformis is intrinsically resistant
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 8.49673%; height: 1.38889%;">to quinolones.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 28.9141%; width: 34.3137%; height: 1.38889%;">Prevention: Sandfly control with residual insecticide; avoid
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">endemic areas after sunset; use insect repellents and covering
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 39.7059%; height: 1.38889%;">clothes; insecticide-treated bednets. Active case finding in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.3137%; height: 1.13636%;">households where cases occur. Vector-control efforts
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">should target the homes of incident case patients. Patients
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 22.3856%; height: 1.38889%;">should be kept in sandfly-proof wards.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 38.0719%; height: 2.77778%;">Epidemiology: Bartonellosis due to B. bacilliformis was origi-
nally restricted to high, dry mountain valleys from 600 to 3,200
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.26263%;">meters in the Andes of Colombia, Ecuador and Peru. Since
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 42.298%; width: 34.3137%; height: 1.38889%;">1997 it has expanded geographically to the Utcubamba river
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">valley, Cusco, La Libertad and the low-lying hills below 600
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">meters in coastal Ecuador. The cause for this expansion is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 2.77778%;">unknown. The disease incidence is increasing in Peru, partic-
ularly in children. In endemic areas attack rates of 12.7/100
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">person-years are found, with highest rates in children under 5.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.3137%; height: 1.38889%;">There is a decreasing incidence with increasing age due to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">acquired immunity. For each year of age, the risk of infection
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">diminishes by 4%. Most cases cluster, with 70% occurring in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">only 18% of households in the community where the outbreak
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 5.39216%; height: 1.38889%;">happens.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 58.4596%; width: 34.3137%; height: 1.38889%;">Map source: The Bartonella bacilliformis map was made by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 34.3137%; height: 1.38889%;">geocoding reported cases in the medical literature up to 2010.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.2374%; width: 24.3464%; height: 1.13636%;">Elevation, rivers and lakes are also shown.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 63.8889%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 39.8693%; height: 1.38889%;">Chamberlin J, et al. (2002) Epidemiology of endemic Bartonella
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 66.5404%; width: 32.8431%; height: 2.77778%;">bacilliformis: a prospective cohort study in a Peruvian moun-
tain valley community. J Infect Dis 186(7):983–990.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">Del Valle LJ, et al. (2010) Bartonella bacilliformis, endemic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.5808%; width: 33.0065%; height: 1.38889%;">pathogen of the Andean region, is intrinsically resistant to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 24.6732%; height: 1.38889%;">quinolones. Int J Infect Dis 14(6):e506–10.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 73.2323%; width: 34.4771%; height: 1.38889%;">Maguiña C, et al. (2009) Bartonellosis. Clin Dermatol
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 74.6212%; width: 6.69935%; height: 1.13636%;">27:271–280.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 85.1307%; top: 9.21717%; width: 1.79739%; height: 1.0101%;">45
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/b1f33992-f37f-465d-942c-b273db2534fe" class="aLF-aPX-aPF-aPE-J3" alt="Page 2 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 3 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 65.8497%; height: 2.39899%;">Disease: Bartonellosis, Bartonella quintana
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.3464%; height: 1.26263%;">Classification: ICD-9 083.1; ICD-10 A79.0
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.4771%; height: 2.77778%;">Synonyms: Trench fever, quintana fever, quintan fever, shin-
bone fever, shank fever, His-Werner disease, and Wolhynia
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 3.59477%; height: 1.13636%;">fever.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 42.8105%; height: 1.38889%;">Agent: Bartonella quintana (formerly Rochalimaea quintana and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">Rickettsia quintana), a fastidious intracellular Gram-negative
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 6.37255%; height: 1.13636%;">bacterium.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 22.0588%; height: 1.38889%;">Reservoir: Humans and possibly cats.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">Vector: The principle vector is the human body louse
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.2172%; width: 34.4771%; height: 1.38889%;">(Pediculus humanus corporis), which lives in clothes. B. quintana
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 37.5817%; height: 4.0404%;">has also been detected in cat and monkey fleas. Transmission: Transmission to humans occurs by rubbing
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.3137%; height: 1.38889%;">infected louse feces into abraded skin or into the conjunctivae.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.3137%; height: 1.38889%;">Cycle: B. quintana multiplies in the louse’s intestine and is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">excreted in the feces. Body lice feed several times per day that
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 38.3987%; height: 2.65152%;">leads to itchiness and scratching, by which the skin is inocu-
lated with louses’ contaminated feces. Chronic B. quintana
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 32.3529%; height: 1.38889%;">bacteremia facilitates infection in lice and further spread.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 32.1895%; height: 1.38889%;">Incubation period: 5–20 days, with a median of 8 days.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">Clinical findings: ‘Classic’ trench fever is characterized by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">febrile attacks that last 1 to 3 days, with headache, shin pain,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">and dizziness. The attacks recur every 4 to 6 days, with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">succeeding attacks being less severe; no deaths have been
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">reported. ‘Urban’ trench fever generally occurs generally in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.3137%; height: 1.38889%;">homeless people and clincal features are highly variable,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.4771%; height: 4.0404%;">including severe disease with endocarditis, non-specific symp-
toms with or without fever, and chronic asymptomatic bacter-
emia. Infection with B. quintana (or B. henselae) may also cause
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 30.0654%; height: 1.38889%;">bacillary angiomatosis, usually in patients with HIV.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Blood culture with prolonged incubation
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 2.77778%;">(42 days); lysis centrifugation blood culture systems or sub-
culture of blood culture bottles onto fresh chocolate agar
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.4771%; height: 1.38889%;">enhances sensitivity. Several serological assays are available
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 16.7929%; width: 34.3137%; height: 1.38889%;">(CFT, ELISA, IFA), but cross-reactivity occurs; PCR on
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 9.96732%; height: 1.13636%;">blood and tissue.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 38.8889%; height: 1.38889%;">Therapy: Treatment of uncomplicated B. quintana bacteremia
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">is with a macrolide (erythromycin, azithromycin) or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">doxycyclin. In case of endocarditis 4–6 months of therapy is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 34.4771%; height: 2.65152%;">recommended in combination with a third-generation cepha-
losporin or gentamicin for the first 2–3 weeks. Heart valve
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 16.5033%; height: 1.38889%;">replacement may be needed.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 30.1768%; width: 34.3137%; height: 1.38889%;">Prevention: Lice infestation (pediculosis) can be controlled by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 2.77778%;">treating clothes and bedding with insecticides or boiling (bed-
ding at shelters is a major source of lice infestation). The body
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">does not need to be deloused as the lice live and lay their eggs
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">in clothes or bedding. Oral ivermectin has been effective in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 15.8497%; height: 1.38889%;">delousing homeless people.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 39.6465%; width: 34.3137%; height: 1.26263%;">Epidemiology: Trench fever is named afterinfected soldiers in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">the trenches during World War I. Little data exist on the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">incidence and distribution of B. quintana infections. Infections
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">have been reported from every continent. Trench fever is a sign
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">of social turmoil and personal hardship. For instance, an
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.3137%; height: 1.38889%;">epidemic of trench fever erupted in a refugee camp in Burundi.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 36.9281%; height: 1.38889%;">In Europe and North America, B. quintana infections are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">associated with poverty, alcoholism, and homelessness,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">known as urban trench fever. Crowded and unhygienic living
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 36.1111%; height: 2.77778%;">conditions facilitate exposure of B. quintana infected indivi-
duals to lice that subsequently pass on the infection to others.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">Trench fever is a re-emerging disease due to the increase in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 26.7974%; height: 1.38889%;">homeless people and HIV-infected individuals.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 58.4596%; width: 34.3137%; height: 1.38889%;">Map sources: The Bartonella quintana map was made by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">geolocating reported cases (1990–2010) in the medical
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.2374%; width: 5.88235%; height: 1.0101%;">literature.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 63.8889%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 34.8039%; height: 1.38889%;">Foucault C, et al. (2006) Bartonella quintana characteristics and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 66.5404%; width: 31.0458%; height: 1.38889%;">clinical management. Emerg Infect Dis 12(2):217–223.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">Maguina C, et al. (2009) Bartonellosis. Clin Dermatol
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.3182%; width: 6.69935%; height: 1.0101%;">27:271–280.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">Ohl ME, et al. (2000)Bartonella quintana and urban trench fever.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 17.6471%; height: 1.38889%;">Clin Infect Dis 31:131–135.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 85.1307%; top: 9.21717%; width: 1.79739%; height: 1.0101%;">47
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/11dce7c5-f0af-44d2-b3cb-3ed32abd6865" class="aLF-aPX-aPF-aPE-J3" alt="Page 3 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 4 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 27.451%; height: 2.0202%;">Disease: Botulism
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.3464%; height: 1.26263%;">Classification: ICD-9 005.1; ICD-10 A05.1
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.5707%; width: 24.8366%; height: 1.13636%;">Syndromes and synonyms: None.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 42.6471%; height: 2.65152%;">Agent: Botulinum toxin, produced by the anerobic spore-
forming bacterium Clostridium botulinum types A, B, E and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">rarely F. Type E and F neurotoxins have been recovered from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 43.7909%; height: 1.38889%;">infants with botulism due to C. butyricum and C. barati. C.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 28.7582%; height: 1.38889%;">botulinum is considered a biological warfare agent.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">Reservoir: C. botulinum spores are found in soil, dust, honey,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.4394%; width: 34.3137%; height: 1.26263%;">marine sediments, and in intestines of fish and land animals.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.0909%; width: 12.9085%; height: 1.13636%;">Vector: None.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.6162%; width: 34.4771%; height: 1.38889%;">Transmission: By ingestion of contaminated food (honey
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.0051%; width: 34.4771%; height: 1.38889%;">in infant botulism), injection of contaminated drugs, or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.2677%; width: 34.4771%; height: 1.38889%;">contamination of wounds by soil, dust or gravel. There is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 40.6566%; width: 19.7712%; height: 1.13636%;">no human-to-human transmission.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.3081%; width: 34.4771%; height: 1.26263%;">Incubation period: Usually 12–36 hours; sometimes several
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 44.5707%; width: 23.5294%; height: 1.38889%;">days; up to 2 weeks for wound botulism.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.2222%; width: 34.3137%; height: 2.65152%;">Clinical findings: Descending flaccid skeletal muscle paraly-
sis beginning at the shoulders in the absence of fever; fatigue,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.8737%; width: 34.4771%; height: 1.38889%;">weakness, vertigo, blurred vision, dry mouth, difficulty in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.1364%; width: 34.4771%; height: 1.38889%;">speaking and swallowing, progressing to an inability to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 52.5253%; width: 34.4771%; height: 1.38889%;">breathe without assistance. Vomiting, diarrhea or constipation
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.9141%; width: 34.4771%; height: 1.38889%;">may occur. The CFR in the USA after treatment is 5–10%;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.1768%; width: 34.4771%; height: 1.38889%;">recovery may take months. Infants present with constipation,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 56.5657%; width: 34.4771%; height: 1.38889%;">anorexia, weakness, an altered cry, difficulty sucking, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.9545%; width: 34.4771%; height: 1.38889%;">swallowing. Muscle weakness progresses in a symmetric
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.3434%; width: 34.3137%; height: 1.26263%;">descending fashion over hours to a few days. The prognosis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 60.6061%; width: 18.4641%; height: 1.38889%;">is excellent when treated timely.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.2576%; width: 34.4771%; height: 1.26263%;">Diagnostic tests: Detection of toxin in serum, stool or wound
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 64.5202%; width: 34.4771%; height: 1.38889%;">by mouse inoculation or ELISA; culture of the bacterium from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.9091%; width: 20.2614%; height: 1.38889%;">stool or wound; electromyography.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 68.5606%; width: 34.4771%; height: 1.38889%;">Therapy: Food-borne botulism: intensive supportive care
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.9495%; width: 34.3137%; height: 1.38889%;">and polyvalent botulinum antitoxin iv. Wound botulism:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.2121%; width: 34.4771%; height: 1.38889%;">wound debridement, antibiotics (penicillin) and polyvalent
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 72.601%; width: 34.4771%; height: 1.38889%;">botulinum antitoxin iv. Equine botulinum antitoxin can
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.9899%; width: 34.4771%; height: 1.38889%;">prevent progression of illness and shorten symptoms in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 75.2525%; width: 34.3137%; height: 1.38889%;">food-borne and wound botulism if administered early.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.6414%; width: 34.4771%; height: 1.38889%;">Avoid aminoglycoside antibiotics as these may potentiate
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 78.0303%; width: 34.4771%; height: 1.38889%;">the toxin and result in a complete neuromuscular blockade
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 79.2929%; width: 13.7255%; height: 1.38889%;">and resultant paralysis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 2.77778%;">Prevention: Food for canning or bottling should be thor-
oughly cooked; consumption of inadequately smoked or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 1.13636%;">salted food and uneviscerated fish should be avoided. Also
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.3137%; height: 1.38889%;">avoid honey and dusty excavation sites with infants.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">A pentavalent botulinum toxoid (PBT) vaccine is available
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 8.66013%; height: 1.13636%;">from the CDC.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 34.4771%; height: 2.77778%;">Epidemiology: Rare, but good disease burden data are lack-
ing. Underdiagnosis is common. There are four main types of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 2.39899%;">botulism: intestinal/infant, food-borne, wound and inadver-
tent. Infant botulism is the most common form of botulism in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">the USA and is caused by growth of spores germinating the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">immature gut of infants and releasing the toxin, or rarely in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">adults with abnormal intestinal tracts. Honey is a common
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.26263%;">source, but in 85% of infants, the source is unknown.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">Infant cases occur from 6 days to 12 months of age and affect
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">equally both sexes. Food-borne botulism is the result of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 36.6013%; height: 1.38889%;">eating fermented, salted, or smoked fish, seafood or meat
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 2.65152%;">that has not been cured for long enough to eliminate contam-
ination. It is also due to incorrect home canning or bottling
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">of vegetables or fruit. Botulism usually occurs in outbreaks
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">in those exposed to the same food. The largest numer of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">reported cases per country over the decade 2000–2009 in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.26263%;">ProMED mail have occurred in Thailand (83 cases from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.26263%;">deer meat, 163 from bamboo shoots), Poland (276 from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 48.366%; height: 4.16667%;">preserved food), and Georgia (217 from home-preserved – vegetables). Food-borne botulism outbreaks occur in indige-
nous tribes in Alaska and Canada by consuming improperly
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">preserved fish products (seal, salmon, salmon eggs). Wound
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 34.4771%; height: 1.13636%;">botulism results from failure to remove contaminated soil
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 34.4771%; height: 2.77778%;">completely from wounds and sealing them, permitting anaer-
obic growth of the bacteria. Inadvertent botulism is a recent
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">phenomenon resulting from the use of diluted Botulinum
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">toxin to treat patients for several disorders and for cosmetic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 62.7525%; width: 34.4771%; height: 3.78788%;">reasons. Map sources: Reported human botulism outbreaks in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.5404%; width: 34.3137%; height: 1.26263%;">ProMED-mail between 2000 and 2009, available at: www.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 67.9293%; width: 9.80392%; height: 1.38889%;">promedmail.org.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 70.7071%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 71.9697%; width: 33.9869%; height: 2.65152%;">Brook I (2006) Botulism: the challenge of diagnosis and treat-
ment. Rev Neurol Dis 3(4):182–189.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 74.6212%; width: 30.719%; height: 1.26263%;">Brook I (2007) Infant botulism. J Perinat 27:175–180.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 76.0101%; width: 34.3137%; height: 1.26263%;">Smith LA (2009) Botulism and vaccines for its prevention.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 77.2727%; width: 14.0523%; height: 1.38889%;">Vaccine 27(4):33–39.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 78.6616%; width: 31.3726%; height: 1.38889%;">Sobel J (2005) Botulism. Clin Infect Dis 41(8):1167–1173.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 85.1307%; top: 9.21717%; width: 1.79739%; height: 1.0101%;">49
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/e97bada7-319e-40f8-ad37-91dda475e331" class="aLF-aPX-aPF-aPE-J3" alt="Page 4 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 5 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 30.5556%; height: 2.0202%;">Disease: Brucellosis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 23.366%; height: 1.26263%;">Classification: ICD-9 023; ICD-10 A23.1
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.3137%; height: 1.26263%;">Syndromes and synonyms: Undulant fever, malta fever,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 12.2549%; height: 1.13636%;">Mediterranean fever.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 44.281%; height: 2.77778%;">Agent: Brucella melitensis, B. abortus, B. suis, and B. canis, intracellular Gram-negative bacilli.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">Reservoir: Cattle, swine, goats, sheep, and various wildlife
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 21.4052%; height: 1.38889%;">species. B. canis in dogs and coyottes.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.3137%; height: 1.38889%;">Transmission: Enteric by ingestion of unpasteurized milk or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">milk products (soft cheese, yoghurt) from infected animals;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 34.4771%; height: 1.0101%;">direct inoculation of mucosa or skin with infected animal
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">tissue (usually occupational in farmers or butchers); inhalation
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.4771%; height: 1.38889%;">in housing of infected animals. Brucellosis is an occupational
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">disease in shepherds, abattoir workers, veterinarians, dairy
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.4771%; height: 2.77778%;">industry workers, and microbiology laboratory staff. No per-
son-to-person transmission apart from isolated case reports of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 11.7647%; height: 1.13636%;">sexual transmission.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.3137%; height: 1.38889%;">Cycle: Brucella spp. is introduced into animals via inhalation,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">broken skin, or mucosa and invades local lymph nodes where
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.3137%; height: 1.38889%;">it propagates and enters the bloodstream and disseminates to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">mainly the reticulo-endothelial system (bone marrow, spleen,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 2.77778%;">liver, lymph nodes), kidneys and placenta in pregnant ani-
mals. From infected organs, like mammary glands, kidneys,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">and placenta, viable bacteria are shedded into the environment
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">by milk, urine, and uterine discharge, leading to new infections
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 18.7909%; height: 1.38889%;">in exposed animals and humans.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.3137%; height: 1.38889%;">Incubation period: Usually 14–21 days, up to several months.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.3137%; height: 1.26263%;">Clinical findings: Acute irregular fever, chills, sweating,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.4771%; height: 1.38889%;">arthralgia, headache, and depression. Evidence of localized
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 4.0404%;">suppurative infections may be found in liver, spleen, genito-
urinary tract, and osteo-articular (joints and sacrum). Symp-
toms may last for months and vary from mild to severe and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 12.9085%; height: 1.26263%;">even fatal (CFR: &lt;2%).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.3137%; height: 1.26263%;">Diagnostic tests: Blood or bone marrow culture and other
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 28.9216%; height: 1.38889%;">infected bodily tissues (urine, CSF); serology; PCR.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">Therapy: Doxycycline for 6 weeks, in combination with either
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">rifampicin for 6 weeks, or streptomycin for 2–3 weeks, or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 15.0327%; height: 1.38889%;">gentamicin for 1–2 weeks.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 22.2222%; width: 34.3137%; height: 1.38889%;">Prevention: Pasteurize milk; do not eat unpasteurized dairy
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">products, especially in endemic areas; brucellosis control in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">domestic animals; hygienic measures in farms and slaughter
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">houses; screening of livestock. Laboratory infections occur
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 25%; height: 1.38889%;">where biosafety measures are not adequate.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 30.1768%; width: 34.3137%; height: 1.38889%;">Epidemiology: Brucellosis is a common zoonosis with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">approximately 500,000 new cases per year world wide. The
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">disease occurs mostly in areas where it is common to consume
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">unpasteurized dairy products (soft cheese) and where poor
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 40.0327%; height: 1.38889%;">veterinary health systems exist. The main Brucella infecting
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">species vary by region. Incidence is highest in males with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">occupational exposure. The highest incidences are recorded in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.26263%;">Mediterranean countries, Middle East, Central America, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">Central Asia. Five of 10 countries with highest incidences are in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 2.77778%;">the Middle East, with Syria leading. Many of the high-inci-
dence countries were formerly part of the Soviet Union. Since
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 2.65152%;">their independence the veterinary health system has deterio-
rated, leading to an increase in brucellosis cases. In the USA it is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">mainly reported in Hispanics eating imported infected food.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 2.65152%;">The disease is not considered highly endemic in South Amer-
ica. Data from Brazil is lacking, despite high cattle densities in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">this country (see Livestock map). Many western European
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 2.65152%;">countries have brucellosis-free status. Mediterannean Euro-
pean countries implemented eradication campaigns, but still a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">high prevalence exists, especially in the Balkan peninsula. In
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 30.3922%; height: 1.38889%;">eastern Europe the disease is limited to veterinarians.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 59.8485%; width: 34.3137%; height: 1.38889%;">Map sources: The Brucellosis map is a modified version
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.2374%; width: 14.7059%; height: 1.26263%;">from Pappas et al. (2006).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 63.8889%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">Akhvlediani T, et al. (2010) The changing pattern of human
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 66.5404%; width: 33.1699%; height: 2.77778%;">brucellosis: clinical manifestations, epidemiology, and treat-
ment outcomes over three decades in Georgia. BMC Infect
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.3182%; width: 11.7647%; height: 1.0101%;">Dis 10:346.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.5808%; width: 33.9869%; height: 2.77778%;">Pappas G, et al. (2006) The new global map of human brucel-
losis. Lancet Infect Dis 6:91–99.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 85.1307%; top: 9.21717%; width: 1.79739%; height: 1.0101%;">51
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/ac45ee80-d362-4137-8d6a-f8a927bcf9de" class="aLF-aPX-aPF-aPE-J3" alt="Page 5 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 6 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 32.0261%; height: 2.0202%;">Disease: Buruli Ulcer
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.3464%; height: 1.26263%;">Classification: ICD-9 031.1; ICD-10 A31.1
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">Syndromes and synonyms: Bairnsdale ulcer (southern
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 34.4771%; height: 1.26263%;">Australia), Daintree ulcer (northern Australia) Kumusi ulcer
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 19.1176%; height: 1.38889%;">(Papua New Guinea), Searl ulcer.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">Agent: Mycobacterium ulcerans, an acid-fast, slow-growing
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">bacillus. There are at least four geographically distinct
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">strains: African, American, Asian, and Australian. They all
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">produce mycolactone, which destroys tissue and suppresses
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">the immune system. Variations in the structure of mycolactone
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 31.5359%; height: 1.38889%;">may correlate with disease severity in different regions.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.2172%; width: 38.7255%; height: 1.38889%;">Reservoir: This is unknown at present. M. ulcerans has been
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 39.2157%; height: 2.77778%;">found in biofilms on vegetation in swamps and other perma-
nent wetlands, aquatic insects, snails, and fish. In Australia,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">some land animals, particularly native possums, have been
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 32.0261%; height: 1.38889%;">found to carry M. ulcerans in their gastrointestinal tracts.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.4771%; height: 1.38889%;">Vector: Aquatic insects; in southern Australia mosquitoes; not
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 12.2549%; height: 1.38889%;">yet fully understood.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">Transmission: Contamination of a break in the skin by bacilli
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">in the environment, or by the bite of an infected aquatic insect
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 29.085%; height: 1.38889%;">or mosquito. Person-to-person transmission is rare.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.3137%; height: 1.38889%;">Cycle: The disease ecology is not completely understood.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 19.9346%; height: 1.38889%;">Humans are likely dead end hosts.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">Incubation period: From 2–3 months to several years. Most
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 21.0784%; height: 1.38889%;">infections do not progress to disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 2.65152%;">Clinical findings: Chronic, painless skin nodule that pro-
gresses to a severe,deforming ulcer. One-third of early nodules
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.3137%; height: 1.38889%;">heal spontaneously. Most nodules appear on limbs, but also
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">face and breast; skin lesions may also appear as plaques or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.4771%; height: 2.77778%;">indurated edematous lesions; osteomyelitis. Typical charac-
teristic is the presence of deeply undermined ulcers. Sequelae
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 32.5163%; height: 1.38889%;">include contracture, deformity, and permanent disability.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Ziehl–Neelsen stain on smears or biopsies,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 27.7778%; height: 1.38889%;">culture (takes 6–12 weeks), PCR, histopathology.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">Therapy: In early and limited disease: 4 weeks of streptomycin
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 4.0404%;">and rifampicin followed by 4 weeks of rifampicin and clari-
thromycin. For more extensive disease: rifampicin plus strep-
tomycin for 8 weeks; extensive lesions may require
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">reconstructive surgery and physiotherapy. Lesions &lt; 5cm
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 21.4052%; height: 1.13636%;">can be excised under local anesthetic.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 26.1364%; width: 34.3137%; height: 1.26263%;">Prevention: Wear clothes that cover extremities; cover skin
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 25.1634%; height: 1.38889%;">lesions; insect repellent; cover water supply.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 30.1768%; width: 34.3137%; height: 1.38889%;">Epidemiology: Buruli ulcer is named after Buruli county
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">in Uganda, where the disease was common in the 1960s.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">The disease is reported in 30 countries with tropical
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">climates, but it may occur in some temperate regions. West
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">Africa is the most affected region. Typical Buruli endemic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 2.65152%;">regions are areas with slow-flowing or stagnant water. Flood-
ing due to deforestation or the construction of dams,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 2.77778%;">and irrigation systems such as rice fields, can lead to out-
breaks. Outbreaks have also been associated with mining
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">activities in Africa, due to creation of pits with stagnant
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.13636%;">water. In southern Australia several coastal towns have
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">reported local outbreaks. It is unclear what triggered these
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">outbreaks. World wide, mainly children are susceptible to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 11.9281%; height: 1.13636%;">Buruli ulcer disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 50.3788%; width: 34.3137%; height: 1.38889%;">Map sources: The Buruli ulcer map was made by geolocating
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.3137%; height: 1.38889%;">confirmed cases reported in the medical literature up to 2010.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">As Buruli ulcer is associated with water, the humidity index is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 7.02614%; height: 1.13636%;">also shown.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 57.197%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 38.2353%; height: 1.38889%;">Johnson PDR, et al. (2005) Buruli ulcer (M. ulcerans infection):
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 59.8485%; width: 33.1699%; height: 1.38889%;">New insights, new hope for disease control. PLoS Med
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 61.2374%; width: 5.55556%; height: 1.26263%;">2(4):e108.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 62.5%; width: 34.4771%; height: 1.38889%;">Fyfe JAM, et al. (2010) A major role for mammals in the ecology
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 63.8889%; width: 35.4575%; height: 1.38889%;">of Mycobacterium ulcerans. PLoS Negl Trop Dis 4(8):e791.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">Nienhuis WA, et al. (2010) Antimicrobial treatment for early,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 66.5404%; width: 32.6797%; height: 2.65152%;">limited Mycobacterium ulcerans infection: a randomised con-
trolled trial. Lancet 375(9715):664–672.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">Portaels F, et al. (2008) First cultivation and characterization of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.5808%; width: 33.1699%; height: 1.38889%;">Mycobacterium ulcerans from the cnvironment. PLoS Negl
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 14.7059%; height: 1.38889%;">Trop Dis 2(3):e178.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 85.1307%; top: 9.21717%; width: 1.79739%; height: 1.0101%;">53
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/b7810cc0-1df4-4227-90d8-8ef674e1d5ff" class="aLF-aPX-aPF-aPE-J3" alt="Page 6 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 7 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 25.6536%; height: 2.0202%;">Disease: Cholera
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 22.3856%; height: 1.26263%;">Classification: ICD-9 001; ICD-10 A00
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.3137%; height: 1.26263%;">Syndromes and synonyms: Summer diarrhea, acute
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 5.39216%; height: 1.13636%;">diarrhea.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.6405%; height: 2.77778%;">Agent: Enterotoxin-producing Vibrio cholerae 01 and 0139 Ben-
gal. Serogroup 01 has two biotypes, classical and El Tor, each
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 33.1699%; height: 1.38889%;">with three serotypes: Inaba, Ogawa, and the rarer Hikojima.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">Reservoir: Principally humans; also warm-water marine and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">estuarine copepods, other zooplankton. Crabs, shrimps, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 30.8824%; height: 1.38889%;">shellfish carry the vibrio on their carapaces and shells.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 34.4771%; height: 1.13636%;">Vector: Main transmission is fecal–oral, but houseflies act as
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">supplementary vectors by contaminating food after feeding on
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 12.7451%; height: 1.38889%;">exposed human feces.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.3137%; height: 1.38889%;">Transmission: Consuming fecally contaminated food or water,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 2.65152%;">raw or undercooked contaminated shellfish. Person-to-
person transmission through indirect fecal–oral transmission
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.3137%; height: 1.38889%;">occurs. The role of bacteriophages needs further elucidation.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 2.77778%;">Cycle: Two interacting cycles can be distinguished: (1) a persis-
tent cycle in the aquatic reservoir, and (2) in the human
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 30.8824%; height: 1.38889%;">host, leading to amplification through fecal–oral spread.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.3137%; height: 1.38889%;">Incubation period: A few hours to 5 days; usually 2–3 days.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.3137%; height: 1.38889%;">Clinical findings: Among those infected, about 20% develop
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">acute watery diarrhea, of which 10–20% develop severe
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">watery diarrhea with vomiting, leading to severe dehydration
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">which may be lethal if not treated. The CFR is typically below
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.3137%; height: 1.38889%;">5%, but in crowded refugee camps it can run as high as 50%.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 33.9869%; height: 2.77778%;">Diagnostic tests: Dipstick test, dark-field or phase micros-
copy on fecal or rectal swab smear; bacterial culture.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">Therapy: Oral rehydration therapy (ORT) using reduced
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.3137%; height: 1.38889%;">osmolarity ORS; intravenous rehydration in severe cases.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">Antibiotics are only useful to prevent spread, as they do not
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 18.6275%; height: 1.38889%;">affect the already released toxin.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 34.4771%; height: 1.38889%;">Prevention: Hygiene, access to clean water and sanitation. An
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.4771%; height: 1.38889%;">oral cholera vaccine is available which is safe and provides
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 34.4771%; height: 1.26263%;">sustained protection of &gt; 50% that lasts for 2 years in endemic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.2727%; width: 34.4771%; height: 1.38889%;">populations. The vaccine does not protect against infections
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 78.6616%; width: 34.4771%; height: 1.38889%;">with O139 strains. Chemoprophylaxis for contacts may consist
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.3137%; height: 1.38889%;">of tetracycline or doxycycline. Breast-feeding protects infants.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">Quarantine is ineffective. Infection results in limited protection
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">against homologous strains, but there is no cross-protection.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.4771%; height: 1.38889%;">Cholera must be reported to national health authorities as small
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 25.4902%; height: 1.38889%;">local outbreaks may become large epidemics.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 34.4771%; height: 2.65152%;">Epidemiology: Cholera is a common cause of epidemic diar-
rhea throughout the developing world. There are an estimated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 1.26263%;">3 to 5million cholera cases and 100,000 to 130,000 deaths due to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">cholera each year. The disease is endemic on the Indian
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.26263%;">subcontinent, Southeast Asia and Sub-Saharan Africa. It has
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">a seasonal pattern with one or two peaks corresponding to the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">warm season. Areas with overcrowding and poor sanitation
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 41.5033%; height: 4.0404%;">such as slums, refugee camps, and regions with political conflicts are at high risk for cholera outbreaks. Natural dis-
asters (e.g. flooding) can be followed by cholera outbreaks due
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">to disruption of the sanitation system (see Natural Disasters
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">map). In 2010, a severe cholera epidemic was introduced into
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.3137%; height: 1.38889%;">Haiti by human activity from a distant geographic source.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">Cholera was absent from Haiti for at least 100 years. Cases
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.13636%;">have also been detected in Florida and the Dominican
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 5.55556%; height: 1.38889%;">Republic.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 46.3384%; width: 33.1699%; height: 1.38889%;">Current-circulating V. cholerae strains are of the O1 and O139
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">serotype. Cholera caused by O1 strains of the El Tor biotype
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">occurs world wide. The O1 classical biotype is confined to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">Bangladesh. In India, some recently isolated strains display
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">characteristics of both the classical and El Tor biotype. Since
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 53.1566%; width: 34.3137%; height: 1.38889%;">1992, the O139 serotype has caused cholera in Bangladesh and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 41.3399%; height: 1.38889%;">India. Other serotypes of toxin-producing Vibrio cholerae (e.g.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">O141 and O75) have caused severe diarrhea in patients who
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 29.085%; height: 1.13636%;">consumed seafood from the Gulf Coast of the USA.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 59.8485%; width: 34.3137%; height: 1.38889%;">Map sources: The Cholera map was made with data
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.2374%; width: 34.4771%; height: 1.0101%;">obtained from WHO and the medical literature from 2004
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 62.5%; width: 34.4771%; height: 1.38889%;">to 2010. The Haiti cholera outbreak was reported at the end of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 3.26797%; height: 1.13636%;">2010.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 66.6667%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">Chin CS, et al. (2011) The origin of the Haitian cholera outbreak
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.1919%; width: 24.0196%; height: 1.38889%;">strain. N Engl J Med 364(1):33–42.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">Emch M, et al. (2008) Seasonality of cholera from 1974 to 2005: a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 34.3137%; height: 1.38889%;">review of global patterns. Int J Health Geogr 7:31.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 73.2323%; width: 34.4771%; height: 1.38889%;">Nelson EJ, et al. (2009) Cholera transmission: the host,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 74.6212%; width: 38.7255%; height: 1.38889%;">pathogen and bacteriophage dynamic. Nat Rev Microbiol 7
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 76.0101%; width: 7.51634%; height: 1.26263%;">(10):693–702.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 77.2727%; width: 34.4771%; height: 1.38889%;">Reidl J, et al. (2002) Vibrio cholerae and cholera: out of the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 78.6616%; width: 37.4183%; height: 1.38889%;">water and into the host. FEMS Microbiol Rev 26(2):125–139.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 85.1307%; top: 9.21717%; width: 1.79739%; height: 1.0101%;">55
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/b4b2aa0d-11f7-4733-827b-5b78c3f9f91c" class="aLF-aPX-aPF-aPE-J3" alt="Page 7 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.who.int/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.who.int/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.who.int/&amp;ust=1666162860000000&amp;usg=AOvVaw0Tifat_sRQaV_yADiVUjyq&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 73.6928%; top: 58.4596%; width: 13.0719%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 8 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 29.902%; height: 2.39899%;">Disease: Diphtheria
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 22.3856%; height: 1.26263%;">Classification: ICD-9 032; ICD-10 A36
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">Syndromes and synonyms: Veldt sore (cutaneous
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 6.86275%; height: 1.38889%;">diphtheria).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.3137%; height: 1.38889%;">Agent: Corynebacterium diphtheriae is a Gram-positive, aerobic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">rod that is classified into three potentially toxigenic biotypes,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">intermedius, mitis, and gravis. Toxin producing strains of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 40.0327%; height: 2.77778%;">C. diphtheriae carry a bacteriophage-derived tox gene. Toxin-
producing strains of C. ulcerans may also cause respiratory
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 6.37255%; height: 1.38889%;">diphtheria.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">Reservoir: Humans. Cattle and other livestock may harbor
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.2172%; width: 34.4771%; height: 6.81818%;">C. ulcerans. Transmission: Respiratory droplets from people with respi-
ratory diphtheria, or from asymptomatic throat or nasal car-
riers. Direct contact with discharge from the skin of cutaneous
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">diphtheria cases. People recovering from diphtheria may carry
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.4771%; height: 1.38889%;">the organism in the nasopharynx for weeks. Rarely from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">contaminated items. In the past, outbreaks have been linked
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 24.5098%; height: 1.38889%;">to consumption of contaminated raw milk.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 32.1895%; height: 1.38889%;">Incubation period: Usually 2–5 days (range 1–10 days).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 4.16667%;">Clinical findings: Respiratory diphtheria is classically associ-
ated with fever, inflammation of the pharynx or larynx, pseu-
domembrane formation, lymphadenopathy and edema of the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">soft tissues of the neck. However, most cases are mild and may
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">resemble streptococcal pharyngitis and the pseudomembrane
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.9673%; height: 2.77778%;">may be absent. The exotoxin of C. diphtheriae can cause poly-
neuritis and myocarditis. Nasal diphtheria is usually mild and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 2.65152%;">chronic with nasal discharge and ulceration. Cutaneous diph-
theria is characterized by chronic, sharply demarcated ulcers
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 41.5033%; height: 2.77778%;">with an adherent gray pseudomembrane. It is usually associ-
ated with skin infections caused by Staphylococcus aureus and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.2778%; width: 12.4183%; height: 1.26263%;">group A streptococci.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 42.3203%; height: 1.38889%;">Diagnostic tests: Isolation of C. diphtheriae and C. ulcerans by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 33.1699%; height: 1.38889%;">culture and toxigenicity testing of strains at reference labs.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.4771%; height: 2.65152%;">Therapy: Therapy is aimed at neutralizing the potent exo-
toxin, eradicating the organism, and providing supportive
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.4771%; height: 1.38889%;">care. Immediate treatment with diphtheria antitoxin and iv
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 20.2614%; height: 1.26263%;">antibiotics (penicillin or macrolide).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 16.7929%; width: 34.3137%; height: 1.38889%;">Prevention: Immunization with diphtheria toxoid, usually
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.3137%; height: 1.38889%;">formulated in a multivalent vaccine (see DTP3 map).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">Recommended schedule is a primary course of three
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.4771%; height: 1.13636%;">doses in the first 4 months of life and one or two boosters
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">between 18 months and 5 years. Treatment of cases and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 33.9869%; height: 2.52525%;">carriers with antibiotics to eradicate the organism and pre-
vent further transmission.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 27.5253%; width: 34.3137%; height: 1.38889%;">Epidemiology: In the early 20th century diphtheria was the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">leading cause of death in children aged 4–10 years in Europe,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">and many countries experienced large diphtheria outbreaks
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 2.77778%;">during World War II. Childhood vaccination has now virtu-
ally eliminated diphtheria as a public health problem in most
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">developed countries, and diphtheria cases reported to WHO
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">have fallen by almost 93% between 1980 and 2008. The
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 2.52525%;">WHO has estimated that around 5,000 deaths from diphthe-
ria occurred in 2004, with 4,000 of these in children under 5
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">years of age. However, a steady decline in the global number
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">of reported diphtheria cases from 1980 was interrupted by a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">large recrudescence in the early to mid-1990s in the former
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">Soviet Union. Since 1990, diphtheria outbreaks have also
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.26263%;">occurred in Africa, the Middle East, Asia, and South America.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 40.6863%; height: 4.16667%;">Without periodic immunological boosting through vaccina-
tion or natural exposure to toxigenic strains of C. diphtheriae, adults may become susceptible to infection. Epidemics may
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">then occur, exacerbated by poor living conditions or the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">emergence of new toxigenic variants. This has led to the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.13636%;">introduction of booster doses of toxoid in adolescents in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 17.1569%; height: 1.13636%;">some non-endemic countries.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 57.0707%; width: 34.1503%; height: 1.38889%;">Map sources: The Diphtheria map was made with data
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 34.3137%; height: 1.38889%;">obtained from WHO, available at: http://www.who.int/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 18.3007%; height: 1.38889%;">immunization_monitoring/en/.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 62.6263%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">Galazka A (2000) The changing epidemiology of diphtheria
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 65.1515%; width: 31.8627%; height: 1.38889%;">in the vaccine era. JID 181(Suppl 1):S2–9.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">World Health Organization (2009) State of the World’s Vaccines
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 67.9293%; width: 33.1699%; height: 1.26263%;">and Immunization, 3rd edn. Geneva, WHO, UNICEF, World
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.1919%; width: 7.67974%; height: 1.38889%;">Bank Report.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">World Health Organization (2009) WHO Vaccine-Preventable
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 32.6797%; height: 2.65152%;">Diseases: Monitoring System. 2009 Global Summary: Immu-
nization, Vaccines, and Biologicals.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 85.1307%; top: 9.21717%; width: 1.79739%; height: 1.0101%;">57
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/1774dd33-ad35-45ef-8b53-c7ecab9815f8" class="aLF-aPX-aPF-aPE-J3" alt="Page 8 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 9 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 33.4967%; height: 2.0202%;">Disease: Donovanosis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 22.7124%; height: 1.26263%;">Classification: ICD-9 99.2; ICD-10 A58
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 33.9869%; height: 2.52525%;">Syndromes and synonyms: Granuloma inguinale, granu-
loma venereum.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 37.7451%; height: 2.77778%;">Agent: Klebsiella granulomatis, formerly Calymmatobacter-
ium granulomatis, a Gram-negative facultative aerobic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 8.49673%; height: 1.13636%;">coccobacillus.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 14.5425%; height: 1.13636%;">Reservoir: Human.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.6919%; width: 12.9085%; height: 1.0101%;">Vector: None.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">Transmission: By sexual contact. In children with no history
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">of abuse, the route of transmission is unclear. Several reported
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.4771%; height: 1.38889%;">pediatric cases have been in contact with infected adults, but
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 20.098%; height: 1.13636%;">without evidence of sexual contact.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 31.5359%; height: 1.38889%;">Incubation period: Approximately 50 days, but varies.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">Clinical findings: A progressive chronic illness of the skin and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">mucous membranes in the genital and perigenital regions with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 2.77778%;">painless granulomatous ulcers and regional lymphadenopa-
thy. Nodular skin lesions can appear as lymphadenopathy,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.3137%; height: 1.38889%;">known as ‘pseudobulbar.’ The painless lesions are often found
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">in warm moist body regions and bleed easily. Lesions can be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">progressive and cause local tissue destruction. Systemic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">spread is rare but bones and internal organs may eventually
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 6.86275%; height: 1.13636%;">be infected.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 2.77778%;">Diagnostic tests: Detection of Donovan bodies in cytodiag-
nostic or histopathologic examination (may be absent when
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">pretreated with antibiotics); histology is similar to that of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 11.9281%; height: 1.13636%;">rhinoscleroma; PCR.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">Therapy: Doxycycline; erythromycin for pregnant women;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.3137%; height: 1.26263%;">alternatives are ceftriaxone, norfloxacin and trovofloxacin;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">in cases of no response: gentamicin; surgery in advanced
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.4343%; width: 33.9869%; height: 5.30303%;">cases. Prevention: Early diagnosis and treatment; safe sexual prac-
tices (condom use). Proper bodily hygiene.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 25.3788%; width: 34.4771%; height: 2.77778%;">Epidemiology: It is endemic in tropical and subtropical cli-
mates, such as Papua New Guinea, South Africa, parts of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.0303%; width: 34.3137%; height: 1.38889%;">India and Indonesia, and among the aborigines of Australia.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 29.4192%; width: 34.4771%; height: 1.38889%;">Some cases have been reported in the countries of Central
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.8081%; width: 34.4771%; height: 1.26263%;">and South America and the Caribbean. The disease may be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.0707%; width: 34.4771%; height: 1.13636%;">related more to socioeconomic conditions than to racial or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 33.4596%; width: 34.4771%; height: 1.38889%;">geographical factors. In some settings it is a common cause
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.8485%; width: 34.4771%; height: 1.38889%;">of chronic genital ulcers in HIV patients. In the USA, it is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.1111%; width: 34.4771%; height: 1.38889%;">more common in African-Americans, of people in lower
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 37.5%; width: 34.4771%; height: 1.38889%;">socioeconomic status, and those with poor hygiene. It has
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.7626%; width: 34.4771%; height: 1.38889%;">been hypothesized that the natural habitat of K. granulomatis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 40.1515%; width: 34.4771%; height: 1.38889%;">is the intestine and that the skin is affected by direct contact
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.5404%; width: 34.4771%; height: 1.38889%;">during anal coitus, or indirectly through contamination of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.803%; width: 34.4771%; height: 1.38889%;">the genitals by fecal material. There is no gender difference
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 44.1919%; width: 34.4771%; height: 1.38889%;">in incidence; most cases occur in adults between the ages of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.5808%; width: 34.4771%; height: 2.65152%;">20 and 40 years. There are no reports of congenital infec-
tions, but cases have been reported in newborn and nursing
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 48.2323%; width: 34.4771%; height: 1.38889%;">babies; the course of the disease is more aggressive during
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.6212%; width: 34.4771%; height: 1.38889%;">gestation. Donovanosis increases the risk of subsequent HIV
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.8838%; width: 5.71895%; height: 1.13636%;">infection.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.9141%; width: 34.3137%; height: 2.77778%;">Map sources: The Donovanosis map was made by geolocat-
ing reported cases in the medical literature from 1990 to 2009.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 56.6919%; width: 34.4771%; height: 1.38889%;">Countries considered hotspots (relative high number of cases)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.9545%; width: 14.7059%; height: 1.38889%;">by experts are visualized.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 61.1111%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 62.3737%; width: 34.4771%; height: 1.38889%;">O’Farrell N (2002) Donovanosis. Sex Transm Inf 78(6):452–457.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.7626%; width: 34.3137%; height: 1.26263%;">Velho P, et al. (2008) Donovanosis. Braz J Infect Dis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 65.0253%; width: 8.16994%; height: 1.38889%;">12(6):521–525.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 85.1307%; top: 9.21717%; width: 1.79739%; height: 1.0101%;">59
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/6af42f2b-2a1a-4d9d-a5c8-d455b9099b71" class="aLF-aPX-aPF-aPE-J3" alt="Page 9 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.cdc.gov" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.cdc.gov" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.cdc.gov&amp;ust=1666162860000000&amp;usg=AOvVaw0jbCAwN0S8YcX3HA8IM5YF&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 77.7778%; top: 59.3434%; width: 8.16994%; height: 1.38889%;"></a><a href="http://www.kolonin.org" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.kolonin.org" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.kolonin.org&amp;ust=1666162860000000&amp;usg=AOvVaw1guLVkiiLmoxmK43P-kjZ8&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 53.5948%; top: 62.1212%; width: 10.4575%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 10 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 32.3529%; height: 2.0202%;">Disease: Ehrlichioses
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.3464%; height: 1.26263%;">Classification: ICD-9 083.8; ICD-10 A77.4
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">Syndromes and synonyms: Human monocytic ehrlichioses
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 34.4771%; height: 1.38889%;">(HME), human granulocytic anaplasmosis (HGA), Sennetsu
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 3.59477%; height: 1.13636%;">fever.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.495%; width: 34.4771%; height: 1.38889%;">Agent: Obligate intracellular, pleomorphic bacteria of the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 25.8838%; width: 37.2549%; height: 2.77778%;">family Anaplasmataceae, which invade host leukocytes. Ehrli-
chia chaffeensis infects mononuclear phagocytes; E. ewingii
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.5354%; width: 37.4183%; height: 1.38889%;">and Anaplasma phagocytophilum infects neutrophils. E. canis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 29.9242%; width: 43.4641%; height: 2.77778%;">may cause human disease in Venezuela. In 2009 an E. muris-
like organism was discovered in USA. Neorickettsia sennetsu
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.5758%; width: 12.9085%; height: 1.13636%;">causes Sennetsu fever.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.2273%; width: 34.4771%; height: 2.77778%;">Reservoir: Deer and dogs (E. chaffeensis, E. ewingii). The white-
tailed deer is a complete host for maintaining the transmission
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 37.8788%; width: 39.8693%; height: 1.38889%;">cycle of E. chaffeensis. Deer, ruminants, and field rodents (A.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.2677%; width: 34.4771%; height: 1.38889%;">phagocytophilum); unknown for N. sennetsu; other members of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 40.6566%; width: 33.9869%; height: 2.39899%;">the genus parasitize the trematode worms of aquatic verte-
brates and invertebrates.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 44.5707%; width: 40.3595%; height: 4.0404%;">Vector: Ticks of the genera Amblyomma and Ixodes. Transmission: By tick bites, except for N. sennetsu, which is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 48.6111%; width: 34.4771%; height: 2.65152%;">probably transmitted through ingestion of uncooked, parasit-
ized aquatic hosts. No person-to-person spread except by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.2626%; width: 10.4575%; height: 1.13636%;">blood transfusion.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.9141%; width: 42.4837%; height: 1.26263%;">Cycle: Tick to mammalian host to tick for Ehrlichia and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.1768%; width: 34.4771%; height: 1.38889%;">Anaplasma; trematode to aquatic host to trematode for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 56.5657%; width: 34.4771%; height: 1.38889%;">Neorickettsia. Human is a dead-end host for all. During the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.9545%; width: 34.4771%; height: 1.38889%;">eclipse phase of both HME and HGA infection, the blood
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.2172%; width: 29.2484%; height: 1.38889%;">remains potentially infectious by blood transfusion.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.8687%; width: 34.4771%; height: 1.38889%;">Incubation period: 7–10 days for HME, 7–14 days for HGA,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.2576%; width: 15.5229%; height: 1.38889%;">14 days for Sennetsu fever.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.9091%; width: 34.4771%; height: 1.26263%;">Clinical findings: HME, HGA: fever, headache, anorexia,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.298%; width: 34.3137%; height: 2.65152%;">myalgia, nausea, and vomiting; occasionally a rash. Leucope-
nia and thrombopenia are common and thrombopenia may be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.9495%; width: 34.3137%; height: 2.65152%;">life-threatening. HME cases may progress to meningoenceph-
alitis. Sennetsu fever: sudden onset fever, chills, malaise,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 72.601%; width: 34.3137%; height: 1.38889%;">headache, muscle and joint pain, sore throat; generalized
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.9899%; width: 34.4771%; height: 1.38889%;">lymphadenopathy. Reinfection can occur. CFR is 2.7% for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 75.3788%; width: 33.0065%; height: 1.38889%;">HME, &lt;1% for HGA, and absent for E. ewingii infection.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 78.0303%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Serology (IFA on acute and convalescent
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 79.4192%; width: 34.4771%; height: 1.38889%;">serum); cross-reactivity occurs. Microscopy of blood or bone
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">marrow smears is insensitive; PCR on acute phase whole
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 27.2876%; height: 1.38889%;">blood; isolation by cell culture in reference labs.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.4545%; width: 34.4771%; height: 1.38889%;">Therapy: Doxycycline for all patients. Rifampicin may be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 21.8434%; width: 33.6601%; height: 1.38889%;">useful for HGA in younger children and pregnant patients.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 24.2424%; width: 34.3137%; height: 1.38889%;">Prevention: Standard antitick precautions; avoidance of raw
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 25.5051%; width: 32.3529%; height: 1.38889%;">aquatic food from N. sennetsu endemic regions.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 28.0303%; width: 34.1503%; height: 1.38889%;">Epidemiology: Ehrlichiosis occurs worldwide, principally
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 29.2929%; width: 34.4771%; height: 1.38889%;">following the distribution of the transmitting tick vectors
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.6818%; width: 34.4771%; height: 1.38889%;">and reservoir species. Less is known of the epidemiology
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.0707%; width: 40.6863%; height: 2.65152%;">and ecology ofE. chaffeensis as compared to A. phagocytophilum. Most HME cases are reported in the south-central and -
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.7222%; width: 39.3791%; height: 1.38889%;">eastern USA, where A. americanum reaches high population
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.1111%; width: 34.4771%; height: 1.26263%;">densities. Approximately 70% of HME cases occur from May
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 37.3737%; width: 34.4771%; height: 1.38889%;">to July in the USA, corresponding to the peak feeding activity
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.7626%; width: 34.4771%; height: 1.38889%;">period of the ticks. HME is most commonly diagnosed in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 40.1515%; width: 34.4771%; height: 1.26263%;">adults, with a male-to-female ratio of &gt; 2:1. Most HME
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.4141%; width: 34.4771%; height: 1.38889%;">cases are single and not clustered. Recreational or occupational
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.803%; width: 34.4771%; height: 1.38889%;">activities in rural tick-infested habitats are at risk. Majority of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 44.1919%; width: 34.4771%; height: 1.38889%;">the cases have a history of a tick bite. Ehrlichiosis is often not
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.4545%; width: 34.4771%; height: 1.38889%;">recognized in Africa, where the primary diagnostic focus is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.8434%; width: 34.4771%; height: 1.38889%;">malaria and typhoid fever. Sennetsu fever occurs in Asian
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 48.1061%; width: 39.5425%; height: 1.38889%;">regions where the eating of raw fish is common, such as in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.495%; width: 34.4771%; height: 1.38889%;">Japan. N. sennetsu has been detected in the climbing perch
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.8838%; width: 34.4771%; height: 1.38889%;">in Laos, a fish common throughout the Mekong River, Basin.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 52.2727%; width: 31.6993%; height: 1.26263%;">Climbing perch is widely distributed and eaten in Asia.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 54.6717%; width: 34.1503%; height: 1.38889%;">Map sources: The Ehrlichioses map was made with the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 56.0606%; width: 35.7843%; height: 3.40909%;">following data and updates from medical literature: • Average annual incidence of ehrlichiosis and anaplasmosis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.5948%; top: 59.3434%; width: 32.3529%; height: 1.38889%;">reported to CDC (2001–2002), available at: www.cdc.gov
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 60.7323%; width: 37.2549%; height: 1.38889%;">• Vector distributions from Fauna of Ixodid Ticks of theWorld, at:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.5948%; top: 62.1212%; width: 10.6209%; height: 1.38889%;">www.kolonin.org.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 64.5202%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.7828%; width: 34.4771%; height: 1.38889%;">Ganguly S, et al. (2008) Tick-borne ehrlichiosis infection in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 67.1717%; width: 28.4314%; height: 1.26263%;">human beings. J Vector Borne Dis 45:273–280.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 68.4344%; width: 34.4771%; height: 1.38889%;">Ndip LM, et al. (2009) Molecular and clinical evidence of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.8232%; width: 33.1699%; height: 1.38889%;">Ehrlichia chaffeensis infection in Cameroonian patients
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.2121%; width: 33.1699%; height: 1.26263%;">with undifferentiated febrile illness. Ann Trop Med Parasitol
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 72.4748%; width: 8.82353%; height: 1.38889%;">103(8):719–725.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 73.8636%; width: 34.4771%; height: 1.38889%;">Newton P, et al. (2009) Sennetsu neorickettsiosis: a probable
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 75.2525%; width: 33.3333%; height: 1.26263%;">fish-borne cause of fever rediscovered in Laos. Am J Trop
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 76.5152%; width: 17.8105%; height: 1.38889%;">Med Hyg 81(2):190–194.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 77.904%; width: 34.4771%; height: 1.38889%;">Paddock CD, et al. (2003) Ehrlichia chaffeensis: a prototypical
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 79.1667%; width: 34.4771%; height: 1.38889%;">emerging pathogen. Clin Microbiol Rev 16(1):37–64.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 85.1307%; top: 9.21717%; width: 1.79739%; height: 1.0101%;">61
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/cbcbc835-2c34-450d-9d02-9bcf03e95b86" class="aLF-aPX-aPF-aPE-J3" alt="Page 10 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 11 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 52.451%; height: 2.39899%;">Disease: Endemic Treponematosis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">Classification: ICD-9 102.0 (yaws), 103.0 (pinta), 104.0
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">(endemic syphilis); ICD-10 A65 (endemic syphilis), A66
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 11.4379%; height: 1.38889%;">(yaws), A67 (pinta).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 33.9869%; height: 4.0404%;">Syndromes and synonyms: Endemic syphilis (bejel, non-
venereal) syphilis, pinta (carate), yaws (frambesia), non-
venereal treponematosis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 43.3007%; height: 1.38889%;">Agent: Treponema pallidum ssp. endemicum (bejel), T. pallidum
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 40.0327%; height: 1.38889%;">ssp. pertenue (yaws), and T. carateum (pinta), spirochetes that
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 41.3399%; height: 1.38889%;">are morphologically and serologically similar to T. pallidum
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 19.7712%; height: 1.38889%;">ssp. pallidum, the agent of syphilis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">Reservoir: Mainly humans; yaws is also found in non-human
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 26.7974%; height: 1.38889%;">primates (baboons, chimpanzees, and gorillas).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 45.4248%; height: 1.38889%;">Vector: Possibly mechanic transmission by non-biting flies
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 26.9608%; height: 1.38889%;">(Hippelates pallipes) in the transmission of yaws.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.4771%; height: 1.13636%;">Transmission: Direct transmission via skin to skin or oral
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">contact (also via sharing drinking and eating utensils). Sharing
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">of drinking vessels plays an important role in transmission of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 33.9869%; height: 2.77778%;">endemic syphilis in arid regions. There is little or no mother-to-
child transmission during pregnancy.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.6313%; width: 34.3137%; height: 1.38889%;">Incubation period: Endemic syphilis and yaws: 2 weeks to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 52.0202%; width: 15.3595%; height: 1.38889%;">3 months; pinta: 18 weeks.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.9242%; width: 34.4771%; height: 2.65152%;">Clinical findings: Similar to syphilis, the clinical manifesta-
tions can be classified into early and late stages. Early-stage
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.5758%; width: 34.4771%; height: 1.38889%;">lesions are generally infectious and may last up to 5 years,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.9646%; width: 34.4771%; height: 1.38889%;">with periods of latency. The disease has a relapsing clinical
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 60.2273%; width: 34.4771%; height: 1.38889%;">course with mainly skin manifestations, which is the only
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.6162%; width: 34.4771%; height: 1.38889%;">finding in pinta. In yaws and endemic syphilis there is also
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.005%; width: 34.3137%; height: 1.13636%;">involvement of the mucous membranes and the bones.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 64.2677%; width: 34.3137%; height: 1.38889%;">Cardiovascular and neurological lesions are extremely rare.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.0455%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Serology; there is no serological test that can
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 68.3081%; width: 39.3791%; height: 1.38889%;">distinguish between T. pallidum and the non-venereal
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.697%; width: 34.3137%; height: 1.38889%;">T. pallidum subspecies. Definitively diagnosis by PCR and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.0859%; width: 7.02614%; height: 1.38889%;">sequencing.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.7374%; width: 33.0065%; height: 1.38889%;">Therapy: Single im injection with benzathine penicillin G.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 2.77778%;">Prevention: Prevent intimate contact with cases and contam-
ination of environment from lesions. Lesions or discharge from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 1.13636%;">the lesions are infectious. Treat close contacts. There has been a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.4771%; height: 2.77778%;">drastic decline in global disease prevalence since mass treat-
ment campaigns with penicillin under the technical guidance
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">ofWHO and with material support from UNICEF in the 1950s
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 6.37255%; height: 1.13636%;">and 1960s.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 27.5253%; width: 34.3137%; height: 1.38889%;">Epidemiology: Endemic treponematoses is now rarely
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 2.65152%;">reported since the eradication campaign. Complete eradica-
tion may have been achieved if surveillance was continued and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">rural healthcare services improved. Disease foci still exist, but
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">reports are lacking. Several nations fail to report to avoid the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.3137%; height: 1.26263%;">stigma of ‘being backward.’ The WHO has estimated that 2.5
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">million people are still infected with endemic treponemes, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">about 460,000 are actively infectious. The disease primarily
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 2.77778%;">afflicts children in tropical and subtropical areas. The distri-
bution of endemic treponematoses is patchy and associated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">with poverty and poor access to social and healthcare services;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 4.16667%;">it thus affects mainly rural communities in developing coun-
tries (see Human Development map). Endemic syphilis gen-
erally affects individuals in hot, arid climates, and yaws affects
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">those in hot and humid areas. Pinta is found only in Central
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">and South America, but has not been reported for over 40
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">years. No endemic syphilis cases have been reported since the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 50.3788%; width: 34.3137%; height: 1.38889%;">1980s. Yaws is also rare and currentlyis only reported from foci
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">in West Africa and Indonesia. Also, no new yaws cases have
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">been reported in India since 2004. It has been suggested that
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">the presence of non-venereal treponematoses indicates that the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 31.5359%; height: 1.38889%;">country or region has a poor-quality healthcare system.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 58.4596%; width: 34.1503%; height: 1.38889%;">Map sources: The Endemic Treponematosis map was made
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 33.8235%; height: 1.38889%;">by combining data from Farnsworth et al. (2006) and WHO.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 62.8788%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 64.1414%; width: 35.7843%; height: 1.26263%;">Antal GM, et al. (2002) The endemic treponematoses. Microbes
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 65.404%; width: 11.2745%; height: 1.38889%;">Infect 4(1):8394.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.7929%; width: 34.4771%; height: 1.38889%;">Asiedu K, et al. (2008) Yaws eradication: past efforts and future
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 68.1818%; width: 29.4118%; height: 1.38889%;">perspectives. WHO Bulletin 86(7):499.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.4444%; width: 34.4771%; height: 1.38889%;">Farnsworth N, et al. (2006) Endemic treponematosis: review
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.8333%; width: 34.3137%; height: 2.77778%;">and update. Clin Dermatol. Harper KN, et al. (2008) On the origin of the treponematoses:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.4849%; width: 35.1307%; height: 1.38889%;">a phylogenetic approach. PLoS Negl Trop Dis 2(1):e148.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 85.1307%; top: 9.21717%; width: 1.79739%; height: 1.0101%;">63
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/34be2fdc-6221-4c01-8337-2310bfb87f2f" class="aLF-aPX-aPF-aPE-J3" alt="Page 11 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://apps.who.int/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://apps.who.int/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://apps.who.int/&amp;ust=1666162860000000&amp;usg=AOvVaw2FEmDv1eOx2rFG75sBOh5A&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 74.183%; top: 53.1566%; width: 12.5817%; height: 1.38889%;"></a><a href="http://www" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www&amp;ust=1666162860000000&amp;usg=AOvVaw3r0-jExfJXbk9KOSwK91IW&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 78.7582%; top: 55.8081%; width: 7.84314%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 12 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 64.3791%; height: 2.39899%;">Disease: Haemophilus influenzae Type b
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.3464%; height: 1.26263%;">Classification: ICD-9 320.0; ICD-10 G00.0
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.5707%; width: 24.8366%; height: 1.13636%;">Syndromes and synonyms: None.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">Agent: Haemophilus influenzae, a Gram-negative bacterium
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">that can be uncapsulated or capsulated. Capsulated strains
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">are classified into serotypes a–f. H. influenzaetype b (Hib) is the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 15.1961%; height: 1.38889%;">most pathogenic serotype.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 14.5425%; height: 1.13636%;">Reservoir: Humans.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.3137%; height: 1.38889%;">Transmission: Hib is transmitted from person to person via
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.3137%; height: 1.38889%;">airborne droplets or direct contact with respiratory secretions.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 25.9804%; height: 1.38889%;">Incubation period: Approximately 2–4 days.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.4771%; height: 2.77778%;">Clinical findings: Hib is a common invasive bacterial infec-
tion that primarily causes pneumonia, meningitis, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 2.65152%;">bacteremia. Pneumonia due to Hib is clinically indistinguish-
able from other causes of bacterial pneumonia. Hib meningitis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 2.77778%;">may present acutely or subacutely with fever, vomiting, leth-
argy, irritability, and a bulging fontanelle in infants or a stiff
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 2.77778%;">neck in older children. Bacteremia may be present with men-
ingitis or pneumonia but may also occur without an obvious
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">focus of infection. Hib may also cause epiglottitis, which
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">presents with fever, sore throat, and difficulty swallowing,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">talking and breathing. Infections of soft tissue, bones, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 23.366%; height: 1.38889%;">joints with H. influenzae may occur.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.3137%; height: 1.26263%;">Diagnostic tests: Gram stain and culture of CSF, blood, or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">synovial fluid. Capsular polysaccharide antigen detection by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">latex agglutination or other techniques. PCR from normally
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 6.37255%; height: 1.13636%;">sterile site.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.4771%; height: 1.38889%;">Therapy: Third generation cephalosporins (e.g. ceftriaxone or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">cefotaxime). Other beta-lactam antibiotics may be used in case
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">the organism is susceptible, like amoxicillin. Alternative
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 33.4967%; height: 1.38889%;">agents are: fluoroquinolones, macrolides, and tetracyclines.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.3137%; height: 1.13636%;">Prevention: Vaccination of children with three doses of Hib
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">conjugate vaccine from the age of 2 months, with a booster dose
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.4771%; height: 1.38889%;">aged 12–15 months. Since household contacts of confirmed
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 34.3137%; height: 1.26263%;">cases of invasive Hib disease are at increased risk of disease,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.4771%; height: 1.38889%;">rifampicin prophylaxis is recommended for all household
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 34.4771%; height: 1.26263%;">members if the household contains an infant or inadequately
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.2727%; width: 25.6536%; height: 1.38889%;">immunized children under the age of 3 years.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 2.77778%;">Epidemiology: In the absence of vaccination, Hib is com-
monly carried in the nose and throats of healthy individuals
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">and almost all children are exposed to Hib by the age of 5. In
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.4771%; height: 1.38889%;">developed countries (prior to immunization), Hib was the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">commonest cause of bacterial meningitis in young children,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">but in countries with high vaccination coverage Hib is now
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">almost eliminated as a public health problem. In developing
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">countries Hib meningitis is common but Hib pneumonia
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">appears to be even more common, with pneumonia
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">morbidity and mortality exceeding that of meningitis. In
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.13636%;">2000 Hib is estimated to have caused around 8 million cases
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.26263%;">of severe invasive disease and 360,000 deaths in children under
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">5 years of age. Ten countries, all in Africa and Asia, accounted
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">for an estimated 61% of all these Hib deaths. Hib pneumonia is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">estimated to be responsible for around 16% of pneumonia
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">deaths in HIV-negative children, therefore Hib makes an
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">important contribution to the high childhood mortality rates
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 2.77778%;">and low life expectancy of Sub-Saharan Africa. Global cover-
age with three doses of Hib vaccine was estimated at 28% in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">2008, with overall coverage of around 90% in the Americas,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">65% in Europe, 40% in Africa, and less than 5% in Asia and the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.0101%;">Pacific. The introduction of Hib vaccination has however been
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">accelerating and by the end of 2009, in 83% of WHO Member
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.26263%;">States (160/193), Hib is included in the national immunization
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 5.55556%; height: 1.13636%;">schedule.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 51.7677%; width: 37.9085%; height: 1.38889%;">Map sources: Data for the Haemophilus influenzae map were
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.3137%; height: 1.38889%;">obtained from WHO, available at: http://apps.who.int/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 33.8235%; height: 1.38889%;">immunization_monitoring/en/globalsummary/timeseries/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 34.3137%; height: 1.38889%;">tscoveragehib3.htm (vaccination coverage) and http://www.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 24.6732%; height: 1.38889%;">who.int/nuvi/hib/db_hib1.jpg (incidence).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 59.8485%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.2374%; width: 42.4837%; height: 4.0404%;">Levine OS, et al. (2010) Global status of Haemophilus influ- enzae type b and pneumococcal conjugate vaccines: evi-
dence, policies, and introductions. Curr Opin Infect Dis 23
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 65.1515%; width: 6.86275%; height: 1.38889%;">(3):236–241.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.5404%; width: 34.4771%; height: 2.77778%;">Watt J.P, et al. (2009) Burden of disease caused by Haemophi-
lus influenzae type b in children younger than 5 years: global
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.1919%; width: 20.4248%; height: 1.38889%;">estimates. Lancet 374(9693):903–911.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.5808%; width: 34.3137%; height: 1.38889%;">WHO, UNICEF, World Bank (2009) State of theWorld’s Vaccines
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 32.6797%; height: 2.65152%;">and Immunization, 3rd edn. Geneva, World Health Organi-
zation, Report.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 85.1307%; top: 9.21717%; width: 1.79739%; height: 1.0101%;">65
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/647590f5-f4fa-4b2d-92bd-ae51e442d608" class="aLF-aPX-aPF-aPE-J3" alt="Page 12 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.who.int/lep/situation/en/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.who.int/lep/situation/en/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.who.int/lep/situation/en/&amp;ust=1666162860000000&amp;usg=AOvVaw3nRDiaHZG-TFaSgJj80aAl&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 56.3725%; top: 63.8889%; width: 18.9542%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 13 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 25.9804%; height: 2.39899%;">Disease: Leprosy
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 22.3856%; height: 1.26263%;">Classification: ICD-9 030; ICD-10 A30
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">Syndromes and synonyms: Hansen disease, multibacillary
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 33.9869%; height: 2.77778%;">leprosy (ML), paucibacillary leprosy (PL), lepromatous lep-
rosy, tuberculoid leprosy.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 36.1111%; height: 2.65152%;">Agent: Mycobacterium leprae, a slow-growing, acid-fast, intra-
cellular bacterium. It grows best at 27–30 C, which explains
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">the main target organs of M. leprae: skin, peripheral nerves,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 27.2876%; height: 1.38889%;">nasal mucosa, upper respiratory tract, and eyes.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 40.5229%; height: 2.77778%;">Reservoir: Humans are the main reservoir. Subclinical infec-
tion is likely common in endemic areas, as M. leprae DNA
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">can be found in nasal swabs in up to 5% of healthy individuals
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">in Asian endemic regions. Subclinical infection generally does
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.4771%; height: 1.38889%;">not develop into clinical disease. Natural infection occurs in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 18.6275%; height: 1.38889%;">armadillos and several primates.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">Transmission:The precise mechanism is unclear: probably by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.4771%; height: 1.38889%;">aerosol spread of nasal secretions from a case to respiratory
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">mucosa of close contacts.M. leprae cannot cross intact skin. The
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">relative risk for leprosy disease in household contacts is 8 to 10
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 33.9869%; height: 2.77778%;">for multibacillary (lepromatous) leprosy and 2 to 4 for pauci-
bacillary (tuberculoid) leprosy.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.3137%; height: 1.38889%;">Incubation period: 3 to 5 years (range 9months to &gt; 20 years);
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 15.6863%; height: 1.13636%;">shorter for PL than for ML.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.3137%; height: 2.77778%;">Clinical findings: The disease mainly affects the skin, periph-
eral nerves, mucosa of the upper respiratory tract and the eyes,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">shown by patches of pigmented or reddish skin with loss of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">sensation, peripheral nerve enlargement with loss of sensation,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.3137%; height: 1.38889%;">sometimes paralysis, muscle wasting and trophic ulcers.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.3137%; height: 1.26263%;">Patients are classified as having either PL or ML. PL
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.3137%; height: 1.38889%;">is milder and characterized by &lt; 5 skin patches or lesions.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">ML is defined as 5 skin patches or lesions. Skin lesions are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">often symmetric. Involvement of the nasal mucosa results in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.3137%; height: 1.38889%;">nasal congestion and epistaxis. Reduced sensation of digits
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">may lead to their loss due to trauma. Up to 10% of cases with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 23.366%; height: 1.38889%;">early lesions may resolve spontaneously.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 42.4837%; height: 2.65152%;">Diagnostic tests: According to the WHO leprosy case defi- nition, at least one of the following: (1) hypopigmented or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.4771%; height: 1.38889%;">reddish skin lesion(s) with loss of sensation, (2) thickening of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 34.4771%; height: 1.26263%;">the peripheral nerves with loss of sensation, and (3) acid-fast
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.2727%; width: 34.4771%; height: 1.38889%;">bacilli in skin smear (often negative). Histology is the gold
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 78.6616%; width: 36.9281%; height: 1.38889%;">standard. M. leprae cannot be cultured in vitro.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.3137%; height: 1.38889%;">Therapy: PL: dapsone and rifampicin for 6 months. ML:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">dapsone, rifampicin, amd clofazimine for 24 months. Relapses
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 23.366%; height: 1.38889%;">may occur in up to 2.5% of treated cases.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 22.2222%; width: 34.3137%; height: 1.38889%;">Prevention: Leprosy control is achieved by timely detection
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 2.77778%;">and treatment of new cases. BCG vaccination provides vari-
able protection: from 34% to 80%. Chemoprophylaxis and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 35.6209%; height: 1.38889%;">quarantine are not recommended. M. leprae bacilli remain
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">viable for 9 days in dried nasal secretions and about 6
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 11.4379%; height: 1.13636%;">weeks in moist soil.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 31.5657%; width: 34.3137%; height: 1.38889%;">Epidemiology: The disease is thought to have originated in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">the tropics and subtropics of Africa and Asia. WHO reported
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">213,036 leprosy cases at the beginning of 2009. Although the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">worldwide prevalence has declined in the last two decades, the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.13636%;">incidence has remained the same. India had the most new
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.3137%; height: 2.77778%;">cases in 2008 (134,000), followed by Brazil (39,000), and Indo-
nesia (17,000). Males are affected more than females (2:1);
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">young children are rarely infected. Epicurves for PL show a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">peak at age 15 followed by a trough at age 20. WHO considers
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">that leprosy has been eliminated as a public health problem in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">any country when the prevalence is less than 1 case per 10,000
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">population. In 2007, the DRC and Mozambique achieved that
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">status. Also India reported that their national prevalence is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">below 1/10,000. However, pockets of high endemicity still
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 2.77778%;">remain in some areas within those countries. Decreased prev-
alence without a reduction in incidence maylead to an increase
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">of cases as countries may be less committed to control them
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">once they meet elimination status. Foci in Brazil are found in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">the Amazonian jungle, but also in arid areas. Poverty and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">crowded dwellings are important risk factors. Leprosy in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">North America and Europe has declined to zero cases in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 24.8366%; height: 1.38889%;">line with improvement in living conditions.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 62.5%; width: 34.3137%; height: 1.38889%;">Map sources: Data for the Leprosy map were obtained from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">WHO: www.who.int/lep/situation/en/. The leprosy clusters
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 27.451%; height: 1.38889%;">in Brazil were obtained from Penna et al. (2009).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 67.9293%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.1919%; width: 31.0458%; height: 1.38889%;">Britton WJ, et al. (2004) Leprosy. Lancet 363:1209–1219.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">Penna MLF, et al. (2009) Spatial distribution of leprosy in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 33.3333%; height: 1.38889%;">Amazon region of Brazil. Emerg Infect Dis 15(4):650–652.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 73.2323%; width: 34.3137%; height: 1.38889%;">Scollard DM, et al. (2008) The continuing challenges of leprosy.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 74.6212%; width: 22.7124%; height: 1.26263%;">Clin Microbiol Rev 19(2):338–381.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 76.0101%; width: 34.4771%; height: 1.26263%;">World Health Organization (2009) Global leprosy situation,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 77.2727%; width: 25.1634%; height: 1.38889%;">2009. Weekly Epidemiol Rec 33(84):333–340.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 85.1307%; top: 9.21717%; width: 1.79739%; height: 1.0101%;">67
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/c71ed618-8a68-401c-ab02-e1b2ea722ebf" class="aLF-aPX-aPF-aPE-J3" alt="Page 13 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 14 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 34.3137%; height: 2.39899%;">Disease: Leptospirosis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 22.3856%; height: 1.26263%;">Classification: ICD-9 100; ICD-10 A27
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">Syndromes and synonyms: Weil disease, swamp fever, cane
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 32.6797%; height: 1.38889%;">cutters disease, hemorrhagic jaundice, swineherd disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">Agent: Multiple species of the spirochetal genus, including
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">Leptospira interrogans, whichis the species associated withmost
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">severe disease. There are currently 8 species found to be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">pathogenic for humans, associated with &gt; 250 serovars
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">belonging to the pathogenic species. Antigenically related
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">serovars are grouped into 24 serogroups. A single serovar
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 30.2288%; height: 1.38889%;">may belong to different Leptospira species.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">Reservoir: Rats and other rodents, dogs, cattle, and pigs are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 33.4967%; height: 1.38889%;">the most important zoonotic reservoirs of human infection.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.3137%; height: 1.38889%;">Transmission: Direct contact of abraded skin or conjunctival
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">mucosa to urine of infected animals or exposure to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">environmental sources where urine is deposited. Infection
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.4242%; width: 15.8497%; height: 1.26263%;">via ingestion is uncommon.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">Cycle: Leptospira chronically colonize the proximal renal
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">tubules of many animals and are excreted in the urine into
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 37.2549%; height: 2.77778%;">the environment. Animals can shed Leptospira into the envi-
ronment for prolonged periods without any signs of disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 19.7712%; height: 1.26263%;">Incubation period: 1–3 weeks.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">Clinical findings: From asymptomatic to fatal. Acute febrile
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.3137%; height: 2.65152%;">illness with chills, headache, severe myalgia (with mild rhab-
domyolysis), conjunctivitis and gastrointestinal symptoms.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.4771%; height: 2.77778%;">Less common findings are hepatomegaly, rash, lymphadenop-
athy, jaundice, and aseptic meningo-encephalitis. Pulmonary
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">symptoms may occur varying from cough, dyspnea, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.4771%; height: 1.38889%;">hemoptysis, to adult respiratory distress syndrome. Weil
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.3137%; height: 1.38889%;">disease is a severe form of leptospirosis and is characterized
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">by jaundice, renal failure and hemorrhage with a CFR of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 4.24837%; height: 1.13636%;">5–20%.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.3137%; height: 1.38889%;">Diagnostic tests: Serology (acute and convalescent sera)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">using the microscopic agglutination test (MAT). Isolation of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.4771%; height: 1.38889%;">leptospira from blood or CSF during first 10 days of illness and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 34.4771%; height: 1.38889%;">urine during the 2nd and 3rd weeks; PCR may provide early
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 31.0458%; height: 1.38889%;">diagnosis. Dark-field microscopy is not recommended.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">Therapy: Supportive and antibiotics: oral doxycycline,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">ampicillin or amoxicillin for mild disease, parenteral penicillin
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 26.634%; height: 1.26263%;">G, ceftriaxone or cefotaxime for severe disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 22.2222%; width: 34.3137%; height: 1.38889%;">Prevention: Occupational hygiene by the use of protective
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">clothing and avoiding contaminated surface waters
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 41.3399%; height: 2.52525%;">(difficult in case of flooding in developing countries). Envi-
ronmental control measures, like rodent and flood control,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">are difficult to implement. Chemoprophylaxis for adventure
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">travelers, military personnel who visit endemic areas, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 19.1176%; height: 1.38889%;">after an accidental lab exposure.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 32.9545%; width: 34.1503%; height: 1.38889%;">Epidemiology: Leptospirosis has a worldwide distribution, is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 2.65152%;">more common in tropical regions where it is both an occupa-
tional disease and a disease of ‘daily lives,’ mainly during
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">heavy rainfall. Most foci are found in Latin America and the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 4.16667%;">Caribbean, India, Southeast Asia, Oceania, and eastern Eur-
ope. The agent favors warm, humid environments. The prev-
alence of different serovars depends on the reservoir in which
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">animals are present, local environmental conditions, local
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">occupation, and agricultural practices. Protective measures
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">have decreased the occupational risk in high-risk jobs, like
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">mining, sewermaintenance, farming, veterinary work, and the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">military. In the tropics, occupational exposures (rice and sugar
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">cane farming, fishing) and other agricultural activities remain
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">an important risk. Leptospirosis is an emerging disease in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">slums, especially during rainy seasons. Also large recreational
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">events with water exposure can be an important source of big
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 14.2157%; height: 1.13636%;">multinational outbreaks.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 57.0707%; width: 34.3137%; height: 1.38889%;">Map sources: The Leptospirosis map was made by geocoding
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">reported human leptospirosis outbreaks in ProMED-mail and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 26.1438%; height: 1.13636%;">the medical literature between 2000 and 2010.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 62.6263%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">Adler B, et al. (2010) Leptospira and leptospirosis. Vet Microbiol
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 65.1515%; width: 10.1307%; height: 1.38889%;">140(3–4):287–296.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">Bhart AR, et al. (2003) Leptospirosis: a zoonotic disease of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 67.9293%; width: 29.7386%; height: 1.38889%;">global importance. Lancet Infect Dis 3:757–771.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.1919%; width: 34.3137%; height: 1.38889%;">Pappas G, et al. (2008) The globalization of leptospirosis:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.5808%; width: 34.1503%; height: 1.38889%;">worldwide incidence trends. Int J Infect Dis 12:351–357.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 71.9697%; width: 34.4771%; height: 1.38889%;">Reis RB, et al. (2008) Impact of environment and social gradient
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.2323%; width: 41.8301%; height: 1.38889%;">on leptospira infection in urban slums. PLoS Negl Trop Dis 2
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 74.6212%; width: 5.06536%; height: 1.26263%;">(4):e228.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 85.1307%; top: 9.21717%; width: 1.79739%; height: 1.0101%;">69
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/6ace695f-da6d-4c52-ac25-4e68fe5e28fc" class="aLF-aPX-aPF-aPE-J3" alt="Page 14 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 15 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 29.4118%; height: 2.0202%;">Disease: Listeriosis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.6732%; height: 1.26263%;">Classification: ICD-9 027.0; ICD-10 A 32.1
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 29.7386%; height: 1.26263%;">Syndromes and synonyms: Listeriasis, listerellosis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">Agent: Listeria monocytogenes, a Gram-positive rod-shaped
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">intracellular bacterium. There are at least 13 serotypes, with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.9673%; height: 1.38889%;">serotypes 1/2a, 1/2b, and 4b causing most disease. L. ivanovii
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 30.0654%; height: 1.38889%;">is a very rare enteric opportunistic human pathogen.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.3137%; height: 1.38889%;">Reservoir: Soil, (decaying) vegetation, and ruminants.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 33.8235%; height: 1.38889%;">Humans and ruminants can carry listeria in their intestines.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">Transmission: Food-borne and transplacental (mother to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">child). Ingestion of L. monocytogenes occurs commonly
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">world wide. Development of the disease depends on the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 8.98693%; height: 1.38889%;">host immunity.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.4771%; height: 1.26263%;">Cycle: Listeria bacteria in the environment or food are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">ingested by ruminants and humans, colonize the intestine
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 35.7843%; height: 2.77778%;">and shed again into the environment with the feces. L. mono-
cytogenes is able to cross the intestinal mucosa under specific
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">conditions, resulting in systemic disease or hematogeneous
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">spread to the central nervous system and, in the case of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 9.96732%; height: 1.38889%;">pregnancy, fetus.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">Incubation period: 3 to 70 days, usually about 3 weeks. For
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 32.8431%; height: 1.38889%;">gastroenteritis: hours to 10 days with a mean of 24 hours.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.3137%; height: 1.26263%;">Clinical findings: Non-invasive GI listeriosis: fever, muscle
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.3137%; height: 1.38889%;">aches, nausea and diarrhea. Invasive listeriosis: septicemia,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.3137%; height: 2.77778%;">meningoencephalitis, and perinatal listeriosis. Meningoenceph-
alitis: headache, stiff neck (often absent), confusion, convulsions
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.3137%; height: 1.38889%;">and coma (CFR: 20–30%). Infection during pregnancy can lead to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">miscarriage, stillbirth and infection of the newborn. Pregnant
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.4771%; height: 1.38889%;">womenmost commonly haveflu-likesymptoms. Focalinfections
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">in any organ may occur. Focal cutaneous and eye infections can
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">occur after direct inoculation with contaminated tissue, usually
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 28.1046%; height: 1.38889%;">occupational. Listerial gastroenteritis is uncommon.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: L. monocytogenes can be detected from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.3137%; height: 2.77778%;">blood and CSF by microscopy/culture or PCR. MRI is indi-
cated for suspected brainstem infection (rhombencephalitis).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 20.4248%; height: 1.38889%;">Serology is not useful for diagnosis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 34.4771%; height: 1.26263%;">Therapy: First choice is ampicillin or penicillin G. Gentamicin
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.2727%; width: 34.4771%; height: 1.38889%;">is added in case of immunosuppression, endocarditis, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 78.6616%; width: 32.0261%; height: 1.38889%;">meningitis. Alternative: trimethoprim-sulfamethoxazole.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 16.7929%; width: 34.3137%; height: 1.38889%;">Prevention: Pasteurization. Persons at high risk of infection
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 36.4379%; height: 1.38889%;">should avoid high-risk foods (smoked fish, raw meat sausage,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 2.77778%;">soft cheeses) and sufficiently heat foods (e.g. left-overs), che-
moprophylaxis can be given to susceptible persons at risk after
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">exposure to contaminated food. The organism can replicate at
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 14.8693%; height: 1.38889%;">refrigerator temperatures.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 26.1364%; width: 34.1503%; height: 1.38889%;">Epidemiology: The disease is distributed worldwide, with the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">majority cases attributed to contaminated processed foods.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">Listeriosis is, after salmonellosis, the second most frequent
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">cause of food-borne infection-related deaths in Europe. The
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.26263%;">disease incidence has decreased in the USA, while it increased
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">in Europe for unknown reasons. The more regular use of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">immunosuppressive medications and the increasing size of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">the elderly population has increased the population at risk in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">both Europe and the USA. The majority of invasive listerial
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.3137%; height: 1.38889%;">infections occurs in individuals with predisposing conditions:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">pregnancy, corticosteroid use, or other immunosuppressive
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">conditions. One-third of reported cases occur in pregnant
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">women. In non-pregnant patients corticosteroid use is the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">most important predisposing factor. Clinical data from Asia,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 41.6667%; height: 1.38889%;">Africa, and South America are lacking. L.monocytogenes has
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">been found in food products from these regions. Food-borne
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 2.77778%;">outbreaks, many of which are manifested by febrile gastroen-
teritis, have been described with a variety of foods. The most
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">common are processed/delicatessen meats, hot dogs, soft
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">cheeses, smoked seafood, meat spreads, and pates. Infections
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">from animal contact are uncommon and generally occur in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 25.4902%; height: 1.26263%;">veterinarians, abattoir workers, and farmers.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 57.0707%; width: 34.3137%; height: 1.38889%;">Map sources: The Listeria map was made by geocoding
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">human listeria outbreaks (at least two related cases) reported
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 34.4771%; height: 1.13636%;">in ProMED-mail and the medical literature between 2000 and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.2374%; width: 3.26797%; height: 1.0101%;">2010.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 63.8889%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">Allerberger F, et al. (2010) Listeriosis: a resurgent foodborne
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 66.5404%; width: 24.8366%; height: 1.38889%;">infection. Clin Microbiol Infect 16(1):16–23.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 67.9293%; width: 43.7909%; height: 1.38889%;">Guillet C, et al. (2010) Human listeriosis caused by Listeria
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.1919%; width: 23.6928%; height: 1.38889%;">ivanovii. Emerg Infect Dis 16(1):136–138.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">Siegman-Igra Y, et al. (2003) Listeria monocytogenes infection
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 33.0065%; height: 1.38889%;">in Israel and review of cases worldwide. Emerg Infect Dis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.2323%; width: 7.51634%; height: 1.38889%;">8(3):305–310.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 85.1307%; top: 9.21717%; width: 1.79739%; height: 1.0101%;">71
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/35877380-788f-4070-80d2-3c11508e36f5" class="aLF-aPX-aPF-aPE-J3" alt="Page 15 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.cdc.gov/ncidod/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.cdc.gov/ncidod/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.cdc.gov/ncidod/&amp;ust=1666162860000000&amp;usg=AOvVaw3pkCL3RerdnjijAafOne9q&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 73.2026%; top: 60.4798%; width: 13.5621%; height: 1.38889%;"></a><a href="http://www.kolonin.org" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.kolonin.org" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.kolonin.org&amp;ust=1666162860000000&amp;usg=AOvVaw1guLVkiiLmoxmK43P-kjZ8&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 74.0196%; top: 64.5202%; width: 10.4575%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 16 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 34.4771%; height: 2.39899%;">Disease: Lyme Disease
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 25%; height: 1.26263%;">Classification: ICD-9 088.81; ICD-10 A69.2
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.3137%; height: 1.38889%;">Syndromes and synonyms: Lyme borreliosis, erythema
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 34.4771%; height: 1.38889%;">(chronicum) migrans (EM), tick-borne meningopolyneuritis,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 20.7516%; height: 1.38889%;">acrodermatitis chronica atrophicans.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.495%; width: 34.4771%; height: 1.38889%;">Agent: The spirochete Borrelia burgdorferi. Initially identified
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 25.8838%; width: 34.4771%; height: 1.38889%;">as a single species,B. burgdorferi has been separatedinto at least
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.2727%; width: 46.732%; height: 1.38889%;">12 species. Almost all cases of Lyme disease are caused by B.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.5354%; width: 36.7647%; height: 1.38889%;">burgdorferi sensu stricto, B. garinii, and B. afzelii, and very few
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 29.9242%; width: 34.4771%; height: 3.66162%;">by B. spielmanii and B. lusitaniae. Reservoir: Small rodents (mice, voles, rats) and insectivores
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 33.5859%; width: 34.4771%; height: 1.38889%;">(shrews, hedgehogs) are the most common animal reservoirs
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.9747%; width: 34.3137%; height: 1.38889%;">of Borrelia, while larger animals (deer, livestock) serve as
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.2374%; width: 34.3137%; height: 1.38889%;">hosts for the tick vectors. Hares and birds may also serve as
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 37.6263%; width: 34.4771%; height: 1.38889%;">reservoirs. Ticks by trans-stadial transmission; transovarial
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.0152%; width: 17.8105%; height: 1.13636%;">transmission in ticks is limited.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.2879%; width: 38.0719%; height: 1.38889%;">Vector: Hard ticks, principally Ixodes scapularis (formerly
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.6768%; width: 34.4771%; height: 1.38889%;">I. dammini) and I. pacificus in North America, I. persulcatus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 44.0657%; width: 34.4771%; height: 1.38889%;">and I. ricinus in Eurasia. In Russia, the principal vectors are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.3283%; width: 31.5359%; height: 1.38889%;">I. persulcatus in the west and I. ricinus in the east.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 48.1061%; width: 33.9869%; height: 2.65152%;">Transmission: By tick bite or blood transfusion. Most trans-
mission to humans is by the nymphal tick stage.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 52.1465%; width: 34.4771%; height: 1.38889%;">Cycle: Tick-small mammals and birds-tick; large mammals
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.4091%; width: 34.4771%; height: 1.38889%;">are necessary to maintain tick populations. Humans and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.798%; width: 15.5229%; height: 1.13636%;">lizards are dead-end hosts.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.4495%; width: 34.4771%; height: 1.38889%;">Incubation period: 3–32 days, mean 7–10 days for EM. Since
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.8384%; width: 34.3137%; height: 1.26263%;">EM can remain absent, the interval between the tick bite and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 60.101%; width: 16.1765%; height: 1.38889%;">disease can be much longer.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.8788%; width: 34.4771%; height: 1.38889%;">Clinical findings: Lyme borreliosis is a multisystem disease
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 64.1414%; width: 34.4771%; height: 2.77778%;">that can affect the skin, heart, nervous system and, less com-
monly, the eyes, kidneys, and liver. Often there is an annular
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.9192%; width: 34.4771%; height: 1.38889%;">skin rash that develops at the bite site, known as EM. After
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 68.1818%; width: 34.4771%; height: 1.38889%;">several months, approximately 60% of patients with untreated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.5707%; width: 34.4771%; height: 1.38889%;">infection will have intermittent arthritis. Up to 5% of untreated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.9596%; width: 34.4771%; height: 1.38889%;">patients develop chronic neurological complaints months to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 72.2222%; width: 24.8366%; height: 1.38889%;">years after infection. Re-infection can occur.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 75%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Lyme disease is a clinical diagnosis and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.2626%; width: 34.4771%; height: 1.38889%;">laboratory testing is supportive. ELISA or IFA, confirmed by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.6515%; width: 34.4771%; height: 1.38889%;">IgM and IgG Western or striped blot test. PCR on blood, CSF,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 79.0404%; width: 23.8562%; height: 1.13636%;">urine and tissues, but is not standardized.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">Therapy: Early Lyme disease is generally treated for 10–14
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">days, late Lyme disease for 21–30 days. Oral antibiotics
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">commonly used are: doxycycline or amoxicillin. Patients
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.4771%; height: 1.38889%;">with neurological or cardiac forms of illness may need iv
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 13.8889%; height: 1.38889%;">ceftriaxone or penicillin.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 24.495%; width: 34.1503%; height: 1.38889%;">Prevention: Tick bite prevention by avoiding wooded and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 25.8838%; width: 34.4771%; height: 1.38889%;">bushy areas with high grass and leaf litter, especially in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.2727%; width: 34.4771%; height: 1.38889%;">summer months; insect repellents; minimize bare skin check
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.5354%; width: 27.2876%; height: 1.13636%;">for tick bites and remove them within 24 hours.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 31.3131%; width: 34.1503%; height: 1.38889%;">Epidemiology: Lyme disease is the most commonly reported
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.5758%; width: 34.4771%; height: 1.38889%;">vector-borne diseasein bothNorthAmerica and Europe, where
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 33.9646%; width: 34.4771%; height: 1.38889%;">its incidence is increasing. Incidence is seasonal, corresponding
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.2273%; width: 41.8301%; height: 1.38889%;">to increased vector activity during summer. The three Borrelia
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.6162%; width: 34.4771%; height: 2.77778%;">species differ in geographic location, vectors, and clinical man-
ifestations: B. burgdorferi ss is present both in North America
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.2677%; width: 37.9085%; height: 1.38889%;">and Europe, but is absent from Asia; B. garinii andB. afzelii occur
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 40.6566%; width: 38.0719%; height: 1.38889%;">in Europe and Asia. A recent study showed that B. garinii is the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.0455%; width: 34.4771%; height: 1.38889%;">main genotype in China. Data of B. burgdorferi presence are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.3081%; width: 34.4771%; height: 1.38889%;">lacking for South America, Sub-Saharan Africa, South and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 44.697%; width: 34.4771%; height: 1.13636%;">Southeast Asia. In the USA the disease is focal: most cases
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.0859%; width: 34.4771%; height: 2.65152%;">come from limited areas in the northeastern and upper mid-
western regions. In the Baltic region, disease rates are several
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 48.7374%; width: 34.3137%; height: 1.38889%;">fold higher than in the USA. Incidences vary, ranging from 0.3/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 50.1263%; width: 34.3137%; height: 1.38889%;">100,000 in the UK to 130/100,000 in Austria. Climate change,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.3889%; width: 34.4771%; height: 1.38889%;">more housing in wooded areas, and expanding populations of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 52.7778%; width: 34.4771%; height: 1.38889%;">deer, and small rodents may be responsible for the increase in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.0404%; width: 34.4771%; height: 1.38889%;">Lyme disease cases. None of the mammal species identified as
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.4293%; width: 34.4771%; height: 1.38889%;">reservoir hosts and none of the transmitting ticks are present in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 56.8182%; width: 5.71895%; height: 1.13636%;">Australia.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 59.2172%; width: 34.3137%; height: 1.26263%;">Map sources: The Lyme disease map was made with data
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 60.4798%; width: 34.3137%; height: 1.38889%;">obtained from the CDC for USA (www.cdc.gov/ncidod/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.8687%; width: 34.4771%; height: 1.38889%;">dvbid/lyme/) and R. Smith et al. (2006) for Europe. Tick
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.2576%; width: 45.098%; height: 1.0101%;">distributions were redrawn from Kolonin’s website on Fauna
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 64.5202%; width: 32.3529%; height: 1.38889%;">of Ixodid Ticks of the World, available at: www.kolonin.org.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 67.298%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 68.5606%; width: 40.6863%; height: 2.52525%;">Goodman JL (eds), et al. (2005) Tick-Borne Diseases of Humans. ASM Press.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 71.2121%; width: 34.3137%; height: 1.38889%;">Gratz N (2004) The Vector-Borne Human Infections of Europe:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 72.601%; width: 33.1699%; height: 1.13636%;">Their Distribution and Burden on Public Health. WHO
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.9899%; width: 21.732%; height: 1.38889%;">Regional Office for Europe, pp. 1–144.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 75.2525%; width: 37.5817%; height: 1.38889%;">Hao Q, et al. (2011) Distribution of Borrelia burgdorferi sensu
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 76.6414%; width: 24.8366%; height: 1.26263%;">lato in China. J Clin Microbiol 49(2):647–650.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 78.0303%; width: 37.0915%; height: 2.65152%;">Smith R, et al. (2006) Lyme borreliosis: Europe-wide coordi-
nated surveillance and action needed? Euro Surveill 11(25).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 85.1307%; top: 9.21717%; width: 1.79739%; height: 1.0101%;">73
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/0c05a3e4-872b-4f2e-b3d7-e6e86fdeb14b" class="aLF-aPX-aPF-aPE-J3" alt="Page 16 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.worldclim.org" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.worldclim.org" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.worldclim.org&amp;ust=1666162860000000&amp;usg=AOvVaw1Mr2Vdb8SpO80-szJXICn8&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 70.098%; top: 59.8485%; width: 11.7647%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 17 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 31.2092%; height: 2.0202%;">Disease: Melioidosis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 26.9608%; height: 1.26263%;">Classification: ICD-9 025; ICD-10 A24.1-A24.4
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 27.451%; height: 1.26263%;">Syndromes and synonyms: Whitmore disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 40.1961%; height: 1.38889%;">Agent: Burkholderia pseudomallei, (formerly Pseudomonas
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">pseudomallei), an aerobic, motile Gram-negative bacillus of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">the beta-proteobacteria group. It is oxidase positive, resistant
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.4771%; height: 2.77778%;">to a wide range of antibiotics including gentamicin, poly-
myxin, and the second-generation cephalosporins. A similar
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.3137%; height: 1.38889%;">disease of equines called glanders, now rare (extinct in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 48.0392%; height: 1.38889%;">Americas), is caused by the related bacterium B. mallei. Both
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">B. mallei and B. pseudomallei are listed as potential biological
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 9.15033%; height: 1.38889%;">warfare agents.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">Reservoir: B. pseudomallei is a soil and water saprophyte and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.4771%; height: 1.38889%;">can survive for long periods in moist soil and mammalian
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">tissues. Infection has been found in a wide range of animals,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 24.0196%; height: 1.38889%;">but none is thought to be a reservoir host.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.4771%; height: 1.38889%;">Transmission:Through breaks in skin, ingestion or aspiration
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 1.26263%;">of contaminated water, inhalation of contaminated dust. There
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">are rare reports of transmission from human or animal cases to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.3137%; height: 1.38889%;">humans. Laboratory workers have been infected by aerosols.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.4771%; height: 2.65152%;">Incubation period: 1–21 days for most acute cases but acti-
vation of latent infection has occurred from 25 to 63 years after
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 52.0202%; width: 5.71895%; height: 1.13636%;">exposure.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 2.77778%;">Clinical findings: Range from asymptomatic pulmonary con-
solidation to mild bronchitis, through acute pneumonic or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">rapidly fatal septicemic presentations to chronic suppurative
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">infection. Pulmonary cavitation, osteomyelitis and empyema
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">may also be seen. Easily confused clinically with typhoid fever
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">and tuberculosis, and laboratories may not recognize the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 28.9216%; height: 1.38889%;">causative organism and report it as a contaminant.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Isolation of agent from blood, urine,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 33.9869%; height: 2.77778%;">sputum, pus or skin lesions; direct immunofluorescence; serol-
ogy. PCR may be of value on samples other than blood.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">Therapy: Drain abscesses, iv ceftazidime, meropenem or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.4771%; height: 2.65152%;">imipenem followed by eradication treatment using cotrimox-
azole, with or without doxycycline. Amoxicillin-clavulanic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.4771%; height: 1.13636%;">acid is an alternative for those with resistant strains or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 34.4771%; height: 1.26263%;">where co-trimoxazole is contraindicated. Also usually
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.3137%; height: 1.38889%;">sensitive to piperacillin or ticarcillin with clavulanic acid.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 19.7712%; height: 1.38889%;">There is an up to 10% relapse rate.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 20.8333%; width: 34.3137%; height: 1.38889%;">Prevention: Avoid contamination of skin by potentially
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 29.4118%; height: 1.13636%;">infected soil or water. There is no vaccine available.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 34.4771%; height: 4.0404%;">Epidemiology: The true worldwide distribution and inci-
dence is unknown. Antibody prevalence in humans and live-
stock in countries with sporadic cases suggest that most
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">human infections are subclinical or benign, or misdiagnosed
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 11.4379%; height: 1.38889%;">and underreported.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 31.5657%; width: 33.1699%; height: 1.38889%;">Cases are mainly sporadic and have been reported in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">humid areas of the tropics and subtropics world wide, mainly
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">during the rainy season. Cases have been reported in dryer
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">areas, like northeastern Brazil and north Iran. This is likely
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">explained by the fact that these two areas have irrigated rice
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">fields. In Southeast Asia, it is a disease of mainly rice farmers
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">and others who are occupationally exposed to contaminated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 2.65152%;">soil or water. In northeast Thailand, 20% of community-
acquired septicemic cases are due to melioidosis, which
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 2.77778%;">accounts for 39% of fatal septicemias and 36% of fatal com-
munity-acquired pneumonias. Up to 80% of cases occur in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 2.77778%;">those who are predisposed by underlying immunocompro-
mising conditions such as diabetes, chronic renal disease, or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">alcoholism, age, chronic infection, or immunosuppressive
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">therapy. Sporadic human infections with glanders (B. mallei),
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.1503%; height: 2.77778%;">occur in equine veterinarians and pathologists, horse butch-
ers, and laboratory workers.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 55.8081%; width: 34.3137%; height: 1.38889%;">Map sources: The Melioidosis map was made by geocoding
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 34.3137%; height: 1.38889%;">confirmed cases reported in the medical literature up to 2010.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">Imported cases were excluded. The global precipitation data
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 30.0654%; height: 1.38889%;">are obtained from WorldClim (www.worldclim.org).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 62.6263%; width: 7.02614%; height: 1.0101%;">References
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">Cheng AC (2010) Melioidosis: advances in diagnosis and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 65.1515%; width: 27.1242%; height: 1.38889%;">treatment. Curr Opin Infect Dis 23(6):554–559.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.5404%; width: 38.7255%; height: 2.77778%;">Cheng AC, et al. (2005) Melioidosis: epidemiology, pathophys-
iology, and management. Clin Microbiol Rev 18(2):383–416.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">Currie BJ (2008) Advances and remaining uncertainties in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.5808%; width: 32.6797%; height: 2.77778%;">epidemiology of Burkholderia pseudomallei and melioido-
sis. Trans R Soc Trop Med Hyg 102(3):225–227.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 73.2323%; width: 34.4771%; height: 1.38889%;">Peacock SJ (2006) Melioidosis. Curr Opin Infect Dis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 74.6212%; width: 8.16994%; height: 1.26263%;">19(5):421–428.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 85.1307%; top: 9.21717%; width: 1.79739%; height: 1.0101%;">75
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/cc5372a8-308d-447f-8c11-d97bf624f9bb" class="aLF-aPX-aPF-aPE-J3" alt="Page 17 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://portal.iri.columbia.edu/portal/server" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://portal.iri.columbia.edu/portal/server" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://portal.iri.columbia.edu/portal/server&amp;ust=1666162860000000&amp;usg=AOvVaw3LDBZFPsrMB8s4Tl1Awg7B&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 60.9477%; top: 61.2374%; width: 25.6536%; height: 1.26263%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 18 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 54.085%; height: 2.39899%;">Disease: Meningococcal Meningitis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.3464%; height: 1.26263%;">Classification: ICD-9 036.0; ICD-10 A39.0
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.5707%; width: 24.8366%; height: 1.13636%;">Syndromes and synonyms: None
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 34.4771%; height: 2.65152%;">Agent: Neisseria meningitidis, a Gram-negative aerobic diplo-
coccus. Pathogenic N. meningitidis produce a polysaccharide
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 33.9869%; height: 2.52525%;">capsule, used for serogrouping. Five serogroups are responsi-
ble for most cases: A, B, C, W135, and Y.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.3137%; height: 1.38889%;">Reservoir: Humans. Asymptomatic carriage of N.meningitidis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">in the oropharynx is common, although carriage rates vary
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">widely by geographic and epidemiological setting. The carrier
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 33.9869%; height: 2.65152%;">state is immunizing and development of meningococcal dis-
ease is associated with recent acquisition.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.4771%; height: 1.38889%;">Route of transmission: N. meningitidis is transmitted from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 23.366%; height: 1.38889%;">person to person by respiratory droplets.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 29.4118%; height: 1.38889%;">Incubation period: 2–10 days, commonly 3–4 days
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 4.0404%;">Clinical findings: Classically meningococcal meningitis pre-
sents with fever, headache, neck stiffness, photophobia, nau-
sea, and vomiting. In infants and young children the clinical
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 33.9869%; height: 2.77778%;">picture may be non-specific. If the patient also has meningo-
coccal bacteremia, a hemorrhagic skin rash may be seen.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.4771%; height: 2.77778%;">Diagnostic tests: Gram stain and microscopy of cerebrospi-
nal fluid, and culture. Latex agglutination tests for detection of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 25.6536%; height: 1.38889%;">group-specific capsular polysaccharide. PCR.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.197%; width: 34.3137%; height: 1.38889%;">Therapy: Early iv or im antibiotic therapy: iv benzylpenicillin,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.5859%; width: 29.2484%; height: 1.26263%;">third-generation cephalosporin or chloramphenicol.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.4771%; height: 1.38889%;">Prevention: Polysaccharide vaccines against A, C, Y, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.6263%; width: 34.4771%; height: 1.0101%;">W135 are available. These vaccines are safe and effective in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">adults and older children but are poorly immunogenic in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.2778%; width: 34.4771%; height: 1.38889%;">children under the age of 2 and the duration of protection is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">limited to 3–5 years. The development of a group C conjugated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">meningococcal vaccine that is effective in children under the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.3182%; width: 34.4771%; height: 1.38889%;">age of 2 years has been an important advance, and conjugate
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 4.16667%;">vaccines are now available for A, C, Y, and W135. The devel-
opment of a group B vaccine remains a challenge. Chemopro-
phylaxis of close contacts eradicates carriage and reduces the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 33.9869%; height: 2.77778%;">incidence of secondary cases. Vaccination of household con-
tacts may also prevent further cases.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 16.7929%; width: 34.3137%; height: 1.38889%;">Epidemiology: World wide, but the epidemiology of the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">meningococcal meningitis is regionally heterogeneous
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">and dynamic. Group A causes the highest incidence and is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.4771%; height: 1.38889%;">responsible for large epidemics every 5–10 years in a belt
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">that stretches across the semi-arid regions of Sub-Saharan
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">Africa: the ‘meningitis belt.’ These epidemics occur in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">dry season and are associated with periods of low absolute
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">humidity and dusty conditions. The map opposite shows the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">probability of meningococcal meningitis epidemics in Africa
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">based on reported epidemics occurring between 1841 and 1999
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">and predicted from differences in physical environmental
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">conditions between the regions where epidemics have ever
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.3137%; height: 2.39899%;">and never occurred. The map provides a reasonable descrip-
tion of ‘at-risk’ areas and matches well with the WHO defined
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">‘meningitis belt.’ However, other factors will also influence
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">the epidemiology, e.g. demographic and social patterns, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">immunological susceptibility. While epidemic meningococcal
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 45.915%; height: 1.38889%;">disease does occur in Asia (China – serogroups A, C; India –
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">serogroup A; Philippines – serogroup A) endemic disease
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">activity appears to be low, for reasons that are unclear.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">Group A epidemics used to occur in western countries but
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.3137%; height: 1.38889%;">disappeared after World War II and now groups B and C
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">predominate, tending to cause sporadic cases or small clusters
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">in temperate climates and in South America. A significant
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">proportion of disease due to serogroup Y has been reported
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">from Canada, the USA, Columbia, and South Africa. Group
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.13636%;">W135 had been rare until outbreaks were detected in association
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.26263%;">with the annual Islamic pilgrimage to Mecca in Saudi Arabia
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 54.4192%; width: 34.3137%; height: 1.38889%;">(The Hajj) in 2000. It has now emerged as a cause of epidemics in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 26.634%; height: 1.38889%;">the meningitis belt, South Africa and Argentina.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 58.4596%; width: 34.1503%; height: 1.38889%;">Map sources: The Meningococal Meningitis map was made
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 34.4771%; height: 1.13636%;">with data from the International Research Institute for Climate
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.2374%; width: 34.3137%; height: 1.26263%;">and Society (http://portal.iri.columbia.edu/portal/server.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 62.5%; width: 28.7582%; height: 1.38889%;">pt), Harisson et al. (2009), and Savory et al. (2006).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 65.2778%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.5404%; width: 33.9869%; height: 2.52525%;">Harrison LH, et al. (2009) Global epidemiology of meningo-
coccal disease. Vaccine 27S:B51–B63.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.1919%; width: 34.1503%; height: 2.77778%;">Molesworth AM, et al. (2003) Environmental risk and meningi-
tis epidemics in Africa. Emerg Infect Dis 9(10): 1287–1293.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 71.9697%; width: 34.4771%; height: 1.38889%;">Savory EC, et al. (2006) Evaluation of the meningitis epidemics
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.2323%; width: 30.3922%; height: 1.38889%;">risk model in Africa. Epidemiol Infect 134(5):1047–1051.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 74.6212%; width: 33.9869%; height: 2.65152%;">Stephens DS, et al. (2007) Epidemic meningitis, meningococ-
caemia, and Neisseria meningitidis. Lancet 369:2196–2210.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 85.1307%; top: 9.21717%; width: 1.79739%; height: 1.0101%;">77
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/0e7a6ec1-f7d5-4e36-a03a-69049e1e3364" class="aLF-aPX-aPF-aPE-J3" alt="Page 18 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 19 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 22.7124%; height: 2.0202%;">Disease: Noma
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.3464%; height: 1.26263%;">Classification: ICD-9 528.1; ICD-10 A69.0
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.5707%; width: 34.3137%; height: 1.26263%;">Syndromes and synonyms: Cancrum oris, gangrenous
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 5.88235%; height: 1.13636%;">stomatitis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 2.77778%;">Agent: Oral commensal bacteria such as Fusobacterium necro-
phorum, F. nucleatum and a spirochete (formerly identified as
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 29.902%; height: 1.38889%;">Borrelia vincenti) are the suspected etiological agents.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.4771%; height: 4.0404%;">Reservoir: Human buccal flora. Transmission: Noma is an opportunistic infection with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 20.7516%; height: 4.0404%;">endogenous buccal flora. Incubation period: Days to weeks.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">Clinical findings: Noma is an opportunistic infection that
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.4771%; height: 4.0404%;">evolves rapidly from a gingival inflammation to severe, muti-
lating orofacial gangrene, which is painless and usually uni-
lateral. It begins as a small vesicle or ulcer on the gingiva that
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">rapidly becomes necrotic and spreads to produce extensive
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.0101%;">destruction of the buccal and labial mucosa and tissues of the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 2.77778%;">face, including the bone, which may result in severe disfigure-
ment and even death. Noma can also cause tissue damage to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 16.8301%; height: 1.38889%;">the genitals (noma pudenda).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: None. Diagnosis is made by clinical
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 7.67974%; height: 1.13636%;">examination.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.3137%; height: 2.65152%;">Therapy: Penicillin and metronidazole; rehydration; nutri-
tional rehabilitation; treatment of predisposing diseases (e.g.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.1503%; height: 2.77778%;">malaria, measles, tuberculosis); wound disinfection; recon-
structive surgery.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.4771%; height: 2.77778%;">Prevention: Noma can be prevented through health educa-
tion, poverty reduction, improved nutrition, promotion of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">breastfeeding, proper prenatal care and immunisations
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 15.6863%; height: 1.38889%;">against childhood diseases.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 20.8333%; width: 34.3137%; height: 1.38889%;">Epidemiology: The incidence of Noma and the prevalence of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 2.65152%;">survivors of Noma are not well known. In 1998, WHO esti-
mated that 770,000 people had been affected in the past and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 34.4771%; height: 1.26263%;">survived the affection, and that 140,000 new cases were
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">reported each year, of which 100,000 were between 1 and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">7 years old and living in Sub-Saharan Africa. An estimation of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">the global incidence based on epidemiological field work in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">north-west Nigeria indicates 30,000 to 40,000 new cases per
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">year. It occurs predominantly in debilitated and malnourished
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 2.65152%;">children, especially in underdeveloped countries. Peak inci-
dence is at age 1–4 years, the period of growth retardation in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.3137%; height: 1.38889%;">deprived children. The etiology is multifactorial: malnutrition,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.26263%;">concurrent infections with malaria or measles, bad oral
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 2.77778%;">hygiene, severe diarrhea and severe necrotic ulcerative gingi-
vitis are risk factors. In developed countries sporadic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">cases occur in immune-compromised patients, neonates,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 19.9346%; height: 1.38889%;">HIV-positive and diabetic patients.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 45.0758%; width: 34.3137%; height: 1.38889%;">Map sources: The Noma map is modified from Enwonwu
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">et al. (2006) and updated with cases reported in the medical
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.26263%;">literature (2000–2009). The Noma belt was drawn based on
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">expert opinion that stated that African countries directly
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 35.1307%; height: 1.38889%;">under Sahara (Senegal to Ethiopia) are ‘the noma belt of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 12.9085%; height: 3.91414%;">the world’. Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 36.6013%; height: 1.26263%;">Enwonwu CO, et al. (2006) Noma (cancrum oris). Lancet
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 57.197%; width: 7.35294%; height: 1.0101%;">368:147–156.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">Fieger A, et al. (2003) An estimation of the incidence of noma in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 59.8485%; width: 34.9673%; height: 1.38889%;">north-west Nigeria. Trop Med Int Health 5:402–407.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 85.1307%; top: 9.21717%; width: 1.79739%; height: 1.0101%;">79
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/b929d3b5-31db-4fc4-982e-b6270c745c8a" class="aLF-aPX-aPF-aPE-J3" alt="Page 19 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://apps.who.int/immunization_monitoring/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://apps.who.int/immunization_monitoring/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://apps.who.int/immunization_monitoring/&amp;ust=1666162860000000&amp;usg=AOvVaw0dRBTWxc2FlhZZlfcGfk9h&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 59.9673%; top: 58.4596%; width: 26.7974%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 20 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 27.9412%; height: 2.0202%;">Disease: Pertussis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 31.6993%; height: 1.26263%;">Classification: ICD-9 033.0, 033.9; ICD-10 A37.0, A37.9
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 26.9608%; height: 1.38889%;">Syndromes and synonyms: Whooping cough
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 34.4771%; height: 2.65152%;">Agent : Bordetella pertussis a Gram-negative, fastidious bacte-
rium (Bordetella parapertussis causes a milder illness called
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 8.66013%; height: 1.38889%;">parapertussis).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.6515%; width: 14.5425%; height: 1.0101%;">Reservoir: Humans.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.303%; width: 34.3137%; height: 1.26263%;">Transmission: Direct person-to-person transmission via
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 11.7647%; height: 1.38889%;">respiratory droplets.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 33.1699%; height: 1.26263%;">Incubation period: Average 7–10 days (range 5–21 days).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.4771%; height: 1.38889%;">Clinical findings: Classical pertussis has a prodromal stage of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">1–2 weeks with coryza and a mild, persistent cough that
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">progresses to paroxysms of violent coughing interspersed
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">with an inspiratory whoop. Vomiting may follow coughing
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.4771%; height: 1.38889%;">bouts. This stage can last 4–6 weeks. Adolescents and adults
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">often do not have paroxysms and whooping, presenting more
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">commonly with a prolonged cough. Asymptomatic infection
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">may also occur. Infants under 6 months may present with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">apnea, and deaths occur mostly in this age group. Serious
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.3137%; height: 1.38889%;">complications include pneumonia, seizures, cerebral hypoxia,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 12.0915%; height: 1.38889%;">and encephalopathy.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.4771%; height: 2.65152%;">Diagnostic tests: Culture is the gold standard but is insensi-
tive. PCR is more sensitive than culture. Serology may
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">be helpful in patients presenting 3 weeks or more after
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">cough onset, when both culture and PCR are likely to be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 5.39216%; height: 1.38889%;">negative.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">Therapy: Antibiotic treatment with a macrolide antibiotic is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.4771%; height: 2.77778%;">mainly indicated to reduce communicability in those present-
ing within 3 weeks of onset. Hospitalization may be needed in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 19.281%; height: 1.38889%;">severe causes for supportive care.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">Prevention: Two or more doses of a pertussis-containing
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">vaccine are necessary for protection. Global coverage with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">three doses of a pertussis-containing vaccine are shown
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.3137%; height: 1.38889%;">elsewhere (see DTP3 map). Infants under the age of 3–5
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 34.4771%; height: 1.38889%;">months are, depending on the vaccination schedule, too
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.4771%; height: 1.38889%;">young to have received two doses and are also vulnerable
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 34.4771%; height: 1.26263%;">to complications of pertussis. This group therefore suffers the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 2.77778%;">greatest burden of pertussis mortality. Post-exposure pro-
phylaxis with a macrolide antibiotic may be recommended
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 33.9869%; height: 2.77778%;">for contacts in households where there is a susceptible mem-
ber (e.g. an infant).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 23.4848%; width: 34.3137%; height: 1.26263%;">Epidemiology: Pertussis immunization has been successful in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">reducing the burden of pertussis disease and deaths, with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">around 150,000 cases reported in 2008 compared to almost
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 2.77778%;">2 million cases in 1980. However, these figures must be inter-
preted with great caution since reporting is mostly based on
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">clinical diagnosis, whichis not easyin neonates, older children,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">and adults. The WHO estimated that nearly 18 million cases
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.26263%;">and 254,000 deaths occurred in 2004, of which 90% were in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">developing countries. Although pertussis disease has clearly
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">been reduced by immunization, it is not clear to what extent
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 4.0404%;">immunization has reduced circulation of B. pertussis. The con-
tinued risk of pertussis in unimmunized infants and the per-
sistence of epidemic cycles indicate that B. pertussis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">transmission continues despite vaccination programs. Several
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 4.16667%;">developed countries with high coverage in children have expe-
rienced outbreaks of pertussis in adolescents and adults. Immu-
nity following natural pertussis infection or vaccination is not
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">permanent, therefore high coverage with pertussis vaccines in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 4.0404%;">children has shifted susceptibility and peak incidence to ado-
lescents and young adults; these age groups are then transmit-
ting infection to young infants. Since pertussis in adults usually
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">manifests as only a prolonged cough it is difficult to identify
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 14.3791%; height: 1.38889%;">cases and protect infants.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 55.8081%; width: 34.1503%; height: 1.38889%;">Map sources: The Pertussis map was made with pertussis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 34.4771%; height: 1.26263%;">incidence and immunization data obtained from WHO,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 34.3137%; height: 1.38889%;">available at: http://apps.who.int/immunization_monitoring/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 2.77778%; height: 1.26263%;">en/.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 62.6263%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">Cherry JD (2005) The epidemiology of pertussis: a comparison
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 65.1515%; width: 33.0065%; height: 2.77778%;">of the epidemiology of the disease pertussis with the epide-
miology of Bordetella pertussis infection. Pediatrics
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 67.9293%; width: 8.00654%; height: 1.13636%;">15:1422–1427.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">Wood N et al. (2008) Pertussis: review of epidemiology,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.5808%; width: 33.1699%; height: 1.38889%;">diagnosis, management and prevention. Pediatric Resp Rev
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 6.04575%; height: 1.13636%;">9:201–212.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 73.2323%; width: 34.4771%; height: 1.38889%;">World Health Organization (2009) State of the World’s Vaccines
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 74.6212%; width: 33.1699%; height: 1.26263%;">and Immunization, 3rd edn. WHO, UNICEF, World Bank
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 76.0101%; width: 4.90196%; height: 1.0101%;">Geneva.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 85.1307%; top: 9.21717%; width: 1.79739%; height: 1.0101%;">81
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/192625e2-03d6-42a0-8d92-6b947341ef9d" class="aLF-aPX-aPF-aPE-J3" alt="Page 20 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.cdc.gov/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.cdc.gov/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.cdc.gov/&amp;ust=1666162860000000&amp;usg=AOvVaw1pEBx1miTd_wdBj23rt0lN&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 77.9412%; top: 59.8485%; width: 8.82353%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 21 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 24.3464%; height: 2.39899%;">Disease: Plague
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 22.3856%; height: 1.26263%;">Classification: ICD-9 020; ICD-10 A20
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">Syndromes and synonyms: Pestis, pest, bubonic plague,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 26.1438%; height: 1.38889%;">pneumonic plague, black plague, black death.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.1061%; width: 42.6471%; height: 1.38889%;">Agent: Yersinia pestis, a Gram-negative bacillus. Y. pestis is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.3687%; width: 27.1242%; height: 1.38889%;">considered a potential biological warfare agent.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.6414%; width: 34.3137%; height: 1.38889%;">Reservoir: Rodents, principally rats and sylvatic ground
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.0303%; width: 34.4771%; height: 1.38889%;">squirrels: marmots, susliks, and prairie dogs. Rabbits, camels,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 29.2929%; width: 34.4771%; height: 1.38889%;">carnivores, and domestic cats may also be infected. Cats
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.6818%; width: 34.4771%; height: 1.38889%;">can also develop pneumonic plague. The desert regions of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.0707%; width: 34.4771%; height: 1.38889%;">Central Asia contain endemic plague foci where the great
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 33.3333%; width: 13.2353%; height: 1.38889%;">gerbil is the main host.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">Vector: Fleas, especially the rat flea (Xenopsylla cheopis) and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 23.6928%; height: 1.38889%;">possibly human flea (Pulex irritans).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.2677%; width: 34.4771%; height: 1.26263%;">Transmission: By flea bite for the bubonic form, by the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 40.5303%; width: 34.4771%; height: 1.38889%;">respiratory route for the pneumonic form; handling carcasses
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.9192%; width: 33.9869%; height: 4.0404%;">or eating meat of infected animals. Person-to-person transmis-
sion occurs through the bite of fleas (bubonic form) or respira-
tory droplets (pneumonic form).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.9697%; width: 46.8954%; height: 2.65152%;">Cycle: There are different cycles, including a sylvatic rodent– flea cycle, a commensal rodent–flea cycle, and a cycle of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.6212%; width: 35.4575%; height: 1.38889%;">pneumonic transmission in humans. Y. pestis can survive in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.0101%; width: 34.3137%; height: 1.38889%;">the environment, mainly in rodent burrows in a sylvatic cycle.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 52.2727%; width: 34.3137%; height: 1.38889%;">In case an infected flea feeds on a commensal rodent (rat), a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.6616%; width: 34.3137%; height: 1.38889%;">rodent–flee–rodent cycle starts. When the rodents dies, their
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.0505%; width: 34.4771%; height: 1.38889%;">fleas move to alternative hosts, possibly humans. If humans
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 56.3131%; width: 34.4771%; height: 1.38889%;">develop pneumonic plague, the infection can be transmitted
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.702%; width: 26.4706%; height: 1.38889%;">from person to person via respiratory droplets.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 60.101%; width: 34.4771%; height: 1.38889%;">Incubation period: 1–4 days for pneumonic, 2–7 days for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.3636%; width: 9.47712%; height: 1.38889%;">bubonic plague.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.6364%; width: 34.4771%; height: 1.26263%;">Clinical findings: Sudden onset of fever, chills, headaches,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.0253%; width: 34.4771%; height: 1.38889%;">body aches, sore throat, vomiting and nausea. Bubonic plague
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.2879%; width: 34.4771%; height: 1.38889%;">is most common, producing swollen, painful and eventually
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.6768%; width: 34.3137%; height: 1.38889%;">suppurating lymph nodes (buboes) which are usually inguinal.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.0657%; width: 34.4771%; height: 2.65152%;">In the septicemic form, Y. pestis spreads through the blood-
stream usually affecting the lungs, ending in fatal endotoxic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.7172%; width: 34.4771%; height: 1.26263%;">shock and DIC. The CFR of the bubonic form is 40–70%; of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 72.9798%; width: 34.4771%; height: 1.38889%;">pneumonic and septicemic plague in the absence of prompt
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.3687%; width: 13.2353%; height: 1.38889%;">treatment, nearly 100%.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.6414%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Microscopy of stained smear from a bubo,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 78.0303%; width: 34.4771%; height: 1.38889%;">sputum or CSF shows characteristic ‘safety-pin’ shape; serology
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 79.2929%; width: 33.3333%; height: 1.38889%;">(IFA; ELISA); rapid dipstick test. Culture takes about 4 days.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">Therapy: Streptomycin, tetracyclines, and sulfonamides are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 39.2157%; height: 1.38889%;">standard; alternatives are gentamicin and fluoroquinolones.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">Chloramphenicol in cases of plague meningitis. Treatment
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.4771%; height: 1.38889%;">should be started within 18 hours of onset. Buboes may
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 11.2745%; height: 1.13636%;">need to be drained.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 34.4771%; height: 2.65152%;">Prevention: A killed vaccine is available for laboratory work-
ers, but is not recommended for use in epidemics. In buildings
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 1.26263%;">or rodent burrows, flea control with insecticide should be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 38.8889%; height: 1.38889%;">followed by rat destruction (killing rats liberates fleas); rat
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">control in ports and ships. Chemoprophylaxis of pneumonic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 30.2288%; height: 1.38889%;">plague contacts. Pneumonic cases should be isolated.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 34.3434%; width: 34.3137%; height: 1.26263%;">Epidemiology: There are an estimated 1,000–3,000 human
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">cases per year, but there is considerable underreporting and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">underdiagnosis. The last plague pandemic of 1894 started in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">Hong Kong establishing many endemic foci world wide. New
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">foci continue to arise, as was seen in Algiers, in 2003. Warm
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 4.0404%;">springs and wet summers have increased the plague preva-
lence in the great gerbil in Kazakhstan. Similar climatic con-
ditions may have resulted in past plague pandemics. Infection
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">control and antibiotics can decrease plague morbidity and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">mortality but plague cannot be eradicated as it is widespread
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">in wild rodents. There has been a large shift in case load from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.3137%; height: 1.38889%;">Asia to Africa, with more than 90% of cases occurring in Africa.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">The most common form is bubonic plague, but outbreaks of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 2.77778%;">pneumonic plague still occur. Plague is possibly more com-
mon in Africa as poor rural communities in Africa live in close
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">proximity to rodents, which are widely hunted and eaten in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 12.9085%; height: 1.38889%;">plague-endemic areas.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 58.4596%; width: 34.3137%; height: 1.38889%;">Map sources: The Plague map is modified from the CDC map
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 34.3137%; height: 1.38889%;">‘Distribution of Plague 1998’, available at: www.cdc.gov/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">ncidod/dvbid/plague/world98.htm. The map is updated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 62.5%; width: 33.9869%; height: 2.65152%;">with recent literature and expert opinion. Africa plague distri-
bution data was obtained from S.B. Neerinckx et al. (2008).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 66.6667%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 67.9293%; width: 33.9869%; height: 2.65152%;">Gratz N. (1999) Plague Manual Epidemiology, Distribution, Sur-
veillance and Control. WHO Report, Geneva.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.5808%; width: 34.4771%; height: 2.77778%;">Neerinckx SB, et al. (2008) Geographic distribution and eco-
logical niche of plague in sub-Saharan Africa. Int J Health
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.2323%; width: 15.5229%; height: 1.38889%;">Geog 7:54.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 74.6212%; width: 37.7451%; height: 1.38889%;">Stenseth NC, et al. (2008) Plague: past, present and future. PLoS
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 75.8838%; width: 15.1961%; height: 1.38889%;">Med 5(1):e3.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 77.2727%; width: 34.4771%; height: 1.38889%;">World Health Organization (2005) Plague. Weekly Epidemiol
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 78.6616%; width: 12.4183%; height: 1.13636%;">Rec 80:138–140.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 85.1307%; top: 9.21717%; width: 1.79739%; height: 1.0101%;">83
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/9b137f74-804b-4a10-a366-d1ca01d7731f" class="aLF-aPX-aPF-aPE-J3" alt="Page 21 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.who.int" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.who.int" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.who.int&amp;ust=1666162860000000&amp;usg=AOvVaw0W9UExHTZLQL7zArFgSjZi&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 67.4837%; top: 63.8889%; width: 8.33333%; height: 1.13636%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 22 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 49.0196%; height: 2.0202%;">Disease: Pneumococcal Disease
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.3464%; height: 1.26263%;">Classification: ICD-9 041.2; ICD-10 A40.3
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.5707%; width: 24.8366%; height: 1.13636%;">Syndromes and synonyms: None.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 34.4771%; height: 2.65152%;">Agent: Streptococcus pneumoniae (pneumococcus), an encap-
sulated Gram-positive bacterium, with &gt; 90 serotypes based
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 33.9869%; height: 4.0404%;">on capsular polysaccharide antigens. Approximately 23 ser-
otypes are responsible for 90% if the infections in the devel-
oped world.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 39.5425%; height: 1.38889%;">Reservoir: Healthy humans can carry S. pneumoniae in their
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.6919%; width: 13.3987%; height: 1.26263%;">upper respiratory tract.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">Transmission: Direct person-to-person transmission between
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">close contacts by droplet spread or direct oral contact; through
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 26.9608%; height: 1.38889%;">objects contaminated with respiratory secretions.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 19.7712%; height: 1.38889%;">Incubation period: 1 to 3 days.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.3137%; height: 1.38889%;">Clinical findings: Depends on the type of infection and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 2.77778%;">severity. S. pneumoniae is an important cause of severe pneu-
monia, meningitis, and sepsis. It also is a common cause of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.3137%; height: 1.38889%;">otitis media and sinusitis. It can cause deep-seated infections
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 26.7974%; height: 1.38889%;">involving any organ in a disseminated disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 35.7843%; height: 1.38889%;">Diagnostic tests: Recovery of S. pneumoniae from sputum,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 39.3791%; height: 1.38889%;">blood, CSF or other normally sterile fluids by culture or PCR. S.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 18.4641%; height: 1.38889%;">pneumoniae antigen test in urine.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">Therapy: Depends on disease severity and type of disease. In
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">areas with high penicillin resistance, ceftriaxone can be used
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 33.9869%; height: 3.78788%;">for severe disease. In case of ceftriaxone resistance, vancomy-
cin is used. For meningitis, dexamethasone is added to antibi-
otic treatment.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">Prevention: Vaccination with vaccines based on capsular
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.3137%; height: 1.38889%;">polysaccharides. Both conjugated and non-jugated vaccines
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">are available. Conjugated vaccines targeting either 7, 9, 10, or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">13 capsule types are recommended for children under 5 years
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 2.77778%;">of age and risk groups. The 23-valent non-conjugated vac-
cine can only be used in individuals older than 2 years and at
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.4771%; height: 1.38889%;">high risk of disease. National surveillance of pneumococcal
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">disease and infecting serotypes is required to detect vaccine
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">escapees, requiring vaccine modification. Individuals are not
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">protected against pneumococcal capsule types not in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.4771%; height: 1.38889%;">vaccine. Through the GAVI Alliance, low-income countries
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.3137%; height: 1.38889%;">can access pneumococcal vaccines with a small contribution.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">Rwanda was the first GAVI-eligible country that introduced
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 11.7647%; height: 1.13636%;">the vaccine in 2009.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 27.5253%; width: 34.3137%; height: 1.38889%;">Epidemiology: S. pneumoniae is an important cause of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">severe pneumonia, meningitis, and sepsis in children and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">adults. Risk factors for severe disease are: older age ( &gt; 65
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">years), diabetes, chronic disease (heart, lung, kidney, liver),
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">alcoholism, cancer, HIV, non-functioning or absent spleen,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">and sickle cell disease. A global burden of disease study
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">estimated that in 2000 about 14.5 million episodes of serious
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">pneumococcal disease occurred world wide, leading to about
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">826,000 deaths in children &lt;5 years. The most common
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">presentation of severe disease is pneumonia. The majority
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.26263%;">of deaths (95%) occurred in Africa and Asia. Since 2000 the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 2.77778%;">pneumococcal vaccine has been introduced, mostly in devel-
oped countries,while developing countries need themmost. In
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">2008, 24 high-income and two middle-income countries had
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">pneumococcal vaccination in their program, accounting for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.3137%; height: 1.38889%;">less than 0.2% of childhood pneumococcal deaths in 2000.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 4.0404%;">Many deaths in low-income countries are due to poor health-
care infrastructure and inadequate treatment options. Penicil-
lin and chloramphenicol are still widely used to treat
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">meningitis despite high resistance levels against these agents
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">in some areas. Vaccination and access to proper treatment are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">needed in Africa and Asia. Interventions should be targeted on
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">countries with large populations and moderate incidence, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 25.3268%; height: 1.38889%;">countries with high incidence and mortality.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 61.2374%; width: 34.1503%; height: 1.26263%;">Map sources: The Pneumococcal Disease map is reproduced
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 62.5%; width: 34.4771%; height: 1.38889%;">from K.L. O’Brien et al. (2009). The Vaccination schedule data
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 23.8562%; height: 1.26263%;">was obtained from WHO (www.who.int).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 66.6667%; width: 8.66013%; height: 1.13636%;">Key reference
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 67.9293%; width: 43.7909%; height: 2.65152%;">O’Brien KL, et al. (2009) Burden of disease caused by Strepto-
coccus pneumoniae in children younger than 5 years: global
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.5808%; width: 17.6471%; height: 1.13636%;">estimates. Lancet 374:893–902.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 85.1307%; top: 9.21717%; width: 1.79739%; height: 1.0101%;">85
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/c8a4c425-468b-48ab-9fce-bd5c898b0e6a" class="aLF-aPX-aPF-aPE-J3" alt="Page 22 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 23 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 25.4902%; height: 2.0202%;">Disease: Q Fever
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 23.6928%; height: 1.26263%;">Classification: ICD-9 083.0; ICD-10 A78.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 30.8824%; height: 1.38889%;">Syndromes and synonyms: Coxiellosis, Query fever.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">Agent: A zoonosis caused by Coxiella burnetii, an intracellular
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 42.3203%; height: 1.38889%;">Gram-negative bacterium, and is closely related to Legionella
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 39.7059%; height: 1.38889%;">spp., Francisella tularensis, and Rickettsia spp. C. burnetii is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 27.6144%; height: 1.38889%;">classified as a potential biological warfare agent.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.3137%; height: 1.38889%;">Reservoir: Domestic and free living ungulates (cattle, sheep,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">and goats). Also found in other livestock, birds, pets (cats and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.3137%; height: 1.38889%;">dogs), and ticks. Infected animals are generally asymptomatic,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 22.2222%; height: 1.38889%;">but infection may lead to late abortion.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 15.8497%; height: 1.38889%;">Vector: Rarely by tick bite.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.4771%; height: 2.77778%;">Cycle: Animals inhale C. burnetii aerosols or ingest contami-
nated straw or hay. C. burnetii bacteria invade local lymph
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 2.65152%;">nodes, where they complete their life cycle within phago-
somes. From the lymph nodes the agent spreads to other
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">organs via the bloodstream. This bacteremic phase lasts for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 2.65152%;">one week. From infected organs, like mammary glands, pla-
centa, and kidneys, it can be excreted into the environment and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 28.268%; height: 1.38889%;">lead to infection in exposed animals and humans.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">Transmission:Inhalation of contaminated aerosols generated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.3137%; height: 1.38889%;">from infected animal body fluids (placenta, urine, milk, feces)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.4771%; height: 1.13636%;">or dust contaminated with dried animal excretions. Less
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">common routes are enterally when consuming contaminated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 33.9869%; height: 2.65152%;">food products and possibly through skin inoculation. Person-
to-person transmission is rare.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 1.26263%;">Incubation period: About 2–3 weeks for acute Q fever. One to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 16.3399%; height: 1.26263%;">20 years for chronic Q fever.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 2.65152%;">Clinical findings: Half of the infected patients are asymptom-
atic and those with symptoms usually have mild disease. The
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">most common presentations of acute Q fever are pneumonia,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">hepatitis, and isolated fever. Other symptoms are neurological
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">(headache, confusion, peripheral neuropathy), sore throat,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">chills, sweats, rash, and non-productive cough. Proportion
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.4771%; height: 1.38889%;">of people presenting with pneumonia or hepatitis varies by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 34.3137%; height: 1.38889%;">region and immune status. CFR: 1–2%. Chronic Q fever occurs
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.4771%; height: 1.38889%;">1 to 20 years after acute infection and most often presents as
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 34.4771%; height: 1.26263%;">endocarditis in patients with pre-existing heart disease (valve
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.2727%; width: 8.00654%; height: 1.38889%;">abnormality).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 16.7929%; width: 34.3137%; height: 1.38889%;">Diagnostic tests: IgG and IgM antibody detection to phase I
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">and II antigens by IFA, CFT, or ELISA; immunohistology;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 19.281%; height: 1.26263%;">PCR; ultrasound for endocarditis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">Therapy: Doxycycline for acute Q fever. Chronic Q fever
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 33.9869%; height: 2.77778%;">endocarditis: a combination of doxycycline and hydroxychlor-
oquine for approximately 18 months.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 27.5253%; width: 34.3137%; height: 1.38889%;">Prevention: C. burnetii is resistant to many disinfectants and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">extreme environmental conditions. The organism can survive
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">in aerosols for 2 weeks and in soil up to 5 months. Prevention is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">targeted to those working with livestock, mainly sheep and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">goats; appropriate disposal of birth products; routine testing of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.13636%;">risk animals; restricted movement of animals in infected
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">regions; culling of infected animals; a human and veterinary
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 32.1895%; height: 1.38889%;">vaccine is available in several countries; pasteurize milk.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 39.6465%; width: 34.3137%; height: 1.26263%;">Epidemiology: Q fever has been described world wide, with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">the exception of New Zealand. Though small outbreaks are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">reported from tropical countries, serological studies do show
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">that the prevalence of disease is higher there than in temperate
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.3137%; height: 1.38889%;">regions. Most human outbreaks involve either goats or sheep.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">The largest global outbreak ever reported occurred in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">Netherlands between 2007 and 2010, mainly in the southeast
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">where there is a high density of dairy goat farms. The outbreak
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">led to a high incidence of infections in people exposed to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">aerosols living in the vicinity of infected farms but had no
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">occupational exposure. People living within 2 km of a farm had
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.4771%; height: 2.77778%;">a much higher risk than those living &gt; 5km away. The hospi-
talization rate was relatively high, 20% versus around 5%
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 16.0131%; height: 1.38889%;">which is normally reported.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 59.8485%; width: 34.3137%; height: 1.38889%;">Map sources: The Q-fever map was made by geocoding
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">reported Q-fever outbreaks in ProMED-mail and the medical
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 62.5%; width: 34.4771%; height: 1.13636%;">literature between 2000 and 2010. The Netherlands outbreak
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">map is modified from W. van der Hoek et al. (2010). The sheep
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 26.9608%; height: 1.38889%;">and goat density data was obtained from FAO.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 67.9293%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.1919%; width: 33.9869%; height: 1.38889%;">Angelakis E, et al. (2010) Q fever. Vet Microbiol 140:297–309.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">Raoult D, et al. (2005) Natural history and pathophysiology of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 23.6928%; height: 1.38889%;">Q fever. Lancet Infect Dis 5:219–226.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 73.2323%; width: 32.0261%; height: 1.38889%;">Van der Hoek W, et al. (2010) Euro Surveill 15(12):19520.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 74.6212%; width: 34.4771%; height: 1.38889%;">Woldehiwet Z. (2004) Q fever (coxiellosis): epidemiology and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 76.0101%; width: 18.9542%; height: 1.26263%;">pathogenesis. Vet Sci 77:93–100.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 85.1307%; top: 9.21717%; width: 1.79739%; height: 1.0101%;">87
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/9b4b89a0-d215-4fea-924d-48f7e890148a" class="aLF-aPX-aPF-aPE-J3" alt="Page 23 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 24 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 35.1307%; height: 2.0202%;">Disease: Rat Bite Fever
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 22.3856%; height: 1.26263%;">Classification: ICD-9 026; ICD-10 A25
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 33.9869%; height: 4.16667%;">Syndromes and synonyms: Streptobacillosis, streptobacil-
lary fever, Haverhill fever, epidemic arthritic erythema, spir-
illosis, spirillary fever, sodoku.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 40.8497%; height: 4.0404%;">Agents: Streptobacillosis: Streptobacillus moniliformis (for-
merly Actinobacillus muris, Haverhillia multiformis), a Gram-
negative, non-motile pleiomorphic rod-like bacterium.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">Spirillosis: Spirillum minus (minor), a Gram-negative motile
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 9.80392%; height: 1.38889%;">spiral bacterium.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">Reservoir: Rats are the main host species involved in human
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">rat bite fever for both agents. The main location for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">S. moniliformis in rats is the pharynx. S. minusis mainly present
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.3137%; height: 1.38889%;">in the blood and tongue of rats and salivary glands of mice.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 44.4444%; height: 1.38889%;">Other rodent species such as mouse, squirrel, and gerbil – and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">non-rodent species – have occasionally been identified as
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">possible sources of infection. The rat population is estimated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 33.9869%; height: 2.77778%;">to be 10 billion, which is one-third of the total global mamma-
lian population.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">Cycle: Rodent to rodent with spill over to humans in case of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 11.2745%; height: 1.38889%;">adequate exposure.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">Transmission: Via a bite or a scratch by an infected host
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.8039%; height: 1.38889%;">animal. Human infection via S. moniliformis ingestion (milk,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 35.2941%; height: 2.65152%;">water, food) is known as Haverhill fever. Some streptobacil-
losis cases may occur by close contact with the oral flora of pet
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 33.9869%; height: 2.65152%;">rats through kissing and sharing food. There is no person-to-
person transmission.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.3137%; height: 1.38889%;">Incubation period: 3–10 days for streptobacillosis, 1–3 weeks
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 8.00654%; height: 1.26263%;">for spirillosis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.3137%; height: 1.38889%;">Clinical findings: The most common clinical presentation for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">streptobacillosis is a triad of (1) relapsing fever, (2) severe,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">migratory polyarthralgias, and (3) a peripheral, hemorrhagic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">maculopapular rash. The most prominent symptom is severe
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">myalgia with prostration. Polyarthralgias occur in two-thirds
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">of reported cases. In spirillosis, the bite site becomes indurated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.4771%; height: 1.38889%;">and may ulcerate with regional lymphadenopathy; arthritic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 34.4771%; height: 1.38889%;">symptoms are rare. If untreated, the disease may progress to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.4771%; height: 1.38889%;">bacterial endocarditis, pericarditis, parotitis, tenosynovitis,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 34.4771%; height: 1.0101%;">and focal abscesses of soft tissues or the brain. CFR in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">untreated cases may be as much as 13%. There is a significant
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">risk of streptobacillary endocarditis with associated CFR
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 4.57516%; height: 1.13636%;">of 50%.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 22.2222%; width: 34.3137%; height: 1.38889%;">Diagnostic tests: Microscopy, isolation of the agent from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">lesion, blood or pus by inoculation into mouse footpad or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 30.8824%; height: 1.38889%;">guinea pigs, or culture; serum agglutination test; PCR.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 1.26263%;">Therapy: Penicillin for both forms of rat bite fever. Penicillin
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 33.9869%; height: 2.65152%;">resistance in S. moniliformis is rare. Tetracycline in penicillin-
allergic patients.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 2.65152%;">Prevention: Rodent control; those with occupational expo-
sure to rodents (e.g. sewage workers) should wear personal
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">protective clothing; avoid close contact with reservoir animals,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">including pets; prophylaxis with penicillin or doxycycline
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 10.4575%; height: 1.38889%;">following rat bite.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 41.0354%; width: 34.3137%; height: 1.38889%;">Epidemiology: Rat bite fever is a rare and underreported
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 37.4183%; height: 1.13636%;">disease with a worldwide distribution. S. minus infection is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">reported less frequently than S. moniliformis and occurs mainly
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">in Asia, particularly Japan. World wide, millions of people are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">bitten by animals each year and rats are responsible for about
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 47.7273%; width: 34.3137%; height: 1.13636%;">1% of these bites. It is estimated that 2% of rat bites lead to an
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">infection (all causes). It is unknown what the proportion of rat
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.13636%;">bite fever is of these infections. The relation between humans
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">and animals is changing which may alter the epidemiology of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">rat bite fever. Rats have become a pet in several countries, while
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">it used to be considered a pest. Children handling pet rats may
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">be a special risk group. More than half of the reported cases of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 17.4837%; height: 1.13636%;">rat bite fever occur in children.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 34.4771%; height: 2.65152%;">Map sources: The Rat Bite Fever map was made by geocod-
ing reported case in the medical literature between 1950 and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 62.5%; width: 3.26797%; height: 1.13636%;">2010.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 65.2778%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.5404%; width: 34.4771%; height: 1.26263%;">Gaastra W, et al. (2009) Rat bite fever. Vet Microbiol
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 67.9293%; width: 7.35294%; height: 1.13636%;">133:211–228.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.1919%; width: 33.9869%; height: 2.52525%;">Elliott SP. (2007) Rat bite fever and Streptobacillus monilifor-
mis. Clin Microbiol Rev 20:13–22.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 71.9697%; width: 43.1373%; height: 2.65152%;">Wullenweber M. (1995) Streptobacillus moniliformis – a zoo- notic pathogen. Taxonomic considerations, host species,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 74.6212%; width: 33.1699%; height: 1.38889%;">diagnosis, therapy, geographical distribution. Lab Anim
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 76.0101%; width: 4.90196%; height: 1.0101%;">29:1–15.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 85.1307%; top: 9.21717%; width: 1.79739%; height: 1.0101%;">89
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/53977088-88e4-4152-963a-c6ecec26ccca" class="aLF-aPX-aPF-aPE-J3" alt="Page 24 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.ciesin" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.ciesin" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.ciesin&amp;ust=1666162860000000&amp;usg=AOvVaw0U5t6_Lktwsq2cc-8wTjg3&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 75.3268%; top: 59.8485%; width: 11.2745%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 25 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 38.0719%; height: 2.39899%;">Disease: Relapsing Fever
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 36.9281%; height: 1.26263%;">Classification: ICD-9 087; ICD-10 A68.0 – A68.1
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.4771%; height: 2.77778%;">Syndromes and synonyms: Epidemic or louse-borne relaps-
ing fever (LBRF), endemic or tick-borne relapsing fever
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 4.73856%; height: 1.26263%;">(TBRF).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">Agent: For LBRF, Borrelia recurrentis, a Gram-negative
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 36.7647%; height: 1.38889%;">spirochete. For TBRF, at least 15 Borrelia species, each
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">specific to a particular species of tick vector. Since the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 36.4379%; height: 1.38889%;">1980s, the number of new Borrelia species associated with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">relapsing fever has increased, in part due to improved
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 7.18954%; height: 1.38889%;">diagnostics.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 34.4771%; height: 1.13636%;">Reservoir: For LBRF, humans; for TBRF, wild rodents, bats
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.3137%; height: 1.38889%;">and ticks (by trans-stadial and transovarian transmission).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.3137%; height: 1.26263%;">B. duttonii has thus far not been detected in wild animals,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">only in humans and tick vector O. moubata. Livestock may also
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 9.80392%; height: 1.13636%;">become infected.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 40.6863%; height: 1.38889%;">Vector: TBRF is primarily transmitted by Ornithodoros ticks.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 40.0327%; height: 1.38889%;">LBRF is transmitted by the human body louse (Pediculus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">humanus); neither the head louse nor the pubic louse has
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 20.4248%; height: 1.13636%;">been shown to transmit the disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">Transmission:LBRF is not transmitted by the bite itself but by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.3137%; height: 1.38889%;">feces or louse gut fluid entering broken skin by scratching.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.3137%; height: 1.38889%;">TBRF: by bite or coxal fluid of infected ticks. Transmission may
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 31.2092%; height: 1.38889%;">also occur through blood transfusion or transplacental.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">Cycle: Lice become infective 4–5 days after an infectious blood
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">meal and remain so for life (20–30 days). Infected ticks remain
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 22.0588%; height: 1.38889%;">infective for life (in excess of 10 years).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">Incubation period: LBRF: 5–15 days (usually 8); TBRF: 2–18
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 9.64052%; height: 1.38889%;">days (usually 7).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">Clinical findings: Characterized by high fever of 2–7 days
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">alternating with afebrile periods of 4–14 days, relapsing up to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">13 times. Initial symptoms include generalized body aches,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 2.77778%;">myalgias, arthralgias, headache, chills, sweats, and a transi-
tory rash. Later symptoms may include nausea, vomiting, dry
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.3137%; height: 2.65152%;">cough, photophobia, neck pain, conjunctivitis, jaundice, hepa-
tosplenomegaly, confusion; rarely hematuria and epistaxis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.3137%; height: 1.38889%;">Long-term sequelae of TBRF include cardiac, neurological,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 34.4771%; height: 1.26263%;">and renal abnormalities, ophthalmia and abortion. LBRF is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">generally more severe than TBRF, but associated with fewer
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 5.22876%; height: 1.38889%;">relapses.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 20.8333%; width: 34.3137%; height: 1.38889%;">Diagnostic tests: Detection of spirochetemia in blood smears
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">with dark-field or conventional microscopy; blood culture in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">special media or mouse inoculation; quantitative buffy coat
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 24.8737%; width: 14.5425%; height: 1.26263%;">(QBC) fluorescence; PCR.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">Therapy: Tetracyclines, chloramphenicol, or penicillins for 7
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.3137%; height: 1.38889%;">days have all been shown to be effective for treating TBRF.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">LBRF can be treated with a single dose of antibiotics. When
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 46.8954%; height: 2.52525%;">initiating antibiotic therapy, watch closely for a Jarisch– Herxheimer reaction.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 33.9869%; height: 2.77778%;">Prevention: Standard louse control and personal tick protec-
tion. Chemoprophylaxis may be used for bite victims.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 39.6465%; width: 34.3137%; height: 1.38889%;">Epidemiology: The louse-borne agent is responsible for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">epidemics, with a CFR of 30–70%; tick-borne agents cause
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">endemic disease, with a CFR of 2–10%. LBRF has disappeared
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">from Europe; tick-borne relapsing fever is found world
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">wide, except in Australia and New Zealand, and is rare in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">Europe and North America. Human TBRF is frequent in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">endemic areas where people live in close proximity to burrows
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">of reservoir animals. Otherwise, the disease is sporadic. LBRF
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">is now found sporadically in epidemics in Africa, and is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.3137%; height: 1.38889%;">associated with refugee camps, natural disasters, and famine.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.3137%; height: 1.38889%;">LBRF used to be common world wide with large epidemics
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">during the two world wars. It may re-establish anywhere in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 19.7712%; height: 1.38889%;">louse-infested human populations.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 58.4596%; width: 34.1503%; height: 1.38889%;">Map sources: The Relapsing Fever map was made with data
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 34.3137%; height: 1.38889%;">from: S. Rebaudet et al. (2006), CIESIN (http://www.ciesin.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.2374%; width: 32.6797%; height: 1.26263%;">org/docs/001-613/map30.gif), and P. Parola et al. (2001).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 63.8889%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">Gratz N (2006) The Vector- and Rodent-Borne Diseases of Europe
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 66.5404%; width: 32.6797%; height: 2.77778%;">and North America: Their Distribution and Public Health Bur-
den. Cambridge University Press.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">Parola P, et al. (2001) Ticks and tickborne bacterial diseases
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.5808%; width: 33.1699%; height: 1.38889%;">in humans: an emerging infectious threat. Clin Infect Dis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 8.16994%; height: 1.26263%;">32(6):897–928.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 73.2323%; width: 34.4771%; height: 1.38889%;">Rebaudet S, et al. (2006) Epidemiology of relapsing fever
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 74.6212%; width: 33.1699%; height: 1.38889%;">borreliosis in Europe. FEMS Immunol Med Microbiol
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 76.0101%; width: 7.02614%; height: 1.26263%;">48(1):11–15.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 85.1307%; top: 9.21717%; width: 1.79739%; height: 1.0101%;">91
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/dc4c3aa9-9603-4d9a-9f7f-9a96cb0d7847" class="aLF-aPX-aPF-aPE-J3" alt="Page 25 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.cdc.gov/ticks/geographic_" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.cdc.gov/ticks/geographic_" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.cdc.gov/ticks/geographic_&amp;ust=1666162860000000&amp;usg=AOvVaw1BtSQcvKJBs8cFb-IlhTLE&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 64.8693%; top: 58.4596%; width: 19.1176%; height: 1.38889%;"></a><a href="http://www.ciesin.org/docs/001-613/001-613.html" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.ciesin.org/docs/001-613/001-613.html" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.ciesin.org/docs/001-613/001-613.html&amp;ust=1666162860000000&amp;usg=AOvVaw0pVKsYyB4sIC3Cmmht6FM_&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 52.451%; top: 59.8485%; width: 34.4771%; height: 2.39899%;"></a><a href="http://www.kolonin.org" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.kolonin.org" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.kolonin.org&amp;ust=1666162860000000&amp;usg=AOvVaw1guLVkiiLmoxmK43P-kjZ8&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 69.6078%; top: 70.5808%; width: 10.4575%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 26 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 70.915%; height: 2.27273%;">Disease: Rickettsioses, Tick-borne, New World
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.3464%; height: 1.26263%;">Classification: ICD-9 082.0; ICD-10 A77.0
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.3182%; width: 34.4771%; height: 1.38889%;">Syndromes and synonyms: Rocky Mountain spotted fever
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.7071%; width: 34.4771%; height: 1.38889%;">(RMSF), North American tick typhus, New World spotted
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.096%; width: 34.4771%; height: 1.26263%;">fever, Tick-borne or tick typhus, Tobia fever (Colombia),
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.3586%; width: 45.5882%; height: 1.26263%;">Sao Paulo fever or ‘febre maculosa’ (Brazil), and fiebre
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.7475%; width: 11.7647%; height: 1.26263%;">manchada (Mexico).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.2727%; width: 39.2157%; height: 2.65152%;">Agent: Rickettsia rickettsii, R. parkeri and R. africae, Gram-
negative intracellular bacilli. R. rickettsii is the agent of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 29.9242%; width: 44.7712%; height: 2.77778%;">RMSF, R. parkeri causes a RMSF-like illness. R. africae causes African tick bite fever and is rarely found in the new world.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.5758%; width: 27.2876%; height: 1.38889%;">New agents are still being discovered regularly.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.101%; width: 34.4771%; height: 1.38889%;">Reservoir: Hard ticks (Ixodidae). Depending on the tick species,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.4899%; width: 34.3137%; height: 2.77778%;">they can acquire infection via feeding on animals with rickettse-
mia, or via venereal, transovarial, and trans-stadial passage.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.1414%; width: 34.4771%; height: 1.38889%;">Animals preferred for feeding varies by tick species and their
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 40.5303%; width: 34.3137%; height: 1.38889%;">life stage.Rodent hosts include ground squirrels, mice, and voles.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.0556%; width: 34.3137%; height: 1.13636%;">Vector: The Ixodid ticks are both vector and reservoir.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 44.4444%; width: 43.6275%; height: 2.65152%;">Amblyomma americanum, Dermacentor andersoni and D. variabi-
lis (American dog tick) in Canada and the USA, Rhipicephalus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.096%; width: 41.9935%; height: 1.38889%;">sanguineus in Mexico and Central America, and A. cajennense
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 48.4848%; width: 34.4771%; height: 1.13636%;">from the southern states of the USA southwards as far as
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.7475%; width: 34.4771%; height: 1.38889%;">Argentina. D. variabilis is the primary vector for RMSF in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.1364%; width: 35.7843%; height: 1.38889%;">USA. A. maculatum is the main vector of R. parkeri in North
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 52.5253%; width: 22.7124%; height: 1.13636%;">America and A. triste in South America.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.0505%; width: 34.3137%; height: 1.38889%;">Transmission: By tick bite or crushing an infected tick or its
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 56.3131%; width: 34.4771%; height: 1.38889%;">feces into a break in the skin or mucous membrane. Also by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.702%; width: 27.7778%; height: 1.38889%;">blood transfusion and, in the laboratory, aerosol.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 60.2273%; width: 34.3137%; height: 1.26263%;">Cycle: Tick–vertrebrate–tick with humans as accidental host.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.6162%; width: 34.4771%; height: 1.38889%;">Animals preferred for feeding depends on tick species and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.005%; width: 8.66013%; height: 1.38889%;">their life stage.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.5303%; width: 25.3268%; height: 1.38889%;">Incubation period: 2–14 days (usually 5–7).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 68.0556%; width: 38.8889%; height: 4.0404%;">Clinical findings: RMSF and R. parkeri rickettsiosis are char-
acterized by fever, myalgia, malaise, headache, and a macu-
lopapular eruption that can involve the palms or soles. R.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 72.096%; width: 34.4771%; height: 1.38889%;">parkeri rickettsiosis is milder than RMSF, and often does not
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.3586%; width: 34.4771%; height: 1.38889%;">require hospitalization. RMSF cases may progress and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.7475%; width: 34.3137%; height: 1.38889%;">develop stupor, delirium, ataxia, or coma; RMSF CFR is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.1364%; width: 34.4771%; height: 1.38889%;">about 7%. Untreated RMSF is often progressive with a CFR
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.399%; width: 40.6863%; height: 2.77778%;">of 20%, which is not the case for untreated R. parkeri rick-
ettsiosis. Most ( &gt; 90%) R. parkeri cases have an eschar, which is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">rare in RMSF. GI symptoms are common in RMSF and rare in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 12.2549%; height: 1.38889%;">R. parkeri disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 20.8333%; width: 34.3137%; height: 1.38889%;">Diagnostic tests: PCR on blood or skin biopsy, or IFA on the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">latter. Serology is unspecific due to cross-reactivity. Until
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 30.719%; height: 1.38889%;">recently, R. parkeri cases were misdiagnosed as RMSF.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">Therapy: Doxycycline is the treatment of choice. Generally,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">treatment is continued for at least 3 days after the patient
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 6.20915%; height: 1.13636%;">is afebrile.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 31.5657%; width: 34.3137%; height: 1.38889%;">Prevention: Search for ticks on the whole body daily and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">remove them without crushing. Use tick repellent on skin
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 33.1699%; height: 1.26263%;">and an acaricide on clothing. There is no effective vaccine.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 41.1765%; height: 2.65152%;">Epidemiology: The distribution of RMSF and R. parkeri rick-
ettsiosis is limited by the tick vector distribution. Average annual
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">RMSF incidence of the disease in the USA was 2.2 cases per
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">million between 1997 and 2002, and approximately 250–1,200
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">cases are reported each year. Many cases of RMSF may actually
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 47.3856%; height: 1.38889%;">have been caused by other rickettsial agents, as was seen with R.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">parkeri. Many rickettsiae of unknown pathogenicity are present in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.3137%; height: 1.38889%;">ticks and new disease causing agents are still being discovered.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">RMSF in the USA follows a seasonal pattern with most cases in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.26263%;">warmer months, when ticks are most active. RMSF cases are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.3137%; height: 1.38889%;">usually found in rural areas, and less commonly in urban areas.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 2.77778%;">Residing in wooded regions or areas with high grass and expo-
sure to dogs increases the risk of RMSF. RMSF is sporadic and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 13.3987%; height: 1.38889%;">rarely occurs in clusters.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 57.0707%; width: 34.1503%; height: 1.38889%;">Map sources: The Spotted Fever, New World map was made
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 34.4771%; height: 2.77778%;">with data from: CDC (www.cdc.gov/ticks/geographic_ dis-
tribution.html), CIESIN (www.ciesin.org/docs/001-613/001-
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">613.html), G.V. Kolonin (2009), recent literature and expert
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 62.6263%; width: 4.90196%; height: 1.26263%;">opinion.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 65.2778%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.5404%; width: 36.9281%; height: 1.38889%;">Dantas-Torres F (2007) Rocky Mountain spotted fever. Lancet
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 67.9293%; width: 15.1961%; height: 1.38889%;">Infect Dis 7(11):724–732.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">Kolonin GV (2009) Fauna of Ixodid Ticks of the World (Acari,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.5808%; width: 26.4706%; height: 1.38889%;">Ixodidae). Moscow. Website: www.kolonin.org.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 71.9697%; width: 34.4771%; height: 1.38889%;">Paddock CD, et al. (2008) Rickettsia parkeri rickettsiosis and its
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.2323%; width: 36.9281%; height: 1.38889%;">clinical distinction from Rocky Mountain spotted fever. Clin
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 74.6212%; width: 15.1961%; height: 1.38889%;">Infect Dis 47:1188–1196.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 76.0101%; width: 34.4771%; height: 1.26263%;">Parola P, et al. (2005) Tick-borne rickettsioses around the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 77.2727%; width: 36.4379%; height: 1.38889%;">world: emerging diseases challenging old concepts. Clin
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 78.6616%; width: 20.098%; height: 1.38889%;">Microbiol Rev 18(4):719–756.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 85.1307%; top: 9.21717%; width: 1.79739%; height: 1.0101%;">93
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/22f27cb2-5aa6-47fe-b6d9-12dfd7c24c18" class="aLF-aPX-aPF-aPE-J3" alt="Page 26 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.kolonin.org" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.kolonin.org" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.kolonin.org&amp;ust=1666162860000000&amp;usg=AOvVaw1guLVkiiLmoxmK43P-kjZ8&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 52.451%; top: 65.1515%; width: 10.4575%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 27 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.7424%; width: 69.281%; height: 2.39899%;">Disease: Rickettsioses, Tick-borne, Old World
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 22.3856%; height: 1.26263%;">Classification: ICD-9 082; ICD-10 A77
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.3137%; height: 2.77778%;">Synonyms: Mediterranean spotted fever (MSF), Israeli spot-
ted fever (ISF), Siberian or North Asian tick typhus (STT/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">NATT), Queensland tick typhus (QTT), Japanese or Oriental
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">spotted fever (JSF/OSF), Astrakhan fever (AF), African tick
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">bite fever (ATBF), Flinders Island spotted fever (FISF), Indian
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 21.2418%; height: 1.38889%;">tick typhus (ITT), Boutonneuse fever.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">Agent: Rickettsia aeschlimannii, R. africae (ATBF), R. australis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 35.2941%; height: 1.38889%;">(QTT), R. conorii caspia (AF), R. conorii conorii (MSF), R. conorii
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 35.6209%; height: 1.38889%;">indica (ITT), R. conorii israelensis (ISF), R. helvetica, R. honei
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 41.3399%; height: 1.38889%;">(FISF), R. japonica (JSF/OSF), R. massiliae, R. sibirica (STT/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">NATT), Gram-negative intracellular bacilli. New agents are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 18.1373%; height: 1.38889%;">still being discovered regularly.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">Reservoir: Hard ticks (Ixodidae). Depending on the tick
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">species, they can acquire infection via feeding on animals
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 2.65152%;">with rickettsemia, or via venereal, transovarial, and trans-
stadial passage. Animals preferred for feeding varies by tick
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">species and their life stage. Hosts include dogs, rodents, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 8.33333%; height: 1.0101%;">other animals.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.4771%; height: 2.77778%;">Vector: Hard ticks (Ixodidae). The brown dog tick (Rhipice-
phalus sanguineus), the principal vector of MSF, ISF, ITT, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">AF, is most active during spring and summer, has a low
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.3137%; height: 2.77778%;">human affinity, and prefers dogs in a peridomestic environ-
ment. The southern African bont tick (Amblyomma hebraeum)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 42.3203%; height: 1.38889%;">and A. africanum are the principal vectors of R. africae in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 35.7843%; height: 1.38889%;">southern Africa. A. hebraeum is an aggressive, human-biting
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">tick and has high rates of rickettsia infection, and ATBF cases
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">therefore often occur in clusters. See key references for further
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 25.3268%; height: 1.38889%;">reading on ticks and tick-borne rickettsioses.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.3137%; height: 1.38889%;">Transmission: By tick bite or crushing an infected tick or its
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">feces into a break in the skin or mucous membrane. Also by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 27.7778%; height: 1.38889%;">blood transfusion and, in the laboratory, aerosol.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">Cycle: There is a natural cycle between ticks and animals with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 15.3595%; height: 1.13636%;">humans as accidental host.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.4771%; height: 1.38889%;">Incubation period: Varies by agent but is generally 7 days
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 17.9739%; height: 1.38889%;">with a range from 1 to 15 days.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 34.4771%; height: 1.26263%;">Clinical findings: Boutonneuse fever (group name for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.2727%; width: 34.3137%; height: 1.38889%;">R.conorii infections: MSF, ISF, ITT), QTT and STT/NATT:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">mild febrile illness that may last up to 2 weeks, eschar at bite
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">site with regional lymphadenopathy (in ISF, eschars are rare),
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">generalized maculopapular erythematous rash on palms on
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.4771%; height: 1.38889%;">soles after 4–5 days. The disease can be severe with a CFR up
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 1.26263%;">to 3%. ATBF is milder than other rickettsioses, fever and rash
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">are less common, multiple eschars may be present with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 16.3399%; height: 1.38889%;">regional lymphadenopathy.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 27.5253%; width: 34.3137%; height: 1.38889%;">Diagnostic tests: PCR on blood or skin biopsy, or IFA on the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 29.2484%; height: 1.38889%;">latter. Serology is unspecific due to cross-reactivity.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">Therapy: Doxycycline is the treatment of choice. Generally,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">treatment is continued for at least 3 days after the patient
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 6.20915%; height: 1.0101%;">is afebrile.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 36.995%; width: 34.3137%; height: 1.38889%;">Prevention: Search for ticks on the whole body daily and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">remove them without crushing. Use tick repellent on skin and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 14.2157%; height: 1.38889%;">an acaricide on clothing.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 42.298%; width: 34.3137%; height: 1.38889%;">Epidemiology: Ecological characteristics of the ticks influence
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 43.6275%; height: 1.38889%;">the epidemiology of tick-borne rickettsioses. In 1910, the first
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 44.7712%; height: 2.65152%;">case of Mediterranean spotted fever (MSF) R. conorii was considered to be the only agent of tick-borne spotted fever
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 35.1307%; height: 1.38889%;">group rickettsioses in Europe and Africa. Similarly, R. sibirica
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 48.0392%; height: 1.38889%;">was thought to be the only agent in Russia and China and R.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">australis in Australia. The reason for this was that diagnosis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">was made by serologic testing, which cross-reacts with other
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">rickettsial species. Due to improved diagnostics, particularly
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">molecular, the understanding of rickettsioses has increased,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">and new agents are being found regularly. Multiple distinct
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 34.3137%; height: 1.38889%;">tick-borne spotted fever group rickettsioses are recognized.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">The name of the agent informs us where the agent was initially
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 34.3137%; height: 1.38889%;">found, but most agents have a more widespread distribution.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 62.5%; width: 34.1503%; height: 1.38889%;">Map sources: The Tick-Borne Rickettioses map (Old World)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 34.4771%; height: 1.26263%;">was made with data obtained from P. Parola et al. (2005),
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">www.kolonin.org, and updated with recent publications and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.5404%; width: 8.98693%; height: 1.38889%;">expert opinion.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 69.3182%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.5808%; width: 34.4771%; height: 1.26263%;">Parola P, et al. (2001) Ticks and tickborne bacterial diseases
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 33.1699%; height: 1.38889%;">in humans: an emerging infectious threat. Clin Infect Dis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.3586%; width: 6.69935%; height: 1.0101%;">32:897–928.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 74.6212%; width: 34.4771%; height: 1.26263%;">Parola P, et al. (2005) Tick-borne rickettsioses around the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 75.8838%; width: 36.4379%; height: 1.38889%;">world: emerging diseases challenging old concepts. Clin
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 77.2727%; width: 20.098%; height: 1.38889%;">Microbiol Rev 18(4):719–756.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 54.5752%; height: 1.26263%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 84.2172%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 85.1307%; top: 9.21717%; width: 1.79739%; height: 1.0101%;">95
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/6afaee0a-aecd-47fd-adeb-50a5e445aade" class="aLF-aPX-aPF-aPE-J3" alt="Page 27 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 28 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 34.8039%; height: 2.39899%;">Disease: Scrub Typhus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.3464%; height: 1.26263%;">Classification: ICD-9 081.2; ICD-10 A75.3
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.4771%; height: 2.77778%;">Syndromes and synonyms: Tsutsugamushi disease, mite-
borne typhus fever, chigger-borne rickettsioses, coastal fever
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 6.69935%; height: 1.26263%;">(Australia).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 2.65152%;">Agent: Orientia tsutsugamushi, obligate intracellular bacte-
rium, before 1995 known as Rickettsia tsutsugamushi. In
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.3137%; height: 5.42929%;">2010, a new species that can cause scrub typhus was discov-
ered in Dubai, O. chuto. Reservoir: Larval stage mites, so-called chiggers from the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.4771%; height: 2.65152%;">genus Leptotrombidium. A number of small rodents, particu-
larly wild rats, are the natural hosts for scrub typhus without
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 10.1307%; height: 1.38889%;">apparent disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.5101%; width: 34.4771%; height: 1.38889%;">Vector: Larval mites. Nymphs and adults do not feed on
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.899%; width: 34.3137%; height: 1.38889%;">vetebrate hosts. The vector has adapted to various ecologies,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.2879%; width: 25.3268%; height: 1.38889%;">including mountainous and tropical regions.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 44.1919%; width: 34.3137%; height: 1.38889%;">Transmission:Bite of infected larval mites (chiggers). There is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.4545%; width: 23.0392%; height: 1.38889%;">no direct person-to-person transmission.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 48.3586%; width: 34.4771%; height: 1.38889%;">Cycle: The mites are infected by feeding on reservoir
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.7475%; width: 34.4771%; height: 2.65152%;">animals (small rodents), and maintain the infection through-
out their life stages. The infection is passed on by transovarial
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 52.399%; width: 34.4771%; height: 1.38889%;">transmission. O. tsutsugamushi are present in the salivary
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.7879%; width: 34.4771%; height: 1.38889%;">glands of the larvae and injected into the host during
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.1768%; width: 4.90196%; height: 1.26263%;">feeding.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.8283%; width: 28.5948%; height: 1.38889%;">Incubation period: 10–12 days, range: 6–21 days.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 60.7323%; width: 34.4771%; height: 1.38889%;">Clinical findings: Typical skin ulcer, eschar, may develop at
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.1212%; width: 34.3137%; height: 1.38889%;">the site of the mite’s bite. Several days later fever, headache,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.3838%; width: 34.4771%; height: 1.38889%;">myalgia, and lymphadenopathy may develop. Dry cough with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 64.7727%; width: 34.4771%; height: 1.38889%;">signs of pneumonitis, jaundice, and meningoencepahlitis may
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.1616%; width: 33.9869%; height: 2.65152%;">occur. Scrub typhus severity and clinical presentation is prob-
ably strain dependent.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.3283%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Serology (IF, EIA); PCR; culture in mice or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.7172%; width: 5.55556%; height: 1.13636%;">cell lines.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.3137%; height: 1.38889%;">Therapy: Tetracycline, doxyxyline. Alternative:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 10.1307%; height: 1.38889%;">chloramphenicol.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 20.8333%; width: 34.3137%; height: 1.38889%;">Prevention: Avoid areas with mites; mite bite prevention by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 33.9869%; height: 2.52525%;">impregnating clothes with miticides; mite elimination in high-
risk areas; no effective vaccine is available.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 26.1364%; width: 34.3137%; height: 1.38889%;">Epidemiology: It is estimated that over one million cases of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">scrub typhus occur each year. Infections most often occur in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">rural areas where diagnostic facilities are limited. Scrub typhus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 41.1765%; height: 4.16667%;">is thought to occur within the so-called ‘Scrub typhus triangle,’ bounded by Siberia (north), Kamchatka Peninsula (east), Paki-
stan (west), and Australia (south). O. tsutsugamushi infection
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">primarily occurs in tropical climate in Asia, but is also found in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">temperate zones and semi-arid climates, including in scrub,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">gardens, forests, beach areas, and mountain deserts. In 2010
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">the western limit of the Orientia genus extended westwards to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 50.3268%; height: 1.38889%;">Dubai when a patient was diagnosed with a new Orientia
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 2.65152%;">species (O. chuto). In southern China, human infections typi-
cally occur in the summer and in northern areas the disease
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">occurs mainly during autumn and winter. The migration of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.0101%;">infested or infected rodents can lead to the establishment of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 11.4379%; height: 1.13636%;">new foci of disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 49.1162%; width: 34.1503%; height: 1.38889%;">Map sources: The Scrub Typhus map is modified from D.J.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">Kelly et al. (2). Data on vector distribution was obtained from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 28.7582%; height: 1.38889%;">the WHO report (1989) (see key references below).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 54.5455%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 40.8497%; height: 1.38889%;">Izzard L, et al. (2010) Isolation of a novel Orientia species
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 57.0707%; width: 35.9477%; height: 1.38889%;">(O. chuto sp. nov.) from a patient infected in Dubai. J Clin
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 58.4596%; width: 15.3595%; height: 1.38889%;">Microbiol 48(12):4404–4409.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">Kelly DJ, et al. (2009) Scrub typhus: the geographic distribution
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 61.2374%; width: 32.6797%; height: 2.65152%;">of phenotypic and genotypic variants of Orientia tsutsuga-
mushi. Clin Infect Dis 48:S203–S230.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 34.4771%; height: 4.0404%;">World Health Organization (1989) Areas of endemic chigger-
borne rickettsiosis and distribution of the Leptotrombidium vec-
tors. Geographical distribution of arthropod-borne diseases and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 67.9293%; width: 33.0065%; height: 1.38889%;">their principal vectors. Unpublished document WHO/VBC/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.3182%; width: 9.15033%; height: 1.0101%;">89.967. Geneva.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">Zhang et al. (2010) Scrub typhus in previously unrecorgnized
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 33.0065%; height: 1.38889%;">areas of endemicity in China. J Clin Microbiol 48:1241–1244.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 85.1307%; top: 9.21717%; width: 1.79739%; height: 1.0101%;">97
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/944696fb-7a51-406e-b2a8-07015537549f" class="aLF-aPX-aPF-aPE-J3" alt="Page 28 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.fao.org/ag/againfo/resources/en/glw/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.fao.org/ag/againfo/resources/en/glw/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.fao.org/ag/againfo/resources/en/glw/&amp;ust=1666162860000000&amp;usg=AOvVaw2q9as0WeOkksmI-W0ug16y&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 59.8039%; top: 50.3788%; width: 26.9608%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 29 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 43.3007%; height: 2.39899%;">Disease: Streptococcus suis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 25.3268%; height: 1.26263%;">Classification: ICD-9 A41.09; ICD-10 A40.8
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.5707%; width: 24.8366%; height: 1.13636%;">Syndromes and synonyms: None.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">Agent: Streptococcus suis, a Gram-positive alpha-hemolytic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 2.77778%;">bacterium, with 35 serotypes based on capsular polysaccha-
ride antigens. The predominant one causing human disease is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.2626%; width: 6.53595%; height: 1.26263%;">serotype 2.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">Reservoir: Pigs; occasionally found in wild boar, horses, dogs,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">cats, and birds. Asymptomatic pigs typically carry the bacteria
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 8.66013%; height: 1.13636%;">in their tonsils.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">Transmission: Through wounds on the skin, including
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">minor abrasions. Infection via ingestion of contaminated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.4771%; height: 1.38889%;">improperly cooked pork products. No human-to-human
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.3838%; width: 8.00654%; height: 1.0101%;">transmission.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 31.6993%; height: 1.38889%;">Cycle: Pig-to-pig, with occasional spill-over to humans.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 29.5752%; height: 1.38889%;">Incubation period: From a few hours up to 3 days.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.3137%; height: 1.38889%;">Clinical findings: Fever and signs of meningitis (headache,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">vomiting, neck stiffness, intolerance of light, and decreased
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">level of consciousness). Hearing loss, generally permanent, in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">around 50% of those infected. Arthritis, pneumonia, and fatal
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 28.1046%; height: 1.38889%;">toxic shock syndrome are possible complications.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Recovery of bacteria from the cerebrospinal
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 37.0915%; height: 2.65152%;">fluid, blood or fluid from arthritic joints; culture; PCR. Strep-
tococcus suis is often misidentified as another streptococcus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 22.0588%; height: 1.38889%;">species and therefore underdiagnosed.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">Therapy: For meningitis or septicemia, prompt treatmentwith
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.4771%; height: 1.38889%;">appropriate antibiotics (penicillin, ceftriaxon) will lead to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">recovery. Specific organ involvement like the heart, requires
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">specialist treatment. Early treatment with dexamethason can
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 17.6471%; height: 1.38889%;">reduce the risk of hearing loss.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 16.7929%; width: 34.3137%; height: 1.38889%;">Prevention: During outbreaks: strict control on animal
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">movements and slaughtering; health education of everyone
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">who butchers, prepares, and cooks pork, including in their
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.4771%; height: 1.38889%;">homes; wearing gloves to handle raw or uncooked pork,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">careful washing of hands and utensils. Adequate cooking
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 2.77778%;">essential; WHO recommends cooking pork to reach an inter-
nal temperature of 70 C, or until the juices are clear rather
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 6.20915%; height: 1.38889%;">than pink.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 28.9141%; width: 34.3137%; height: 1.38889%;">Epidemiology: Rarely reported in the Americas and Europe,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">sporadic in parts of Southeast Asia, especially Thailand,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">China, and Vietnam. Most important risk factor is contact
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">with pigs or uncooked pig products, typically by farmers,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 2.52525%;">veterinary personnel, abattoir workers, and butchers. Fur-
thermore, in several Asian countries it is common to consume
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">uncooked pork products, like blood, which is a risk for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 2.77778%;">acquiring the disease. Individuals who are immunosup-
pressed, including those who have been splenectomized,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.26263%;">are also at increased risk. Since S. suis is often misidentified,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">S. suis may be more common in certain parts of the world with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 10.9477%; height: 1.38889%;">high pig densities.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 46.3384%; width: 34.3137%; height: 1.38889%;">Map sources: The Streptococcus suis map was made by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">geocoding all reported human cases in the medical literature
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">up to 2010. The pig density data is obtained from FAO,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.3137%; height: 1.38889%;">available at: www.fao.org/ag/againfo/resources/en/glw/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 6.86275%; height: 1.13636%;">home.html.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 54.5455%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">Gottschalk M, et al. (2007) Streptococcus suis infections in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 57.0707%; width: 33.1699%; height: 1.38889%;">humans: the Chinese experience and the situation in North
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 58.4596%; width: 29.5752%; height: 1.38889%;">America. Anim Health Res Rev 8(1):29–45.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">Lun ZR, et al. (2007) Streptococcus suis, an emerging zoonotic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 61.1111%; width: 24.8366%; height: 1.38889%;">pathogen. Lancet Infect Dis 7(3):201–209.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 62.5%; width: 34.4771%; height: 1.38889%;">Mai NT, et al. (2008) Streptococcus suis meningitis in adults in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 63.8889%; width: 23.2026%; height: 1.38889%;">Vietnam. Clin Infect Dis 46:659–667.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">Wertheim H, et al. (2009) Streptococcus suis: an emerging
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 66.5404%; width: 23.6928%; height: 1.38889%;">pathogen. Clin Infect Dis 48:617–625.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 85.1307%; top: 9.21717%; width: 1.79739%; height: 1.0101%;">99
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/442a90db-f377-4992-a24e-c1329f4ddf76" class="aLF-aPX-aPF-aPE-J3" alt="Page 29 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://apps.who.int/immunization_monitoring/en/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://apps.who.int/immunization_monitoring/en/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://apps.who.int/immunization_monitoring/en/&amp;ust=1666162860000000&amp;usg=AOvVaw1edKFLr5riCHPJf4qyHEHY&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 56.2092%; top: 66.5404%; width: 29.7386%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 30 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 25.9804%; height: 2.0202%;">Disease: Tetanus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 27.9412%; height: 1.26263%;">Classification: ICD-9 037, 771.3; ICD-10 A33–35
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 24.8366%; height: 1.38889%;">Syndromes and synonyms: Lockjaw.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 34.3137%; height: 1.38889%;">Agent: Clostridium tetani, a Gram-positive, spore-forming
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">anaerobic bacterium. The spores can remain viable in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">environment for years. C. tetani produces a highly potent
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">exotoxin, tetanospasmin, which is responsible for the clinical
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 11.1111%; height: 1.13636%;">features of tetanus.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 33.9869%; height: 1.26263%;">Reservoir: Intestinal tract of animals and humans, and soil.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.4771%; height: 1.26263%;">Route of transmission: Contamination of wounds with soil,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">dust or animal feces that contain C. tetani spores. Puncture
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">wounds are most commonly associated with tetanus but it can
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.4771%; height: 2.65152%;">result from even minor abrasions. Through injection of con-
taminated street drugs. Neonatal tetanus results from infection
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.4771%; height: 2.77778%;">of the umbilical cord, either through the use of unclean instru-
ments to cut the cord or through dressing the stump with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 13.8889%; height: 1.13636%;">contaminated materials.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.3137%; height: 1.38889%;">Cycle: Tetanus spores enter the body through wounds and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">under anaerobic conditions, the spores germinate and produce
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">toxin. The toxins are disseminated via the blood and lymphatic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">system and bind to nerve endings, preventing the release of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 33.9869%; height: 2.52525%;">inhibitory neurotransmitters. This results in unopposed skele-
tal muscle contraction.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">Incubation period: Most cases occur within 14 days (range:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">1 day to months). Shorter incubation periods are associated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">with more heavily contaminated wounds and an inoculation
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">site closer to the central nervous system. Neonatal tetanus has
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.3137%; height: 1.38889%;">a shorter incubation period, with an average of around 6 days.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.3137%; height: 1.38889%;">Clinical findings: The principal clinical feature of tetanus is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">painful skeletal muscle spasms and rigidity. Three clinical
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">forms are recognized. The commonest is generalized tetanus,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">which usually begins with spasms of the facial muscles and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">spreads in a descending pattern. On presentation patients
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">commonly have ‘lockjaw’ (trismus), neck stiffness, difficulty
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">swallowing, and abdominal rigidity. Generalized spasms may
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.4771%; height: 1.38889%;">result in an arched posture (opisthotonus). Other symptoms
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 34.3137%; height: 1.38889%;">include elevated temperature, blood pressure, and sweating.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.3137%; height: 1.38889%;">Localized tetanus presents as localized spasms of muscles
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 34.4771%; height: 1.26263%;">around the entry wound. Cephalic tetanus is rare
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.2727%; width: 34.4771%; height: 1.26263%;">and results from infection in the head and neck, and affects
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 78.6616%; width: 8.49673%; height: 1.13636%;">cranial nerves.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 16.7929%; width: 34.3137%; height: 1.38889%;">Diagnostic tests: The diagnosis is based on characteristic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">clinical features. The bacterium is usually not cultured from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">wounds and a positive culture does not confirm the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 6.20915%; height: 1.38889%;">diagnosis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">Therapy: Clean wounds, perform debridement and remove
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">foreign objects. A one-off dose of im or iv human tetanus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">immunoglobulin removes unbound toxin but does not affect
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">bound toxin. Metronidazole in large doses for 7–14 days to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">eradicateC. tetani infection. Since the effect of bound toxin may
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.3137%; height: 1.38889%;">last for 4–6 weeks, prolonged supportive care is required.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.3137%; height: 1.38889%;">Tetanus does not induce immunity. Vaccination with tetanus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 26.4706%; height: 1.38889%;">toxoid is therefore indicated during treatment.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 35.6061%; width: 34.3137%; height: 1.26263%;">Prevention: Immunization with tetanus toxoid (inactivated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">tetanus toxin). Immunization of pregnant women protects
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 17.1569%; height: 1.13636%;">infants from neonatal tetanus.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 41.0354%; width: 34.3137%; height: 1.38889%;">Epidemiology: Tetanus is globally distributed but is more
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">common in highly populated agricultural areas, and in warm
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">and wet regions. In the late 1980s tetanus was estimated to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">cause around 1 million deaths per year, mostly in newborn
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 2.77778%;">infants. The current distribution of cases represents the cov-
erage of tetanus immunization in children and adults. In
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">countries with good vaccine coverage in children, adult
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">cases may still be common, as natural immunity plays no
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">role in the epidemiology of tetanus. The DTP3 Vaccination
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">Coverage map shows coverage with the third dose of a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">tetanus-containing vaccine in childhood. The elimination
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 34.4771%; height: 2.65152%;">of neonatal tetanus was set as a goal in 1989 and by mid-
2010 neonatal tetanus had been eliminated in 79% (153/193)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 34.6405%; height: 1.38889%;">of WHO Member States. However, since C. tetani will always
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">remain present in nature, tetanus will always remain a threat,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">and high levels of immunization must be maintained
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 62.5%; width: 7.18954%; height: 1.38889%;">indefinitely.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 65.1515%; width: 34.3137%; height: 1.38889%;">Map sources: Data for the Tetanus map was obtained from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.5404%; width: 33.8235%; height: 1.38889%;">WHO http://apps.who.int/immunization_monitoring/en/.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 69.3182%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.5808%; width: 39.0523%; height: 1.38889%;">Thwaites CL, et al. (2003) Preventing and treating tetanus. Br
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 14.2157%; height: 1.26263%;">Med J 326(7381):117–118.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 73.2323%; width: 37.0915%; height: 1.38889%;">Roper MH, et al. (2007) Maternal and neonatal tetanus. Lancet
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 74.6212%; width: 12.0915%; height: 1.26263%;">370(9603):1947–1959.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 75.8838%; width: 34.4771%; height: 1.38889%;">World Health Organization (2009) State of the World’s Vaccines
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 77.2727%; width: 33.1699%; height: 1.26263%;">and Immunization, 3rd edn. Geneva. WHO, UNICEF, World
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 78.6616%; width: 3.43137%; height: 1.13636%;">Bank.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">101
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/e538f97e-5e7d-40c1-bdde-7fe935065151" class="aLF-aPX-aPF-aPE-J3" alt="Page 30 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.who.int/blindness/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.who.int/blindness/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.who.int/blindness/&amp;ust=1666162860000000&amp;usg=AOvVaw3CnIh6nhn7Se3rSkcUsemJ&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 71.8954%; top: 57.0707%; width: 14.8693%; height: 1.26263%;"></a><a href="http://www.iceh.org.uk/display/WEB/Global" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.iceh.org.uk/display/WEB/Global" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.iceh.org.uk/display/WEB/Global&amp;ust=1666162860000000&amp;usg=AOvVaw24k9TsT4n2e5wr9iaVyy40&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 52.451%; top: 61.2374%; width: 23.0392%; height: 1.26263%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 31 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 29.085%; height: 2.0202%;">Disease: Trachoma
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 23.366%; height: 1.26263%;">Classification: ICD-9 076.1; ICD-10 A71
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.3137%; height: 1.38889%;">Syndromes and synonyms: Chronic follicular conjunctivitis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 42.4837%; height: 2.65152%;">Agent: Repeated re-infection with Chlamydia trachomatis ser- ovars A, B, Ba, and C, an obligate intracellular bacterium.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">The genital serovars D to K can infect the conjunctiva, but
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">generally do not lead to blindness as they cause self-limited
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 21.0784%; height: 1.38889%;">infections that typically do not recur.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.303%; width: 14.5425%; height: 1.0101%;">Reservoir: Humans.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">Vector: Flies contribute to the spread of ocular serovars of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.2172%; width: 34.4771%; height: 5.42929%;">C. trachomatis. Transmission: Repeated direct contact with infected secre-
tions from infected individual (mainly from eye or nose); also
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.3137%; height: 1.38889%;">by hands and fomites (shared clothes, towels or bedlinen).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">Flies also play a role in the transmission. High risk of infection
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 22.7124%; height: 1.13636%;">in close contacts of infected individuals.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.3137%; height: 1.38889%;">Incubation Period: 5 to 12 days for conjunctivitis; years to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.3137%; height: 1.38889%;">decades for trichiasis and eventually corneal damage and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">blindness. Repeated re-infection over many years is required
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.3137%; height: 1.38889%;">for deposition of sufficient conjunctival scar to lead to the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">blinding complications; host genetic factors are probably also
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 6.37255%; height: 1.38889%;">important.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">Clinical findings: Self-limiting conjunctivitis, including
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.3137%; height: 2.65152%;">watery or mucopurulent discharge. Typical findings are lym-
phoid follicles and papillary hypertrophy. Repeated infections
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">lead to scarring of the conjunctiva and trichiasis. Trichiasis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 2.65152%;">damages the corneal surface, resulting in keratitis, vasculari-
zation of the cornea, and impaired defence against secondary
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 33.9869%; height: 2.77778%;">bacterial and fungal infection. Corneal damage produces cor-
neal scar, leading to blindness.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Clinical diagnosis of active disease by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 2.65152%;">presence of follicles and papillae on the conjunctival epithe-
lium of the upper eyelid. Trichiasis and corneal opacity are also
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">diagnosed clinically. Presence or absence of infecting agent (by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.4771%; height: 2.65152%;">any method, including PCR) has poor correlation with pres-
ence or absence of disease or its severity; serology has no
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 9.80392%; height: 1.38889%;">diagnostic value.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.3137%; height: 1.38889%;">Therapy: Individuals with trichiasis require eyelid surgery.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 2.65152%;">Active disease requires antibiotics: azithromycin or tetracy-
cline eye ointment are recommended. Treatment of individual
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.4771%; height: 3.91414%;">cases has little impact, because of rapid reinfection. Commu-
nity management using the SAFE strategy (Surgery for trichi-
asis, Antibiotics to clear infection, Facial cleanliness and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">Environmental improvement [water and sanitation] to reduce
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">transmission) is the recommended means for control in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">endemic areas; this strategy includes both treatment and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 6.86275%; height: 1.38889%;">prevention.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 31.5657%; width: 34.3137%; height: 1.38889%;">Prevention: Community management by SAFE strategy (see
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.26263%;">above). The WHO Alliance for the Global Elimination of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">Trachoma (GET 2020) seeks to eliminate trachoma as a public
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 13.8889%; height: 1.38889%;">health problem by 2020.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 38.2576%; width: 34.3137%; height: 1.38889%;">Epidemiology: Trachoma is the leading infectious cause of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">blindness world wide and is generally a disease of poor rural
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">communities. These communities are often in hot and dry
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">regions. It is estimated that there are about 41 million people
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">with active trachoma and 8 million with trichiasis. Highest
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">prevalences are found in Sub-Saharan Africa. There is a high
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">burden in Ethiopia and Sudan, where active trachoma in some
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">communities can be found in &gt; 50% of 1–9-year-old children
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.13636%;">and trichiasis in &gt; 19% of adults. In Asia and Central and South
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.26263%;">America, the distribution ismore focal. Overall the incidence of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">trachoma is declining and the disease has disappeared from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.3137%; height: 1.38889%;">Europe and North America due to improved living conditions.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 55.8081%; width: 34.1503%; height: 1.38889%;">Map sources: Data for the Active Trachoma map (all ages) is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 34.3137%; height: 1.26263%;">obtained from WHO, available at: www.who.int/blindness/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">data_maps/en/. More detailed maps are available from the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 34.3137%; height: 1.38889%;">International Center of Eye Health, available at: https://
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.2374%; width: 45.2614%; height: 1.26263%;">www.iceh.org.uk/display/WEB/Global distribution of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.9216%; top: 62.5%; width: 18.1373%; height: 1.38889%;">trachoma maps.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 65.2778%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">Burton MJ, et al. (2010) The global burden of trachoma: a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 67.9293%; width: 25.1634%; height: 1.38889%;">review. PLoS Negl Trop Dis 3(10):e46.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.1919%; width: 34.3137%; height: 1.38889%;">Hu VH, et al. (2010) Epidemiology and control of trachoma:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">systematic review. Trop Med Int Health 15(6):673–691.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 71.9697%; width: 34.4771%; height: 1.38889%;">Polack S, et al. (2005) Mapping the global distribution of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.2323%; width: 18.7909%; height: 1.13636%;">trachoma. WHO Bull 83:913–919.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 74.6212%; width: 32.5163%; height: 1.38889%;">Wright HR, et al. (2007) Trachoma. Lancet 371:1945–1954.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">103
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/7c7b5ec3-0ac6-40fd-86e0-b49c9d4e04d3" class="aLF-aPX-aPF-aPE-J3" alt="Page 31 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 32 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 33.3333%; height: 2.0202%;">Disease: Tuberculosis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 27.6144%; height: 1.26263%;">Classification: ICD-9 010-018; ICD-10 A15–A19
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">Syndromes and synonyms: Consumption, white plague,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 2.28758%; height: 1.13636%;">TB.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 45.915%; height: 1.38889%;">Agent: Mycobacterium tuberculosis complex, including M.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 37.9085%; height: 2.65152%;">tuberculosis, M. africanum, M. canetti, and M. bovis, slow grow-
ing acid-fast rods. M. bovis is not discussed further.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">Reservoir: Mainly humans; rarely non-human primates and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 9.47712%; height: 1.13636%;">other mammals.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.3137%; height: 1.38889%;">Transmission: Person-to-person via inhalation of infectious
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">aerosols from cases with pulmonary TB, particularly after
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">prolonged exposure over time. Extrapulmonary tuberculosis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.4771%; height: 1.38889%;">is generally not communicable. HIV-infected individuals are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 15.3595%; height: 1.38889%;">more likely to develop TB.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 2.65152%;">Incubation period: 2–10 weeks to primary lesion or tubercu-
lin-positive skin test; around 10% progresses to active disease
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">annually, but it may remain latent for decades to lifelong,. This
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 33.9869%; height: 2.65152%;">percentage is higher in children and in HIV-infected or other-
wise immune-suppressed individuals.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">Clinical findings: TB is a chronic disease with a gradual
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 2.77778%;">onset. Pulmonary lesions occur in 70% of cases, extrapul-
monary (meningitis, skeletal, any other organ, disseminated)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">in 30%. Extrapulmonary TB is more common in children &lt;5
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">years. Early symptoms of pulmonary TB are weight loss,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">fever, and night sweats, progressing to cough, chest pain, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">hemoptysis. Findings of extrapulmonary TB depends
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 33.9869%; height: 2.77778%;">on infected organ(s), and may present together with pulmo-
nary TB.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.4771%; height: 1.26263%;">Diagnostic tests: Direct: acid fast smear/culture and PCR of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 2.65152%;">sputum and other body fluids, depending on clinical presen-
tation; serological: tuberculin skin test (Mantoux); interferon
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">gamma release assays (IGRAs). Culture in liquid media is gold
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">standard and allows for antibiotic susceptibility testing but
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">takes weeks to months; PCR allows for early detection, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">recent assays include detection of resistance-associated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 6.37255%; height: 1.13636%;">mutations.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.4771%; height: 1.38889%;">Therapy: WHO recommended regimen (Directly Observed
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 34.3137%; height: 1.26263%;">Treatment Short-course or DOTS) is 2 months of rifampicin,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.2727%; width: 34.4771%; height: 1.38889%;">isoniazid, pyrazinamide, and ethambutol, followed by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 2.77778%;">4 months of rifampicin plus isoniazid. If resistance to rifampi-
cin or isoniazid is suspected, treatment must continue with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 33.9869%; height: 2.77778%;">second-line drugs for at least 18 months. Drug-resistant tuber-
culosis (MDR and XDR-TB) require special regimens.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 22.2222%; width: 40.3595%; height: 1.13636%;">MDR-TB is defined as resistance to two main first-line TB
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">drugs: isoniazid and rifampicin. XDR-TB (Extensive Drug
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 44.4444%; height: 2.65152%;">Resistant TB) is defined as MDR-TB with resistance to fluor- oquinolones and one second-line injectable drug.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 28.9141%; width: 34.3137%; height: 1.38889%;">Prevention: Primary: BCG vaccination of children protects
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">against disseminated disease. Secondary: intensive search for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 2.77778%;">and treatment of source cases; contact investigation and treat-
ment of positive cases with chemoprophylaxis. WHO has
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">established a ‘Stop TB Partnership’ program to control
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 9.15033%; height: 1.13636%;">TB world wide.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 38.2576%; width: 34.3137%; height: 1.38889%;">Epidemiology: TB is a major cause of death and disability
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">world wide, especially in developing countries. Morbidity
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.3137%; height: 1.38889%;">and mortality rates increase with age, and are higher in males.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">In regions of high incidence, morbidity peaks in adults of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">working age. Morbidity is higher in urban populations,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">among the poor, and in closed institutions such as prisons
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">and military barracks. There were an estimated 9.27 million
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">incident cases of TB in the world in 2007 (14% HIV positive),
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 2.65152%;">an almost 50% increase from 1990, and an estimated one-
third of the world’s population is either latently or actively
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.26263%;">infected with TB. Most of the cases in 2007 were in Asia (55%)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 10.4575%; height: 1.26263%;">and Africa (31%).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 54.4192%; width: 33.1699%; height: 1.38889%;">MDR-TB is a serious problem in Russia, former Russian
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">republics, India and China. In 2007 there were an estimated 0.5
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">million MDR-TB cases. By 2008, 55 countries reported at least
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 10.4575%; height: 1.13636%;">one XDR-TB case.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 61.2374%; width: 34.3137%; height: 1.26263%;">Map sources: The Tuberculosis map was made with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 62.5%; width: 34.3137%; height: 1.26263%;">incidence and resistance data from WHO, available at www.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">who.int/tb/country/global_tb_database/en/ and WHO
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 10.9477%; height: 1.38889%;">report No. 4 (2008).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 67.9293%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">Dye C, et al. (2008)Measuring tuberculosis burden, trends, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.5808%; width: 33.1699%; height: 1.38889%;">the impact of control programmes. Lancet Infect Dis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 6.04575%; height: 1.13636%;">8:233–423.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 73.2323%; width: 34.4771%; height: 1.38889%;">World Health Organization (2008) Anti-Tuberculous Drug
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 74.6212%; width: 29.5752%; height: 1.38889%;">Resistance in the World. WHO Report No. 4, Geneva.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 76.0101%; width: 34.4771%; height: 1.26263%;">Wright A, et al. (2009) Epidemiology of antituberculosis drug
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 77.399%; width: 23.366%; height: 1.0101%;">resistance 2002–07. Lancet 373:1861–1873.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">105
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/01095412-cfd1-4911-b015-4b68d1309012" class="aLF-aPX-aPF-aPE-J3" alt="Page 32 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.cdc.gov/tularemia/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.cdc.gov/tularemia/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.cdc.gov/tularemia/&amp;ust=1666162860000000&amp;usg=AOvVaw2uauUveRknqXMmbzje4yVM&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 54.2484%; top: 65.1515%; width: 15.0327%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 33 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 29.085%; height: 2.0202%;">Disease: Tularemia
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 22.3856%; height: 1.26263%;">Classification: ICD-9 021; ICD-10 A21
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">Syndromes and synonyms: Rabbit fever, deerfly fever, hare
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 28.7582%; height: 1.38889%;">fever, lemming fever, Ohara fever, Francis disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.3137%; height: 1.38889%;">Agent: Francisella tularensis tularensis (Type A), F. tularensis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">holarctica (Type B), F. tularensis mediasiatica, Gram-negative
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.3137%; height: 1.38889%;">non-motile intracellular coccobacilli that infect macrophages.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">Type A is highly virulent and divided into two clades: A.I
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">and A.II. F. tularensis is considered a potential biological
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 25.4902%; height: 1.38889%;">warfare agent. F. novicida is rarely virulent.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">Reservoir: Lagomorphs and rodents (ground squirrels) for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.2172%; width: 34.4771%; height: 1.38889%;">F. tularensis (Types A and B) in North America. Aquatic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.4771%; height: 1.26263%;">rodents (beavers, muskrats) in North America, hares and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 39.7059%; height: 1.38889%;">small rodents in northern Eurasia, for F. holarctica (Type B).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 20.098%; height: 1.38889%;">The bacterium can persist in water.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 42.1569%; height: 1.38889%;">Vector: The primary vectors are ticks and biting flies (deer
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 41.5033%; height: 1.38889%;">flies, tabanids). In central Europe: Dermacentor reticulatus and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 38.5621%; height: 1.38889%;">Ixodes ricinus are important vectors. In eastern USA, D.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">variabilis is the most important vector. In western USA, biting
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">flies are the predominant vectors in arid regions. In Russia,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 30.8824%; height: 1.38889%;">transmission is both by ticks (Ixodes) and mosquitoes.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">Transmission: By arthropod bite handling or processing of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.4771%; height: 2.77778%;">infected animal carcasses or tissues, by ingestion of contami-
nated water, soil or food, or by inhalation of contaminated dust
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 6.69935%; height: 1.13636%;">or aerosols.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 35.9477%; height: 1.38889%;">Cycle: Generally enzootic cycles of F. tularensis are unnoticed,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 16.5033%; height: 1.13636%;">humans are accidental hosts.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 32.8431%; height: 1.26263%;">Incubation period: 1–14 days; most commonly 3–5 days.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 1.26263%;">Clinical findings: Tularemia has six characteristic clinical
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.3137%; height: 2.77778%;">syndromes, depending on the site of infection: ulcerogland-
ular (commonest), glandular, oropharyngeal, pneumonic,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">oculoglandular, and typhoidal. Clinical signs include sudden
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">onset of high fever, chills, generalized aches, and chronic ulcer
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">at the bite site (ulceroglandular). From the primary site,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.4771%; height: 2.65152%;">lymphatic spread to regional lymphnodes. Further hemato-
geneous dissemination to other organs. CFR for Type A
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.4771%; height: 1.38889%;">(ulcero) glandular disease is &lt; 2% if treated promptly (5 to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 34.4771%; height: 1.26263%;">30% if not treated). In the acute septic form (typhoidal) of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.2727%; width: 34.4771%; height: 1.38889%;">the disease, lymphadenopathy and ulcer are absent, and the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 78.6616%; width: 34.4771%; height: 2.65152%;">CFR is high (30–60%). Oculoglandular disease is rare. Inges-
tion of infected material may result in oropharyngeal or GI
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">tularemia. In the oropharyngeal form signs are: throat pain,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">large tonsils, pseudomembrane, and enlarged cervical lymph
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">nodes. Symptoms in GI tularemia range from mild persistent
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.4771%; height: 1.13636%;">diarrhea to extensive intestinal ulcers and death. Pneumonic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">tularemia occurs after inhalation of bacteria, or secondary
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">from other entry sites and may progress to severe pneumonia,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 17.3203%; height: 1.38889%;">respiratory failure, and death.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 27.5253%; width: 34.3137%; height: 1.38889%;">Diagnostic tests: Culture (cysteine-enriched media) or PCR
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">on specimens of affected tissues. Blood cultures are often
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">negative. Testing should be done in a BSL-3 facility. Serology
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 18.1373%; height: 1.13636%;">on acute and convalescent sera.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">Therapy: Streptomycin is recommended, with gentamicin as
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.3137%; height: 1.38889%;">an alternative. Tetracyclines may be used for less severe cases.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 38.2576%; width: 34.3137%; height: 1.38889%;">Prevention: Wear impermeable gloves when handling or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">skinning rodents or lagomorphs; cook wild game well; avoid
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">drinking water from untreated sources; wear long-sleeved
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 33.3333%; height: 1.38889%;">clothes and use repellent to protect against arthropod bites.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 45.0758%; width: 34.3137%; height: 1.38889%;">Epidemiology: F. tularensis tularensis Type A is found in North
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.26263%;">America and the distributionis associatedwith wild rabbits, ticks,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">and tabanid flies. Type B is found throughout the northern
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">hemisphere, mainly in Eurasia and is associated with multiple
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 2.65152%;">rodent species, hares, ticks, blood-feeding mosquitoes, and taba-
nid flies. There is also an association with water bodies (streams)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">and flooding. In the USA, around 200 human tularemia cases are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">reported each year,mostly in rural areas during summer months.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">In Europe, most cases are reported from Sweden, Finland, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">Russia, and is recently emerging in Spain. Rural populations are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">most at risk (e.g. farmers, hunters). Human outbreaks often
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 20.4248%; height: 1.13636%;">coincide with wild animal outbreaks.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 62.5%; width: 34.3137%; height: 1.38889%;">Map sources: The Tularemia map was modified from P. Keim
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">et al. (2007) with a US map inset with data from CDC, available
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 17.1569%; height: 1.38889%;">at: www.cdc.gov/tularemia/.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 67.9293%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.1919%; width: 34.3137%; height: 1.38889%;">Dennis DT, et al. (2001) Tularemia as a biological weapon:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.5808%; width: 46.0784%; height: 1.38889%;">medical and public health management. JAMA 285(21):
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 6.37255%; height: 1.13636%;">2763–2773.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 73.2323%; width: 38.7255%; height: 1.38889%;">Ellis J, et al. (2002) Tularemia. Clin Microb Rev 15(4):631–646.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 74.6212%; width: 34.4771%; height: 1.38889%;">Keim P, et al. (2007) Molecular epidemiology, evolution, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 75.8838%; width: 29.4118%; height: 1.38889%;">ecology of Francisella. Ann NY Acad Sci 1105:30–66.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 77.2727%; width: 36.2745%; height: 2.77778%;">Vogler AJ, et al. (2009) Phylogeography of Francisella tular-
ensis: global expansion of a highly fit clone. J Bacteriol
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 80.0505%; width: 10.1307%; height: 1.26263%;">191(8):2474–2484.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 54.5752%; height: 1.26263%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 84.2172%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">107
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/8abf372b-df57-4574-8ffd-ef61a69537fc" class="aLF-aPX-aPF-aPE-J3" alt="Page 33 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 34 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 35.4575%; height: 2.39899%;">Disease: Typhoid Fever
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 23.366%; height: 1.26263%;">Classification: ICD-9 002.0; ICD-10 A01
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.3137%; height: 1.38889%;">Syndromes and synonyms: Enteric fever, typhus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 7.67974%; height: 1.13636%;">abdominalis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 35.2941%; height: 1.38889%;">Agent: Salmonella enterica enterica serovar Typhi (S. Typhi), a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 41.1765%; height: 2.65152%;">Gram-negative bacillus. S. Typhi belongs to Salmonella ser-
ogroup D and possesses somatic antigen O9, a single flagellar
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">antigen Hd, and virulence antigen Vi. S. Paratyphi A can cause
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 8.98693%; height: 1.13636%;">similar disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">Reservoir: Mainly humans; rarely domestic animals. Humans
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.4771%; height: 1.26263%;">can be short-term carriers after an infection (10%) or become
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">chronic carriers in the biliary tract (1–5%), shedding viable
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">bacteria in the stool. Chronic carriers are mainly adults with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.4771%; height: 1.38889%;">pre-existingbiliary tractpathology.Urinary carriagemay occur
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 41.3399%; height: 1.13636%;">in areas where Schistosoma haematobium is endemic.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 21.0784%; height: 1.13636%;">Vector: Flies can contaminate foods.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 1.26263%;">Transmission: Via fecal contaminated water, drinks or food
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">from infected individuals or carriers; transmission may also
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 21.732%; height: 1.13636%;">occur in men who have sex with men.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.4771%; height: 1.26263%;">Cycle: Infected individuals shed bacteria into environment,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">contaminating water and food products that are subsequently
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 15.3595%; height: 1.38889%;">ingested by other humans.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 31.5359%; height: 1.38889%;">Incubation period: 7–14 days, may be up to 2 months.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 42.4837%; height: 4.0404%;">Clinical findings: Common presenting symptoms are: influ- enza-like symptoms (fever, dry cough, chills, myalgia), head-
ache, malaise, anorexia, nausea, abdominal discomfort with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.4771%; height: 2.65152%;">abdominal tenderness, coated tongue, and hepatosplenome-
galy. Adults may have constipation, while young children and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">HIV patients more often have diarrhea. In 5–30% a rash is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">present on the abdomen and chest. Children &lt;5 years regularly
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.3137%; height: 4.0404%;">have unspecific symptoms and remain undiagnosed. Compli-
cations occur in 10–15%, including GI bleeding (most com-
mon), intestinal perforation, and typhoid encephalopathy.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 23.6928%; height: 1.38889%;">CFR is approximately 2% (range: 0–18%).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 34.3137%; height: 1.38889%;">Diagnostic tests: Bone marrow culture is the gold standard;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.4771%; height: 1.38889%;">blood culture; stool culture; serology; Widal test performance
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 18.3007%; height: 1.26263%;">is poor and should not be used.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">Therapy: Fluorquinolones are recommended in the absence of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">resistance. Resistance to ampicillin, chloramphenicol, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.3137%; height: 2.77778%;">cotrimoxazole is widespread and resistance to older genera-
tion quinolones and third-generation cephalosporins is rising.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">Both gatifloxacin and azithromycin can be recommended for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">the treatment of uncomplicated cases in areas with MDR or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">nalidixic acid resistance. Third-generation cephalosporins is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">used for severe cases. Surgery for abdominal complications
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 27.5253%; width: 34.3137%; height: 1.38889%;">(e.g. perforation). Dexamethason is recommended for severe
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 29.1667%; width: 34.4771%; height: 3.78788%;">cases. Prevention: Vaccination of risk groups; eradicating carriage;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">hygiene; sanitation; access to clean water; pasteurization of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">dairy products; quality control and hygiene procedures
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">for the food industry; exclude typhoid carriers from food
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 5.88235%; height: 1.38889%;">handling.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.8039%; height: 2.77778%;">Epidemiology: In 2000 it was estimated there were approx-
imately 21,650,000 new S. Typhi cases and 216,500 deaths,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">with large regional variability. These estimates are based
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 2.77778%;">on limited data from mainly countries with a high inci-
dence of disease. Typhoid fever incidence is highest among
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">infants and children living in South Central and Southeast
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">Asia and South Africa. Two seasonality patterns are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">observed: (1) higher incidence in warmer dry months
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">leading to higher bacterial loads in the water, and (2)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">higher incidence in the rainy season, due to spillover
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">from sewage to drinking water. Declines are seen in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">regions were living conditions have improved, mainly
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 34.4771%; height: 1.26263%;">due to access to clean water and sanitation (see Water
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 12.7451%; height: 1.38889%;">and Sanitation map).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 59.8485%; width: 34.3137%; height: 1.38889%;">Map sources: The Typhoid Fever map is modified from JA
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.2374%; width: 8.49673%; height: 1.26263%;">Crump (2004).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 63.8889%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 37.9085%; height: 1.38889%;">Crump JA (2004) The global burden of typhoid fever. Bull
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 66.5404%; width: 22.3856%; height: 1.38889%;">World Health Org 82:346–353.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">Crump JA (2010) Global trends in typhoid and paratyphoid
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.1919%; width: 21.2418%; height: 1.38889%;">fever. Clin Infect Dis 50:241–246.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.5808%; width: 42.1569%; height: 1.38889%;">Ochiai RL (2008) A study of typhoid fever in five Asian
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 33.0065%; height: 1.38889%;">countries: disease burden and implications for controls.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.2323%; width: 25%; height: 1.38889%;">Bull World Health Org 86:260–268.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 74.6212%; width: 42.1569%; height: 1.38889%;">Parry CM, et al. (2002) Typhoid fever. N Engl J Med 347(22):
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 76.0101%; width: 6.37255%; height: 1.0101%;">1770–1782.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.0808%; width: 40.6863%; height: 1.38889%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">109
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/26c02c90-afb7-4e6c-b6dd-f250cf63334d" class="aLF-aPX-aPF-aPE-J3" alt="Page 34 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 35 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 35.9477%; height: 2.39899%;">Disease: Blastomycosis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 23.2026%; height: 1.26263%;">Classification: ICD-9 116.0; ICD-10 B40
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">Synonyms: North American blastomycosis, Gilchrist disease
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 41.5033%; height: 1.38889%;">Agent: Blastomyces dermatitidis (teleomorph Ajellomyces
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">dermatitidis), a dimorphic fungus: grows as a pathogenic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.3137%; height: 1.38889%;">yeast at body temperature and as a mold in the environment.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.3137%; height: 1.38889%;">Reservoir: Not completely understood: moist environments
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">close to waterways, in forest or under flooring, also sandy and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">acidic soil and rotten vegetation. Bird excreta have also been
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">implicated as a potential reservoir. Dogs are more commonly
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 28.5948%; height: 1.13636%;">infected than humans but do not transmit disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">Transmission:Inhalation of spores from disturbed soil. There
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 20.7516%; height: 1.38889%;">is no person-to-person transmission.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.3137%; height: 1.38889%;">Cycle: Environment (soil) to human. Fungal spores are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">inhaled and convert to the pathogenic yeast form in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 31.2092%; height: 1.38889%;">lung from where they can disseminate to other organs.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 31.5359%; height: 1.38889%;">Incubation period: Weeks to months; median 45 days.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">Clinical findings: A granulomatous fungal infection of the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">lung, skin, bone or genitourinary tract. Pulmonary infection
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">may be acute or chronic. Acute: fever, cough and pulmonary
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">infiltrate, resolving in 1–3 weeks. Chronic infection is more
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">common and characterized by erythematous papules on the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.3137%; height: 4.0404%;">face and extremities, low-grade fever, and weight loss; pulmo-
nary infection may cavitate. Occasionally bone, prostate, epi-
didymis and central nervous system may be affected.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 33.9869%; height: 2.77778%;">Untreated disseminated or chronic pulmonary disease is gen-
erally fatal. The main differential diagnosis is tuberculosis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Microscopy of sputum smear or material
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">from lesions can show characteristic budding forms of the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 26.634%; height: 1.38889%;">fungus; culture; serology is not routinely used.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.3137%; height: 1.38889%;">Therapy: Amphotericin B is recommended for severe cases.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 16.8301%; height: 1.13636%;">Itraconazole for milder cases.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 20.8333%; width: 15.3595%; height: 1.13636%;">Prevention: None.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 23.4848%; width: 34.1503%; height: 1.38889%;">Epidemiology: Blastomycosis is a sporadic disease with a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">worldwide distribution, though most cases are reported from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">North America. It is endemic in the Mississippi and Ohio river
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 2.77778%;">basins and around the Great Lakes. In endemic areas blasto-
mycosis is frequent in dogs but rare in cats and other animals.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">The annual incidence of blastomycosis in northern Wisconsin
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">is estimated to be 40–100 per 100,000 in humans and 1,400 per
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 32.9545%; width: 34.3137%; height: 1.38889%;">100,000 in dogs. In the USA outbreaks are usually seen in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">the spring and fall, indicating infection 1–3 months earlier.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.13636%;">Cases are commoner in males and the disease is rare in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">children. Blastomycosis occurs close to rivers and lakes with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 2.77778%;">changing water levels. Activities involving shores or water-
ways, like fishing and canoeing, are identified as risk factors
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 7.51634%; height: 1.13636%;">for infection.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 2.77778%;">Map sources: The Blastomycosis map was made by geocod-
ing human blastomycosis cases in the medical literature. The
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">distribution of Blastomycosis in Canada and USA was
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 20.915%; height: 1.26263%;">obtained from KD Reed et al. (2008).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 50.505%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">Pfaller MA, et al. (2010) Epidemiology of invasive mycoses in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 53.1566%; width: 29.5752%; height: 1.26263%;">North America. Crit Rev Microb 36(1):1–53.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 35.9477%; height: 1.38889%;">Reed KD, et al. (2008) Ecologic niche modeling of Blastomyces
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 55.8081%; width: 35.7843%; height: 1.26263%;">dermatitidis in Wisconsin. PLoS ONE 3(4):e2034.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 33.9869%; height: 2.77778%;">Saccente M (2010) Clinical and laboratory update on blasto-
mycosis. Clin Microb Rev 23(2):367–381.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">Watts B, et al. (2007) Clinical problem-solving: building a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 61.2374%; width: 33.0065%; height: 1.26263%;">diagnosis from the ground up; a 49-year-old man came to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 62.5%; width: 33.1699%; height: 1.38889%;">the clinic with a 1-week history of suprapubic pain and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 63.8889%; width: 23.6928%; height: 1.38889%;">fever. N Engl J Med 356:1456–1462.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">113
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/437e4c14-e27a-40ac-9d9e-2a8967170326" class="aLF-aPX-aPF-aPE-J3" alt="Page 35 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.fao.org/geonetwork/srv/en/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.fao.org/geonetwork/srv/en/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.fao.org/geonetwork/srv/en/&amp;ust=1666162860000000&amp;usg=AOvVaw0spbP_vv3ru7-taZmmMaas&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 60.4575%; top: 65.1515%; width: 19.9346%; height: 1.38889%;"></a><a href="http://www.cfsph.iastate.edu" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.cfsph.iastate.edu" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.cfsph.iastate.edu&amp;ust=1666162860000000&amp;usg=AOvVaw0MuH9U5rrFp76zofNTdZS6&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 67.4837%; top: 73.2323%; width: 13.2353%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 36 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 44.6078%; height: 2.39899%;">Disease: Coccidioidomycosis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 22.2222%; height: 1.26263%;">Classification: ICD-9 114; ICD-10 B38
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">Synonyms: Valley fever, San Joaquin fever, Desert fever,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 22.0588%; height: 1.26263%;">Desert rheumatism, California disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 40.0327%; height: 2.77778%;">Agent: Coccidioides immitis (Californian) and C. posadasii (non-
Californian), dimorphic, soil-borne, ascomycete fungi unique
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 15.5229%; height: 1.38889%;">to the western hemisphere.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">Reservoir: Dry, sandy alkaline soil in the semi-arid zones of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">the USA–Mexico border and parts of Central and South
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">America. In North America, the fungus is mainly found in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">the Lower Sonoran Life Zone with low rainfall and high
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">temperatures C. immitis is present in California, and probably
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">northern Mexico and Arizona, and C. posadasii is present in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 9.80392%; height: 1.38889%;">remaining areas.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">Transmission: Inhalation of arthroconidia (reproductive
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">spores) from the environment or dusty fomites. Sometimes
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 33.9869%; height: 2.77778%;">through direct inoculation or transplantation. Person-to-per-
son transmission is extremely rare.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">Cycle: The fungal agent reproduces asexually; the mold
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">forms arthroconidia that are aerosolized and can germinate
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.4771%; height: 2.65152%;">into new mycelia under appropriate conditions. Arthroconi-
dia are infectious when inhaled by an animal or human
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">(accidental hosts). In the lung the arthroconidia convert to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.3137%; height: 2.65152%;">spherules in which endospores can develop untill the spher-
ule ruptures and the endospores are released, forming new
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 6.20915%; height: 1.38889%;">spherules.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.3137%; height: 1.38889%;">Incubation period: Primary infection: 1–4 weeks; chronic/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 30.8824%; height: 1.38889%;">disseminated form of disease may be months to years.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.4771%; height: 2.77778%;">Clinical findings: About 60% of exposures result in asymp-
tomatic infection. Symptoms range from benign pulmonary
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">infection (fever, chills, cough, chest pain, dyspnea), night
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">sweats, anorexia and weight loss to progressive pulmonary
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">or extrapulmonary disease involving skin, bones and/or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.3137%; height: 1.38889%;">joints, the central nervous system, and other organ systems.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">Most patients with primary disease recover spontaneously
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.4771%; height: 1.38889%;">and have life-long immunity to re-infection. Chronic and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 34.4771%; height: 1.38889%;">disseminated disease is estimated to occur in up to 5% of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 33.9869%; height: 2.65152%;">cases. Meningeal infection occurs in less than 1% of extrapul-
monary cases and requires life-long treatment.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 16.7929%; width: 34.1503%; height: 1.38889%;">Diagnostic tests: Microscopy of respiratory secretions,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">pleural fluid, tissue or exudate in which detection of spherules
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 2.77778%;">containing endospores is diagnostic (double-walled struc-
tures, size 20–100 mm) fungal culture of sputum, blood, pus,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">and urine; coccidioidal serologic tests; cocciodin or spherulin
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">skin test (not available in USA). Serology on CSF to diagnose
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 6.53595%; height: 1.38889%;">meningitis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 33.9869%; height: 2.77778%;">Therapy: Amphotericin B desoxycholate and/or azole anti-
fungals; surgery to remove foci.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 31.5657%; width: 34.3137%; height: 1.38889%;">Prevention: It is an occupational risk for those working in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.3137%; height: 1.38889%;">the environment in endemic regions (e.g. farmers, soldiers).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">Dust control where feasible (e.g. paving roads). Arthroconidia
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.13636%;">are resistant to extreme environmental conditions and can
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">survive for many years in dust. Screening of organ donors
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">for coccidioidomycosis in endemic areas. As the fungus is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 24.5098%; height: 1.38889%;">easily aerosolized it is a laboratory hazard.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 42.298%; width: 34.3137%; height: 1.38889%;">Epidemiology: Infections are most frequent in a period of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">drought and winds (dust storms) after heavy rains that
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">advance mold growth, usually late summer or early fall. It is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">estimated that more than 150,000 primary infections occur
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">annually in the USA. Incidence in California and Arizona
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">appears to have increased since 1991 and again since 2001,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">probably driven by immigration of non-immunes andwheather
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">conditions that favor dissemination of the fungus. Prevalence of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">infection in northern Mexico is reported to be 10–40%. Male
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.4771%; height: 2.77778%;">gender, African-American and Filipino race/ethnicity, immu-
nosuppression, diabetes, older age and pregnancy are risk
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 34.4771%; height: 1.13636%;">factors for chronic and disseminated disease. Infections outside
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">the western hemisphere are extremely rare and primarily
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 5.71895%; height: 1.38889%;">imported.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 62.5%; width: 34.3137%; height: 1.38889%;">Map sources: The Coccidioidomycosis map is modified from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 34.3137%; height: 1.38889%;">RF Hector et al. (2005) and combined with aridity index data
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 28.4314%; height: 1.38889%;">from FAO, at: www.fao.org/geonetwork/srv/en/.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 67.9293%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.1919%; width: 34.3137%; height: 1.38889%;">Ampel NM (2010) New perspectives on coccidioidomycosis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.5808%; width: 21.2418%; height: 1.26263%;">Proc Am Thorac Soc 7(3):181–185.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 71.9697%; width: 33.9869%; height: 2.65152%;">Center for Food Security and Public Health (2010) Coccidioi-
domycosis. Factsheet. At www.cfsph.iastate.edu.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 74.6212%; width: 37.7451%; height: 1.38889%;">Hector RF, et al. (2005) Coccidioidomycosis – a fungal disease
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 75.8838%; width: 27.7778%; height: 1.38889%;">of the Americas. PLoS Med 2(1):e2.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">115
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/5705dcbd-432f-4d3c-b92b-d285e3d1104c" class="aLF-aPX-aPF-aPE-J3" alt="Page 36 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.worldclim.org" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.worldclim.org" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.worldclim.org&amp;ust=1666162860000000&amp;usg=AOvVaw1Mr2Vdb8SpO80-szJXICn8&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 54.2484%; top: 65.1515%; width: 11.9281%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 37 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 36.9281%; height: 2.39899%;">Disease: Histoplasmosis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 30.2288%; height: 1.26263%;">Classification: ICD-9 115; ICD-10 B39.0-B39.4, B39.9
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 33.9869%; height: 2.77778%;">Synonyms: Cave disease, Ohio valley disease, reticuloen-
dotheliosis, African histoplasmosis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 49.0196%; height: 2.77778%;">Agent: The dimorphic fungi: Histoplasma capsulatum (world-
wide) and H. capsulatum var. duboisii (Africa). The fungi grow
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">as a mycelium in the soil at ambient temperatures and convert
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 28.5948%; height: 1.38889%;">to the yeast form in the lung at body temperature.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">Reservoir: Soil with high nitrogen content, particularly areas
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">with a lot of bird or bat guano, like barns and caves. Blackbird
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">roosts can also be heavily contaminated. Unlike bats, birds are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.2172%; width: 35.6209%; height: 1.38889%;">not infected by H. capsulatum and do not excrete the fungus in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">their droppings. Bird droppings are considered a nutrient
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 33.1699%; height: 1.38889%;">source for fungal growth in the already contaminated soil.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.3137%; height: 2.77778%;">Transmission: Through inhalation of aerosolized microconi-
dia from disturbed soil or guano. Also by inoculation and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 12.7451%; height: 1.38889%;">organ transplantation.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">Cycle: The fungus grows as a mycelium in the environment
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">and in human or animal tissue it converts into a budding
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.8535%; width: 3.59477%; height: 1.26263%;">yeast.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 28.7582%; height: 1.38889%;">Incubation period: 3 to 17 days; average 10 days.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">Clinical findings: Histoplasmosis may be divided into the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 2.77778%;">following four types: (1) pulmonary histoplasmosis, (2) dis-
seminated histoplasmosis, (3) cutaneous histoplasmosis, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">(4) African histoplasmosis. Most infections are asymptomatic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">or mild and resolve without treatment. The acute phase begins
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">with fever, malaise, chest pains and a dry cough. Chest X-ray
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">findings are normal in 40–70% of cases. Severe infections result
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.4771%; height: 1.38889%;">in mediastinitis, hepatosplenomegaly, lymphadenopathy and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 2.65152%;">adrenal enlargement. Osteomyelitis is rare. Disseminated dis-
ease occurs in patients with altered cellular immunity such as
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 2.77778%;">individuals with AIDS and those receiving immunosuppres-
sive medications. It presents with systemic complaints and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">multiple organ involvement: lung, spleen, bone marrow,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 2.77778%;">adrenals, CNS and GI tract being the most affected. Dissemi-
nated histoplasmosis is fatal unless treated. Past infection
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 34.4771%; height: 1.38889%;">results in partial protection. Reactivation is uncommon but
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.8737%; width: 6.69935%; height: 1.13636%;">may occur.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.2727%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Serology is mainly used (immunodiffusion
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 78.6616%; width: 34.4771%; height: 1.38889%;">and CF tests). Detection of antigen in blood, CSF, urine or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 4.0404%;">bronchoalveolar lavage fluid by radioimmunoassay. Micros-
copy on Giemsa stained bone-marrow or blood smear. His-
toplasma skin tests indicate whether a person has been
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.4771%; height: 1.38889%;">exposed. PCR-based tests are available. Fungal culture is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 8.98693%; height: 1.38889%;">generally slow.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 34.4771%; height: 1.26263%;">Therapy: For mild cases, an oral triazole; for severe cases,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">amphotericin B followed by an oral triazole for at least a year.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 28.9141%; width: 34.3137%; height: 1.38889%;">Prevention: Avoid accumulations of bird or bat droppings
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">such as are found in caves. The USA government provides a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">document, ‘Histoplasmosis: Protecting Workers at Risk’, with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">information on work practices and personal protective
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 6.69935%; height: 1.26263%;">equipment.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 36.995%; width: 36.7647%; height: 1.38889%;">Epidemiology: H. capsulatum grows in soil and material
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">contaminated with bird or guano. The fungus has been
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">found in poultry house litter, caves, areas harboring bats
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 42.3203%; height: 1.38889%;">and in bird roosts. Histoplasma capsulatum is found throughout
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">the world excluding areas of very low and very high rainfall. It
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">is endemic in certain areas of the United States, particularly in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 4.0404%;">states bordering the Ohio river valley and the lower Missis-
sippi river, where 90% of the population have positive histo-
plasmin skin tests, indicating a large amount of asymptomatic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">infection. H. capsulatum var. duboisii is common in caves in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.13636%;">southern and East Africa. Infection can occur outside the cave
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">entrance without entering. Infants, young children, and older
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">persons, in particular those with chronic lung disease, are at
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.4771%; height: 1.13636%;">increased risk for severe disease. Disseminated disease is more
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">frequently seen in people with cancer, AIDS or other forms of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.197%; width: 12.2549%; height: 1.26263%;">immunosuppression.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 34.4771%; height: 2.65152%;">Map sources: The Histoplasmosis map was made by geocod-
ing reported human Histoplasmosis cases in the medical
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 62.5%; width: 34.4771%; height: 1.38889%;">literature up to 2010, and showing annual precipation
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 37.0915%; height: 1.26263%;">obtained from WorldClim – Global Climate Data, available
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 13.8889%; height: 1.38889%;">at: www.worldclim.org.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 67.9293%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.1919%; width: 34.6405%; height: 1.38889%;">Ashbee HR, et al. (2008) Histoplasmosis in Europe. Med Mycol
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.5808%; width: 7.02614%; height: 1.26263%;">46(1):57–65.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 71.9697%; width: 34.4771%; height: 1.38889%;">Lenhart SW, et al. (2004) Histoplasmosis: Protecting Workers
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.2323%; width: 28.9216%; height: 1.38889%;">at Risk. DHHS (NIOSH) Publication No. 2005–109.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 74.6212%; width: 34.3137%; height: 1.38889%;">Gugnani HC, et al. (1997). African histoplasmosis: a review.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 75.8838%; width: 18.3007%; height: 1.38889%;">Rev Iberoam Micol 14(4):155–159.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 77.2727%; width: 34.3137%; height: 1.38889%;">Knox KS, et al. (2010) Histoplasmosis. Proc Am Thorac Soc
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 78.6616%; width: 7.51634%; height: 1.38889%;">7(3):169–172.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">117
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/b3605469-5f29-4955-b460-feee6f8ef9d5" class="aLF-aPX-aPF-aPE-J3" alt="Page 37 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 38 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 29.7386%; height: 2.39899%;">Disease: Mycetoma
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 22.2222%; height: 1.26263%;">Classification: ICD-9 039; ICD-10 B47
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 24.3464%; height: 1.38889%;">Synonyms: Maduromycosis, Madura foot
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 34.3137%; height: 1.38889%;">Agent: There are two different groups of etiologic agents:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">fungi and bacteria. Fungal mycetoma is called eumycetoma,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">and at least 34 fungal species have been implicated. The fungi
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">Madurella mycetomatis and Pseudallescheria boydii are the most
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">common fungal causative agents of eumycetoma. Bacterial
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.4771%; height: 2.65152%;">mycetoma is called actinomycetoma and at least 14 actinomy-
cetes have been implicated, of which the bacterial species of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">Nocardia, Streptomyces and Actinomadura are the most common
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 20.915%; height: 1.38889%;">causative agents of actinomycetoma.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 21.2418%; height: 1.38889%;">Reservoir: Soil, decaying vegetation.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.3137%; height: 1.38889%;">Transmission: Through contamination of penetrating
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 33.9869%; height: 2.77778%;">wounds (e.g. by thorns, splinters). There is no person-
to-person transmission.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 32.6797%; height: 1.38889%;">Cycle: Environment with occasional spillover to humans.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 21.2418%; height: 1.38889%;">Incubation period: Months to years.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">Clinical findings: A chronic inflammatory process of soft
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">tissue, with generally painless swelling and suppuration,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.3137%; height: 1.38889%;">developing sinus tracts from which pus-containing granules
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.3137%; height: 1.38889%;">drains. Lesions on foot or leg below the knee, sometimes hand,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">shoulder, back or elsewhere. The periosteum and bones may
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 7.02614%; height: 1.13636%;">be attacked.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 33.9869%; height: 2.77778%;">Diagnostic tests: Pus contains visible granules, histopathol-
ogy of biopsy, culture (slow).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.4771%; height: 3.91414%;">Therapy: For bacteria, clindamycin, trimethoprim-sulfameth-
oxazole, long-acting sulfonamides; for fungi, itraconazole, keta-
conazole, or voriconazole. Resection of small lesions; advanced
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 28.5948%; height: 1.38889%;">lesions may require amputation of the hand or leg.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 33.9869%; height: 2.77778%;">Prevention: Use closed footwear; thoroughly clean penetrat-
ing wounds in endemic areas.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 20.8333%; width: 34.3137%; height: 1.38889%;">Epidemiology: Common in tropical and subtropical areas
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">world wide among people who go barefoot, endemic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">between 30 N and 15 S of the equator. Mycetoma is endemic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">in areas with a short rainy season of relatively low rainfall and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">a temperature range of 30–37 C, followed by a long dry
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">season with low relative humidity temperatures ranging
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 36.9281%; height: 1.38889%;">from a night-time low of as little as 15 C to a daytime
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">maximum of up to 60 C. This extreme alteration in weather
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">conditions might be necessary to the survival of the causative
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">organism in its natural niche in soil or plant material. Cases
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 2.52525%;">have been exported from the endemic region to many non-
endemic countries. World wide, about 60% of cases are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">caused by actinomycetes; the rest are caused by fungi. In
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">Africa, eumycetomas are more frequently observed than
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">actinomycetomas; in India, actinomycetes are found in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">more than half of the cases reported. In South America,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">90% of the cases are caused by actinomycetes. Infection is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 40.6863%; height: 1.26263%;">most often seen in herdsmen, farmers, and other field
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.0101%;">laborers. Males are 4–5 times more often affected than
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">females, even in areas where both sexes spend a lot of time
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">in the fields. Mycetoma is seen in all age groups, but usuallyin
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 33.9869%; height: 2.65152%;">adults 20–40 years old. The disease progresses faster in HIV-
positive and other immunocompromised patients.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 53.1566%; width: 34.3137%; height: 1.38889%;">Map sources: The Mycetoma map is modified from the thesis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 25.3268%; height: 1.38889%;">of W. van de Sande (2007), with permission.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 57.197%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">Lopez Martinez LJ, et al. (1992) Epidemiology of mycetoma in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 59.8485%; width: 36.9281%; height: 1.38889%;">Mexico: study of 2105 cases. Gac Med Mex 128:477–481.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.1111%; width: 34.4771%; height: 1.38889%;">Van de Sande W (2007) Genetic variability, antigenicity, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 62.5%; width: 33.1699%; height: 1.38889%;">antifungal susceptibility of Madurella mycetomatis. Thesis,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 63.8889%; width: 18.3007%; height: 1.38889%;">Erasmus University, Rotterdam.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">Welsh O, et al. (2007) Mycetoma. Clin Dermatol 25(2):195–202.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">119
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/c9f18cef-bae9-4051-8df5-88336a7eca63" class="aLF-aPX-aPF-aPE-J3" alt="Page 38 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.worldclim.org" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.worldclim.org" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.worldclim.org&amp;ust=1666162860000000&amp;usg=AOvVaw1Mr2Vdb8SpO80-szJXICn8&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 65.6863%; top: 49.1162%; width: 11.9281%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 39 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 50.9804%; height: 2.39899%;">Disease: Paracoccidioidomycosis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 23.0392%; height: 1.26263%;">Classification: ICD-9 116.1; ICD-10 B41
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 33.9869%; height: 2.77778%;">Synonyms: South American blastomycosis, Brazilian blasto-
mycosis, Lutz–Splendore–Almeida disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">Agent: Paracoccidioides brasiliensis, a dimorphic fungus. At
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 33.9869%; height: 2.65152%;">room temperature, P. brasiliensis is a mold and at body tem-
perature (37 C) a yeast.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">Reservoir: The natural reservoir is unclear. The fungus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 34.4771%; height: 2.77778%;">can be isolated from nine-banded armadillos (Dasypus novem-
cinctus). The disease has also been reported in dogs and other
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">animals. Culturing the fungus from soil is difficult and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">regularly negative. As armadillos have close contact with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.4771%; height: 2.65152%;">soil, it is expected that soil is a reservoir. By using nine-
banded armadillos as sentinel animals, it has been shown that
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">the habitat of P. brasiliensis is likely humid vegetation close to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.7727%; width: 8.66013%; height: 1.0101%;">water sources.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.4771%; height: 1.38889%;">Transmission: Not completely understood. Possibly in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">soil the fungus produces infective propagula that can become
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">airborne, inhaled, and lead to respiratory infection. Infections
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">may also occur through traumatic lesions, but this has not been
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 8.33333%; height: 1.13636%;">demonstrated.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 12.2549%; height: 1.38889%;">Cycle: Unknown.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 21.2418%; height: 1.38889%;">Incubation period: Months to years.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.3137%; height: 2.65152%;">Clinical findings: Paracoccidioidomycosis is a chronic pro-
gressive systemic mycosis. There are two disease forms:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">(1) an acute/subacute form in children that mainly involves
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">the reticulo-endothelial system, and (2) a chronic or adult
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">form with a long latent period, that mainly affects men and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.4771%; height: 2.77778%;">generally is a pulmonary infection. The disease can dissemi-
nate to mucous membranes, skin, and lymph nodes. Relapses
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">occur in immune-compromised patients and in those with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">disseminated disease. CFR can be up to 10%, highest in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 33.8235%; height: 1.38889%;">children with underlying conditions, and lowest in adults.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.7071%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Demonstration of multiple-budding cells in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 72.096%; width: 34.3137%; height: 1.38889%;">body fluid aspirates or tissue biopsy specimens by microscopy.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.3586%; width: 30.2288%; height: 1.38889%;">Isolation of the fungus. Serology and histopathology.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 34.4771%; height: 2.77778%;">Therapy: Mild disease: oral itraconazole or trimethoprim-
sulfamethoxazole. For severe cases: iv amphotericin B or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">trimethoprim-sulfamethoxazole. Treatment is long and is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 25.3268%; height: 1.38889%;">monitored by clinical and radiological signs.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 20.8333%; width: 33.8235%; height: 1.13636%;">Prevention: Avoid contact with armadillos or their habitat.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 23.4848%; width: 34.3137%; height: 1.26263%;">Epidemiology: Most South and several Central American
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 34.4771%; height: 2.65152%;">countries between 23 N and 34 S have paracoccidioido-
mycosis endemic regions, particularly Brazil, Colombia,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 2.77778%;">Venezuela, and Argentina. The prevalence of paracoccidioi-
domycosis in endemic areas can be up to 75% in adults, with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">active disease developing in approximately 2% of infected
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">individuals. The endemic areas are generally forest areas
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">with many water streams, mild temperatures, a short winter,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">and a summer with moderate rain. The disease mainly affects
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.26263%;">active rural workers (coffee, cotton, and tobacco farmers),
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">probably due to environmental exposure. This explains why
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.3137%; height: 1.38889%;">the disease is more common in men aged 30 to 60 years.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">Postpubertal women are partially protected by estrogen that
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.3137%; height: 1.38889%;">prevents the fungus from transitioning to the yeast form.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.13636%;">Contact with nine-banded armadillos has also been shown
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 26.1438%; height: 1.38889%;">to be a risk factor for paracoccidioidomycosis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 46.3384%; width: 34.3137%; height: 1.38889%;">Map sources: The Paracoccidioidomycosis map was made by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">mapping endemic regions stated in the medical literature. We
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">used climate data from www.worldclim.org to show regions
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">suitable for paracoccidioidomycosis: mild temperature (17 to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 45.2614%; height: 1.38889%;">24 C) and rainfall between 900 and 1,500 mm/year. The 23 N
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 33.6601%; height: 1.38889%;">and 34 S lines indicate the geographic limits of the disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 55.8081%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 34.3137%; height: 1.38889%;">Bagagli E, et al. (2006) Phylogenetic and evolutionary aspects
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 58.4596%; width: 33.1699%; height: 1.38889%;">of Paracoccidioides brasiliensis reveal a long coexistence with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 59.8485%; width: 33.1699%; height: 1.38889%;">animal hosts that explain several biological features of the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 61.1111%; width: 22.8758%; height: 1.38889%;">pathogen. Infect Genet Evol 6(5):344–351.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 62.5%; width: 34.4771%; height: 2.77778%;">Blotta MHSL, et al. (1999) Endemic regions of paracoccidioi-
domycosis in Brazil: A clinical and epidemiologic study of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 65.1515%; width: 33.1699%; height: 1.38889%;">584 cases in the southeeast region. Am J Trop Med Hyg
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 66.5404%; width: 8.16994%; height: 1.26263%;">61(3):390–394.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">Nucci M, et al. (2009) Paracoccidioidomycosis. Curr Fung Infect
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.1919%; width: 14.8693%; height: 1.38889%;">Rep 3(1):15–20.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.5808%; width: 38.0719%; height: 2.77778%;">Restrepo A, et al. (2001) The habitat of Paracoccidioides brasi-
liensis: how far from solving the riddle? Med Mycol
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.3586%; width: 6.69935%; height: 1.0101%;">39:233–241.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 74.6212%; width: 34.4771%; height: 2.65152%;">Travassos LR, et al. (2008) Treatment options for paracocci-
dioidomycosis and new strategies investigated. Expert Rev
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 77.2727%; width: 18.4641%; height: 1.38889%;">Anti Infect Ther 6(2):251–262.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">121
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/0f540927-f5e0-4745-abc9-27f5f8d11e9a" class="aLF-aPX-aPF-aPE-J3" alt="Page 39 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 40 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 32.1895%; height: 2.0202%;">Disease: Penicilliosis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.183%; height: 1.26263%;">Classification: ICD-9 117.3; ICD-10 B48.4
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.5707%; width: 15.1961%; height: 1.13636%;">Synonyms: None.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">Agent: Penicillium marneffei, a dimorphic fungus. It is the only
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">Penicillium species that is dimorphic: at body temperature or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">37 C it is a yeast form and at cooler temperature it grows as
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 4.73856%; height: 1.13636%;">a mold.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.4771%; height: 2.65152%;">Reservoir: Unclear. Bamboo rats (Rhizomys sinensis, R. pruino-
sus, R. sumatrensis, and Cannomys badius) are natural hosts and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">the fungus is detected in the soil of their burrows. P. marneffei
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">can survive in sterile soil for several weeks and only a few days
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.2172%; width: 34.4771%; height: 1.38889%;">in non-sterile soil. P. marneffei has not been recovered from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.4771%; height: 1.13636%;">environments not associated with bamboo rats. Bamboo rats
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 23.366%; height: 1.38889%;">(except C. badius) eat principally bamboo.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">Transmission: Unclear, but likely through inhalation of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 2.65152%;">P. marneffei conidia from the environment; cutaneous inocula-
tion may also occur. There is no human-to-human
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 7.84314%; height: 1.13636%;">transmission.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">Cycle: Unknown. It has been proposed that bamboo rats may
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 32.0261%; height: 1.38889%;">amplify infectious dispersal stages for human infections.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 24.5098%; height: 1.38889%;">Incubation period: Few weeks to months.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">Clinical findings: Clinical presentation depends on level of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 2.77778%;">immune suppression. P. marneffei is most often an opportunis-
tic infection in HIV patients with low CD4 counts (&lt;100 cells/m
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">L). Most present with fever and typical skin lesions. Other
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.3137%; height: 1.38889%;">findings are anemia, generalized lymphadenopathy, weight
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">loss, and hepatosplenomegaly. Respiratory signs can also be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">observed. Skin lesions are often papules with central necrosis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.3137%; height: 1.38889%;">on the face and neck, but other body sites can also have lesions.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">Other opportunistic infections also need to be excluded in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 8.33333%; height: 1.38889%;">these patients.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Microscopy of infected tissue in which
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">typical intracellular yeast cells are found; culture of blood,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 24.0196%; height: 1.38889%;">bone marrow, skin lesion, or lymph node.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 34.4771%; height: 1.38889%;">Therapy: Amphotericin B iv or itraconazole. Long-term azole
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.4771%; height: 1.38889%;">maintenance treatment is required in HIV patients to prevent
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 5.22876%; height: 1.26263%;">relapses.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 16.7929%; width: 34.1503%; height: 1.38889%;">Prevention: Secondary prophylaxis with itraconazole.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 45.2614%; height: 6.69192%;">HIV patients with low CD4 counts should avoid endemic areas. Epidemiology: Together with tuberculosis and crypto-
coccosis, penicilliosis is a common opportunistic infection
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 39.0523%; height: 1.38889%;">in HIV patients in Southeast Asia. Though we could not find a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">report from Myanmar, it is expected to be present there. In
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 1.13636%;">northern Thailand it causes 15% of the HIV-related diseases.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.3137%; height: 2.65152%;">Before the HIV epidemic it was a rare disease in immuno-
compromised patients residing in endemic areas in Asia.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">Cases of penicilliosis have been described world wide,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">mainly in HIV patients with a travel history to endemic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">regions. A single case has been described from Ghana
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.3137%; height: 1.38889%;">where there was no clear travel history to Southeast Asia.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.13636%;">The association between bamboo rats and human infection is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.13636%;">unclear. There is an association between infection risk and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">doing agricultural work, suggesting that soil exposure is a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">risk factor. The disease has a seasonal pattern with more cases
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 14.2157%; height: 1.38889%;">during the rainy season.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 45.0758%; width: 34.3137%; height: 1.38889%;">Map sources: The Penicilliosis map was made by geocoding
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.3137%; height: 1.38889%;">reported human cases in the medical literature up to 2010.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">Bamboo richness data is obtained from N. Bystriakova
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">et al. (2010), with permission. Bamboo richness serves as a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">proxy for the distribution of the bamboo rat for whichwe could
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 10.2941%; height: 1.13636%;">not find data.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 54.5455%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">Bystriakova N, et al. (2003) Distribution and conservation
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 57.0707%; width: 43.9542%; height: 2.77778%;">status of forest bamboo biodiversity in the Asia-Pacific Region. Biodiv Conserv 12:1833–1841.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">Cao C, et al. (2011) Common reservoirs for Penicillium marneffei
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 61.1111%; width: 41.1765%; height: 1.38889%;">infection in humans and rodents, China. Emerg Infect Dis 17
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 62.5%; width: 6.86275%; height: 1.38889%;">(2):209–214.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">Pryce-Miller E, et al. (2008) Environmental detection of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 65.1515%; width: 33.1699%; height: 2.77778%;">Penicillium marneffei and growth in soil microcosms in com-
petition with Talaromyces stipitatus. Fungal Ecol 1:49–56.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 67.9293%; width: 34.6405%; height: 1.38889%;">Ustianowski AP, et al. (2008) Penicillium marneffei infection in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.1919%; width: 24.183%; height: 1.38889%;">HIV. Curr Opin Infect Dis 21(1):31–36.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.5808%; width: 35.7843%; height: 1.38889%;">Vanittanakom N, et al. (2006) Penicillium marneffei infection
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 33.1699%; height: 1.38889%;">and recent advances in the epidemiology and molecular
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.2323%; width: 32.0261%; height: 1.38889%;">biology aspects. Clin Microbiol Rev 19(1):95–110.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">123
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/ff5e4008-1e1a-4635-8fcd-ab7cbbaa73ae" class="aLF-aPX-aPF-aPE-J3" alt="Page 40 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 41 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 65.6863%; height: 2.39899%;">Disease: Amebiasis, Entamoeba histolytica
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 22.3856%; height: 1.26263%;">Classification: ICD-9 006; ICD-10 A06
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">Synonyms: Amebiasis, amebic dysentery, amebic liver
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 17.8105%; height: 1.26263%;">abscess, ameboma, amoebiasis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">Agent: A protozoan parasite, Entamoeba histolytica, that
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 4.0404%;">exists in two forms: non-motile cyst and motile tropho-
zoite. E. histolytica needs to be distinguished from the non-
pathogenic E. dispar. E. moshkovskii is a common cause of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 12.9085%; height: 1.13636%;">non-invasive diarrhea.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">Reservoir: Humans; the parasite has also been detected in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 39.0523%; height: 1.38889%;">non-human primates (cynomolgus monkeys, macaques). E.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.2172%; width: 34.4771%; height: 1.38889%;">moshkovskii can be found in varying wet environments: clean
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 29.7386%; height: 1.38889%;">river sediments, sewage, and brackish coastal pools.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">Transmission: Fecal–oral route, mainly exposure to food or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.3137%; height: 2.52525%;">water contaminated with infectious cysts. Direct human-to-
human transmission occurs via oral and anal sexual activities.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">Cycle:IngestedE. histolytica non-motile cysts will excyst in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">gastrointestinal tract and develop to motile trophozoites that
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">can penetrate the gut mucosa. In the colon, the trophozoites
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 27.2876%; height: 1.38889%;">encyst and the cysts are excreted with the feces.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 21.0784%; height: 1.38889%;">Incubation period: Days to months.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.4771%; height: 1.26263%;">Clinical findings: 90% of the cases will be self-limited and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">asymptomatic; 10% develop invasiveintestinal disease (colitis),
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.4771%; height: 1.26263%;">and &lt;1% extra-intestinal disease (liver abscess). Amebic colitis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">presents with abdominal cramps, weight loss, and watery or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">sometimes bloody diarrhea; most patients are afebrile. Amebic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">colitis rarely progresses to necrotizing colitis, ameboma, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">toxic megacolon. Amebic colitis affects children and adults
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.4771%; height: 1.38889%;">equally, but mainly males. Amebic liver-abscess mainly occurs
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.3137%; height: 1.38889%;">in men aged 18 to 50 years, for unknown reasons. E. moshkovskii
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 18.6275%; height: 1.13636%;">can cause non-invasive diarrhea.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Microscopy of stool specimens cannot
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 44.281%; height: 1.38889%;">distinguish between E. histolytica, E. moshkovskii, and E. dispar;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">PCR is able to distinguish between these species; stool antigen
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.3137%; height: 3.91414%;">tests can identify E. histolytica. Therapy: Invasive disease: tinidazole or metronidazole. For
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 34.4771%; height: 1.26263%;">severe amebic colitis antibiotics are added to prevent and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">treat bacterial peritonitis. Surgery for intra-abdominal
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">complications (e.g. bleeding, perforation). Aspiration for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">liver abscesses. Intraluminal parasites and asymptomatic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 23.5294%; height: 1.38889%;">infection are treated with paromomycin.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 23.8636%; width: 34.3137%; height: 1.13636%;">Prevention: Sanitation and access to clean water. Personal
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 25.2525%; width: 33.9869%; height: 2.65152%;">hygiene during food preparation and sexual activities. Screen-
ing and treatment of close contacts.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 29.5455%; width: 34.4771%; height: 2.77778%;">Epidemiology: E. histolytica is distributed world wide, espe-
cially in countries with poor sanitation and little access to clean
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.3232%; width: 41.0131%; height: 1.26263%;">water (see Water and Sanitation maps). It is estimated that E.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 33.5859%; width: 34.3137%; height: 1.38889%;">histolytica is responsible for 40,000 to 100,000 deaths per year.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.9747%; width: 34.4771%; height: 1.38889%;">Most prevalence studies in the past did not distinguish
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.2374%; width: 37.2549%; height: 1.38889%;">between E. histolytica and the non-pathogenic E. dispar, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 37.6263%; width: 34.4771%; height: 1.38889%;">therefore little is known of the current disease prevalence of the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.0152%; width: 34.4771%; height: 1.38889%;">pathogenic E. histolytica. E. histolytica infection is endemic in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 40.2778%; width: 34.4771%; height: 1.26263%;">Mexico, India, South Africa, some Central and South American
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.6667%; width: 34.4771%; height: 1.38889%;">countries, and Asian Pacific countries. Community-based
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.0556%; width: 34.4771%; height: 1.38889%;">studies in urban slums in Bangladesh showed that: 9% of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 44.3182%; width: 34.4771%; height: 1.38889%;">preschool children suffer from amebic diarrhea each year,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.7071%; width: 34.4771%; height: 1.38889%;">with 2% requiring a hospital visit. In developed countries,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.096%; width: 34.4771%; height: 1.38889%;">amebiasis is seen in travelers and immigrants from developing
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 48.3586%; width: 34.4771%; height: 1.38889%;">countries, and cases may also be found in closed psychiatric
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.7475%; width: 34.4771%; height: 1.38889%;">institutions. MSM are also a risk group, since they are more
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.0101%; width: 5.39216%; height: 1.38889%;">exposed.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 54.0404%; width: 34.3137%; height: 1.38889%;">Map sources: The Amebiasis map was made with data from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.4293%; width: 34.4771%; height: 1.38889%;">C. Ximenez et al. (2009) and shows data from prevalence
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 56.8182%; width: 34.4771%; height: 1.38889%;">surveys of various populations. There is a lack of data on
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.0808%; width: 40.6863%; height: 2.77778%;">the amebiasis disease burden since the discovery of E. dispar. Global burden data is urgently needed.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 62.6263%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 34.4771%; height: 1.26263%;">Ali IKM, et al. (2003) Entamoeba moshkovskii infections in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 65.1515%; width: 32.3529%; height: 1.38889%;">children in Bangladesh. Emerg Infect Dis 9(5):580–584.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.5404%; width: 38.3987%; height: 1.38889%;">Haque R, et al. (2003) Amebiasis. N Engl J Med 348:1565–1573.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">Haque R, et al. (2009) Association of common enteric
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.1919%; width: 33.0065%; height: 1.38889%;">protozoan parasites with severe diarrhea in Bangladesh.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.5808%; width: 17.6471%; height: 1.38889%;">Clin Infect Dis 48:1191–1197.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 71.9697%; width: 31.2092%; height: 1.38889%;">Stanley Jr, SL (2003) Amoebiasis. Lancet 361:1025–1034.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 73.2323%; width: 34.4771%; height: 2.77778%;">Ximenez C, et al. (2009) Reassessment of the epidemio-
logy of amebiasis: state of the art. Infect Genet Evol
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 76.0101%; width: 7.67974%; height: 1.0101%;">9:1023–1032.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">127
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/6c30b571-3549-417a-8072-17d121dc3615" class="aLF-aPX-aPF-aPE-J3" alt="Page 41 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 42 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 33.3333%; height: 2.0202%;">Disease: Anisakidosis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.0196%; height: 1.26263%;">Classification: ICD-9 127.1; ICD-10 B81.0
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">Synonyms: Anisakiasis, pseudaterranovosis, Cod worm
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 34.3137%; height: 1.38889%;">disease, Herring worm disease, Whaleworm disease, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 10.7843%; height: 1.13636%;">Sealworm disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 44.281%; height: 2.65152%;">Agent: The nematodes: Anisakis simplex, A. physeteris, Pseudoterranova decipiens, and Contracaecum spp. A. simplex
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">and P. decipiens are the most important species for human
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">disease. Anisakis larvae are whitish, tightly coiled, 1.5–2 cm
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 35.2941%; height: 1.38889%;">in length, and difficult to see in fish flesh. Pseudoterranova
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 30.719%; height: 1.38889%;">larvae are 2–3 cm in length and red to brown in color.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 34.4771%; height: 2.52525%;">Reservoir: Marine mammals (definitive host), marine inver-
tebrates (intermediate host), and fish (intermediate host). Fish
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.4771%; height: 1.38889%;">are frequently infected: tuna, cod, mackerel, herring, red
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 42.3203%; height: 1.38889%;">snapper, pike, sardines, salmon. A. simplex and A. physeteris
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">are parasites of whales, seals, walruses, sea lions, and related
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">mammals. P. decipiens is found in Pinnipeds (seals, sea lions,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.4771%; height: 1.38889%;">walruses). Contracaecum spp. are parasites of sea eels and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 33.6601%; height: 1.38889%;">whiting, and have been associated with human anisakiasis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 42.3203%; height: 1.38889%;">Transmission: Ingestion of raw or undercooked fish. There is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 19.4444%; height: 1.38889%;">no person-to-person transmission.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">Cycle: Ova are excreted with the feces of infected animals, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.3137%; height: 1.38889%;">develop into larvae which are ingested by squid and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 41.9935%; height: 1.38889%;">other invertebrates – these in turn are ingested by fish which
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 33.6601%; height: 1.38889%;">may be eaten raw by humans. Humans are accidental hosts.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">Incubation period: Few hours for gastric anisakiasis, several
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.4771%; height: 2.77778%;">weeks for intestinal anisakiasis. Immediate for anisakis-
associated hypersensitivity after eating (either raw or cooked)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 16.5033%; height: 1.26263%;">food containing the allergen.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">Clinical findings: Gastric anisakidosis: findings depend on
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.3137%; height: 1.38889%;">where in the gastrointestinal tract the ingested larvae embed.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">Gastric anisakidosis is the predominant form with acute severe
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.3137%; height: 1.38889%;">gastric pain, nausea, and vomiting and sometimes hematemesis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.3137%; height: 1.38889%;">Intestinal anisakiasis can cause abdominal pain, obstruction,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 2.77778%;">peritonitis, ulceration, and bleeding. Anisakis-associated hyper-
sensitivity is increasingly being reported and varies from acute
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 34.4771%; height: 1.38889%;">urticaria to anaphylaxis. Pharyngeal anisakiasis is rare with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 23.6928%; height: 1.38889%;">pharyngeal irritation as the main symptom.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 16.7929%; width: 34.1503%; height: 1.38889%;">Diagnostic tests: Endoscopic identification of larvae.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">Eggs and larvae are not found in the feces. Specific antibody
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 33.0065%; height: 1.38889%;">tests are available for anisakis-associated hypersensitivity.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.3137%; height: 1.38889%;">Therapy: Endoscopic removal of larvae; albendazole; surgery
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 33.9869%; height: 1.38889%;">for complications. Allergic patients: symptomatic treatment.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 26.1364%; width: 34.1503%; height: 1.38889%;">Prevention: Avoid consumption of inadequately cooked
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">marine fish. Clean the fish early after they are caught as larvae
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">migrate from viscera into fish flesh after death. Freezing
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">at 20 C for at least 7 days kills larvae. Larvae can survive
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">50 days in vinegar. For allergic patients: avoid food that may
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 9.64052%; height: 1.38889%;">contain allergen.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 35.6061%; width: 34.3137%; height: 1.38889%;">Epidemiology: Anisakidosis occurs world wide, mainly in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 52.9412%; height: 1.38889%;">coastal regions, and in cultures where consumption of raw fish
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">occurs. Risky fish dishes are sushi, sashimi, Filipino bagoong,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">salted or smoked herring, gravlax, Hawaiian lomi-lomi and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.3137%; height: 1.38889%;">palu, South American ceviche, and Spanish pickled anchovies.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">Anisakidosis is increasingly common in western European
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">countries and the USA due to the increasing popularity of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">eating raw fish (usually Sashimi). In the USA most cases are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">related to Pacific salmon consumption and in Europe to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 2.77778%;">herring consumption. It is unclear why anisakidosis is com-
mon in Japan, but rarely reported in Taiwan or coastal China
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 2.77778%;">where similar fish products are eaten. Overall there is under-
diagnosis of the disease due to the physicians’ inexperience of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">the disease. Pseudoterranovosis (codworm) is relatively more
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">common in North America than in Europe or Japan. Most
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">allergic cases are reported from Mediterranean Europe. In
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">Spain it is mainly related to the consumption of cooked
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 11.7647%; height: 1.13636%;">hake and anchovies.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 61.2374%; width: 34.3137%; height: 1.26263%;">Map sources: The Anisakidosis map was made by geocoding
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 62.5%; width: 28.9216%; height: 1.38889%;">reported cases in the medical literature up to 2009.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 65.2778%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">Audicana MT, et al. (2008) Anisakis simplex: from obscure
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 67.9293%; width: 33.0065%; height: 1.38889%;">infectious worm to inducer of immune hypersensitivity.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.1919%; width: 22.7124%; height: 1.38889%;">Clin Microbiol Rev 21(2):360–379.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">Huss HH, et al. (2003) Assesment and Management of Seafood
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 30.719%; height: 1.38889%;">Safety and Quality. FAO Fisheries Technical Paper 444.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 73.2323%; width: 34.4771%; height: 1.38889%;">Sakanari JA, et al. (1989) Anisakiasis. Clin Microbiol Rev
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 74.6212%; width: 7.51634%; height: 1.26263%;">2(3):278–284.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">129
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/d6b5b1ff-64ef-4d13-9b14-56756417de33" class="aLF-aPX-aPF-aPE-J3" alt="Page 42 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.kolonin.org" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.kolonin.org" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.kolonin.org&amp;ust=1666162860000000&amp;usg=AOvVaw1guLVkiiLmoxmK43P-kjZ8&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 53.7582%; top: 66.5404%; width: 10.2941%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 43 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 30.0654%; height: 2.0202%;">Disease: Babesiosis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.0196%; height: 1.26263%;">Classification: ICD-9 088.8; ICD-10 B60.0
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 25.3268%; height: 1.38889%;">Synonyms: Nantucket fever, Piroplasmosis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 41.9935%; height: 1.38889%;">Agent: Intraerythrocytic, protozoan parasites, Babesia spp.:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 1.26263%;">B. microti in North America, B. duncani on the west coast of the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 39.2157%; height: 1.38889%;">USA and B. divergens-like in four states; B. divergens in Cape
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 47.2222%; height: 2.77778%;">Verde, western Europe, and Finland; B. venatorum in Switzer-
land, Italy, and Austria; B. microti-like in Taiwan and Japan;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">Babesia strain KO1 in South Korea. Species are uncertain in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 21.8954%; height: 1.38889%;">China, Egypt, India, and South Africa.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.3137%; height: 1.38889%;">Reservoir: Rodents, voles (B. microti), cattle (B. divergens),
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.2172%; width: 34.3137%; height: 1.38889%;">lagomorphs (B.divergens-like), possibly horses (B. duncani,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 32.6797%; height: 1.38889%;">formerly type WA1), or sheep (Babesia type KO1).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">Vector: Minute hard ticks: Ixodes ricinus in Eurasia, possibly
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">Hemaphysalis longicornisin Korea, I. ovatusin Japan. I. scapularis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 46.8954%; height: 1.38889%;">(formerly I. dammini) in eastern North America, possibly I.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.4771%; height: 1.38889%;">dentatus in the central USA, I. pacificus in California and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 13.7255%; height: 1.38889%;">Washington state, USA.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.3137%; height: 1.38889%;">Transmission: By tick bite; rarely by blood transfusion and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">transplacental/perinatal. Ticks must feed for more than 24
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 18.1373%; height: 1.13636%;">hours for transmission to occur.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">Cycle: Ticks introduce Babesia spp. sporozoites from the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">ticks’ salivary glands into small mammals/humans during
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">feeding. The sporozoites infect erythrocytes in which they
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">asexually reproduce by budding and develop through various
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 2.77778%;">stages into gametocytes. Ticks can take up circulating game-
tocytes during feeding on an infected animal. The gametocytes
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">fertilize in the tick gut and develop into sporozoites in their
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 9.31373%; height: 1.26263%;">salivary glands.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.3137%; height: 1.38889%;">Incubation period: 1–9 weeks; relapses up to more than a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.404%; width: 3.10458%; height: 1.13636%;">year.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.3137%; height: 1.38889%;">Clinical findings: Often asymptomatic in healthy individuals.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">Symptomatic cases: fever, chills, myalgia, fatigue, and jaundice,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.3137%; height: 1.38889%;">hemolytic anemia; severe cases: retinal infarctions, ecchymoses
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.4771%; height: 2.65152%;">and petechiae, acute respiratory failure, congestive heart fail-
ure, DIC, liver and renal failure, and splenic rupture, with a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.4771%; height: 1.38889%;">mortality rate of 5–9%, higher in immunocompromised
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 34.4771%; height: 1.26263%;">patients. The differential diagnosis is chloroquine-resistant
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.2727%; width: 34.1503%; height: 1.38889%;">malaria, Lyme disease, or human granulocytic anaplasmosis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 16.7929%; width: 34.3137%; height: 1.38889%;">Diagnostic tests: Microscopy on Giemsa-stained thick or thin
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.26263%;">film blood smear; PCR; isolation in hamsters (2–4 weeks for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.1503%; height: 1.38889%;">result); serology (IFA) on paired acute and convalescent sera.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">Therapy: Combination of atovaquone and azithromycin for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">mild-to-moderate illness, clindamycin and quinine for severe
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 34.3137%; height: 1.38889%;">disease. Exchange transfusion for life-threatening infection,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 32.8431%; height: 1.38889%;">dialysis in case of renal failure. Chloroquine is ineffective.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 28.9141%; width: 34.3137%; height: 1.38889%;">Prevention: Control deer population; avoid areas with ticks;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">tick bite precautions: cover skin, repellent on skin and clothing
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 31.5657%; width: 34.3137%; height: 1.38889%;">(permethrin, DEET), check daily for attached ticks and remove.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 34.3434%; width: 34.3137%; height: 1.26263%;">Epidemiology: Immunocompromised, asplenic, and elderly
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">people are at higher risk of symptomatic disease. The number
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">of cases diagnosed in the USA has increased markedly since
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 38.2576%; width: 34.3137%; height: 1.38889%;">1975 due to an increase in the white-tailed deer population,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 44.6078%; height: 1.38889%;">hosts of the adult vector ticks. Nearly all patients with Babesia
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.3137%; height: 1.38889%;">divergens infection in Europe had been splenectomized and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">exposed to cattle. TheB. divergens-like parasite in the USA has a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.26263%;">reservoir in cottontail rabbits, and is not infectious for cattle; it
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">has been found in only 3 patients. All 3 patients with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.3137%; height: 1.38889%;">B. venatorum (EU1) infection had also been splenectomized.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">Cape Verdean, Egyptian, and Asian cases lie outside the range
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">of Ixodes ricinus; B. duncani and B. divergens-like cases in west
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">coast states of USA lie outside the range of I. scapularis. Possible
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 48.5294%; height: 1.26263%;">vectors for these cases are I. dentatus in the central USA, and I.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">pacificus on the west coast. Infection is seasonal (summer),
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">coinciding with abundance of nymphal ticks in warmer
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 4.90196%; height: 1.13636%;">months.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 58.4596%; width: 34.3137%; height: 1.38889%;">Map sources: The Babesiosis map was made by geocoding
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">reported cases in the medical literature up to 2010. The tick
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.2374%; width: 29.7386%; height: 1.26263%;">distributions are obtained from G.V. Kolonin (2009).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 63.8889%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">Kolonin GV (2009) Fauna of Ixodid Ticks of theWorld; available at
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 66.5404%; width: 10.6209%; height: 1.38889%;">www.kolonin.org.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">Saito-Ito A, et al. (2000) Transfusion-acquired, autochthonous
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.1919%; width: 33.0065%; height: 1.38889%;">human babesiosis in Japan: isolation of Babesia microti-like
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.5808%; width: 33.1699%; height: 1.38889%;">parasites with hu-RBC-SCID mice. J Clin Microbiol
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 8.00654%; height: 1.13636%;">38:4511–4516.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 73.2323%; width: 34.4771%; height: 1.38889%;">Vannier E, et al. (2008) Human babesiosis. Infect Dis Clin N
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 74.6212%; width: 21.5686%; height: 1.13636%;">Am 22:469–488.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 75.8838%; width: 34.4771%; height: 1.38889%;">Vannier E, et al. (2009) Update on babesiosis. Interdisc Persp
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 77.2727%; width: 15.1961%; height: 1.38889%;">Infect Dis 984568.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">131
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/19b6cdd3-9079-4d8d-b6d4-2a095edb8c48" class="aLF-aPX-aPF-aPE-J3" alt="Page 43 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 44 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 48.5294%; height: 2.39899%;">Disease: Capillariasis, Intestinal
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.3464%; height: 1.26263%;">Classification: ICD-9 127.5; ICD-10 B81.1.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">Syndromes and synonyms: Intestinal capillariasis, Pudoc
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 19.1176%; height: 1.38889%;">mystery disease, wasting disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 35.7843%; height: 2.77778%;">Agent: The agent of intestinal capillariasis is Capillaria philip-
pinensis (or Paracapillaria philippinensis), a small nematode
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.3137%; height: 1.38889%;">roundworm (males 2.3 to 3.2mm; females 2.5 to 4.3 mm).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.4771%; height: 4.0404%;">Two other Capillaria species that can cause rare human infec-
tions: hepatic (C. hepatica or Calodium hepaticum) and pulmo-
nary capillariasis (C. aerophila). The map only shows intestinal
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 7.18954%; height: 1.38889%;">capillariasis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.2172%; width: 34.4771%; height: 1.38889%;">Reservoir: For C. philippinensis: fish-eating birds. Freshwater
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 15.5229%; height: 1.13636%;">fish are intermediate hosts.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.4771%; height: 2.77778%;">Transmission: Consumption of raw or undercooked unevis-
cerated fish that have ingested infected feces of humans or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 30.719%; height: 1.38889%;">waterfowl. There is no person-to-person transmission.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">Cycle: For C. philippinensis: eggs are passed in the stools of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">humans and fish-eating birds; after ingestion by freshwater
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">fish, larvae hatch, penetrate the intestinal wall and migrate to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 41.1765%; height: 1.38889%;">the tissues. Ingestion of raw or undercooked fish results in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 37.2549%; height: 2.65152%;">infection of the human and bird host. The adults of C. philip-
pinensis reside in the mucosa of the human small intestine,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 33.9869%; height: 2.77778%;">where the females lay eggs. Released larvae can cause autoin-
fection, which may progress to hyperinfection.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 21.4052%; height: 1.26263%;">Incubation period: At least 2 weeks.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">Clinical findings: Intestinal capillariasis starts with mild
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">abdominal pain, borborygmus, and diarrhea, that develops
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">to profuse watery diarrhea. If untreated: chronic diarrhea,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.3137%; height: 2.77778%;">vomiting, malabsorption, leading to weight loss, muscle wast-
ing, cachexia, and eventually death. Hepatic capillariasis (C.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">hepatica) is a (sub)acute hepatitis with eosinophilia, that may
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">disseminate to other organs and can be fatal. Pulmonary
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">capillariasis (C. aerophila) may present with fever, cough,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 26.7974%; height: 1.38889%;">asthma, and pneumonia and may also be fatal.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 20.7071%; width: 34.3137%; height: 1.38889%;">Diagnostic tests: Microscopy for eggs, larvae and/or adult
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.096%; width: 35.2941%; height: 1.38889%;">worms in the stool, or in intestinal biopsies for C. philippinensis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 23.3586%; width: 24.0196%; height: 1.38889%;">(eggs resemble those of Trichuris trichiura).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 22.7124%; height: 1.26263%;">Therapy: Albendazole or mebendazole.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.7879%; width: 37.4183%; height: 2.77778%;">Prevention: For C. philippinensis: sanitation and avoid con-
sumption of raw or improperly cooked fish.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 32.8283%; width: 34.3137%; height: 1.38889%;">Epidemiology: Intestinal capillariasis is generally found in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.2172%; width: 46.0784%; height: 4.0404%;">countries where raw freshwater fish is eaten. The parasite was first reported in 1963 in the northern Philippines. C. philip-
pinensisis endemic in the Philippines, Laos, and Thailand. Rare
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">cases have been reported from other Asian countries and the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.5202%; width: 34.4771%; height: 1.38889%;">Middle East. A single case has been reported in Spain imported
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 40.9091%; width: 34.4771%; height: 1.38889%;">from Colombia, but there are no other reports of cases in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.1717%; width: 42.8105%; height: 1.38889%;">Americas. Rare cases of human infection with C. hepatica and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.5606%; width: 43.1373%; height: 1.38889%;">C. aerophila have been reportedworldwide. Infected fishmay be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 44.9495%; width: 30.8824%; height: 1.38889%;">exported from endemic areas to non-endemic countries.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 47.601%; width: 34.3137%; height: 1.38889%;">Map sources: The Capillariasis map was made by geocoding
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 48.9899%; width: 42.3203%; height: 1.38889%;">reported human cases infected with Capillaria philippinensis up
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.2525%; width: 34.4771%; height: 1.13636%;">to 2010. There is no detailed information on where the human
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.6414%; width: 16.1765%; height: 1.13636%;">cases occurred in Indonesia.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 54.4192%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.6818%; width: 45.4248%; height: 1.38889%;">Cross J (1992) Intestinal capillariasis. Clin Microb Rev 5
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 57.0707%; width: 6.86275%; height: 1.26263%;">(2):120–129.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.3333%; width: 34.4771%; height: 1.38889%;">Belizario VJ Jr, et al. (2010) Intestinal capillariasis, western
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 59.7222%; width: 34.3137%; height: 1.38889%;">Mindanao, the Philippines. Emerg Infect Dis 16(4):736.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.1111%; width: 34.4771%; height: 1.26263%;">Dronda F, et al. (1993) Human intestinal capillariasis in an area
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 62.3737%; width: 41.1765%; height: 1.38889%;">of nonendemicity: case report and review. Clin Infect Dis 17
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 63.7626%; width: 6.86275%; height: 1.26263%;">(5):909–912.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 33.9869%; height: 2.65152%;">Saichua P, et al. (2008) Human intestinal capillariasis in Thai-
land. World J Gastroent 14(4):506–510.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">133
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/b9567dd1-5b03-4a8d-9eba-ce765375ceb1" class="aLF-aPX-aPF-aPE-J3" alt="Page 44 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 45 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 34.6405%; height: 2.0202%;">Disease: Clonorchiasis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.0196%; height: 1.26263%;">Classification: ICD-9 121.1; ICD-10 B66.1
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.3182%; width: 35.1307%; height: 1.26263%;">Syndromes and synonyms: Chinese liver fluke, Oriental
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.7071%; width: 12.5817%; height: 1.13636%;">liver fluke.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.2323%; width: 34.4771%; height: 1.26263%;">Agent: Clonorchis sinensis, a trematode (fluke) 10–25 mm long
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.495%; width: 10.7843%; height: 1.13636%;">and 3–5 mm wide.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.0202%; width: 34.3137%; height: 1.38889%;">Reservoir: Piscivorous (fish-eating) mammals, including:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.4091%; width: 34.4771%; height: 1.38889%;">humans, dogs, cats, pigs, rats, and several species of wild
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 29.6717%; width: 33.0065%; height: 1.13636%;">animals. Humans can remain infected for several decades.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.197%; width: 40.1961%; height: 1.38889%;">Vector: Freshwater operculate snails (mainly Parafossarulus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 33.5859%; width: 20.2614%; height: 1.38889%;">sp. and Bithynia sp.).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.9848%; width: 34.3137%; height: 1.38889%;">Transmission: Consumption of raw or undercooked infected
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 37.3737%; width: 34.4771%; height: 1.38889%;">freshwater fish, mainly Cyprinidae (carp and minnows) or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.7626%; width: 4.73856%; height: 1.26263%;">shrimp.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.2879%; width: 19.281%; height: 1.13636%;">Communicability: None.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 47.549%; height: 1.38889%;">Cycle: Fish-eating mammals (including humans) shed C.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 44.9495%; width: 34.3137%; height: 1.38889%;">sinensis eggs into the environment that are ingested by snails,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">where they develop into cercariae. The motile cercariae are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">released into water and infect freshwater fish and encyst in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 48.9899%; width: 34.4771%; height: 1.38889%;">meat and skin as metacercariae. When ingested by mammals,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">the metacercariae migrate into the bile ducts where they
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.3137%; height: 1.26263%;">develop into adult flukes that produce and excrete eggs into
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.0303%; width: 26.7974%; height: 1.38889%;">feces. The cycle takes approximately 3 months.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.5556%; width: 34.3137%; height: 1.38889%;">Incubation period: Depends on infecting dose. Larvae reach
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 56.9444%; width: 23.2026%; height: 1.38889%;">adult fluke stage in less than one month.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.4697%; width: 34.3137%; height: 1.38889%;">Clinical findings: Loss of appetite, epigastric discomfort,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 60.8586%; width: 34.4771%; height: 1.38889%;">rarely jaundice due to bile duct obstruction, cirrhosis, liver
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.2475%; width: 33.9869%; height: 2.65152%;">enlargement, ascites and edema. After years of chronic infec-
tion there is a risk of cholangiocarcinoma.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.1616%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Visualizing characteristic eggs in feces or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.4242%; width: 17.6471%; height: 1.38889%;">duodenal fluid by microscopy.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.3137%; height: 1.38889%;">Therapy: Praziquantel; surgery in case of biliary obstruction.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 19.697%; width: 43.1373%; height: 1.38889%;">Prevention: Proper cooking, or freezing of fish at 20 C for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 21.0859%; width: 34.4771%; height: 1.38889%;">7 days destroys the parasite. Abandon use of human feces to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.3485%; width: 16.3399%; height: 1.38889%;">fertilize fish ponds.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 25.2525%; width: 40.6863%; height: 1.38889%;">Epidemiology: Clonorchiasis is the most common liver fluke
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.6414%; width: 34.4771%; height: 1.38889%;">in humans. Estimates show that approximately 35 million
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.0303%; width: 34.4771%; height: 1.38889%;">people are infected world wide, of which 15 million are in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 29.2929%; width: 34.4771%; height: 1.38889%;">China. In endemic areas, the highest prevalence is in adults
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.6818%; width: 34.4771%; height: 1.38889%;">over 30 years of age. The intensity of human infection depends
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.0707%; width: 52.7778%; height: 1.38889%;">on the eating habits of the population. In Asia, eating raw fish
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 33.3333%; width: 34.4771%; height: 1.38889%;">is common together with alcohol consumption and, therefore,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.7222%; width: 34.4771%; height: 1.13636%;">men are more often infected than women. The incidence is low
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.1111%; width: 34.4771%; height: 2.65152%;">in children. In China the prevalence in some regions is increas-
ing, probably due to increased consumption of raw freshwater
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.7626%; width: 34.4771%; height: 1.38889%;">fish. The geographical extent of the disease is determined by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 40.1515%; width: 34.4771%; height: 1.38889%;">snail distribution, the eating habits of the local population, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.4141%; width: 34.4771%; height: 1.38889%;">contamination of freshwater with egg-containing feces. In
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.803%; width: 34.4771%; height: 1.38889%;">southern China the disease is maintained by the practice of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 44.1919%; width: 34.4771%; height: 1.38889%;">using human feces in carp raising ponds to promote plankton
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.4545%; width: 34.4771%; height: 1.38889%;">growth, on which the fish feed. In non-endemic areas it
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.8434%; width: 34.4771%; height: 1.38889%;">appears in Asian immigrants, and in people who consume
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 48.1061%; width: 45.2614%; height: 7.07071%;">raw, dried, smoked or pickled fish imported from endemic areas. Map sources: The Clonorchiasis map was made by geocod-
ing human cases reported in the medical literature up
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.1768%; width: 4.90196%; height: 1.0101%;">to 2010.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 58.0808%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.3434%; width: 34.3137%; height: 1.38889%;">Lun ZR, et al. (2005) Clonorchiasis: a key foodborne zoonosis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 60.7323%; width: 24.3464%; height: 1.38889%;">in China. Lancet Infect Dis 5(1):31–41.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 62.1212%; width: 43.7909%; height: 1.38889%;">Marcos LA, et al. (2008) Update on hepatobiliary flukes:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 63.3838%; width: 32.6797%; height: 2.77778%;">fascioliasis, opisthorchiasis and clonorchiasis. Current Opin-
ion Infect Dis 21(5):523–530.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.1616%; width: 34.4771%; height: 1.38889%;">Rim HJ (2005) Clonorchiasis, an update. J Helminth
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 67.4242%; width: 6.86275%; height: 1.13636%;">79:269–281.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">135
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/cde53239-5baa-4c02-bb6f-5a4e3b45e9de" class="aLF-aPX-aPF-aPE-J3" alt="Page 45 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://gamapserver" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://gamapserver" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://gamapserver&amp;ust=1666162860000000&amp;usg=AOvVaw1HmVv6sKvNjB5987TWSPnM&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 75%; top: 56.3131%; width: 11.9281%; height: 1.26263%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 46 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 34.1503%; height: 2.39899%;">Disease: Cysticercosis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.5098%; height: 1.26263%;">Classification: ICD-9 123.1; ICD-10 B 69.0
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 43.7909%; height: 2.77778%;">Syndromes and synonyms: Taenia solium infection, neuro-
cysticercosis, cerebral cysticercosis, taeniosis, taeniasis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.2323%; width: 46.732%; height: 1.38889%;">Agent: Larval stage of the pork tapeworm T. solium. Adult
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.6212%; width: 34.4771%; height: 1.38889%;">T. solium can be 2–5 meters in length and lives in the small
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.0101%; width: 14.0523%; height: 1.13636%;">intestine of human host.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.4091%; width: 33.9869%; height: 2.52525%;">Reservoir: Humans are the definitive host; pigs are an inter-
mediate host.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.197%; width: 34.4771%; height: 1.38889%;">Transmission: Cysticercosis develops after ingesting
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 33.4596%; width: 34.4771%; height: 1.38889%;">T. solium eggs; Taeniasis (tapeworm carriage) occurs after
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.8485%; width: 34.3137%; height: 1.38889%;">ingestion of raw or undercooked pork meat with cysticerci;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.2374%; width: 31.8627%; height: 1.26263%;">human to human transmission is by the feco–oral route.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.6364%; width: 34.4771%; height: 2.77778%;">Cycle: Pigs or humans ingest eggs from contaminated envi-
ronment. Adult tapeworms will only develop in humans
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.2879%; width: 34.3137%; height: 1.38889%;">after eating raw or undercooked pork containing cysticerci.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.6768%; width: 34.4771%; height: 1.13636%;">It takes 2 months for larvae to become an adult worm and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 44.0657%; width: 34.4771%; height: 1.38889%;">produce eggs (up to 300,000 eggs per day). In pigs, eggs invade
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.3283%; width: 34.4771%; height: 1.38889%;">the general circulation via the intestinal wall and migrate to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.7172%; width: 30.719%; height: 1.38889%;">skeletal and heart muscles where they form cysticerci.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">Incubation period: It takes 2 months (range: 5–12 weeks) to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.505%; width: 34.4771%; height: 1.13636%;">mature to an adult worm in the intestine. The incubation
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.8939%; width: 41.6667%; height: 2.65152%;">period of neurocysticercosis (time from infection to first symp-
tom) is extremely variable from months to several years.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.6818%; width: 41.6667%; height: 1.26263%;">Clinical findings: Taeniosis is T. solium infection of the small
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">intestine and varies from asymptomatic (the most frequent) to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.3333%; width: 34.4771%; height: 1.38889%;">weight loss, anorexia and abdominal pain. Cysticercosis is a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.7222%; width: 37.5817%; height: 1.38889%;">tissue infection with T. solium larvae with findings depending
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.1111%; width: 34.3137%; height: 1.26263%;">on where cysticerci develop (subcutaneous, eye, heart, CNS).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.3737%; width: 34.4771%; height: 1.38889%;">Its localization in the CNS, causing neurocysticercosis, is the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.7626%; width: 34.4771%; height: 1.26263%;">most severe form of the disease: seizures, headache, focal
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.3137%; height: 1.38889%;">neurologic signs, epilepsy, and hydrocephalus may develop.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.4141%; width: 9.47712%; height: 1.13636%;">The CFR is low.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 68.9394%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Taeniosis: detection of eggs in stool by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.202%; width: 34.4771%; height: 1.38889%;">microscopy; T. solium eggs can not be distinguished from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.5909%; width: 34.4771%; height: 1.38889%;">T. saginata eggs; serology; Neurocysticercosis: histology; CT
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 72.9798%; width: 34.4771%; height: 1.38889%;">or MRI scan brain; serology is not sensitive or specific for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.3687%; width: 10.7843%; height: 1.26263%;">neurocysticercosis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.6414%; width: 34.4771%; height: 2.77778%;">Therapy: Taeniosis: praziquantel. Neurocysticercosis: Treat-
ment must be individualized case by case but could include
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">cestocidal drugs (albendazole or praziquantel), symptomatic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">measures (antiepileptic drugs, oedema reducing drugs,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">ventriculoperitoneal shunt) and removal by neurosurgery
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 20.8333%; width: 11.7647%; height: 1.26263%;">(limited indications).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.6111%; width: 34.4771%; height: 2.77778%;">Prevention: Sanitation (particularly use of latrine and main-
taining pigs enclosed); hygiene; meat inspection; thorough
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.2626%; width: 33.9869%; height: 2.77778%;">cooking of pig meat before consumption; treatment of tape-
worm carriers. A vaccine has been developed for cattle.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 30.5556%; width: 34.1503%; height: 1.38889%;">Epidemiology: Cysticerosis has a worldwide distribution,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.9444%; width: 34.4771%; height: 2.65152%;">mainly where pigs are consumed and sanitation is substan-
dard (see Streptococcus suis map for pig density and Sanitation
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.596%; width: 34.3137%; height: 2.77778%;">map). In endemic countries it is an important cause of epi-
lepsy, causing a high disease burden in mainly poor families.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 37.3737%; width: 34.4771%; height: 1.26263%;">In several countries neurocysticercosis is the cause of 10–50%
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.6364%; width: 34.4771%; height: 1.38889%;">of seizures. Neurocysticercosis is common in Latin America
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 40.0253%; width: 34.4771%; height: 1.38889%;">and non-Muslim African and Asian countries where pig is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.2879%; width: 34.4771%; height: 1.38889%;">eaten and traditional pig rearing is practiced. Regions with the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.6768%; width: 34.4771%; height: 1.38889%;">habit of eating raw or undercooked pig meat are at increased
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 44.0657%; width: 34.4771%; height: 1.38889%;">risk. In Europe, cysticercosis has largely disappeared due to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.3283%; width: 34.4771%; height: 2.77778%;">strong health system and good sanitation. In several devel-
oped nations, like the USA and Spain, there is an increase in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 48.1061%; width: 34.4771%; height: 1.38889%;">certain regions where lots of migrants live who have come
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.3687%; width: 34.4771%; height: 1.38889%;">from high endemic countries. Tapeworm carriers can cause
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.7576%; width: 34.4771%; height: 1.38889%;">small outbreaks, as was observed in a Jewish community in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 52.1465%; width: 30.2288%; height: 1.26263%;">New York that employed cooks from Latin America.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 54.9242%; width: 34.1503%; height: 1.38889%;">Map sources: The Cysticercosis map is modified from G.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 56.3131%; width: 34.4771%; height: 1.26263%;">Roman et al. (2000) and WHO (2009) at: http://gamapserver
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 57.5758%; width: 33.4967%; height: 1.38889%;">.who.int/mapLibrary/Files/Maps/Global_cysticercosis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.9646%; width: 6.86275%; height: 1.38889%;">_2009.png.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 61.7424%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.1313%; width: 34.4771%; height: 1.38889%;">Carpio A (2002) Neurocysticercosis: an update. Lancet Infect
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 64.3939%; width: 11.7647%; height: 1.13636%;">Dis 2:751–762.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.7828%; width: 34.4771%; height: 1.38889%;">Carpio A, et al. (2008) Effects of albendazole treatment on
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 67.0455%; width: 34.4771%; height: 1.38889%;">neurocysticercosis: a randomised controlled trial. J Neurol
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 68.4344%; width: 20.098%; height: 1.38889%;">Neurosurg Psychiat 79(9):1050–1055.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.8232%; width: 34.3137%; height: 1.38889%;">Dixon HB, et al. (1961) Cysticercosis: an analysis and follow-up
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.0859%; width: 36.4379%; height: 1.38889%;">of 450 cases. Spec Rep Ser Med Res Coun 299:1–58.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 72.4748%; width: 34.8039%; height: 2.77778%;">Engels D, et al. (2003) The control of human (neuro)cysticer-
cosis: which way forward? Acta Trop 87:177–182.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 75.2525%; width: 34.4771%; height: 1.26263%;">Roman G, et al. (2000) A proposal to declare neurocysticercosis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 76.5152%; width: 33.1699%; height: 1.38889%;">an international reportable disease. Bull World Health Organ
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 77.904%; width: 8.16994%; height: 1.26263%;">78(3):399–406.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">137
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/4bcdd12d-dfd6-4035-b8f3-00328d45e6b3" class="aLF-aPX-aPF-aPE-J3" alt="Page 46 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 47 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 41.8301%; height: 2.39899%;">Disease: Diphyllobothriasis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.0196%; height: 1.26263%;">Classification: ICD-9 123.4; ICD-10 B70.0
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 33.9869%; height: 2.77778%;">Syndromes and synonyms: Diphyllobothriosis, Dibothrio-
cephaliasis, broad or fish tapeworm infection
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 44.7712%; height: 1.38889%;">Agent: The cestode Diphyllobothrium latum (fish or broad
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">tapeworm), the largest human tapeworm (up to 25 meters
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 37.2549%; height: 1.38889%;">long). In Japan and eastern Russia D. nihonkaiense is common.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 38.2353%; height: 1.38889%;">At least 13 other Diphyllobothrium species have been reported
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 21.2418%; height: 1.38889%;">to infect humans, but less frequently.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 40.8497%; height: 2.52525%;">Reservoir: In addition to humans, dogs and fish-eating ter-
restrial and marine mammals can also serve as definitive hosts
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.2172%; width: 34.4771%; height: 5.42929%;">for D. latum. Transmission: Consumption of raw or undercooked fresh-
water fish containing infectious larvae. There is no direct
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.5202%; width: 17.6471%; height: 1.38889%;">person-to-person transmission.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.1717%; width: 34.4771%; height: 1.26263%;">Cycle: Eggs are passed in feces into freshwater bodies, mature
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.4343%; width: 34.4771%; height: 1.38889%;">in about 2 to 3 weeks, depending on water temperature, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 44.8232%; width: 34.4771%; height: 4.0404%;">hatch ciliated larvae (coracidia). Coracidia develop into procer-
coid larvae after ingestion by freshwater crustaceans (cope-
pods). The copepods are eaten by a second intermediate host,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 48.8636%; width: 34.4771%; height: 1.38889%;">typically small fish. The larvae migrate into the musculature
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.2525%; width: 34.4771%; height: 1.26263%;">where they develop into the human infectious plerocercoid
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.5152%; width: 34.4771%; height: 1.38889%;">larvae. Larger predator fish (e.g. pike, burbot, perch) ingest
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 52.904%; width: 34.4771%; height: 1.38889%;">the smaller infected fish upon which the plerocercoid larvae
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.1667%; width: 34.4771%; height: 1.38889%;">migrate to the flesh of these larger fish that serve as third
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.5556%; width: 37.0915%; height: 2.77778%;">intermediate hosts harboring larvae. Humans and larger mam-
mals acquire the disease by eating these larger fish raw or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.2071%; width: 34.4771%; height: 1.38889%;">undercooked. The larvae mature into adult tapeworms that
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.596%; width: 34.4771%; height: 2.77778%;">attach to the small intestinal wall by scolex and develop egg-
filled proglottids that detach. Up to 1 million eggs per day per
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.2475%; width: 31.2092%; height: 1.38889%;">worm are passed in the feces, 2–6 weeks after infection.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 64.899%; width: 19.1176%; height: 1.26263%;">Prepatent period: 2–6 weeks.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.4242%; width: 34.3137%; height: 1.38889%;">Clinical findings: Most infections are asymptomatic or mild.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 68.8131%; width: 34.4771%; height: 1.38889%;">Symptoms are: abdominal discomfort, diarrhea, vomiting and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.0758%; width: 34.4771%; height: 1.38889%;">weight loss, rarely anemia. Massive infections may result in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.4646%; width: 33.9869%; height: 2.77778%;">intestinal obstruction. Migration of proglottids can cause cho-
lecystitis or cholangitis. Proglottids can be seen in the stool.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 75.3788%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Microscopic identification of eggs in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.7677%; width: 30.0654%; height: 1.38889%;">stool, visualization of proglottids passed in the stool.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">Therapy: Praziquantel and niclosamide are the drugs of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">choice. In untreated cases the worms can live up to 25 years
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 10.7843%; height: 1.38889%;">and produce eggs.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 22.3485%; width: 35.2941%; height: 1.38889%;">Prevention: Avoid ingesting raw freshwater fish. Adequate
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.7374%; width: 34.4771%; height: 1.38889%;">cooking, freezing at 20 C for at least 7 days, or irradiation of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 25.1263%; width: 27.2876%; height: 1.38889%;">fish or meat will kill encysted larvae. Sanitation.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 28.0303%; width: 34.3137%; height: 1.26263%;">Epidemiology: Human infection is associated with cold
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 29.2929%; width: 34.4771%; height: 1.38889%;">waters in the northern hemisphere. A 2005 estimate stated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.6818%; width: 34.4771%; height: 1.38889%;">that 20 million people were infected world wide. It is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.0707%; width: 34.4771%; height: 1.38889%;">common in communities, as in Japan, that have a habit of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 33.3333%; width: 36.1111%; height: 1.38889%;">eating raw or undercooked fish. Risky fish dishes are sushi,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.7222%; width: 34.4771%; height: 1.38889%;">sashimi, South American ceviche, fish carpaccio, salmon
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.1111%; width: 34.6405%; height: 1.13636%;">tartare, and salted or marinated fillets in Scandinavia or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 37.3737%; width: 34.4771%; height: 1.38889%;">Baltic region. Historically, Finland and Alaska had a high
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.7626%; width: 34.4771%; height: 1.38889%;">disease prevalence, but this has decreased due to preventive
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 40.1515%; width: 34.4771%; height: 1.38889%;">measures. Women seem more at risk, probably due to being
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.4141%; width: 34.4771%; height: 1.38889%;">involved in meal preparation. The disease incidence is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.803%; width: 34.4771%; height: 1.38889%;">increasing in some countries such as Russia, South Korea,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 44.1919%; width: 34.4771%; height: 1.38889%;">Japan, and Brazil. Cases are also reported from regions
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.4545%; width: 34.4771%; height: 2.77778%;">where diphyllobothriasis was expected to have been elimi-
nated, such as Alpine lakes in Switzerland, northern Italy,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 48.1061%; width: 34.4771%; height: 1.38889%;">and eastern France. It is not clear whether the cases reported
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.495%; width: 34.4771%; height: 1.38889%;">in Hawaii and Brazil are autochthonous or from imported
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.8838%; width: 34.4771%; height: 1.38889%;">fish. D. nihonkaiense, present in Japan and far eastern Russia,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 52.1465%; width: 34.3137%; height: 2.77778%;">has been reported from a patient who ate raw Pacific sock-
eye salmon (Oncorhynchus nerka) from British Columbia,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.9242%; width: 34.4771%; height: 2.65152%;">Canada. D. pacificum (formerly D. arctocephalinum) is increas-
ingly reported as a human parasite along the coast of South
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.5758%; width: 34.4771%; height: 1.38889%;">America. Infected fish can be transported to any part of the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.9646%; width: 14.2157%; height: 1.38889%;">world for consumption.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 61.8687%; width: 34.3137%; height: 1.38889%;">Map sources: The Diphyllobothriasis map was made by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.2576%; width: 34.4771%; height: 1.38889%;">visualizing regions or countries were cases have been reported
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 64.5202%; width: 20.4248%; height: 1.38889%;">in the medical literature up to 2010.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 67.5505%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 68.8131%; width: 50.6536%; height: 1.38889%;">Rausch RL, et al. (2010) Identity of Diphyllobothrium spp.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.0758%; width: 33.1699%; height: 1.38889%;">(Cestoda: Diphyllobothriidae) from sea lions and people
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.4646%; width: 33.3333%; height: 1.38889%;">along the Pacific Coast of South America. J Parasit
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 72.8535%; width: 8.16994%; height: 1.26263%;">96(2):359–365.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 74.2424%; width: 34.4771%; height: 1.26263%;">Scholz T, et al. (2009) Update on the human broad tapeworm
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 75.5051%; width: 36.7647%; height: 1.38889%;">(genus Diphyllobothrium), including clinical relevance. Clin
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 76.8939%; width: 20.098%; height: 1.26263%;">Microbiol Rev 22(1):146–160.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">139
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/67a5f11a-1d38-466b-a00e-357ce5951366" class="aLF-aPX-aPF-aPE-J3" alt="Page 47 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://apps.who.int/dracunculiasis" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://apps.who.int/dracunculiasis" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://apps.who.int/dracunculiasis&amp;ust=1666162860000000&amp;usg=AOvVaw13lk-h0L1obBNnIujlBsWd&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 66.1765%; top: 57.3232%; width: 20.7516%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 48 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 36.2745%; height: 2.0202%;">Disease: Dracunculiasis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 23.2026%; height: 1.26263%;">Classification: ICD-9 125.7; ICD-10 B72
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.4771%; height: 1.26263%;">Syndromes and synonyms: Guinea worm disease, Medina
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.7071%; width: 34.4771%; height: 1.38889%;">worm disease, Pharaoh worm disease, serpent worm disease,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.096%; width: 7.35294%; height: 1.13636%;">dracontiasis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.6212%; width: 34.4771%; height: 1.26263%;">Agent: Dracunculus medinensis, a nematode roundworm. The
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.0101%; width: 34.3137%; height: 1.38889%;">longest adult female recorded is 80 cm, and adult male 40 cm.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.6616%; width: 14.5425%; height: 1.13636%;">Reservoir: Humans.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.3131%; width: 34.3137%; height: 1.38889%;">Vector: Cyclops spp., microscopic copepods (crustaceans)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.5758%; width: 34.4771%; height: 4.0404%;">commonly known as water fleas. Transmission: By ingestion of infected copepods, usually
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.4899%; width: 12.0915%; height: 1.38889%;">with drinking water.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.1414%; width: 34.3137%; height: 1.26263%;">Cycle: Human–copepod–human. Adult female worm expels
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 40.404%; width: 34.4771%; height: 1.38889%;">larvae through a hole in the skin of the leg or foot of an infected
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.7929%; width: 34.4771%; height: 1.38889%;">person into stagnant water where they are ingested by the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.1818%; width: 34.4771%; height: 1.0101%;">vectors. The larvae become infectious in 2 weeks and when the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 44.4444%; width: 34.4771%; height: 1.38889%;">vectors are ingested and digested, the larvae are freed and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.8333%; width: 34.4771%; height: 1.38889%;">migrate into the subcutaneous tissue of the abdomen and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.2222%; width: 34.4771%; height: 1.38889%;">thorax. There they mature into adults. Larvae are shed for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 48.4848%; width: 34.4771%; height: 1.38889%;">2–3 weeks, are viable in water for up to 5 days, and develop in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.8737%; width: 14.5425%; height: 1.38889%;">the copepod for 2 weeks.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 52.399%; width: 32.1895%; height: 1.38889%;">Incubation period: About 12 months (10 to 18 months).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.0505%; width: 34.3137%; height: 1.38889%;">Clinical findings: Blister,usually onthelegor foot,which burns
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 56.3131%; width: 34.3137%; height: 1.38889%;">or itches, fever, nausea, vomiting, diarrhea, dyspnea, dizziness
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.702%; width: 34.3137%; height: 1.38889%;">and generalized urticaria. Multiple and repeat infections occur,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.0909%; width: 34.4771%; height: 1.38889%;">there is no protective immunity. Painful and infected ulcers can
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 60.3535%; width: 34.4771%; height: 1.38889%;">incapacitate patients for months. Secondary bacterial infection
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.7424%; width: 34.4771%; height: 1.38889%;">can lead to abscesses, synovitis, ankylosis andlimbcontractures,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.1313%; width: 23.366%; height: 1.38889%;">septic arthritis, and life-threatening sepsis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.6566%; width: 34.4771%; height: 2.77778%;">Diagnostic tests: Visual inspection for adult worm protrud-
ing from the skin lesion; microscopic identification of larvae
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 68.3081%; width: 24.6732%; height: 1.13636%;">released when lesion is immersed in water.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.9596%; width: 34.3137%; height: 1.38889%;">Therapy: Adult worm can be extracted by carefully and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 72.2222%; width: 34.4771%; height: 1.38889%;">slowly winding the worm around a stick over a period of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.6111%; width: 33.9869%; height: 2.77778%;">days. Metronidazole or thiabendazole can facilitate the extrac-
tion process, but should be used with caution.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.6515%; width: 34.6405%; height: 1.38889%;">Prevention: Use of safe water by filtering or boiling or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 79.0404%; width: 34.4771%; height: 1.26263%;">disinfection with temephos (insecticide). Avoid wading in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">contaminated water, especially people with an apparent
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">worm. There is no vaccine, but tetanus toxoid may be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 2.77778%;">given to prevent tetanus. The Global Guinea Worm Eradi-
cation Programme is led by the Carter Center, CDC, WHO,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.3137%; height: 1.13636%;">UN Children’s Fund and the individual efforts of endemic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.6111%; width: 4.90196%; height: 1.0101%;">nations.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 26.2626%; width: 34.3137%; height: 1.38889%;">Epidemiology: Historically, dracunculiasis was endemic in 20
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.6515%; width: 34.4771%; height: 1.26263%;">countries in Sub-Saharan Africa and Asia, with an incidence of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">3.5 million cases per year (1986). An international control effort
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.303%; width: 41.6667%; height: 1.38889%;">reduced that to just over 1,785 cases detected in five African
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.6919%; width: 34.4771%; height: 1.38889%;">countries by 2010: Mali, Ghana, South Sudan, Chad, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">Ethiopia. Nearly 95% of the cases are reported from South
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.38889%;">Sudan. Additionally, Niger reported 3 imported cases from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">Mali. Chad did not report cases for more than 10 years when an
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.13636%;">outbreak occurred with 10 cases in 2010. In Mali and Southern
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.3838%; width: 34.4771%; height: 1.38889%;">Sudan, violence has interfered with the eradication campaign,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 2.77778%;">but Ghana and Ethiopia are close to eradication. Ghana diag-
nosed their last indigenous case in May 2010. Dracunculiasis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.4242%; width: 34.4771%; height: 1.38889%;">mainly affects poor communities without a safe portable water
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.8131%; width: 34.3137%; height: 1.26263%;">supply and is mainly limited to remote nomadic communities.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">There is a marked increase in infection in the dry season when
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.4646%; width: 34.4771%; height: 1.38889%;">stagnant pools are the only source of water. Most cases are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">young (working) adults who may be exposed to contaminated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">water sources more frequently. There is no particular age or sex
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.505%; width: 34.4771%; height: 1.38889%;">predilection. Countries free of transmission neighboring
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">endemic countries should remain alert for imported cases
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 22.8758%; height: 1.38889%;">and take adequate preventive measures.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 55.9343%; width: 34.1503%; height: 1.38889%;">Map sources: The Dracunculiasis map was made with data
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.3232%; width: 34.4771%; height: 1.38889%;">obtained from WHO (http://apps.who.int/dracunculiasis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 58.5859%; width: 34.3137%; height: 1.38889%;">/dradata/) and the CDC’s Guinea Worm Wrap Up Nr. 202
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 59.9747%; width: 3.92157%; height: 1.38889%;">(2011).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 62.8788%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 64.1414%; width: 34.4771%; height: 1.38889%;">Centers for Disease Control and Prevention (2010) Progress
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 65.5303%; width: 33.1699%; height: 1.38889%;">toward global eradication of dracunculiasis, January
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 66.7929%; width: 34.3137%; height: 1.38889%;">2009–June 2010. Morb Mortal Wkly Rep 59(38):1239–1242.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 68.1818%; width: 34.4771%; height: 1.26263%;">Centers for Disease Control and Prevention (2011) Guinea
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.4444%; width: 34.4771%; height: 2.77778%;">Worm Wrap Up nr 202. Memorandum. Glenshaw MT, et al. (2009) Guinea worm disease outcomes in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 72.2222%; width: 33.1699%; height: 1.38889%;">Ghana: determinants of broken worms. Am J Trop Med Hyg
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.6111%; width: 8.16994%; height: 1.26263%;">81(2):305–312.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 74.8737%; width: 39.0523%; height: 1.38889%;">Iriemenam NC, et al. (2008) Dracunculiasis – the saddle is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 76.2626%; width: 25.9804%; height: 1.38889%;">virtually ended. Parasitol Res 102(3):343–347.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 77.6515%; width: 34.4771%; height: 1.38889%;">Lodge M (2010) And then there were four: more countries beat
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 78.9141%; width: 26.4706%; height: 1.38889%;">guinea worm disease. Brit Med J 340:c496.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">141
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/a64bc9a7-7b58-43df-9751-264a14ed67a8" class="aLF-aPX-aPF-aPE-J3" alt="Page 48 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 49 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 60.7843%; height: 2.27273%;">Disease: Echinococcosis, Echinococcus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 28.7582%; top: 14.2677%; width: 21.5686%; height: 2.14646%;">multilocularis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.3182%; width: 27.7778%; height: 1.26263%;">Classification: ICD-9 122.7; ICD-10 B67.5–B67.7
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 21.8434%; width: 34.4771%; height: 1.26263%;">Syndromes and synonyms: Alveolar or multilocular
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.1061%; width: 8.82353%; height: 1.13636%;">echinococcosis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 25.8838%; width: 34.3137%; height: 1.38889%;">Agent: Echinococcus multilocularis, a small (3–6 mm long)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.2727%; width: 19.1176%; height: 1.38889%;">cyclophyllid cestode (tapeworm).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 29.9242%; width: 34.3137%; height: 1.38889%;">Reservoir: Foxes (including urban foxes) are the definitive
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.3131%; width: 34.3137%; height: 1.38889%;">hosts, wild rodents (mainly Arvicolidae), voles and lemmings
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.5758%; width: 34.4771%; height: 1.13636%;">are intermediate hosts. Foxes have extended their distribution
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 33.9646%; width: 34.4771%; height: 1.38889%;">into urban areas, partly due to a decrease in rabies deaths in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.3535%; width: 17.1569%; height: 1.13636%;">foxes since rabies vaccination.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.0051%; width: 34.4771%; height: 1.38889%;">Transmission: Ingestion of tapeworm eggs from feces of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.3939%; width: 34.4771%; height: 1.38889%;">foxes, dogs, and cats or contaminated fomites. There is no
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 40.7828%; width: 17.6471%; height: 1.26263%;">person-to-person transmission.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.4343%; width: 34.4771%; height: 2.65152%;">Cycle: Fox–rodent–fox (sylvatic cycle). Foxes are the defini-
tive hosts of the adult worm. Eggs are excreted with the feces
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.0859%; width: 34.3137%; height: 1.38889%;">and ingested by humans or the intermediate rodent host,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.4747%; width: 34.4771%; height: 1.38889%;">where they hatch. The larvae penetrate the intestinal wall and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 48.7374%; width: 34.3137%; height: 1.38889%;">via the blood they reach the liver, lungs, brain, and heart.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.1263%; width: 34.4771%; height: 1.38889%;">There they form metacestodes in which protoscolices
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.5152%; width: 34.3137%; height: 1.38889%;">develop. When the rodent is eaten by the definitive host,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 52.7778%; width: 34.3137%; height: 1.38889%;">these attach to the small intestine and grow into adult worms.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.1667%; width: 34.4771%; height: 1.38889%;">Occasionally wild carnivores (e.g. coyotes or wolves) can be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.5556%; width: 34.3137%; height: 1.26263%;">definitive hosts. In some rural areas there is a synanthropic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 56.8182%; width: 34.3137%; height: 1.38889%;">cycle in which dogs or cats are definitive hosts, acquiring the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.2071%; width: 16.0131%; height: 1.38889%;">parasite from wild rodents.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 60.8586%; width: 34.3137%; height: 1.38889%;">Incubation period: 5–15 years in humans (5–7 weeks in dogs).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.6364%; width: 34.4771%; height: 1.38889%;">Clinical findings: Headache, nausea, vomiting, abdominal
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 64.899%; width: 34.4771%; height: 1.38889%;">pain, and hepatomegaly. In the later stage of the disease, the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.2879%; width: 34.4771%; height: 1.38889%;">metacestode may grow into neighboring organs (e.g. through
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.6768%; width: 34.4771%; height: 1.38889%;">the diaphragm into the lungs), and metastases can form
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 68.9394%; width: 34.4771%; height: 1.38889%;">anywhere. The differential diagnosis is hepatic cirrhosis or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.3283%; width: 20.4248%; height: 1.13636%;">carcinoma. The disease can be fatal.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 72.9798%; width: 33.9869%; height: 2.77778%;">Diagnostic tests: Histopathology; imaging tests; serodiag-
nosis with purified E. multilocularis antigen; PCR.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.0202%; width: 34.4771%; height: 1.38889%;">Therapy: Mebendazole or albendazole; radical surgical
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 78.4091%; width: 5.22876%; height: 1.13636%;">excision.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 19.3182%; width: 34.3137%; height: 1.38889%;">Prevention: Avoid exposure to feces of reservoir species wash
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.5808%; width: 34.4771%; height: 1.38889%;">hands, fruit and vegetables, periodically treat high-risk dogs,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 21.9697%; width: 34.4771%; height: 1.38889%;">eliminate ownerless dogs. Praziquantel-containing baits have
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.2323%; width: 34.4771%; height: 2.77778%;">reduced infection in urban foxes and water voles in Switzer-
land and Germany. Eggs are highly sensitive to elevated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.0101%; width: 33.9869%; height: 3.78788%;">temperatures and desiccation, but survive for months at freez-
ing temperatures and are not affected by common disinfec-
tants or ethanol.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 31.4394%; width: 34.3137%; height: 1.26263%;">Epidemiology: Echinococcosis is restricted to the northern
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.8283%; width: 34.4771%; height: 2.65152%;">hemisphere, and is most commonly found in adults. The distri-
bution of infected foxes is highly uneven; sandy soils, dry
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.4798%; width: 34.4771%; height: 1.38889%;">habitats and large forests are unfavorable for the parasite. In
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.8687%; width: 34.4771%; height: 1.38889%;">Europe, foxes have adapted well to urban life and urban fox
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.26263%;">densities now can exceed rural fox densities. However, there is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.5202%; width: 34.4771%; height: 1.13636%;">no clear correlation between fox densities and cases of human
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 40.9091%; width: 34.4771%; height: 1.13636%;">alveolar echinococcosis. In some areas there is a shift from a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.1717%; width: 34.4771%; height: 1.38889%;">sylvatic to a synantropic cycle, including domestic dogs, as
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.5606%; width: 34.4771%; height: 1.38889%;">was seen in China and Alaska. Such a shift leads to a higher
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 44.9495%; width: 34.4771%; height: 1.38889%;">risk of infection in humans. The prevalence in dogs and cats
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.2121%; width: 34.4771%; height: 1.38889%;">is still very low in Europe, even in areas highly endemic for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.601%; width: 9.96732%; height: 1.13636%;">infection in foxes.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 50.3788%; width: 34.3137%; height: 1.38889%;">Map sources: The Echinococcosis (E. multilocularis) map was
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">modified from a map provided by Peter Deplazes, University
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">of Zurich, Switzerland. The map shows areas where there is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.3137%; height: 1.38889%;">convincing parasite detection in intermediate or definitive
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 14.3791%; height: 1.38889%;">hosts, including humans.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 58.7121%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.9747%; width: 34.4771%; height: 1.38889%;">Deplazes P, et al. (2004)Wilderness in the city: the urbanization
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 61.2374%; width: 32.3529%; height: 1.38889%;">of Echinococcus multilocularis. Trends Parasit 20(2):77–84.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 62.6263%; width: 34.4771%; height: 1.38889%;">Hegglin D, et al. (2003) Anthelmintic baiting of foxes against
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 64.0152%; width: 35.7843%; height: 1.26263%;">urban contamination with Echinococcus multilocularis. Emerg
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 65.2778%; width: 15.1961%; height: 1.38889%;">Infect Dis 9(10):1266–1272.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.6667%; width: 34.4771%; height: 1.38889%;">Romig T, et al. (2006) The present situation of echinococcosis in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 68.0556%; width: 18.6275%; height: 1.38889%;">Europe. Parasit Int 55:S187–S191.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.3182%; width: 34.4771%; height: 1.38889%;">Tackmann T, et al. (1998) Spatial distribution patterns of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.7071%; width: 33.0065%; height: 1.26263%;">Echinococcus multilocularis (Leuckart 1863) (Cestoda:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 72.096%; width: 33.1699%; height: 2.65152%;">Cyclophyllidea: Taeniidae) among red foxes in an ende-
mic focus in Brandenburg, Germany. Epidemiol Infect
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 74.7475%; width: 7.35294%; height: 1.13636%;">120:101–109.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 76.0101%; width: 34.4771%; height: 1.38889%;">Veit P, et al. (1995) Influence of environmental factors on the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 77.399%; width: 33.1699%; height: 1.38889%;">infectivity of Echinococcus multilocularis eggs. Parasitology
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 78.7879%; width: 6.20915%; height: 1.13636%;">110:79–86.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">143
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/a67b4e4a-c67b-420d-af3d-a84065aba22d" class="aLF-aPX-aPF-aPE-J3" alt="Page 49 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 50 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 50.4902%; height: 2.39899%;">Disease: Eosinophilic Meningitis,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 28.5948%; top: 14.2677%; width: 45.2614%; height: 2.52525%;">Angiostrongylus cantonensis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.3182%; width: 24.183%; height: 1.26263%;">Classification: ICD-9 128.8; ICD-10 B83.2
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 21.3384%; width: 33.9869%; height: 2.65152%;">Syndromes and synonyms: Eosinophilic meningoenceph-
alitis, angiostrongyliasis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.495%; width: 34.4771%; height: 1.38889%;">Agent: Angiostrongylus cantonensis, a nematode lungworm of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 25.8838%; width: 34.3137%; height: 1.38889%;">rats. Adult worms are 17 to 25 mm long. Angiostrongylus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.2727%; width: 34.4771%; height: 1.38889%;">costaricensis is the causal agent of abdominal, or intestinal,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.5354%; width: 33.9869%; height: 4.16667%;">angiostrongyliasis and is not shown on the map. Other patho-
gens, like Gnathostoma spinigerum, are able to cause eosino-
philic meningitis, but are not shown on the map.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 33.0808%; width: 45.7516%; height: 2.77778%;">Reservoir: Rats (Rattus, particularly R. norvegicus and Bandi-
cotta spp.). Infected dogs, wild mammals, and marsupials have
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.8586%; width: 34.3137%; height: 1.38889%;">been found, but do not contribute to the spread of the disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 37.8788%; width: 34.4771%; height: 1.38889%;">Vector: Snails, slugs, and land planarians. The giant African
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.1414%; width: 34.4771%; height: 1.38889%;">snail, Achatina fulica, is the major source of infection world
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 40.5303%; width: 34.4771%; height: 1.38889%;">wide; but has been replaced by the imported South American
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.9192%; width: 33.9869%; height: 2.39899%;">golden apple snail, Pomacea canaliculata, in Taiwan and main-
land China.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.202%; width: 34.3137%; height: 1.26263%;">Transmission: Consumption of raw or undercooked vector
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.4646%; width: 34.4771%; height: 1.38889%;">molluscs, infested vegetables or vegetable juice, or other fresh
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.8535%; width: 11.1111%; height: 1.13636%;">water related food.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.7475%; width: 34.3137%; height: 1.26263%;">Cycle: Rat–mollusc–rat; humans are incidental dead-end hosts.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.0101%; width: 34.4771%; height: 1.38889%;">Larvae are excreted with rat feces, ingested by vectormolluscs, in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 52.399%; width: 34.4771%; height: 1.38889%;">which they develop into the infecting third stage larvae in about
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.7879%; width: 34.3137%; height: 1.38889%;">12 days. When ingested by a rat, the larvae enter the brain,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.1768%; width: 34.4771%; height: 1.26263%;">mature into adults, and migrate through the bloodstream to the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 56.4394%; width: 34.4771%; height: 1.38889%;">lungs. There, female worms lay eggs (about 15,000 per day) that
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.8283%; width: 34.4771%; height: 1.38889%;">hatch into larvae, which in 6–8 weeks migrate through the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.2172%; width: 34.4771%; height: 1.26263%;">bronchial system up the trachea to the pharynx, are swallowed
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 60.4798%; width: 34.4771%; height: 1.38889%;">and excreted. When ingested by a human, the third stage larvae
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.8687%; width: 31.2092%; height: 1.38889%;">also migrate to the CNS, but the worm does not mature.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.7626%; width: 34.4771%; height: 1.38889%;">Incubation period: 1 day to several months, depending on
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 18.7909%; height: 1.38889%;">parasite load; usually 1–3 weeks.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.0455%; width: 34.3137%; height: 1.38889%;">Clinical findings: Cough, rhinorrhea, sore throat, malaise,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 68.3081%; width: 34.4771%; height: 1.38889%;">and fever can develop when the worms move through the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.697%; width: 34.4771%; height: 1.38889%;">lungs. In about 5 to 14 days the larvae reach the central nervous
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.0859%; width: 34.4771%; height: 2.65152%;">system, leading to subacute meningitis. Eosinophilic meningi-
tisis defined asmeningitiswith &gt; 10 eosinophils/mLin CSFor
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.7374%; width: 34.4771%; height: 1.38889%;">at least 10% eosinophils in the total CSF leukocyte count. Some
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 75.1263%; width: 34.4771%; height: 1.38889%;">caseshavelow-grade fever and temporary facial paralysis. Signs
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.3889%; width: 34.4771%; height: 2.77778%;">of raised intracranial pressure, like diplopia. Worms occasion-
allyenter theeye.Thecourse of theillnessranges from a fewdays
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 79.0404%; width: 17.9739%; height: 1.13636%;">to several months. Death is rare.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.3182%; width: 34.4771%; height: 2.65152%;">Diagnostic tests: Mainly a clinical diagnosis: subacute eosin-
ophilic meningitis in an endemic area. Most common test is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 21.9697%; width: 34.4771%; height: 2.65152%;">serology, but there are often false-positives due to cross-reac-
tivity with other parasites. Worms are rarely seen in CSF by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.6212%; width: 33.1699%; height: 1.38889%;">microscopy. MRI or CT scan of the brain is not diagnostic.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.6414%; width: 34.4771%; height: 2.77778%;">Therapy: Mebendazole or albendazole with adjunctive corti-
costeroids. Lumbar puncture relieves the headache. Ocular
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 29.2929%; width: 15.0327%; height: 1.38889%;">infection requires surgery.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 31.3131%; width: 34.1503%; height: 1.38889%;">Prevention: Avoid eating raw slugs, snails, other molluscs,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.702%; width: 34.4771%; height: 1.38889%;">freshwater prawns, land crabs, and uncooked vegetables
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.0909%; width: 34.4771%; height: 1.38889%;">grown in ponds (e.g. watercress) from endemic areas.Washing
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.3535%; width: 34.4771%; height: 2.52525%;">of vegetables does not guarantee absence from larval contam-
ination. Boil snails and crustaceans for 5 minutes or freeze at
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 38.1313%; width: 14.0523%; height: 1.13636%;">15 C for 24 hours.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 40.1515%; width: 34.3137%; height: 1.38889%;">Epidemiology: An estimated 650 million people are at risk in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 41.4141%; width: 34.3137%; height: 1.38889%;">10 provinces of China. The distribution is closely correlated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.803%; width: 34.4771%; height: 1.38889%;">with the habit of consuming raw terrestrial molluscs, reptiles,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 44.1919%; width: 34.4771%; height: 1.38889%;">or amphibians. The majority of cases are in adults, except in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.4545%; width: 40.6863%; height: 2.77778%;">Taiwan where most cases are in children. Pomacea canaliculata, a snail native to South America, was imported into Taiwan in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 48.1061%; width: 34.3137%; height: 1.13636%;">1981 as a food source and then into mainland China. It has
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.495%; width: 37.2549%; height: 2.52525%;">replaced A. fulica as the main intermediate host of A. canto-
nensis and has become the main source of human infection in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 52.2727%; width: 34.3137%; height: 1.26263%;">Taiwan and mainland China. Depending on the region, up to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.5354%; width: 23.0392%; height: 1.13636%;">70% of P. canaliculata can be infected.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 54.9242%; width: 33.0065%; height: 1.38889%;">Eating raw frogs also lead to human infections in China, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 56.3131%; width: 34.4771%; height: 1.26263%;">the USA. Consumption of lizards caused several cases in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.5758%; width: 34.4771%; height: 1.26263%;">Thailand, Sri Lanka, and India. Cases have been seen in at
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.9646%; width: 34.4771%; height: 1.38889%;">least five countries in Europe and New Zealand in travelers
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 60.2273%; width: 34.4771%; height: 1.38889%;">returning from endemic regions. Malnutrition and debilitating
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.6162%; width: 21.0784%; height: 1.13636%;">diseases can exacerbate the infection.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 63.6364%; width: 34.1503%; height: 1.38889%;">Map sources: The Eosinophilic meningoencephalitis map
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.0253%; width: 34.4771%; height: 1.38889%;">was made by geocoding reported cases in the medical
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.2879%; width: 35.7843%; height: 1.38889%;">literature. The inset map with A. cantonensis prevalence in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 67.6768%; width: 23.5294%; height: 1.26263%;">snails is obtained from S. Lv et al. (2009).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 69.697%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 71.0859%; width: 34.4771%; height: 1.38889%;">Wang Q-P, et al. (2008) Human angiostrongyliasis. Lancet Infect
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 72.3485%; width: 11.7647%; height: 1.38889%;">Dis 8(10):621–630.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 73.7374%; width: 34.3137%; height: 1.38889%;">Lv S, et al. (2009) Invasive snails and an emerging infectious
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 75.1263%; width: 25.3268%; height: 1.38889%;">disease. PLoS Negl Trop Dis 3(2):e368.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 76.3889%; width: 34.4771%; height: 1.38889%;">Ramirez-Avila L, et al. (2009) Eosinophilic meningitis due to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 77.7778%; width: 33.0065%; height: 1.38889%;">Angiostrongylus and Gnathostoma species. Clin Infect Dis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 79.0404%; width: 8.16994%; height: 1.38889%;">48(3):322–327.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">145
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/923694aa-652f-49d0-a50b-2563f4432ce7" class="aLF-aPX-aPF-aPE-J3" alt="Page 50 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 51 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 31.2092%; height: 2.0202%;">Disease: Fascioliasis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.0196%; height: 1.26263%;">Classification: ICD-9 121.3; ICD-10 B66.3
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 33.9869%; height: 2.77778%;">Syndromes and synonyms: Sheep liver fluke disease, pha-
ryngeal fascioliasis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.3137%; height: 1.38889%;">Agent: Large trematode liver flukes living in blile ducts:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 40.0327%; height: 1.38889%;">Fasciola hepatica and Fasciola gigantica. F. hepatica is 20 to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 30.5556%; height: 1.38889%;">30 mm long and F. gigantica can be up to 75 mm long.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 33.9869%; height: 2.65152%;">Reservoir: Sheep, cattle, water buffalo, and other large herbi-
vores. Occasionally humans.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 27.451%; height: 1.38889%;">Vector: Freshwater (pond) snails (Lymnaeidae).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.4771%; height: 2.77778%;">Transmission: Accidental ingestion of metacercariae via con-
taminated water, watercress, or other contaminated plants
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">(lettuce, alfalfa juice, etc.). Rarely via consumption of raw
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 33.9869%; height: 2.77778%;">sheep or goat liver (pharyngeal fascioliasis). There is no per-
son-to-person transmission.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">Cycle: Eggs hatch in water and release miracidia larvae that
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">penetrate the snail, where they develop to cercariae that encyst
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 4.16667%;">on aquatic plants (e.g. watercress) and become desiccation-
resistant metacercariae. After the plants are eaten by herbi-
vores (e.g. sheep, cattle), or water containing metacercariae is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">drunk, the larvae pass through the intestinal wall into the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">peritoneal cavity, enter the liver, and lay eggs in the bile duct,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.3137%; height: 1.38889%;">which are then excreted in the feces. The whole cycle takes 3 to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 5.88235%; height: 1.13636%;">4 months.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 32.5163%; height: 1.38889%;">Incubation period: 3 to 4 months, but is highly variable.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">Clinical findings: Acute: hepatomegaly, prolonged fever,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.3137%; height: 1.26263%;">anorexia, weight loss, nausea, vomiting, cough, diarrhea,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.4771%; height: 1.38889%;">urticaria, lymphadenopathies, and arthralgias. Significant
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">clinical improvement 3–5 days after specific treatment is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">diagnostic. Chronic (which may be asymptomatic and last
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">for more than 10 years): biliary obstruction with upper
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">abdominal pain, cholecystitis, cholangitis, and extrahepatic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.3137%; height: 1.38889%;">cholestasis. Liver fibrosis may be a complication of the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 5.71895%; height: 1.13636%;">infection.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Microscopy for eggs on stool samples by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.3137%; height: 1.38889%;">the Kato–Katz or rapid sedimentation techniques (RSTs) are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 34.4771%; height: 1.26263%;">diagnostic for the chronic infection. Serological tests (Fas2-
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.2727%; width: 34.4771%; height: 1.38889%;">ELISA) is recommended for acute infection. The intradermal
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 78.6616%; width: 34.4771%; height: 1.38889%;">test is rapid and sensitive, but as it is not sufficiently specific it
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">is no longer used. Radiology, such as computed tomography,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">can demonstrate liver lesions (only in acute infection) similar
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">to metatastic lesions. For chronic infections, a cholangiogram
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.3137%; height: 1.38889%;">can detect bile duct pathology caused by the adult parasites.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 33.9869%; height: 2.77778%;">Therapy: Above 95% cure rate with a single dose triclaben-
dazole. Albendazole or praziquantel are not effective.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 27.5253%; width: 34.3137%; height: 1.13636%;">Prevention: Sanitation to avoid contamination of vector snail
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">habitat with human or animal feces. Improve water drainage,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">use molluscicides and avoid eating uncooked aquatic plants in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 25.6536%; height: 1.38889%;">endemic areas and drinking untreated water.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 34.3434%; width: 34.3137%; height: 1.26263%;">Epidemiology: It is estimated that 17 million people are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.3137%; height: 1.13636%;">infected world wide and 91 million are at risk of infection.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">F. hepatica is endemic on all continents but is of particular
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">public health importance in the Andean countries (especially
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 2.77778%;">Peru and Bolivia), Ecuador, Chile, Argentina, Brazil, Vene-
zuela, Cuba, Mexico, the Islamic Republic of Iran, Egypt,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">Philippines, and western Europe (e.g. France, Portugal, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">Spain). Infections with F. gigantica are restricted to Africa
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">and Asia. Both species of fluke overlap in many areas of Africa
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">and Asia, whereas F. hepatica is the major concern in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">Americas, Europe, and Oceania. The rural areas of the Andean
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.3137%; height: 1.38889%;">region of Peru and Bolivia have prevalence rates of up to 68%.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">Women are affected more than men, with higher prevalence
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">rates, more severe infections, and more reported liver or biliary
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">complications; children are affected more than adults. The
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">main source of infection is the consumption of raw vegetables
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 34.4771%; height: 1.26263%;">contaminated with metacercariae, such as watercress, salads,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">and contaminated water from irrigation channels. Pharyngeal
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 44.1177%; height: 2.52525%;">fascioliasis may occur after ingestion of raw goat or sheep liver – a dish in some Middle Eastern countries.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 62.5%; width: 34.3137%; height: 1.38889%;">Map sources: The Fascioliasis map was made by geocoding
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 34.3137%; height: 1.38889%;">reported human cases in the medical literature up to 2009.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">F. gigantica could be more widespread than shown, because it
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.5404%; width: 39.7059%; height: 1.38889%;">could be the species reported as unspecified Fasciola. We were
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 67.9293%; width: 42.4837%; height: 1.38889%;">only able to find a few reports of human cases with F. gigantica
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.1919%; width: 24.5098%; height: 1.38889%;">in Africa, but it is probably underreported.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 71.9697%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 73.2323%; width: 34.4771%; height: 1.38889%;">Keiser J, et al. (2009) Food-borne trematodiasis. Clin Microbiol
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 74.6212%; width: 14.8693%; height: 1.26263%;">Rev 22(3):466–483.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 76.0101%; width: 43.7909%; height: 1.26263%;">Marcos LA, et al. (2008) Update on hepatobiliary flukes:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 77.2727%; width: 33.0065%; height: 1.38889%;">fascioliasis, opisthorchiasis and clonorchiasis. Curr Opin
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 78.6616%; width: 15.1961%; height: 1.38889%;">Infect Dis 21(5):523–530.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">147
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/ae98aa21-377e-46c4-ba40-27707678a3e5" class="aLF-aPX-aPF-aPE-J3" alt="Page 51 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.fao.org/ag/againfo/resources/en/glw/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.fao.org/ag/againfo/resources/en/glw/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.fao.org/ag/againfo/resources/en/glw/&amp;ust=1666162860000000&amp;usg=AOvVaw2q9as0WeOkksmI-W0ug16y&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 60.2941%; top: 51.0101%; width: 26.4706%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 52 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 36.7647%; height: 2.39899%;">Disease: Fasciolopsiasis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.0196%; height: 1.26263%;">Classification: ICD-9 121.4; ICD-10 B66.5
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.3137%; height: 1.26263%;">Syndromes and synonyms: Giant intestinal fluke infection.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">Agent: Fasciolopsis buski, a large trematode worm that can be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 10.6209%; height: 1.38889%;">up to 75 mm long.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">Reservoir: Pigs and humans are definitive hosts; less often
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 3.43137%; height: 1.38889%;">dogs.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">Transmission: Eating contaminated water plants. There is no
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.6919%; width: 17.6471%; height: 1.26263%;">person-to-person transmission.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">Cycle: Eggs develop in water in 3–7 weeks, hatch producing
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.4771%; height: 1.26263%;">miracidia which enter the intermediate snail hosts, in which
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.4771%; height: 1.38889%;">they develop into cercariae. The cercariae encyst on water
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">plants and develop to metacercariae. When ingested, the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">metacercariae excyst in the duodenum, where theflukes attach
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">to the mucosa of the small intestine, mature, and start egg
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 16.5033%; height: 1.38889%;">production in 2 to 3 months.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 26.9608%; height: 1.26263%;">Incubation period: Varies from 1 to 3 months.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.3137%; height: 1.38889%;">Clinical findings: Usually asymptomatic or mild. Diarrhea
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">alternating with constipation, vomiting and anorexia, edema
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">of the face, abdominal wall and legs, ascites. Heavy worm
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">loads may cause bowel obstruction. Eosinophilia, vitamin B12
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 25.9804%; height: 1.38889%;">deficiency, and secondary anemia may occur.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.3137%; height: 1.38889%;">Diagnostic tests: Detection of eggs in feces (eggs resemble
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">those of Fasciola hepatica). Adult flukes may be seen in the stools
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 5.55556%; height: 1.13636%;">or vomit.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 22.0588%; height: 1.38889%;">Therapy: Praziquantel or niclosamide.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 64.1414%; width: 34.4771%; height: 1.38889%;">Prevention: Sanitation. Avoid eating uncooked water plants
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.5303%; width: 34.4771%; height: 1.38889%;">in endemic areas. Do not fertilize water plants for consumption
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.9192%; width: 34.4771%; height: 1.38889%;">with human or pig feces. Abandon practice of feeding water
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 68.1818%; width: 34.4771%; height: 1.38889%;">plants to pigs. Health education. The eggs can resist low
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.5707%; width: 35.2941%; height: 1.38889%;">temperatures and can be maintained at 4 C for 3 to 4 months;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">they are killed at 50 C in 4 hours. Water can be chemically
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 21.732%; height: 1.13636%;">treated to kill the flukes.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 20.4545%; width: 34.3137%; height: 1.38889%;">Epidemiology: Especially prevalent in pig-rearing regions of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 21.8434%; width: 34.4771%; height: 1.38889%;">Southeast Asia, where it is estimated that 10 million people are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.2323%; width: 34.4771%; height: 1.0101%;">infected. The disease is most common in lowlands where the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.495%; width: 34.4771%; height: 1.38889%;">snail host is present and it is common practice to fertilize water
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 25.8838%; width: 34.4771%; height: 1.38889%;">plants with pig or human feces. Disease spread is facilitated by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.2727%; width: 34.4771%; height: 4.0404%;">heavy rainfall and extensive flooding, leading to fecal contam-
ination of the water. Highest incidence and intensity of infec-
tion is found in 10 to14 year old children (no sex difference),
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.3131%; width: 34.4771%; height: 1.38889%;">probably because they pick and consume water plants when
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.5758%; width: 34.4771%; height: 1.38889%;">they play. In foci of parasite transmission, the prevalence of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 33.9646%; width: 34.4771%; height: 1.38889%;">infection in children ranges from 57% in mainland China to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.2273%; width: 34.4771%; height: 1.38889%;">25% in Taiwan, and from 50% in Bangladesh and 60% in India
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.6162%; width: 34.4771%; height: 1.38889%;">to 10% in Thailand. Water morning glory (Ipomoea aquatica),
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.0051%; width: 34.4771%; height: 1.38889%;">water caltrop (Trapa bicornis), lotus (Nymphaea lotus), water cress
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 39.2677%; width: 34.3137%; height: 1.38889%;">(Neptunia oleracea), and water hyacinth (Eichhornia speciosa) are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 40.6566%; width: 41.6667%; height: 1.38889%;">most responsible for human infection, but cysts also float on the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.0455%; width: 15.3595%; height: 1.38889%;">surface and may be drunk.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 44.3182%; width: 34.1503%; height: 1.38889%;">Map sources: The Fasciolopsiasis map is made by showing
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.7071%; width: 34.4771%; height: 1.38889%;">the countries that have reported human fasciolopsiasis cases,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.096%; width: 34.4771%; height: 1.38889%;">as reported in the medical literature up to 2010. We also show
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 48.3586%; width: 34.4771%; height: 1.38889%;">pig density data as the disease is endemic in pig-rearing
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.7475%; width: 34.4771%; height: 1.38889%;">regions in Asia. The pig density data is obtained from FAO
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.0101%; width: 34.3137%; height: 1.38889%;">available at: www.fao.org/ag/againfo/resources/en/glw/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 52.399%; width: 6.69935%; height: 1.13636%;">home.html.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 54.798%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 56.1869%; width: 34.4771%; height: 1.38889%;">Graczyk TK, et al. (2001) Fasciolopsiasis: is it a controllable
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 57.4495%; width: 28.268%; height: 1.38889%;">food-borne disease? Parasitol Res 87(1):80–83.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.8384%; width: 34.4771%; height: 1.26263%;">Keiser J, et al. (2009) Food-borne trematodiases. Clin Microbiol
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 60.2273%; width: 14.8693%; height: 1.26263%;">Rev 22(3):466–483.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.4899%; width: 34.4771%; height: 1.38889%;">Sripa B, et al. (2010) Food-borne trematodiases in Southeast
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 62.8788%; width: 33.0065%; height: 1.38889%;">Asia epidemiology, pathology, clinical manifestation and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 64.1414%; width: 18.9542%; height: 1.13636%;">control. Adv Parasitol 72:305–350.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.5303%; width: 34.4771%; height: 1.38889%;">Yoshihara S, et al. (1999) Helminths and helminthiosis of pigs
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 66.9192%; width: 33.0065%; height: 1.38889%;">in the Mekong Delta Vietnam with special reference to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 68.1818%; width: 33.0065%; height: 1.38889%;">ascariosis and Fasciolopsis buski infection. Jap Agric Res
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.5707%; width: 15.1961%; height: 1.38889%;">Qtly 33(3):193–199.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">149
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/f04f68dd-80b4-4eb8-8a6d-b2b70a97d6fa" class="aLF-aPX-aPF-aPE-J3" alt="Page 52 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 53 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 27.2876%; height: 2.0202%;">Disease: Filariasis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 34.4771%; height: 1.26263%;">Classification:ICD-9 125.0, 125.1, 125.6; ICD-10 B74.0, B74.1,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 18.1818%; width: 3.43137%; height: 1.0101%;">B74.2
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 38.2353%; height: 1.38889%;">Syndromes and synonyms: Bancroftian filariasis, Brugian
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 37.0915%; height: 1.38889%;">filariasis, lymphatic filariasis, Malayan filariasis, Timorean
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 5.39216%; height: 1.13636%;">filariasis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 43.4641%; height: 2.77778%;">Agent: Wuchereria bancrofti, Brugia malayi, and B. timori, threadlike nematode worms 80 to 100 mm long (W. bancrofti),
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 17.9739%; height: 1.38889%;">or 43 to 55 mm long (B. malayi).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">Reservoir: Mainly humans. In Southeast Asia, monkeys, wild
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 43.3007%; height: 2.65152%;">carnivores, dogs, and cats may also be infected with B. malayi. W. bancrofti has no known reservoir host.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 41.1765%; height: 1.38889%;">Vector: For W. bancrofti: Culex quinquefasciatus, Anopheles spp.,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 40.6863%; height: 2.77778%;">and Aedes spp. in the Pacific Islands; for B. malayi: Mansonia, Anopheles, and Aedes; for B. timori, An. barbirostris. Anopheles
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 41.0131%; height: 1.38889%;">spp. transmit parasites less efficiently than Culex spp., and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 27.451%; height: 1.38889%;">Culex spp. are more abundant in urban settings.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">Transmission: A large number of infective mosquito bites are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 17.9739%; height: 1.38889%;">necessary to establish infection.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">Cycle: Microfilariae in human blood are ingested by a vector
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">mosquito, and develop in 2 weeks into larvae that enter the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">mouth-parts. Larvae are deposited onto the skin and invade
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">through the wound made at the next mosquito feed. In humans,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 50.3268%; height: 1.38889%;">they travel via thelymphatics, when adults they form ‘nests’ and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">produce microfilariae, which migrate to the blood and display
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 30.8824%; height: 1.38889%;">periodicity coinciding with the peak vector biting times.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">Incubation period: 3–6 months for B. malayi worms to mature
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">and produce microfilariae that appear in the blood; 6–12
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.3137%; height: 4.0404%;">months for W. bancrofti and B. timori. Clinical findings: Infection is often asymptomatic but as the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">adult worms live for 5–10 years, some will develop painful
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">swelling (sometimes enormous) of legs or arms, and, in cases
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">of Bancroftian filariasis, the breasts or scrotum (hydrocele).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">Up to 40% have renal involvement. Acute cases may have
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.4771%; height: 1.38889%;">high fever, recurrent lymphadenitis, and retrograde
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 8.33333%; height: 1.38889%;">lymphangitis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 34.4771%; height: 1.26263%;">Diagnostic tests: Microscopy to detect microfilariae in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.2727%; width: 33.9869%; height: 2.52525%;">finger-prick blood smears; immunochromatic test cards; ultra-
sound to locate ‘nests.’
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">Therapy: For interrupting transmission: mass treatment with a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 2.65152%;">single dose of albendazole or ivermectin combined with diethyl-
carbamazine citrate (DEC) once a year for at least 5 years; or the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.4771%; height: 1.38889%;">regularintakeofDEC-fortifiedsaltforatleastone year;individual
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">treatment: DEC can worsen onchocercal eye disease and cause
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">serious adversereactionsinpatientswithloiasis.Pathogenicityof
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">filarial nematodes is largely due to the immune response to their
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">endosymbioticWolbachiabacteria, therefore doxycycline may be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 24.5098%; height: 1.38889%;">used. The treatment for hydrocele is surgery.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 30.1768%; width: 34.3137%; height: 1.38889%;">Prevention: In 2000, WHO started the Global Programme to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 2.77778%;">Eliminate Lymphatic Filariasis that aims to interrupt trans-
mission and reduce morbidity. Endemic areas are mapped
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">with subsequent mass treatment for the population at-risk (see
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">Therapy) for 5 years. Care needs to be taken in loiasis endemic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">areas to prevent adverse events (see Loiasis map); vector
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 18.4641%; height: 1.38889%;">control (e.g. bed nets, repellent).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 41.0354%; width: 34.3137%; height: 1.26263%;">Epidemiology: WHO (2010) estimates that there are over 120
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 40.8497%; height: 4.0404%;">million infections world wide, with 40 million patients incapaci-
tated or disfigured by the disease, principally in India and Sub-
Saharan Africa. 90% of the infections are due to W. bancrofti.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 2.77778%;">Chronicmanifestationsmainly occurin the elderly.About 27 mil-
lion have hydrocele (men) and 16 million have lymphedema or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">elephantiasis of theleg (mostly women). Asia and South America
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.3137%; height: 2.77778%;">havelowerBancroftianfilariasisprevalences(below8%)thanSub-
SaharanAfrica (up to 37%) and Pacific Island (up to 48%) regions.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">Within areas of low prevalence, pockets of high prevalence may
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">exist (e.g. Reciffe, Brazil). In the Americas there is only active
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">transmission in four countries and mainly affects the poor and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 34.4771%; height: 4.16667%;">slum inhabitants. China has been declared non-endemic for lym-
phatic filariasis since 2007 and Korea in 2008, achieved by exten-
sive controlefforts.Thevectors are stillpresentand therefore there
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.2374%; width: 16.9935%; height: 1.26263%;">remains a risk of re-emergence.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 63.8889%; width: 34.3137%; height: 1.38889%;">Map sources: The Lymphatic filariasis map was made
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 34.4771%; height: 1.26263%;">with information obtained from WHO, CIESIN, and medical
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.5404%; width: 34.3137%; height: 1.13636%;">literature. Useful distribution data are available at: www.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 67.9293%; width: 7.51634%; height: 1.38889%;">filariasis.org.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 70.7071%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 71.9697%; width: 39.8693%; height: 1.38889%;">Addiss DG (2010) Global elimination of lymphatic filariasis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.2323%; width: 20.2614%; height: 1.38889%;">PloS Negl Trop Dis 4(6):e471.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 74.6212%; width: 34.3137%; height: 1.38889%;">Taylor MJ, et al. (2010) Lymphatic filariasis and onchocerciasis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 76.0101%; width: 15.8497%; height: 1.26263%;">Lancet 376(9747):1175–1185.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 77.2727%; width: 34.3137%; height: 1.38889%;">World Health Organization (2010) Lymphatic Filariasis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 78.6616%; width: 76.1438%; height: 4.79798%;">Progress Report 2000–2009 and Strategic Plan 2010–2020. Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">151
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/57e74527-b292-4b2b-9efe-e7e51274b150" class="aLF-aPX-aPF-aPE-J3" alt="Page 53 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.thiswormyworld.org" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.thiswormyworld.org" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.thiswormyworld.org&amp;ust=1666162860000000&amp;usg=AOvVaw0kt3fe8lBrvNGoRfJk7Nhe&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 66.6667%; top: 55.8081%; width: 15.5229%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 54 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 30.5556%; height: 2.0202%;">Disease: Hookworm
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 22.2222%; height: 1.26263%;">Classification: ICD-9 126; ICD-10 B76
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.3137%; height: 1.38889%;">Syndromes and synonyms: Ancylostomiasis, Necatoriasis,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 14.8693%; height: 1.38889%;">Uncinariasis, ground itch.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">Agent: The blood-feeding nematodes Ancylostoma duodenale
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 35.9477%; height: 2.65152%;">and Necator americanus, also known as soil-transmitted hel-
minths (STHs). A. ceylanicum has a limited distribution. The
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 22.3856%; height: 1.38889%;">adult nematodes are up to 10mm long.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.303%; width: 14.5425%; height: 1.0101%;">Reservoir: Humans.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 38.8889%; height: 1.26263%;">Transmission: Infective larvae in soil invade the skin; A.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.2172%; width: 28.1046%; height: 1.38889%;">duodenale larvae can also infect via oral ingestion.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.4771%; height: 1.38889%;">Cycle: Hookworm eggs hatch in the soil and develop to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">infective larvae (L3) that can penetrate the skin. After entering
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">the host, the larvae migrate to the lungs, move up the trachea
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">and swallowed. In the gastrointestinal tract the larvae mature
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.4771%; height: 2.77778%;">to adult worms (both sexes). After mating, the female hook-
worms produce up to 30,000 eggs per day that are shedded
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 21.0784%; height: 1.0101%;">with the stools into the environment.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.3137%; height: 1.26263%;">Incubation period: Varies from weeks to several months,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 18.7909%; height: 1.38889%;">depending on infection intensity.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.3137%; height: 1.38889%;">Clinical findings: Hookworm morbidity is higher in patients
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">infected with large numbers of adult parasites. Attachment of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 1.26263%;">the hookworm to the intestinal mucosa results in loss of blood,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">eventually resulting in anemia and malnutrition in chronic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">cases. Chronic hookworm infection can impair cognitive and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 18.9542%; height: 1.38889%;">growth development in children.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.4771%; height: 2.65152%;">Diagnostic tests: Microscopy (Kato-Katz method). Quanti-
tative fecal egg counts are a marker for worm burden: 2,000 to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">4,000 eggs per gram of feces is considered to be moderate
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 25.817%; height: 1.38889%;">infection, and 4,000 eggs is heavy infection.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">Therapy: Deworming with mebendazole or albendazole;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">repeat treatment in case eggs are still detected in feces. Iron
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 20.2614%; height: 1.38889%;">supplementation to correct anemia.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 16.7929%; width: 34.3137%; height: 1.38889%;">Prevention: The impact of sanitation, footwear, and health
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.26263%;">education is minimal. To reduce the disease burden of STHs,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 2.77778%;">mass treatment campaigns with benzimidazoles and prazi-
quantel are undertaken, and sanitation and access to clean
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">water improved. As most STHs occur in children, control
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">efforts are targeted at schools. Infective larvae can survive
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 15.0327%; height: 1.13636%;">in soil for several months.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 27.5253%; width: 34.3137%; height: 1.38889%;">Epidemiology: The global number of hookworm disease
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.26263%;">cases is estimated to be 740 million individuals, with the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.3137%; height: 1.38889%;">highest prevalence in Sub-Saharan Africa and eastern Asia.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">The majority (85%) of the hookworm infections are caused
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">by Necator americanus, which is the predominant hookworm
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.13636%;">of Latin America, the Caribbean, Sub-Saharan Africa, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 2.77778%;">Southeast Asia. There is strong association between hook-
worm prevalence and poverty (see Human Development
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 37.0915%; height: 2.77778%;">map). The remaining 15% infections by Ancylostoma duode-
nale are in focal pockets in India, especially around Uttar
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">Pradesh and West Bengal, and in China north of the Yangtze
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">river. Mixed infections may also occur. Hookworm disease
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">prevalence rises with age and plateaus in adults. Disease is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">more prevalent where individuals walk barefoot in regions
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">lacking sanitation (see Sanitation map). Hookworm larvae
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">prefer sandy soil in mild humid climates, resulting that
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">individuals living in coastal areas have the highest infection
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.505%; width: 5.55556%; height: 1.26263%;">intensity.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 53.1566%; width: 34.1503%; height: 1.38889%;">Map sources: The Hookworm map is modified from P.J.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">Hotez et al. (2005). For more detailed information on the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 30.0654%; height: 1.38889%;">distribution of STHs, see www.thiswormyworld.org.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 58.5859%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">Hotez PJ, et al. (2005) Hookworm: ‘the great infection of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 61.1111%; width: 24.3464%; height: 1.38889%;">mankind.’ PLoS Med 2(3):e67.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 62.5%; width: 34.3137%; height: 1.38889%;">Hotez PJ, et al. (2004) Current concepts: Hookworm infection.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 63.8889%; width: 20.2614%; height: 1.38889%;">N Engl J Med 351:799–807.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 34.3137%; height: 1.38889%;">De Silva NR, et al. (2003) Soil-transmitted helminth infections:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 66.5404%; width: 31.6993%; height: 1.38889%;">updating the global picture. Trends Parasitol 19:547–551.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">153
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/d629cc51-e3b0-41ff-94ea-f1ea7d150d33" class="aLF-aPX-aPF-aPE-J3" alt="Page 54 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.who.int/leishmaniasis/leishmaniasis_maps/en/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.who.int/leishmaniasis/leishmaniasis_maps/en/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.who.int/leishmaniasis/leishmaniasis_maps/en/&amp;ust=1666162860000000&amp;usg=AOvVaw1q18yn7aEWXwWGylL6T13x&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 57.0261%; top: 65.404%; width: 29.7386%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 55 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 53.4314%; height: 2.27273%;">Disease: Leishmaniasis, Cutaneous
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 28.7582%; top: 14.2677%; width: 37.9085%; height: 2.27273%;">and Mucosal, New World
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.3182%; width: 22.2222%; height: 1.26263%;">Classification: ICD-9 085; ICD-10 B55
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 21.5909%; width: 33.9869%; height: 2.77778%;">Syndromes and synonyms: Cutaneous and mucosal leish-
maniasis (CL): Espundia, Uta, Chiclero ulcer, forest yaws.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 25.3788%; width: 40.3595%; height: 4.16667%;">Agent: Leishmania species, protozoa, members of the Trypa-
nosomatidae family, order Kinetoplastida. Based on develop-
ment characteristics in the sandfly, Leishmania species
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 29.4192%; width: 42.6471%; height: 2.77778%;">are classified into the subgenera Viannia and Leishmania, within which there are various species complexes. Leishmania
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.197%; width: 44.7712%; height: 5.30303%;">species causing (muco)cutaneous disease in the Americas are: L. (Viannia) braziliensis (espundia), L. (Viannia) colombiensis, L. (Leishmania) mexicana (chiclero ulcer), L. (Leishmania) pifanoi, L. (Viannia) liansoni, L. (Leishmania) garnhami, L. (Leishmania)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 37.5%; width: 34.4771%; height: 1.38889%;">amazonensis, L. (Viannia) panamensis, L. (Viannia) guyanensis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.8889%; width: 34.4771%; height: 1.38889%;">(forest yaws), and L. (Viannia) peruviana (Uta). L. infantum/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 40.2778%; width: 39.3791%; height: 1.26263%;">chagasi can cause both visceral and cutaneous leishmaniasis. L.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.5404%; width: 35.7843%; height: 1.38889%;">chagasi is considered to be the same species as L. infantum, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.9293%; width: 34.3137%; height: 3.66162%;">will be referred to as L. infantum/chagasi. Reservoir: Mainly rodents and other sylvatic mammals.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.5909%; width: 34.4771%; height: 1.38889%;">Canines are a reservoir for L. infantum/chagasi and possible
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.9798%; width: 22.0588%; height: 1.38889%;">reservoir for L. (Viannia) spp.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 39.7059%; height: 1.38889%;">Vector: Female phlebotomine sandflies (Lutzomyia spp.).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 52.904%; width: 34.1503%; height: 1.38889%;">Transmission: By bite of an infected phlebotomine sandfly.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.303%; width: 34.4771%; height: 1.38889%;">Cycle: During bloodmeal, the sandfly ingests infected blood
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 56.6919%; width: 41.3399%; height: 2.77778%;">with amastigotes. The amastigotes develop to motile promas-
tigotes that multiply in the sandfly gut, and finally motile
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.3434%; width: 34.4771%; height: 1.38889%;">promastigotes travel to the mouth parts and are injected into
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 60.7323%; width: 34.4771%; height: 1.38889%;">another host during feeding. In the host cell the promastigotes
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.1212%; width: 14.7059%; height: 1.38889%;">develop into amastigotes.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 64.3939%; width: 34.3137%; height: 1.26263%;">Incubation period: Varies from one week to several months.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.9192%; width: 34.3137%; height: 1.38889%;">Clinical findings: Painless cutaneous lesions appear at the site
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 68.1818%; width: 34.3137%; height: 1.38889%;">of sandfly bite and typically these develop into ulcers with a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.5707%; width: 34.4771%; height: 1.38889%;">raised border. Occasionally nodular and rarely verrucous
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.9596%; width: 34.4771%; height: 1.38889%;">lesions. Multiple lesions and regional lymphadenopathy
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 72.3485%; width: 34.4771%; height: 1.26263%;">may be present. Lesions may resolve spontaneously or remain
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.6111%; width: 34.4771%; height: 1.38889%;">for several months to years. Rarely dissemination to mucosa
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 75%; width: 40.6863%; height: 4.0404%;">occurs of the upper respiratory tract with local tissue destruc-
tion leading to disfigurement (most often by L. braziliensis, known as espundia), with risk of severe and sometimes fatal
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 79.0404%; width: 12.2549%; height: 1.26263%;">secondary infections.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 19.3182%; width: 34.1503%; height: 1.38889%;">Diagnostic tests: Demonstration of intracellular amastigotes
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.5808%; width: 34.4771%; height: 1.38889%;">in Giemsa stained slit skin smear or biopsy specimen by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 21.9697%; width: 34.4771%; height: 1.38889%;">microscopy; PCR tests have been developed for the different
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.2323%; width: 34.4771%; height: 1.38889%;">Leishmania species; culture of promastigotes with special
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.6212%; width: 34.4771%; height: 1.38889%;">media is laborious and requires experience. The Montenegro
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.0101%; width: 34.4771%; height: 1.38889%;">skin test is simple, sensitive and specific, but does not aid in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.2727%; width: 29.2484%; height: 1.38889%;">differentiating between past and present infections.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">Therapy: Systemic treatment to prevent dissemination with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.4394%; width: 44.6078%; height: 4.0404%;">pentavalent antimonials. Depending on the infecting Leish-
mania species, alternative systemic treatment can be adminis-
tered with: amphotericin B, pentamidine, or miltefosine.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.4798%; width: 34.3137%; height: 1.38889%;">Topical treatment options are: paramomycin, ketoconazole,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.8687%; width: 11.6013%; height: 1.38889%;">and thermotherapy.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 33.9869%; height: 4.0404%;">Prevention: Personal protection from sandfly bites (e.g. pro-
tective clothing, insecticide-treated bednets, residual insecti-
ciding of breeding places).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 45.202%; width: 34.3137%; height: 1.26263%;">Epidemiology: The highest global burden of CL is in the Old
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.4646%; width: 34.4771%; height: 1.26263%;">World. In the Americas, Bolivia, Brazil, and Peru have the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.8535%; width: 34.4771%; height: 1.38889%;">highest burden of CL. In the New World, CL mainly occurs
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.26263%;">in forested areas, whereas in the OldWorldit is associated with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.505%; width: 34.4771%; height: 1.38889%;">semi-arid and desert regions. Transmision can also occur in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.8939%; width: 34.4771%; height: 1.38889%;">deforested areas. Disease mainly occurs in those living or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.2828%; width: 34.4771%; height: 1.26263%;">working in the forests of endemic areas. Outbreaks can
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.5455%; width: 34.4771%; height: 1.38889%;">occur during military training in the jungle or infrastructural
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.9343%; width: 34.4771%; height: 1.38889%;">projetcs in endemic areas. Also, travelers acquire the disease
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.197%; width: 34.4771%; height: 1.38889%;">during visits to rural or jungle regions. Disease prevalence
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.5859%; width: 34.4771%; height: 1.38889%;">increases with age and then plateaus, likely due to acquired
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.9747%; width: 34.4771%; height: 1.38889%;">immunity. Clusters of leishmaniasis are seen in households,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.2374%; width: 34.3137%; height: 1.38889%;">which is probably related to the short flight range of sandflies.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 64.1414%; width: 34.3137%; height: 1.26263%;">Map sources: This map was made by reconciling maps from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.404%; width: 34.3137%; height: 1.38889%;">WHO: (www.who.int/leishmaniasis/leishmaniasis_maps/en/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.7929%; width: 23.5294%; height: 1.38889%;">index. html) and R. Reithinger et al. (2007).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 69.697%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.9596%; width: 34.4771%; height: 1.38889%;">Campbell-Lendrum D, et al. (2001) Domestic and peridomestic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 72.2222%; width: 33.0065%; height: 1.13636%;">transmission of American cutaneous leishmaniasis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.6111%; width: 24.183%; height: 1.26263%;">Mem Inst Oswaldo Cruz 96(2):159–162.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 75%; width: 36.7647%; height: 1.38889%;">Reithinger R, et al. (2007) Cutaneous leishmaniasis. Lancet
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 76.2626%; width: 15.1961%; height: 1.38889%;">Infect Dis 7(9):581–596.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 77.6515%; width: 40.6863%; height: 2.65152%;">World Health Organization (2010) Control of the Leishmaniases. WHO Expert Technical Report Series, Nr 949.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">155
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/10af521e-b50c-4af1-b742-f4e2ac167550" class="aLF-aPX-aPF-aPE-J3" alt="Page 55 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://bioval.jrc.ec.europa.eu/products/glc2000/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://bioval.jrc.ec.europa.eu/products/glc2000/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://bioval.jrc.ec.europa.eu/products/glc2000/&amp;ust=1666162860000000&amp;usg=AOvVaw3KfLj0OPP5UWijRSOH4amu&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 59.3137%; top: 56.8182%; width: 27.451%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 56 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 53.4314%; height: 2.27273%;">Disease: Leishmaniasis, Cutaneous
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 28.7582%; top: 14.2677%; width: 36.4379%; height: 2.27273%;">and Mucosal, Old World
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.3182%; width: 22.2222%; height: 1.26263%;">Classification: ICD-9 085; ICD-10 B55
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 21.9697%; width: 34.4771%; height: 2.65152%;">Syndromes and synonyms: Cutaneous and mucosal leish-
maniasis (CL): Aleppo evil, Baghdad boil, Delhi boil, Oriental
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.6212%; width: 15.8497%; height: 1.26263%;">sore, Delhi boil, and others.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.2727%; width: 41.0131%; height: 2.77778%;">Agent: Leishmania species, protozoa, members of the Trypa-
nosomatidae family, order Kinetoplastida. Leishmania species
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.0505%; width: 40.6863%; height: 2.65152%;">that cause CL in the old world are: Leishmania major, L. tropica, and L. aethiopica. L. killicki is synonymous to L. tropica. L.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.702%; width: 34.4771%; height: 1.38889%;">infantum/chagasi and L. donovani can cause both visceral and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.0909%; width: 34.4771%; height: 1.38889%;">cutaneous leishmaniasis. L. chagasi is considered the same
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.3535%; width: 40.6863%; height: 4.16667%;">species as L. infantum, and are referred to as L. infantum/chagasi. Reservoir: Wild rodents (gerbils) that live in burrows together
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.3939%; width: 40.6863%; height: 5.42929%;">with sandfly vector. Hyraxes for L. aethiopica. Vector: Female phlebotomine sandflies (Phlebotomus papatasi, P. sergenti, P.chadaudi, P. longipes, P. pedifer)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.2121%; width: 34.1503%; height: 1.38889%;">Transmission: By bite of an infected phlebotomine sandfly.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 48.8636%; width: 34.4771%; height: 1.38889%;">Cycle: During bloodmeal, the sandfly ingests infected blood
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.2525%; width: 41.3399%; height: 2.65152%;">with amastigotes. The amastigotes develop to motile promas-
tigotes that multiply in the sandfly gut, and finally motile
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 52.904%; width: 34.4771%; height: 1.38889%;">promastigotes travel to the mouth parts and are injected into
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.1667%; width: 34.4771%; height: 1.38889%;">another host during feeding. In the host cell the promastigotes
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.5556%; width: 14.7059%; height: 1.38889%;">develop into amastigotes.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.2071%; width: 33.4967%; height: 1.38889%;">Incubation period: Varies from a week to several months.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 60.9848%; width: 34.4771%; height: 1.38889%;">Clinical findings: Mainly presents as a dry skin lesion that is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.2475%; width: 34.4771%; height: 1.13636%;">covered with a crust and is smaller than the classic wet
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.6364%; width: 34.4771%; height: 1.38889%;">leishmania skin lesions in the New World. Lesions may persist
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.0253%; width: 34.4771%; height: 1.38889%;">for months or years. Diffuse cutaneous leishmaniasis may be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.2879%; width: 34.3137%; height: 1.38889%;">seen with L. aethiopica; leishmaniasis recidivans may be seen
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.6768%; width: 34.4771%; height: 1.38889%;">with L. tropica. Mucosal leishmaniasis is rare in the Old World,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.0657%; width: 20.5882%; height: 1.13636%;">and more common in the Americas.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.7172%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Demonstration of intracellular amastigotes
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 72.9798%; width: 34.4771%; height: 1.38889%;">in Giemsa stained slit skin smear or biopsy specimen by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.3687%; width: 34.4771%; height: 1.38889%;">microscopy; PCR tests have been developed for the different
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 75.7576%; width: 34.4771%; height: 1.38889%;">Leishmania species; culture of promastigotes with special
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.1465%; width: 34.4771%; height: 1.26263%;">media is laborious and requires experience. The Montenegro
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.3182%; width: 34.4771%; height: 1.38889%;">skin test is simple, sensitive and specific, but does not aid in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.5808%; width: 29.085%; height: 1.38889%;">differentiating between past and present infections.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.6111%; width: 34.4771%; height: 2.77778%;">Therapy: Intravenous, intramuscular, and intralesional appli-
cation of pentavalent antimonials; also miltefosine is being
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.2626%; width: 33.9869%; height: 2.77778%;">tested for its efficacy. Topical treatment options are: paramo-
mycin, ketoconazole, and thermotherapy.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 30.6818%; width: 34.1503%; height: 1.38889%;">Prevention: Personal protection from sandfly bites (e.g.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.0707%; width: 34.4771%; height: 1.38889%;">protective clothing, insecticide-treated bednets, residual
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 33.3333%; width: 34.4771%; height: 1.38889%;">insecticide of breeding places). There is no vaccine for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.7222%; width: 7.02614%; height: 1.13636%;">human use.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 37.6263%; width: 34.4771%; height: 2.77778%;">Epidemiology: World wide there are approximately 1.5 mil-
lion new cases of CL per year, with most cases reported from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 40.2778%; width: 34.4771%; height: 1.38889%;">Afghanistan, Algeria, Pakistan, Saudi Arabia, and Syria in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.6667%; width: 34.4771%; height: 1.38889%;">Old World. The highest burden of CL in the Old Word is in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.0556%; width: 34.4771%; height: 1.38889%;">rural semi-arid and desert regions, but transmission is being
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 44.3182%; width: 34.4771%; height: 2.77778%;">increasingly seen in peri-urban and urban environments. Dis-
ease prevalence increases with age and then plateaus, likely due
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.096%; width: 34.4771%; height: 1.38889%;">to acquired immunity. Clusters of leishmaniasis are seen in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 48.3586%; width: 34.4771%; height: 1.38889%;">households, which is likely related to the short flight range of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.7475%; width: 5.55556%; height: 1.13636%;">sandflies.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 52.7778%; width: 34.3137%; height: 1.26263%;">Map Sources: The Cutaneous and Mucosal Leishmaniasis, Old
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.0404%; width: 34.4771%; height: 1.38889%;">World, map was made by reconciling maps from WHO (www.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.4293%; width: 29.902%; height: 1.38889%;">who.int/leishmaniasis/leishmaniasis_maps/en/index
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 56.8182%; width: 34.1503%; height: 1.38889%;">.html), EU (http://bioval.jrc.ec.europa.eu/products/glc2000/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.2071%; width: 34.4771%; height: 1.26263%;">products.php), and R. Reithinger et al. (2007). The map was
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.4697%; width: 28.7582%; height: 1.38889%;">updated with medical literature and expert opinion.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 62.5%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.7626%; width: 37.5817%; height: 1.38889%;">Ready PD (2010) Leishmaniasis emergence in Europe. Euro
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 65.1515%; width: 11.9281%; height: 1.26263%;">Surveill 15(10):19505.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.4141%; width: 34.4771%; height: 1.38889%;">Lukes J. (2007) Evolutionary and geographical history of the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 67.803%; width: 35.4575%; height: 1.38889%;">Leishmania donovani complex. PNAS 104(22):9375–9380.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.1919%; width: 40.6863%; height: 2.65152%;">World Health Organization (2010) Control of the Leishmaniases. WHO Expert Technical Report Series, Nr 949.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 71.8434%; width: 34.3137%; height: 2.65152%;">Pratlong F, et al. (2009) Geographical distribution and epide-
miological features of Old World cutaneous leishmaniasis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 74.495%; width: 23.6928%; height: 1.38889%;">Trop Med Int Health 14(9):1071–1085.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 75.8838%; width: 34.4771%; height: 1.38889%;">Reithinger R (2007) Cutaneous leishmaniasis. Lancet Infect Dis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 77.2727%; width: 7.51634%; height: 1.26263%;">7(9):581–596.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">157
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/9caf5748-dc6a-4b29-a73d-eb8ca7df71e0" class="aLF-aPX-aPF-aPE-J3" alt="Page 56 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 57 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 49.183%; height: 2.27273%;">Disease: Leishmaniasis, Visceral
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.0196%; height: 1.26263%;">Classification: ICD-9 085.0; IDC-10 B55.0
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">Syndromes and synonyms: Kala-azar (Hindi for black
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 23.2026%; height: 1.26263%;">sickness), black disease, dum-dum fever.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 36.7647%; height: 1.38889%;">Agent: Parasite, kinetoplastida. Leishmania donovani and its
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">subspecies donovani and infantum. L. chagasi is considered to be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.6405%; height: 1.38889%;">the same species asL.infantum, and are referred to asL.infantum/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">chagasi. Occasionally, other Leishmania spp. can cause visceral
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 29.085%; height: 1.38889%;">disease, usually in immunocompromised individuals.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">Reservoir: Humans (mainly L. donovani), wild Canidae (foxes,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">raccoon dogs, jackals, wolves), domestic dogs (mainly
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.2172%; width: 18.7909%; height: 1.38889%;">L. infantum/chagasi), and rodents.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.6405%; height: 1.38889%;">Vector: Phlebotomine sandfly: Lutzomyia spp. (New World)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 19.7712%; height: 1.38889%;">and Phlebotomus spp. (Old World).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">Transmission: Bite of infective female sandfly. Rare reports
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.4771%; height: 1.38889%;">exist of non-vector transmission, including transmission by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">blood transfusion, sharing of syringes, venereal contact, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">possibly transplacentally; potential transmission via organ
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 9.15033%; height: 1.38889%;">transplantation.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">Cycle: During blood meal, the sandfly ingests infected blood
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 41.3399%; height: 2.77778%;">with amastigotes. The amastigotes develop to motile promas-
tigotes that multiply in the sandfly gut, and finally motile
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">promastigotes travel to the mouth parts and are injected into
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">another host during feeding. In the host cell the promastigotes
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 14.7059%; height: 1.38889%;">develop into amastigotes.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.3137%; height: 1.38889%;">Incubation period: Usually 2–6 months (range: 10 days to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 4.08497%; height: 1.38889%;">years).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.4771%; height: 2.65152%;">Clinical findings: Infection may be asymptomatic or progres-
sive and fatal, if untreated. Onset is often insidious. Common
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.3137%; height: 1.38889%;">symptoms include fever, malaise, weight loss, and sweats.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 2.77778%;">Cough may be prominent. Symptoms can come and go. Spleno-
megaly, hepatomegaly, and lymphadenopathy are common
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">findings. HIV-infected individuals are at increased risk for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 2.77778%;">symptomatic infection. Bacterial co-infections, including tuber-
culosis, may occur. Anemia, leucopenia, and thrombocytopenia
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 27.1242%; height: 1.38889%;">are common laboratory findings.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 34.4771%; height: 1.26263%;">Diagnostic tests: Identification of intracellular amastigotes in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.2727%; width: 34.4771%; height: 1.38889%;">stained smears from blood, bone marrow, spleen, liver, lymph
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 78.6616%; width: 34.4771%; height: 1.38889%;">nodes. PCR is sensitive and specific. Serologic tests can be useful,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">though they may be negative in HIV-infected patients with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 30.8824%; height: 1.38889%;">leishmaniasis. Rapid diagnostic tests (rK39) are available.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.4545%; width: 34.4771%; height: 2.77778%;">Therapy: Pentavalent antimonials; pentamidine; amphoteri-
cin. Other drugs and regimens are being tested (including
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.2323%; width: 15.6863%; height: 1.26263%;">paramomycin, miltefosine).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 25.8838%; width: 34.3137%; height: 1.38889%;">Prevention: Vector control; personal protection from sandfly
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.2727%; width: 34.4771%; height: 1.38889%;">bites (e.g. protective clothing, insecticide-treated bednets,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.5354%; width: 34.4771%; height: 2.77778%;">residual insecticiding of breeding places); use of deltame-
thrin-impregnated dog collars and dog vaccination; there is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.3131%; width: 15.1961%; height: 1.13636%;">no vaccine for human use.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 33.5859%; width: 34.1503%; height: 1.26263%;">Epidemiology: VL is found in 62 countries where an estimated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.9747%; width: 34.4771%; height: 1.38889%;">500,000 cases occur annually and 120 million persons are at risk.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.2374%; width: 34.4771%; height: 1.38889%;">Approximately 90% of VLcases occurin rural and suburban areas
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 37.6263%; width: 34.3137%; height: 1.38889%;">of five countries: Bangladesh, India, Nepal, Sudan, and Brazil.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.0152%; width: 34.4771%; height: 2.65152%;">During epidemics, &gt; 5% of a population may develop symptom-
atic infection. Personswho are under age of 5 years,malnourished
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.6667%; width: 34.4771%; height: 1.38889%;">and immunocompromised (including HIV-infected individuals)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.0556%; width: 34.4771%; height: 1.38889%;">are more likely to develop symptomatic, often severe, infection.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 44.3182%; width: 34.4771%; height: 2.77778%;">There are indications that VL is spreading to historically non-
endemic areas, like northern parts of Europe and Western Upper
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.096%; width: 34.4771%; height: 1.38889%;">Nile Sudan. Clearly the distribution of VL is dynamic and adapts
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 48.3586%; width: 34.4771%; height: 1.38889%;">to changes in demographics, human behavior, environment
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 49.7475%; width: 34.3137%; height: 1.26263%;">(deforestation, urbanization), and host factors (HIV). VL is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.0101%; width: 34.4771%; height: 1.38889%;">reported in Chad, DRC, and Zambia, but the infectious agent
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 52.399%; width: 34.4771%; height: 1.38889%;">is unknown.L. donovanishas been foundin Sri Lanka,but only as a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.7879%; width: 18.3007%; height: 1.13636%;">cause of cutaneous leishmaniasis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 56.1869%; width: 34.1503%; height: 1.38889%;">Map sources: The Leishmaniasis (visceral) map was made
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.4495%; width: 34.3137%; height: 1.38889%;">with multiple sources from the medical literature and WHO.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 59.9747%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.2374%; width: 34.3137%; height: 1.38889%;">Alvar J, et al. (2006) Leishmaniasis and poverty. Trends Parasit
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 62.6263%; width: 8.82353%; height: 1.26263%;">22(12):552–557.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 34.3137%; height: 1.38889%;">GramicciaM, etal. (2007) Theleishmaniasesin SouthernEurope.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 65.2778%; width: 33.1699%; height: 2.77778%;">In: Emerging Pests and Vector-Borne Diseases: Ecology and Con-
trol of Vector-Borne Diseases, Vol. 1, pp. 75–95 (eds Takken W
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 68.0556%; width: 28.4314%; height: 1.26263%;">and Knols BGJ). Wageningen Academic Publishers.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.3182%; width: 34.4771%; height: 1.26263%;">Guerin P, et al. (2002) Visceral leishmaniasis: current status of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.7071%; width: 33.1699%; height: 1.38889%;">control, diagnosis, and treatment, and a proposed research
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 72.096%; width: 33.8235%; height: 1.26263%;">and development agenda. Lancet Infect Dis 2:494–501.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 73.3586%; width: 32.3529%; height: 1.26263%;">Herwaldt BL (1999) Leishmaniasis. Lancet 354:1191–1199.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 74.7475%; width: 37.5817%; height: 1.38889%;">Ready PD (2010) Leishmaniasis emergence in Europe. Euro
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 76.0101%; width: 11.9281%; height: 1.38889%;">Surveill 15(10):19505.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 77.399%; width: 40.6863%; height: 2.77778%;">World Health Organization (2010) Control of the Leishmaniases. WHO Expert Technical Report Series, Nr 949.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">159
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/0f4f125c-fe31-4f27-a240-e36f45436c71" class="aLF-aPX-aPF-aPE-J3" alt="Page 57 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 58 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 24.3464%; height: 2.0202%;">Disease: Loiasis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 23.0392%; height: 1.26263%;">Classification: ICD-125.2; ICD-10 B74.3
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.4771%; height: 1.26263%;">Syndromes and synonyms: Loa loa filariasis, loiasis, African
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 15.8497%; height: 1.38889%;">eyeworm, Calabar swelling
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">Agent: Filarial nematode (roundworm), Loa loa. Adult worms
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">are nematodes that live freely in subcutaneous tissue. Adult
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 33.1699%; height: 1.38889%;">females are 40–70 mm long and males are 30–34mm long.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">Reservoir: Humans. Loa loa also infects some monkeys but
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 30.8824%; height: 1.38889%;">the human and simian cycles seem to be independent.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 40.6863%; height: 4.0404%;">Vector: Tabanid adult female flies, mainly Chrysops silacea, C. dimidiata, and C. distinctipennis. These day-biting and blood-
sucking flies breed in forested and damp environments (e.g.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.4771%; height: 1.38889%;">swamps or rotten vegetation). Other favorable environments
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">are cocoa plantations. Chrysops are attracted by movement,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.3137%; height: 1.38889%;">dark objects, and smoke. The vector does not enter structures
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">like homes or barns. Up to 18% of the vector population can be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 21.8954%; height: 1.13636%;">infected with L. loa in endemic areas.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">Transmission: Infective larvae migrate out of the mouth part
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">of the fly during bite onto the skin and subsequently enter the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 29.2484%; height: 1.38889%;">wound. The tabanid bite is painful with blood loss.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">Cycle: Human-deer fly-human. After infectivelarvae enter the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.4771%; height: 4.0404%;">wound they migrate and develop into adult worms in subcu-
taneous tissue. Adult worms produce microfilariae, that cir-
culate in the peripheral blood in daytime and can be taken up
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">by the next fly during feeding. In the fly they develop into
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">larvae in 10–12 days and enter the proboscis, and the cycle
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">repeats. An infected human can remain infectious to the vector
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">for up to 15 years. Transmission is facilitated by the fact that
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.3137%; height: 1.26263%;">microfilaremia and the vector-biting activity occur in daytime.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 26.4706%; height: 1.38889%;">Incubation period: 4 months to several years.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 39.7059%; height: 1.26263%;">Clinical findings: Loiasis is not as severe as other filarial
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.3137%; height: 1.38889%;">diseases. Typical finding is transient subcutaneous swellings
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">(Calabar swellings) which are angiedemas. These swellings
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">are itchy and mainly occur on the limbs, especially forearms
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.4771%; height: 2.65152%;">and when close to joints may restrict movement. Less fre-
quently: giant urticaria, arthritis, and fever. The adult worm
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.3137%; height: 1.38889%;">sometimes migrates across the subconjunctiva of the eye.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 34.4771%; height: 1.26263%;">Encephalopathic reactions may occur during mass ivermectin
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.2727%; width: 34.4771%; height: 1.38889%;">treatment campaigns to control onchocerciasis. These SAEs
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 33.9869%; height: 2.77778%;">mainly occur in those with heavy infection ( &gt; 30,000 micro-
filariae per ml blood).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 21.0859%; width: 34.3137%; height: 1.38889%;">Diagnostic tests: Microscopy of stained thick blood smears
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.3485%; width: 34.3137%; height: 1.38889%;">taken around noon; membrane filtration; PCR. Eosinophilia
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.7374%; width: 29.902%; height: 1.38889%;">and high IgE levels are indicators of active infection.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.6414%; width: 34.3137%; height: 1.38889%;">Therapy: Surgical extraction of adult worms from the eye.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.0303%; width: 34.4771%; height: 1.38889%;">Diethylcarbamazine (DEC) is filaricidal but can cause SAEs
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 29.2929%; width: 33.9869%; height: 4.16667%;">in patients with heavy infection. SAEs can be reduced by co-
administering antihistamines or steroids. Alternative: alben-
dazole with a lower risk of SAEs in case of heavy infection.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 34.9747%; width: 34.3137%; height: 1.38889%;">Prevention: Protection from vector bites by wearing
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.2374%; width: 40.5229%; height: 1.38889%;">permethrin-treated light-colored clothes and fly repellent on
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 37.6263%; width: 34.4771%; height: 1.38889%;">exposed skin. DEC can be used as prophylaxis, but should not
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.0152%; width: 10.4575%; height: 1.38889%;">be used routinely.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 41.9192%; width: 40.5229%; height: 1.38889%;">Epidemiology: Loiasis occurs in areas where the Chrysops
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.3081%; width: 34.4771%; height: 1.26263%;">vectors breed in the tropical rainforest of Central Africa,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 44.5707%; width: 34.4771%; height: 1.13636%;">where it is estimated that 12–13 million humans are infected.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.9596%; width: 34.4771%; height: 1.38889%;">The prevalence of microfilaremia increases with age, and is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.3485%; width: 34.4771%; height: 1.38889%;">more common in men as they are more exposed. Loiasis has
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 48.6111%; width: 34.4771%; height: 1.38889%;">gained attention because of the serious adverse events that
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50%; width: 34.4771%; height: 1.38889%;">can occur during mass ivermectin treatment campaigns for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.2626%; width: 34.4771%; height: 1.38889%;">onchocerciasis control. It has been proposed that areas where
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 52.6515%; width: 34.4771%; height: 1.38889%;">the Loiasis prevalence is &gt; 20%, are at increased risk for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.0404%; width: 28.9216%; height: 1.38889%;">adverse events during mass ivermectin treatment.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 56.9444%; width: 34.3137%; height: 1.38889%;">Map sources: The Loiasis map was made with data from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.2071%; width: 34.4771%; height: 1.38889%;">Boussinesq et al. (1997) and Thomson et al. (2004) and updated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.596%; width: 34.4771%; height: 1.13636%;">with medical literature. The distribution of the vectors was
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 60.9848%; width: 17.4837%; height: 1.38889%;">reproduced from WHO (1989).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 63.8889%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 37.9085%; height: 2.65152%;">Boussinesq M, et al. (1997) Prevalences of Loa loa microfilar-
aemia throughout the area endemic for the infection. Ann
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 67.803%; width: 18.6275%; height: 1.38889%;">Trop Med Parasitol 91(6):573–589.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.1919%; width: 39.7059%; height: 1.38889%;">Boussinesq M. (2006) Loiasis. Ann Trop Med Paras 100(8):
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.5808%; width: 5.22876%; height: 1.0101%;">715–731.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 71.8434%; width: 34.4771%; height: 1.38889%;">Padget JJ, et al. (2008) Loiasis: African eye worm. Trans R Soc
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.2323%; width: 20.5882%; height: 1.38889%;">Trop Med Hyg 102:983–989.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 74.6212%; width: 34.6405%; height: 1.38889%;">World Health Organization (1989) Geographical distribution of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 75.8838%; width: 32.6797%; height: 2.77778%;">arthropod-borne diseases and their principal vectors. Unpub-
lished report.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">161
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/3afb167b-63d1-45d7-bc91-3c8c816c32f6" class="aLF-aPX-aPF-aPE-J3" alt="Page 58 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 59 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 63.3987%; height: 2.39899%;">Disease: Malaria, Plasmodium falciparum
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 22.2222%; height: 1.26263%;">Classification: ICD-9 084; ICD-10 B50
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.3137%; height: 1.38889%;">Syndromes and synonyms: Falciparum malaria, malaria
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 34.4771%; height: 1.38889%;">tropica, tropical fever, blackwater fever, paludism, marsh
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 3.59477%; height: 1.13636%;">fever.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 33.9869%; height: 4.0404%;">Agent: Plasmodium falciparum, an intracellular protozoan par-
asite in the Phylum Apicomplexa. Among the malaria para-
sites, P. falciparum causes the vast majority of mortality.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.303%; width: 14.5425%; height: 1.0101%;">Reservoir: Humans.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">Vector: Mosquito (Anopheles spp.), mainly bites between dusk
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 18.6275%; height: 1.26263%;">and dawn (see Anopheles map).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.6405%; height: 2.65152%;">Transmission: By mosquito bite (Anopheles spp.). Transmis-
sion has been described in needle sharing IVDUs and through
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 10.6209%; height: 1.13636%;">blood transfusion.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.4771%; height: 1.38889%;">Cycle:There is an asexual phase in humans and a sexual phase
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">in the vector mosquito. The mosquito injects sporozoites that
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.3137%; height: 1.38889%;">invade human liver cells where they reproduce and develop to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 4.16667%;">merozoites, which, after release, infect erythrocytes. The eryth-
rocytic stages multiply around 10-fold every 48-hours. Erythro-
cytes can release gametocytes which infect mosquitoes during a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">blood meal. In the mosquito, gametocytes develop into
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 6.86275%; height: 1.38889%;">sporozoites.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 29.4118%; height: 1.38889%;">Incubation period: 7 to 15 days, but can be longer.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">Clinical findings:Uncomplicated malaria: acute febrile illness
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.4771%; height: 2.77778%;">with headache, chills, sweats, nausea, and vomiting; hepatos-
plenomegaly. Findings of severe malaria can be: cerebral
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">malaria (confusion, seizures, impaired consciousness to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.3137%; height: 1.38889%;">coma), hemolysis, severe anemia, hypotension, renal failure,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">metabolic acidosis and death. Often high parasite counts
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">are found in patients with severe malaria ( &gt; 5% infected
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 8.00654%; height: 1.38889%;">erythrocytes).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Light microscopy of Giemsa stained thick
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">and thin blood smears; rapid diagnostic tests (RDTs) based on
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 23.366%; height: 1.38889%;">immunochromatography on blood; PCR.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.4771%; height: 2.65152%;">Therapy: Malaria requires urgent treatment and type of treat-
ment depends on disease severity and drug resistance in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.2727%; width: 42.4837%; height: 2.77778%;">region. Artemisinin resistance has been confirmed in the Thai–- Cambodian border region. Uncomplicated P. falciparum
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">malaria: artemisinin-based combination therapies (ACTs);
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.13636%;">the choice of ACTs is based on the resistance levels of the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.3137%; height: 2.77778%;">partner medicine in the combination. Artemisinin and its deri-
vatives should not be used as monotherapy. Severe malaria:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">artesunate iv or im; complete treatment with an ACT or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 24.6732%; height: 1.38889%;">artesunate plus doxycycline or clindamycin.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.5152%; width: 34.4771%; height: 2.77778%;">Prevention: Vector control; mosquito repellent; insecticide-
treated bed nets; residual spraying of insecticides; treatment of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 29.1667%; width: 34.4771%; height: 1.38889%;">infected humans. Recently control measures are being
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.5556%; width: 34.4771%; height: 1.38889%;">upscaled in a malaria elimination effort. Morocco, United
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.9444%; width: 34.4771%; height: 1.26263%;">Arab Emirates, and Turkmenistan have been certified malaria
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 33.2071%; width: 8.33333%; height: 1.38889%;">free by WHO.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.2374%; width: 43.6275%; height: 2.77778%;">Epidemiology: The limits of P. falciparum malaria is deter-
mined by the presence of vector species and control measures
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.0152%; width: 39.8693%; height: 2.65152%;">within a certain region. P. falciparum malaria causes approxi-
mately 500 million cases each year and around one million
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.6667%; width: 34.4771%; height: 1.13636%;">deaths in Sub-Saharan Africa. In 2007 almost 60% of the 2.4
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.0556%; width: 34.4771%; height: 1.38889%;">billion people at risk of malaria were living in areas with a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 44.3182%; width: 34.4771%; height: 1.38889%;">stable risk of P. falciparum. High endemicity was most common
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.7071%; width: 34.4771%; height: 1.38889%;">and widespread in the African region. In the Americas, those at
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.096%; width: 34.4771%; height: 1.38889%;">risk were all in the low endemicity class. In Asia 88% are in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 48.3586%; width: 34.4771%; height: 1.38889%;">low endemicity class, 11% in the intermediate class, and 1% in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.7475%; width: 34.4771%; height: 1.38889%;">the high endemicity class. Recent progress is being made by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.0101%; width: 34.4771%; height: 1.38889%;">the Global Malaria Action Plan to reduce malaria morbidity
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 52.399%; width: 34.4771%; height: 1.38889%;">and mortality world wide and have a vision for malaria
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.7879%; width: 34.4771%; height: 2.39899%;">elimination. Ranking countries on the possibility of elimina-
tion shows that it is most feasible in the Americas and several
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 56.4394%; width: 34.4771%; height: 1.13636%;">countries in Asia and the west Pacific. It is least feasible in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.8283%; width: 34.4771%; height: 1.26263%;">Africa, where much of west and central Africa need more than
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.2172%; width: 17.6471%; height: 1.0101%;">90% reduction in transmission.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 62.2475%; width: 34.3137%; height: 1.26263%;">Map sources: The Malaria (Plasmodium falciparum) map is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.5101%; width: 34.3137%; height: 1.38889%;">reproduced with permission from the Malaria Atlas Project, S.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 64.899%; width: 34.4771%; height: 1.38889%;">I. Hay et al. (2009). Data on first and second line drugs for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.2879%; width: 40.3595%; height: 2.65152%;">malaria were obtained from WHO’s Global Report on Antima-
larial Drug Efficacy and Drug Resistance 2000–2010 (2010).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 70.7071%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 71.9697%; width: 34.3137%; height: 2.65152%;">Hay SI, et al. (2009) A world malaria map: Plasmodium falci-
parum endemicity in 2007. PloS Med 6(3):e1000048.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 74.6212%; width: 39.3791%; height: 1.26263%;">Lancet Series (2010) Malaria elimination. Lancet 376
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 76.0101%; width: 10.1307%; height: 1.26263%;">(9752):1566–1615.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 77.2727%; width: 34.4771%; height: 1.38889%;">World Health Organization (2010) Guidelines for the Treatment
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 78.6616%; width: 17.9739%; height: 1.38889%;">of Malaria, 2nd edition. Geneva.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">163
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/8529ac02-4348-4154-aa03-faf470a65581" class="aLF-aPX-aPF-aPE-J3" alt="Page 59 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 60 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 60.9477%; height: 2.27273%;">Disease: Malaria, Plasmodium knowlesi
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 23.366%; height: 1.26263%;">Classification: ICD-9 84.4; IDC-10 B53.1
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 25.817%; height: 1.26263%;">Synonym: Knowlesi malaria, simian malaria
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 34.3137%; height: 2.65152%;">Agent: Plasmodium knowlesi, an intacellular protozoan para-
site in the Phylum Apicomplexa. P. knowlesi is an Old World
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 13.8889%; height: 1.38889%;">simian malaria parasite.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.3137%; height: 1.38889%;">Reservoir: Long-tailed and pigtailed macaques, and banded
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.4771%; height: 2.65152%;">leaf monkeys. P. knowlesi can also infect other primates, includ-
ing New World marmosets (Callithrix jacchus), African olive
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">baboons (Papio anubis), Old World macaques, and humans by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 19.7712%; height: 1.38889%;">blood passage and mosquito bites.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 33.9869%; height: 2.77778%;">Vector: P. knowlesi transmission is restricted to the Leuco-
sphyrus group of anophelines, consisting of 20 species.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.3137%; height: 1.38889%;">Transmission: By mosquito bite. Experiments demonstrated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.3137%; height: 1.38889%;">human to human transmission with the mosquito as vector,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 30.0654%; height: 1.13636%;">but there is no direct human-to-human transmission.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">Cycle: Monkey–mosquito–monkey; P. knowlesi has a short
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 31.2092%; height: 1.38889%;">(24-hour) asexual lifeycle; humans are incidental hosts.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 20.4248%; height: 1.38889%;">Incubation period: About 12 days.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.3137%; height: 1.38889%;">Clinical findings: Headache, fever, chills. Abdominal pain,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">renal impairment, jaundice, and thrombocytopenia may
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 18.4641%; height: 1.13636%;">occur. Coma and death are rare.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 35.1307%; height: 1.38889%;">Diagnostic tests: Often misidentified as P. malariae, but
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">skilled microscopists are able to make the distinction. A
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">relatively severe illness with a microscopic diagnosis of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.1111%; width: 34.4771%; height: 1.38889%;">P. malariae should alert clinicians to the possibility of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.4771%; height: 1.38889%;">P. knowlesi because P. malariae malaria is almost invariably
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 28.4314%; height: 1.38889%;">mild. Species can be confirmed by PCR if needed.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 2.77778%;">Therapy: Chloroquine is effective; primaquine is likely unnec-
essary as a gametocidal drug since gametocytes appear to be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 14.0523%; height: 1.38889%;">sensitive to chloroquine.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 2.65152%;">Prevention: Early detection and containment of human-to-
human P. knowlesi transmission in the event of a complete
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 33.9869%; height: 2.65152%;">emergence into the human population; vector control; anti-
mosquito measures.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 28.9141%; width: 34.3137%; height: 1.38889%;">Epidemiology: The first human P. knowlesi case acquired in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 35.4575%; height: 1.38889%;">nature was detected in 1965 in Malaysia. P. knowlesi malaria is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">widely distributed across Sarawak and Sabah in Malaysian
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">Borneo and extends to the state of Pahang in Peninsular
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.2172%; width: 34.4771%; height: 1.38889%;">Malaysia. P. knowlesi malaria cases have also been acquired
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">in Thailand, Myanmar, Singapore, and the Philippines. The
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">distribution and incidence of P. knowlesi malaria is yet
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">unknown. Bases on current knowledge on the vector and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">reservoir, human knowlesi malaria is likely not rare in areas
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.3137%; height: 1.38889%;">inhabited by the natural macaque hosts and the vectors.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">Humans working in the vicinity of forests are considered at
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">risk. Deforestation now also brings humans in semi-urban
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 35.7843%; height: 2.65152%;">areas into contact with reservoir hosts. Interestingly, P. know-
lesi has been used in the past as a pyretic agent for the treatment
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 17.4837%; height: 1.38889%;">of patients with neurosyphilis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 33.9869%; height: 2.77778%;">Map sources: The Malaria, Plasmodium knowlesi map is modi-
fied from in J. Cox-Singh et al. (2008).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 54.5455%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">Cox-Singh J, et al. (2008) Knowlesi malaria: newly emergent
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 57.0707%; width: 37.5817%; height: 1.38889%;">and of public health importance? Trends Parasitol 24
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 58.4596%; width: 6.86275%; height: 1.38889%;">(9):406–410.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">Daneshvar C, et al. (2010) Clinical and parasitological
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 61.2374%; width: 34.4771%; height: 2.65152%;">response to oral chloroquine and primaquine in uncompli-
cated human Plasmodium knowlesi infections. Malar J
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 63.8889%; width: 3.59477%; height: 1.13636%;">9:238.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">165
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/8cc7f368-b676-475a-bfbc-6cf1e4240ed3" class="aLF-aPX-aPF-aPE-J3" alt="Page 60 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 61 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 55.0654%; height: 2.27273%;">Disease: Malaria, Plasmodium ovale
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.0196%; height: 1.26263%;">Classification: ICD-9 084.3; ICD-10 B53.0
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.5707%; width: 26.1438%; height: 1.38889%;">Synonyms: malaria, paludism, tropical fever.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.3485%; width: 34.4771%; height: 1.38889%;">Agent: Plasmodium ovale, an intacellular protozoan parasite in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.7374%; width: 39.3791%; height: 1.38889%;">the Phylum Apicomplexa. Phylogenetically, P. ovale clusters
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 25.1263%; width: 32.1895%; height: 1.38889%;">with other Plasmodium species affecting simian primates.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.904%; width: 35.1307%; height: 2.65152%;">Reservoir: Humans and possibly other primates (chimpan-
zees). Evidence of naturally occurring P. ovale in chimpanzees
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.5556%; width: 10.7843%; height: 1.38889%;">has been reported.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 33.3333%; width: 41.5033%; height: 2.77778%;">Vector: Female mosquito of the genus Anopheles (see Anophe-
les map).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 37.5%; width: 34.4771%; height: 1.38889%;">Transmission: By mosquito bite (Anopheles spp.).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 40.2778%; width: 34.4771%; height: 1.38889%;">Cycle: Infective sporozoites are inoculated by the bite of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.6667%; width: 34.4771%; height: 2.77778%;">anopheles mosquitoes and through the bloodstream and lym-
phatics reach the liver where they differentiate into tissue
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 44.3182%; width: 34.4771%; height: 2.77778%;">schizonts that release merozoites, or to a dormant stage (hyp-
nozoite) that can become active after months or years, causing
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.096%; width: 34.4771%; height: 1.38889%;">relapse. Merozoites released from liver infect erythrocytes that
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 48.3586%; width: 34.4771%; height: 1.38889%;">develop to schizonts, rupture and release merozoites that will
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.7475%; width: 34.4771%; height: 1.38889%;">infect new erythrocytes (this cycle takes 48 hours). Some
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.0101%; width: 34.4771%; height: 1.38889%;">merozoites develop into gametocytes that are able to infect
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 52.399%; width: 18.9542%; height: 1.38889%;">mosquitoes during a blood meal.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.303%; width: 33.4967%; height: 1.26263%;">Incubation period: 12 to 20 days, up to to several months
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.0808%; width: 34.3137%; height: 1.26263%;">Clinical findings: Acute febrile illness with chills, sweats,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.3434%; width: 34.4771%; height: 1.38889%;">nausea, headache, and vomiting. Usually does not last longer
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 60.7323%; width: 8.16994%; height: 1.13636%;">than 2 weeks.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.5101%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Microscopy of Giemsa-stained blood
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 64.899%; width: 36.7647%; height: 1.26263%;">film; differentiation from P. vivax can be difficult and result
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.2879%; width: 34.4771%; height: 1.38889%;">in misidentification; parasite load is generally low and may
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.5505%; width: 34.4771%; height: 1.38889%;">be undetectable by light microscopy; in regions where
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 68.9394%; width: 41.5033%; height: 1.38889%;">P. falciparum/P. vivax predominate, P. ovale is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">frequently overlooked; parasitemia is present for about
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 8.82353%; height: 1.26263%;">2 weeks; PCR.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.7071%; width: 34.4771%; height: 1.38889%;">Therapy: Need to treat both P. ovale blood and liver stage with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.096%; width: 31.3726%; height: 1.38889%;">chloroquine (blood stage) and primaquine (liver stage).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.7475%; width: 33.9869%; height: 2.65152%;">Prevention: Vector control; mosquito repellent; insecticide-
treated bed nets; treatment of infected humans.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 28.6616%; width: 34.3137%; height: 1.38889%;">Epidemiology: P. ovale initally was thought to be limited to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.0505%; width: 34.4771%; height: 1.38889%;">Sub-Saharan Africa, Papua New Guinea, eastern Indonesia,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.3131%; width: 34.4771%; height: 1.38889%;">and the Philippines. It is actually more widely distributed, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.702%; width: 34.4771%; height: 1.38889%;">is reported in the Middle East, the Indian Subcontinent, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.0909%; width: 34.4771%; height: 1.38889%;">various parts of Southeast Asia. P. ovale has not yet been
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.3535%; width: 36.9281%; height: 1.38889%;">reported in South America. In general, P. ovale is relatively
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.7424%; width: 34.4771%; height: 1.38889%;">uncommon, though in West Africa prevalences above 10% are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.1313%; width: 34.4771%; height: 1.26263%;">observed. Also, infections are most common in children &lt;10
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.3939%; width: 34.4771%; height: 1.38889%;">years. There is likely underreporting due to underdiagnosis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 40.7828%; width: 34.4771%; height: 1.38889%;">Due to the short duration of parasitemia and low parasite loads,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.1717%; width: 30.719%; height: 1.26263%;">P. ovale is regularly ‘missed’ in cross-sectional surveys.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 44.8232%; width: 34.1503%; height: 1.38889%;">Map sources: The Malaria (Plasmodium ovale) map ismodified
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.2121%; width: 34.4771%; height: 1.38889%;">from A.J. Lysenko et al. (1969) and updated with recent
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.4747%; width: 34.4771%; height: 1.38889%;">literature. Interestingly, no global map of the geographical
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 48.8636%; width: 34.3137%; height: 1.38889%;">distribution of P. ovale has been produced since that of Lysenko
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.2525%; width: 7.84314%; height: 1.0101%;">et al. in 1969.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 52.904%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.0404%; width: 34.3137%; height: 1.38889%;">Collins WE (2005) Plasmodium ovale: parasite and disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 55.4293%; width: 22.7124%; height: 1.13636%;">Clin Microbiol Rev 18:570–581.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 56.8182%; width: 34.4771%; height: 1.38889%;">Duval L, et al. (2009) Chimpanzee malaria parasites related to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 58.0808%; width: 36.6013%; height: 1.38889%;">Plasmodium ovale in Africa. PLoS ONE 4(5):e5520.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.4697%; width: 34.4771%; height: 1.38889%;">Lysenko AJ, et al. (1969) An analysis of the geographical
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 60.8586%; width: 33.1699%; height: 1.38889%;">distribution of Plasmodium ovale. Bull World Health Org
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 62.2475%; width: 6.69935%; height: 1.0101%;">40:383–394.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.5101%; width: 42.6471%; height: 1.38889%;">Mueller I, et al. (2007) Plasmodium malariae and Plasmodium
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 64.899%; width: 38.0719%; height: 1.38889%;">ovale – the ‘bashful’ malaria parasites. Trends Parasitol 23
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 66.2879%; width: 6.86275%; height: 1.26263%;">(6):278–283.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 67.5505%; width: 34.3137%; height: 1.38889%;">WHO (2010) Guidelines for the Treatment of Malaria, 2nd edn.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 68.9394%; width: 4.90196%; height: 1.13636%;">Geneva.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">167
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/da32e922-96b6-4613-a383-6873de6bc68a" class="aLF-aPX-aPF-aPE-J3" alt="Page 61 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 62 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 55.0654%; height: 2.27273%;">Disease: Malaria, Plasmodium vivax
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 27.9412%; height: 1.26263%;">Classification: ICD-9 084.1; ICD-10 B51.0–B51.9.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.3137%; height: 1.38889%;">Synonyms: Vivax malaria; recurring malaria; tertian malaria;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 16.6667%; height: 1.38889%;">paludism; marsh fever; ague.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">Agent: Plasmodium vivax, an intacellular protozoan parasite in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 15.0327%; height: 1.38889%;">the Phylum Apicomplexa.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.6515%; width: 14.5425%; height: 1.0101%;">Reservoir: Humans.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">Vector: Female mosquito of the genus Anopheles; mainly bites
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 32.0261%; height: 1.38889%;">between dusk and dawn (see Anopheles map).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.2172%; width: 36.1111%; height: 2.77778%;">Transmission: By mosquito bite (Anopheles spp.); trans-
mission has been described in needle sharing IVDUs and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 10.6209%; height: 1.13636%;">blood transfusion.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.4771%; height: 2.77778%;">Cycle: Infective sporozoites are inoculated by bite from anoph-
eles mosquitoes and through the bloodstream and lymphatics
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.4771%; height: 1.38889%;">reach the liver where they differentiateinto tissue schizonts that
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">release merozoites, or to a dormant stage (hypnozoite) that can
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 2.65152%;">become active after months or years, causing relapse. Mero-
zoites released from liver mostly infect reticulocytes that
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">develop to schizonts, rupture and release merozoites that
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 33.9869%; height: 2.65152%;">will infect new reticulocytes (this cycle takes 48 hours). Game-
tocytes are able to infect mosquitoes during a blood meal.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 26.634%; height: 1.38889%;">Incubation period: 12 days to several months
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.3137%; height: 1.38889%;">Clinical findings: Common unspecific symptoms are acute
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 47.3856%; height: 2.77778%;">febrile illness with chills, sweats, nausea, headache, and vomit-
ing; high fever with chills is more common in P. vivax than in P.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 14.8693%; top: 59.8485%; width: 34.6405%; height: 1.38889%;">falciparum malaria. Recent reports provide evidence that vivax
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 42.1569%; height: 1.26263%;">malaria is not as benign as previously thought.P. vivax can lead
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.4771%; height: 1.38889%;">to severe anemia, acute respiratory distress, liver failure, renal
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 19.281%; height: 1.26263%;">failure, and even cerebral malaria.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Microscopy: in Giemsa-stained blood
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">smears Schüfnner’s dots are seen; rapid diagnostic tests
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 7.84314%; height: 1.38889%;">(RDTs); PCR.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.3137%; height: 1.38889%;">Therapy: Need to treat both P. vivax blood and liver stage.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 34.4771%; height: 1.38889%;">Uncomplicated P. vivax malaria: Chloroquine combined with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.4771%; height: 2.65152%;">primaquine (liver stage). In case of resistance: ACTs com-
bined with primaquine. For severe vivax malaria: prompt
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.2727%; width: 48.366%; height: 1.38889%;">treatment and case management as P. falciparum malaria.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 78.6616%; width: 34.3137%; height: 1.38889%;">Treatment needs to be modified in case of G6PD deficiency
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 16.7929%; width: 39.5425%; height: 1.38889%;">(see Inheritable Blood Disorder map). P. vivax chloroquine
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">resistance is established in Papua New Guinea and eastern
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 6.37255%; height: 1.13636%;">Indonesia.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 33.9869%; height: 2.52525%;">Prevention: Vector control; mosquito repellent; insecticide-
treated bed nets; treatment of infected humans.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 26.1364%; width: 34.3137%; height: 1.38889%;">Epidemiology: Vivax malaria is the second most important
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 38.0719%; height: 1.38889%;">malaria species after P. falciparum and accounts for 25–40% of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.3137%; height: 1.38889%;">the cases world wide with 132–391 million cases per year.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">Outside Africa it is the dominant species, mainly in Asia. The
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 40.1961%; height: 1.38889%;">distribution is wider than P. falciparum as it is able to develop at
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.3137%; height: 1.38889%;">lower temperatures and can form hypnozoites in human liver.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">The high prevalence of Duffy negativity in western Africa has
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">influenced the epidemiology of P. vivax, as Duffy-negative
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 2.65152%;">people are apparently resistant to vivax malaria, although sev-
eral reports suggest that Duffy-negative people can be infected
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">withP.vivax.The disease burdenis greatestininfants. In 2010, an
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.3137%; height: 1.38889%;">autochtonousP.vivax casewas diagnosedin northeastern Spain.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">Malariawasdeclarederadicated fromSpainin 1964.P.vivaxmay
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 40.6863%; height: 2.39899%;">have been transmitted by the local vector Anopheles atroparvus, which can transmit Asiatic P. vivax strains.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.3137%; height: 2.77778%;">Map sources: The Malaria (Plasmodium vivax) map is repro-
duced with permission from the Malaria Atlas Project, C.A.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">Guerra et al. (2010). The P. vivax resistance data was obtained
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 18.4641%; height: 1.38889%;">from N.M. Douglas et al. (2010).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 54.5455%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">Douglas NM, et al. (2010) Artemisinin combination therapy for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 57.0707%; width: 27.2876%; height: 1.38889%;">vivax malaria. Lancet Infect Dis 10:405–416.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 37.9085%; height: 2.52525%;">Guerra CA, et al. (2010) The international limits and popula-
tion at risk of Plasmodium vivax transmission in 2009. PloS
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 61.1111%; width: 17.4837%; height: 1.38889%;">Negl Trop Dis 4(8):e774.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 62.5%; width: 38.0719%; height: 2.77778%;">Mueller I, et al. (2009) Key gaps in the knowledge of Plasmo-
dium vivax, a neglected human malaria parasite. Lancet Infect
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 65.2778%; width: 11.7647%; height: 1.0101%;">Dis 9:555–566.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.5404%; width: 42.3203%; height: 1.38889%;">Mercereau-Puijalon O, et al. (2010) Plasmodium vivax and the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 67.9293%; width: 33.1699%; height: 1.38889%;">Duffy antigen: a paradigm revisited. Transf Clin Biol
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.3182%; width: 6.69935%; height: 1.0101%;">17:176–183.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.5808%; width: 34.3137%; height: 1.38889%;">Price RN, et al. (2007) Vivax malaria: neglected and not benign.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 25.3268%; height: 1.38889%;">Am J Trop Med Hyg 77 (6 Suppl):79–87.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 73.2323%; width: 34.4771%; height: 1.38889%;">Santa-Olalla Peralta P, et al. (2010) First autochthonous malaria
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 74.6212%; width: 32.6797%; height: 2.65152%;">case due to Plasmodium vivax since eradication, Spain, Octo-
ber 2010. Euro Surveill 15(41):19684.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 77.2727%; width: 34.4771%; height: 1.38889%;">World Health Organization (2010) Guidelines for the Treatment
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 78.6616%; width: 18.1373%; height: 1.38889%;">of Malaria, 2nd edition, Geneva.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">169
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/da650bae-b355-499f-aa62-8efecc3830d5" class="aLF-aPX-aPF-aPE-J3" alt="Page 62 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 63 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.7424%; width: 37.0915%; height: 2.14646%;">Disease: Onchocerciasis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 21.5686%; height: 1.26263%;">Classification: ICD-9 125.3; ICD-B73
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 33.9869%; height: 2.39899%;">Syndromes and synonyms: River blindness, onchoder-
matitis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.2323%; width: 34.3137%; height: 1.38889%;">Agent: Onchocerca volvulus, a filarial nematode (roundworm).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.6212%; width: 27.9412%; height: 1.38889%;">Adult female worm is approximately 50 cm long.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.2727%; width: 34.4771%; height: 1.38889%;">Reservoir: Humans are the only natural host. The parasite can
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.5354%; width: 26.3072%; height: 1.38889%;">be experimentally transferred to chimpanzees.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.1869%; width: 34.4771%; height: 1.38889%;">Vector: Female blackflies (Simulium). Transmission by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.4495%; width: 34.4771%; height: 1.38889%;">S. damnosum complex in Africa is responsible for &gt; 95%
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 33.8384%; width: 34.4771%; height: 1.38889%;">onchocerciasis cases. S. neavei complex in East Africa and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.2273%; width: 48.6928%; height: 1.38889%;">S. rasyani in Yemen. In Latin America: S. ochraceum (Mexico
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.4899%; width: 37.0915%; height: 1.38889%;">and Guatemala), S. exiguum (Colombia and Ecuador),
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 37.8788%; width: 36.9281%; height: 1.38889%;">S. metallicum (northern Venezuela), and S. guianeense(southern
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.2677%; width: 34.4771%; height: 1.26263%;">Venezuela and Brazil). Blackfly larvae develop in fast-flowing
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 40.5303%; width: 34.3137%; height: 2.77778%;">rivers and the adult fly’s flight range is up to 40 miles, explain-
ing the patchy distribution of the disease. Aided by wind,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.3081%; width: 34.4771%; height: 1.26263%;">blackflies can fly up to 500 km, explaining reinvasion of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 44.5707%; width: 11.4379%; height: 1.13636%;">areas under control.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.2222%; width: 20.915%; height: 1.38889%;">Transmission: By bite of the vector.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.7475%; width: 34.4771%; height: 1.38889%;">Cycle: Microfilariae ingested by the fly develop in about
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.0101%; width: 34.4771%; height: 1.38889%;">7 days into infective L3 stages and migrate to the head and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 52.399%; width: 34.3137%; height: 1.38889%;">escape into the skin during feeding. In the subcutaneous
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.7879%; width: 34.4771%; height: 1.38889%;">tissues the L3 larvae moult into L4 stages and produce nodules
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.1768%; width: 35.9477%; height: 1.26263%;">within which they develop in 10 months into adult filariae and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 56.4394%; width: 34.4771%; height: 1.38889%;">can live there for 14–15 years. The female worms can produce
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.8283%; width: 34.4771%; height: 1.38889%;">microfilariae for 10 years. Microfilariae are typically found
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.2172%; width: 34.4771%; height: 1.26263%;">in the skin, skin lymphatics, and ocular tissues. They have a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 60.4798%; width: 34.4771%; height: 1.38889%;">lifespan of up to 2 years. Humans remain infectious for about
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.8687%; width: 33.9869%; height: 2.39899%;">10 years, the time the female worm remains fertile, bur rein-
fection occurs in endemic areas.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.7828%; width: 34.3137%; height: 1.38889%;">Incubation period: It takes about 10 months for L3 to develop
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.1717%; width: 34.4771%; height: 1.0101%;">into adults. After 12–18 months microfilariae are found in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 68.4344%; width: 5.22876%; height: 1.13636%;">the skin.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.0859%; width: 34.4771%; height: 1.26263%;">Clinical findings: Fibrous subcutaneous nodules in the head
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 72.3485%; width: 34.4771%; height: 1.38889%;">and shoulders (Americas), pelvic girdle and legs (Africa), a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.7374%; width: 34.4771%; height: 1.38889%;">pruritic rash, disfiguring skin lesions (chronic papular and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 75.1263%; width: 34.3137%; height: 1.38889%;">lichenified onchodermatitis), skin depigmentation (leopard
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.3889%; width: 34.4771%; height: 1.38889%;">skin), edema and skin atrophy, inflammatory process in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.7778%; width: 34.4771%; height: 1.38889%;">cornea leading to irreversible blindness, growth arrest, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 79.0404%; width: 34.4771%; height: 1.38889%;">epilepsy. The proportion of depigmentation and blindness is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">most common in older ( &gt; 40 years) age groups. The disease
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 16.8301%; height: 1.38889%;">may lead to excess mortality.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 20.9596%; width: 34.3137%; height: 1.38889%;">Diagnostic tests: Microscopy of fresh skin snips to detect
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.3485%; width: 34.4771%; height: 1.38889%;">microfilariae. Nodule palpation. Rapid card tests based on
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.6111%; width: 34.4771%; height: 1.38889%;">antibody detection have been produced with promising
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 25%; width: 37.0915%; height: 2.65152%;">results (but not yet available commercially). Luciferase immu-
noprecipitation system with a mixture of four O. volvulus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.6515%; width: 34.4771%; height: 1.38889%;">antigens. Less-invasive techniques for disease surveillance
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 29.0404%; width: 34.4771%; height: 2.65152%;">are diethylcarbamazine patch tests (may become commer-
cially available in near future), which provoke a local Mazzotti
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.6919%; width: 7.84314%; height: 1.13636%;">skin reaction.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.4697%; width: 34.4771%; height: 1.38889%;">Therapy: Ivermectin, given as a single, oral dose annually or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.8586%; width: 34.4771%; height: 1.38889%;">every 6 months. There is a risk of SAEs in patients coinfected
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 37.2475%; width: 34.4771%; height: 1.26263%;">with L. loa. Doxycycline gives good results by destroying the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.5101%; width: 34.3137%; height: 1.38889%;">endosymbiotic Wolbachia bacteria and has fewer side effects.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.899%; width: 24.5098%; height: 1.38889%;">Surgical removal of subcutaneous nodules.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.5505%; width: 34.4771%; height: 4.0404%;">Prevention: Insect repellent, protective clothing, and insecti-
ciding of vector-breeding sites. Mass treatment with ivermec-
tin (see ‘Therapy’). In case transmission is interrupted with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.5909%; width: 34.4771%; height: 1.38889%;">ivermectin, it can recur if ivermectin mass treatment is stopped
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.9798%; width: 7.67974%; height: 1.38889%;">prematurely.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 50.6313%; width: 34.3137%; height: 1.38889%;">Epidemiology: It is estimated that 37 million people areinfected
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 52.0202%; width: 34.4771%; height: 1.38889%;">worldwide, 97% of them in Africa, and remaining in small foci in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.2828%; width: 34.4771%; height: 1.13636%;">Central and South America and Yemen. Onchocerciasis was
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.6717%; width: 34.4771%; height: 1.38889%;">imported into Latin America by the slave trade. Onchocerciasis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 56.0606%; width: 34.4771%; height: 1.38889%;">prevalence is related to the proximity to riverine breeding sites of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.3232%; width: 34.4771%; height: 1.38889%;">black flies, with the highest disease burden in communities
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.7121%; width: 34.4771%; height: 1.38889%;">adjacent to rivers. Prevalence of infection rises with age until
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 60.101%; width: 34.4771%; height: 1.38889%;">around 20 years, after which infection profiles vary between
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.3636%; width: 34.4771%; height: 1.38889%;">geographical region and sex. Higher rates of morbidity are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 62.7525%; width: 34.4771%; height: 1.38889%;">reported in men. This variation canbe explainedby heterogeneity
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 64.1414%; width: 29.085%; height: 1.26263%;">in age, gender, and occupational exposure to vectors.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 66.9192%; width: 34.3137%; height: 1.38889%;">Map sources: The Onchocerciasis map is reproduced with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 68.1818%; width: 24.8366%; height: 1.38889%;">permission from M.G. Basañez et al. (2006).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 71.0859%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 72.3485%; width: 34.4771%; height: 1.38889%;">Basañez MG, et al. (2006) River blindness: a success story
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.7374%; width: 26.1438%; height: 1.26263%;">under threat? PLoS Med 3(9):e371.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 75.1263%; width: 34.4771%; height: 1.38889%;">Dadzie Y, et al. (2003) Final report of the conference on the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 76.3889%; width: 30.3922%; height: 1.38889%;">eradicability of Onchocerciasis. Filaria J 2:2.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 77.7778%; width: 34.3137%; height: 1.38889%;">Taylor MJ, et al. (2010) Lymphatic filariasis and onchocerciasis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 79.1667%; width: 12.4183%; height: 1.0101%;">Lancet 376:1175–1185.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">171
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/9e3faae3-3aff-4bb2-aff3-620001a55282" class="aLF-aPX-aPF-aPE-J3" alt="Page 63 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 64 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.7424%; width: 37.5817%; height: 2.52525%;">Disease: Opisthorchiasis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.0196%; height: 1.26263%;">Classification: ICD-9 121.0; ICD-10 B66.0
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 33.9869%; height: 2.52525%;">Syndromes and synonyms: Cat liver fluke disease, food-
borne trematodiasis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 35.9477%; height: 1.38889%;">Agent: Small (6–18 mm long) trematode liver fluke of dogs,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.3137%; height: 1.38889%;">cats, and some other fish-eating mammals:Opisthorchis felineus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.3137%; height: 1.38889%;">in Europe and northern Asia, O. viverrini in Southeast Asia.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 17.1569%; height: 1.38889%;">Both species live in bile ducts.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 29.2484%; height: 1.38889%;">Reservoir: Humans and fish-eating mammals.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 31.0458%; height: 1.38889%;">Vector: Freshwater snails (Bithynia spp.).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.3137%; height: 1.38889%;">Transmission: Consumption of raw, undercooked, dried,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 33.9869%; height: 2.65152%;">salted, or pickled freshwater fish. There is no direct person-
to-person transmission.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">Cycle: Eggs excreted by the mammalian host in the feces into
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.4771%; height: 1.38889%;">freshwater are ingested by the snail vector. They hatch and in 2
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">months pass through various stages in the snail to produce
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 42.4837%; height: 2.65152%;">motile cercariae, which leave the snail and penetrate freshwa-
ter fish. In 6 weeks the cercariae encyst, and when the fish is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">eaten by another mammalian host, they exit the cyst and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">penetrate the bile duct, where in a month they mature into
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 22.549%; height: 1.38889%;">adult worms and start to produce eggs.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.3137%; height: 1.38889%;">Incubation period: Depends on infecting dose. For acute
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">disease, usually 3 to 4 weeks. For chronic disease, up to several
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 56.0606%; width: 3.75817%; height: 1.13636%;">years.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.3333%; width: 34.4771%; height: 4.0404%;">Clinical findings: O. viverrini: usually asymptomatic. Occa-
sionally abdominal pain, flatulence, fatigue, mild hepatomeg-
aly, jaundice, and cholangitis. Cholangiocarcinoma is the most
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.3737%; width: 34.4771%; height: 2.77778%;">serious complication. O. felineus: fever and hepatitis-like symp-
toms in the acute stage (right upper quadrant abdominal pain,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.4771%; height: 2.65152%;">nausea, and emesis). Chronic symptoms: biliary tract obstruc-
tion, inflammation and fibrosis of the biliary tract, liver
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.803%; width: 28.9216%; height: 1.38889%;">abscesses, pancreatitis, and suppurative cholangitis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.4545%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Microscopy for eggs in stool smear
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.8434%; width: 34.4771%; height: 1.38889%;">(Kato–Katz technique) is often inconclusive due to the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">similarity to eggs of other trematodes. Intradermal test is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">rapid and sensitive, but not specific. Immunodiagnosis is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">regarded supportive but not confirmatory. Radiology to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 37.0915%; height: 1.38889%;">demonstrate bile duct pathology. PCR test for O. viverrini
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 7.02614%; height: 1.13636%;">is available.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 25.1263%; width: 36.7647%; height: 1.38889%;">Therapy: Praziquantel; the cure rate for O. viverrini is over
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.3889%; width: 3.10458%; height: 1.13636%;">90%.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 29.2929%; width: 34.3137%; height: 1.13636%;">Prevention: Sanitation to reduce contamination of vector
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.6818%; width: 34.4771%; height: 1.38889%;">snail habitat, together with mass treatment with praziquantel
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.0707%; width: 12.5817%; height: 1.13636%;">and health education.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 34.9747%; width: 34.3137%; height: 1.26263%;">Epidemiology: Food-borne trematodiasis is focal and occurs
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.2374%; width: 38.2353%; height: 1.13636%;">in areas where the snail and freshwater fish – that is consumed
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 37.6263%; width: 34.4771%; height: 1.38889%;">raw or undercooked – coexist. The disease is the leading cause
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.0152%; width: 34.4771%; height: 1.38889%;">of cholangiocarcinoma in the world. O. viverrini is common in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 40.2778%; width: 34.4771%; height: 1.38889%;">Southeast Asia in the Mekong region with 8 million infected in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.6667%; width: 34.4771%; height: 1.13636%;">Thailand and 2 million in Laos. In Thailand about 8.7% of the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.0556%; width: 34.3137%; height: 1.38889%;">population is infected and mainly in the northern provinces.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 44.3182%; width: 34.4771%; height: 2.52525%;">Control activities in Thailand were able to reduce the preva-
lence from 34% to 10% in several areas. No data is available for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.096%; width: 34.4771%; height: 1.38889%;">Cambodia, China, or Vietnam, although opisthorchiasis is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 48.3586%; width: 34.4771%; height: 1.38889%;">likely common there. O. felineus is found in Europe and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.7475%; width: 34.4771%; height: 1.38889%;">northern Asia with approximately 5 million infected. Infected
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.0101%; width: 32.6797%; height: 1.38889%;">fish can be shipped and consumed in non-endemic areas.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.0404%; width: 33.9869%; height: 2.65152%;">Map sources: The Opistorchiasis map was made by geocod-
ing reported cases in the medical literature up to 2009.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 58.3333%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.596%; width: 34.4771%; height: 2.77778%;">Andrews RH, et al. (2008) Opisthorchis viverrini: an under-
estimated parasite in world health. Trends Parasit
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 62.2475%; width: 8.82353%; height: 1.38889%;">24(11):497–501.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.6364%; width: 34.4771%; height: 2.77778%;">Kaewpitoon N, et al. (2008) Opisthorchis viverrini: the carcino-
genic human liver fluke. World J Gastroenterol 14(5):666–674.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.2879%; width: 34.4771%; height: 1.38889%;">Keiser J, et al. (2009) Food-borne trematodiasis. Clin Microbiol
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 67.6768%; width: 14.8693%; height: 1.26263%;">Rev 22(3):466–483.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.0657%; width: 43.7909%; height: 1.38889%;">Marcos LA, et al. (2008) Update on hepatobiliary flukes:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.3283%; width: 33.0065%; height: 1.38889%;">fascioliasis, opisthorchiasis and clonorchiasis. Curr Opin
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.7172%; width: 15.1961%; height: 1.38889%;">Infect Dis 21(5):523–530.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">173
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/411a2e69-de3b-4a41-9954-48fc90af4186" class="aLF-aPX-aPF-aPE-J3" alt="Page 64 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 65 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 37.2549%; height: 2.39899%;">Disease: Paragonimiasis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 23.2026%; height: 1.26263%;">Classification: ICD-121.2; ICD-10 B66.4
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">Syndromes and synonyms: Pulmonary distomiasis, lung
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 7.67974%; height: 1.13636%;">fluke disease
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 39.7059%; height: 1.38889%;">Agent: Several species of Paragonimus trematode flatworms:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 40.6863%; height: 2.65152%;">P. westermani, P. heterotremus, P. miyazakii, P. skrjabini, and P. hueitungensis (the last two may be the same) in Asia,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.3137%; height: 1.38889%;">P. africanus and P. uterobilateralis in Africa, P. mexicanus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 26.634%; height: 1.38889%;">(P. peruvianus) and P. kellicotti in the Americas.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 33.1699%; height: 1.38889%;">Reservoir: Humans, dogs, cats, pigs, and wild carnivores.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.2172%; width: 40.6863%; height: 2.52525%;">Vector: Freshwater snails: Semisulcospira, Thiara, Aroapyrgus, and others.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.3137%; height: 1.38889%;">Transmission: By consumption of infected raw, salted,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">marinated, pickled or undercooked freshwater crabs and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">crayfish. Infected humans can excrete worm eggs in sputum
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.4771%; height: 1.38889%;">and feces for up to 20 years. There is no person-to-person
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 7.84314%; height: 1.13636%;">transmission.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 1.26263%;">Cycle: Crustaceans infected with metacercaria larvae are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">ingested by the reservoir host, excyst in the gut and migrate
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">to the tissues, usually the lungs. There they encapsulate,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">mature, and lay eggs. Eggs enter the sputum which is coughed
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">up and swallowed, then pass out in the feces into water and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">hatch in 2–4 weeks into miracidia larvae. These penetrate the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">body of the vector snail, where they develop in about 2 months
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">into cercaria larvae which enter and encyst in freshwater crabs
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 7.67974%; height: 1.38889%;">and crayfish.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">Incubation period: Flukes begin to lay eggs 6–10 weeks after
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">ingestion of larvae. In humans, incubation is long and highly
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.4771%; height: 1.38889%;">variable depending on the number of larvae ingested and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 9.31373%; height: 1.38889%;">organs affected.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">Clinical findings: Fever, cough, hemoptysis, and pleuritic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">chest pain. Flukes may invade the brain and rarely the spinal
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.3137%; height: 1.38889%;">cord, causing meningitis, intracranial hemorrhage, epilepsy,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 42.4837%; height: 4.0404%;">and paralysis. They may also cause acute and chronic inflam- mation of the pleura, pericardium, and mediastinum. Chest X-
ray findings are similar to tuberculosis. Complications include
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 33.9869%; height: 2.77778%;">pleural effusion, pneumothorax, bronchiectasis, and pulmo-
nary fibrosis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 20.8333%; width: 34.3137%; height: 1.38889%;">Diagnostic tests: Microscopic examination of sputum for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">eggs (acid-fast staining destroys eggs), and examination of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">feces after using concentration techniques; ELISA for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 5.55556%; height: 1.38889%;">serology.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">Therapy: Praziquantel and triclabendazole. Bithionol is an
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.13636%;">alternative treatment but has more side effects. In cerebral
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 20.2614%; height: 1.38889%;">paragonimiasis, steroids are added.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 33.9869%; height: 2.65152%;">Prevention: Thorough cooking of crustaceans, sanitary dis-
posal of sputum and feces and use of molluscicides.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 36.995%; width: 34.3137%; height: 1.38889%;">Epidemiology: The major endemic area is China, with an
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">estimated 20 million people infected, followed by India,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">Laos, and Myanmar. In the Americas, Ecuador has an
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 2.65152%;">estimated 1.5 million cases, but up to 2010 only 9 autochtho-
nous cases of paragonimiasis have been reported from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">North America (excluding 2 outbreaks in 2006 in California
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.3137%; height: 1.38889%;">from eating raw freshwater crab imported from Japan).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.26263%;">In 1992, the Chinese mitten crab from Korean and Chinese
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">waters positive with Paragonimus eggs was found in western
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 6.69935%; height: 1.13636%;">US waters.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 51.7677%; width: 34.1503%; height: 1.38889%;">Map Sources: The Paragonimiasis map was made with data
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">from G.W. Procop (2009) and human cases reported in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 16.8301%; height: 1.38889%;">medical literature up to 2009.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 57.197%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 37.9085%; height: 1.38889%;">Aka NA, et al. (2008) Human paragonimiasis in Africa. Ann
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 59.8485%; width: 19.4444%; height: 1.38889%;">African Med 7(4):153–162.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">Liu Q, et al. (2006) Paragonimiasis: an important food-borne
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 62.5%; width: 28.9216%; height: 1.38889%;">zoonosis in China. Trends in Parastol 24(7):318–323.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">Prasad PK, et al. (2009) Phylogenetic reconstruction using
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 65.1515%; width: 33.1699%; height: 1.38889%;">secondary structures and sequence motifs of ITS2 rDNA
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 66.5404%; width: 33.0065%; height: 1.38889%;">of Paragonimus westermani (Kerbert, 1878) Braun, 1899
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 67.9293%; width: 32.6797%; height: 2.65152%;">(Digenea: Paragonimidae) and related species. BMC Geno-
mics 10 (Suppl 3):S25.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">Procop GW (2009) North American paragonimiasis (caused by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 32.6797%; height: 2.65152%;">Paragonimus kellicotti) in the context of global paragonimia-
sis. Clin Microbiol Rev 22(3):415–446.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">175
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/02c17a75-3a27-43ab-a133-7d82e32e56d7" class="aLF-aPX-aPF-aPE-J3" alt="Page 65 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.who" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.who" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.who&amp;ust=1666162860000000&amp;usg=AOvVaw1Rn2Tq_FNkRzUsHcSiTtO9&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 80.0654%; top: 64.2677%; width: 6.53595%; height: 1.13636%;"></a><a href="http://www.who.int" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.who.int" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.who.int&amp;ust=1666162860000000&amp;usg=AOvVaw0W9UExHTZLQL7zArFgSjZi&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 58.3333%; top: 79.0404%; width: 8.16994%; height: 1.0101%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 66 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 68.4641%; height: 2.27273%;">Disease: Schistosomiasis, Africa &amp; Americas
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 22.2222%; height: 1.26263%;">Classification: ICD-9 120; ICD-10 B65
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.3182%; width: 34.4771%; height: 1.38889%;">Syndromes and synonyms: Bilharziasis, Katayama fever or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.5808%; width: 29.7386%; height: 1.38889%;">syndrome, urogenital and intestinal schistosomiasis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.9798%; width: 34.4771%; height: 2.65152%;">Agent: Trematode worms Schistosoma mansoni, S. haemato-
bium, S. intercalatum, and S. guineensis (formerly known as
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 25.6313%; width: 35.9477%; height: 1.38889%;">S. intercalatum). S. haematobium species group contains 8 species,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.0202%; width: 21.2418%; height: 1.13636%;">of which not all cause human disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 29.2929%; width: 51.4706%; height: 1.13636%;">Reservoir: Humans are the main reservoir. S. haematobium can
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.6818%; width: 33.9869%; height: 2.77778%;">infect primates, livestock and rodents. S. mansoni, S. intercala-
tum, and S. guineensis can infect rodents.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.4697%; width: 37.4183%; height: 1.38889%;">Vector: Freshwater snails: Biomphalaria spp. for S. mansoni,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.8586%; width: 47.549%; height: 1.38889%;">Bulinus spp. for S. haematobium, S. intercalatum, and S.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 37.2475%; width: 34.4771%; height: 1.26263%;">guineensis. Technically, humans are the ‘vector’ as they harbor
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.5101%; width: 32.0261%; height: 1.38889%;">the parasite’s sexual stage. Snails are intermediate hosts.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">Transmission: Contact with freshwater bodies containing
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.4771%; height: 1.38889%;">cercariae that penetrate skin or mucous membranes; drinking
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 19.4444%; height: 1.26263%;">contaminated water (uncommon).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.2121%; width: 34.4771%; height: 1.38889%;">Cycle: Snail–human–snail. Infected humans shed eggs into
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.4747%; width: 34.4771%; height: 1.38889%;">the water, which hatch into larvae (miracidia) that enter
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 48.8636%; width: 34.4771%; height: 1.38889%;">snails and develop into motile larvae (cercariae). The cercariae
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.2525%; width: 34.4771%; height: 1.26263%;">are shed into the water and penetrate the skin of humans in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.5152%; width: 34.4771%; height: 1.26263%;">water, enter the bloodstream and settle in the liver. When
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 52.904%; width: 34.4771%; height: 1.38889%;">matured to adult male and female worms, they migrate to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.1667%; width: 34.3137%; height: 1.38889%;">the abdominal veins (S. mansoni, S. intercalatum, S. guineensis)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.5556%; width: 34.4771%; height: 1.38889%;">or pelvic veins (S. haematobium), mate and produce eggs. Snails
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 56.9444%; width: 34.4771%; height: 1.38889%;">remain infectious for up to 3 months, humans for more than 10
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 3.75817%; height: 1.13636%;">years.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 60.6061%; width: 34.4771%; height: 2.77778%;">Incubation period: Usually 14–84 days for acute schistoso-
miasis (Katayama syndrome); chronic schistosomiasis can be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.2576%; width: 28.1046%; height: 1.38889%;">asymptomatic for a long period, months to years.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.6566%; width: 34.4771%; height: 1.38889%;">Clinical findings: Katayama syndrome is an acute form of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.0455%; width: 34.3137%; height: 4.0404%;">schistosomiasis, caused by the host immune response to devel-
oping larvae and early egg production and presents with noc-
turnal fever, cough, myalgia, headache, and abdominal pain.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.0859%; width: 34.4771%; height: 2.65152%;">Katayama syndrome is more common among infected non-
immune individuals (e.g. travelers) and relatively rare among
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.7374%; width: 34.4771%; height: 1.38889%;">local residents with exposure since childhood. S. mansoni
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 75.1263%; width: 34.4771%; height: 1.26263%;">causes intestinal schistosomiasis with: diarrhea, abdominal
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.3889%; width: 34.4771%; height: 1.38889%;">pain, blood in the stool, hepatosplenomegaly. S. haematobium
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.7778%; width: 34.4771%; height: 1.38889%;">causes urogenital schistosomiasis with dysuria, hematuria,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 79.0404%; width: 42.6471%; height: 1.38889%;">hemospermia, and dyspareunia. S. intercalatumand S. guineensis:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">granulomas, rectal polyps and ulcers. Chronic infection may lead
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.3137%; height: 1.38889%;">toliverfibrosis,hepatosplenomegaly, and portal hypertension (S.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">mansoni), obstructive uropathy, bacterial infection,infertility, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.4771%; height: 1.38889%;">bladder cancer (S. haematobium); rectitis, salpingitis, infertility and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">abortion (S. intercalatum, S. guineensis); anemia and altered
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">growth and cognitive development in infected children. Rarely,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 43.1373%; height: 1.38889%;">CNS disease may follow S. haematobium and S. guineensis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 5.39216%; height: 1.13636%;">infection.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 28.6616%; width: 34.1503%; height: 1.38889%;">Diagnostic tests: Microscopy for eggs in stool (S. mansoni)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.0505%; width: 34.4771%; height: 1.38889%;">or urine (S. haematobium) samples; quantification of eggs in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.3131%; width: 34.4771%; height: 1.38889%;">stool by Kato–Katz method and in urine by standardized
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.702%; width: 15.0327%; height: 1.38889%;">filtration techniques; PCR.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.2273%; width: 35.9477%; height: 5.17677%;">Therapy: Praziquantel is recommended; alternative: oxamni-
quine for S. mansoni, metrifonate for S. haematobium. Prevention: Access to clean water and sanitation; protective
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 40.2778%; width: 34.4771%; height: 1.38889%;">clothing foroccupational risk; after accidental exposure, dry the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.6667%; width: 34.4771%; height: 1.38889%;">skin and apply 70% alcohol; mollusciciding; avoid contact with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.0556%; width: 15.6863%; height: 1.13636%;">contaminated water bodies.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 45.4545%; width: 34.3137%; height: 1.26263%;">Epidemiology: It is estimated that more than 207 million
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.8434%; width: 34.3137%; height: 1.38889%;">people are infected world wide, with 85% of them in Africa.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 48.1061%; width: 34.3137%; height: 1.38889%;">Infection does not produce full immunity, so reinfection occurs.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.495%; width: 34.4771%; height: 1.38889%;">Schistosomiasis is a water-based disease that mainly affects rural
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.8838%; width: 34.4771%; height: 1.38889%;">agricultural and fishing communities. Higher disease prevalence
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 52.1465%; width: 34.4771%; height: 1.38889%;">rates in endemic regions are found close to irrigation projects or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.5354%; width: 34.4771%; height: 1.38889%;">dams. Man-made water bodies like dams can lead to changes in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.9242%; width: 36.2745%; height: 4.0404%;">snail habitat and cause a shift from urogenital to intestinal schis-
tosomiasis (Egypt) and vice versa (Senegal). S. mansoni was pre-
sumably introduced with the slave trade from west Africa into
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.9646%; width: 44.7712%; height: 1.38889%;">South America and the Caribbean S. intercalatum and S. guineensis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 60.2273%; width: 29.7386%; height: 1.38889%;">are geographically restricted to Central Western Africa.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 63.005%; width: 34.3137%; height: 1.38889%;">Map sources: The Schistosomiasis map is modified from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 64.2677%; width: 34.3137%; height: 1.38889%;">WHO (1987) Global Schistosomiasis Atlas at: www.who.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.6566%; width: 23.8562%; height: 1.38889%;">int/wormcontrol/documents/maps/en/.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 68.3081%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.5707%; width: 41.1765%; height: 1.26263%;">Murinello A, et al. (2006) Liver disease due to Schistosoma
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.9596%; width: 29.2484%; height: 1.38889%;">guineensis – a review. J Port Gastrenterol 13:97–104.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 72.2222%; width: 34.4771%; height: 1.38889%;">Ross AGP, et al. (2007) Katayama syndrome. Lancet Infect Dis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.6111%; width: 6.04575%; height: 1.13636%;">7:218–224.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 75%; width: 34.4771%; height: 1.26263%;">Steinman P, et al. (2006) Schistosomiasis and water
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 76.2626%; width: 32.5163%; height: 1.38889%;">resources development. Lancet Infect Dis 6:411–425.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 77.6515%; width: 35.4575%; height: 1.38889%;">World Health Organization (2011) Schistosomiasis. Factsheet
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 79.0404%; width: 13.5621%; height: 1.26263%;">Nr 115 (www.who.int).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">177
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/2fc35410-7f26-4435-8969-2eac3d141c52" class="aLF-aPX-aPF-aPE-J3" alt="Page 66 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.who.int/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.who.int/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.who.int/&amp;ust=1666162860000000&amp;usg=AOvVaw0Tifat_sRQaV_yADiVUjyq&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 77.9412%; top: 58.4596%; width: 8.82353%; height: 1.26263%;"></a><a href="http://www.who.int" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.who.int" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.who.int&amp;ust=1666162860000000&amp;usg=AOvVaw0W9UExHTZLQL7zArFgSjZi&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 58.3333%; top: 76.0101%; width: 8.33333%; height: 1.0101%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 67 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 47.0588%; height: 2.27273%;">Disease: Schistosomiasis, Asia
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 22.2222%; height: 1.26263%;">Classification: ICD-9 120; ICD-10 B65
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 33.9869%; height: 2.65152%;">Synonyms: Bilharziasis, snail fever, Katayama fever or syn-
drome, intestinal schistosomiasis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.3137%; height: 1.38889%;">Agent: Trematodeworms Schistosoma japonicum, S. malayensis,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.3137%; height: 4.0404%;">and S. mekongi. Reservoir: Humans, dogs, cats, pigs, cattle, water buffalo and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">wild rodents for S. japonicum, rodents for S. malayensis, pigs
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 36.6013%; height: 4.16667%;">and dogs for S. mekongi. Vector: Freshwater snails: Oncomelania spp. for S. japonicum,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.2172%; width: 40.6863%; height: 4.16667%;">Robertsiella spp. for S. malayensis, Neotricula spp. for S. mekongi. Transmission: Contact with freshwater bodies containing
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">cercariae that penetrate skin or mucous membranes; drinking
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 20.4248%; height: 1.38889%;">contaminated water (less common).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.4771%; height: 1.38889%;">Cycle: Snail–human–snail. Infected humans shed eggs into
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 1.26263%;">the water, which hatch into larvae (miracidia) that enter snails
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">and develop into motile larvae (cercariae). The cercariae are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">shed into the water and penetrate the skin of humans with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.4771%; height: 1.13636%;">water contact. Cercariae enter the bloodstream and settle in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">liver, where they grow into adult male and female worms that
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.3137%; height: 1.38889%;">migrate to the abdominal veins, mate, and produce eggs.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">Snails are infectious for up to 3 months, humans for 10
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.4091%; width: 8.49673%; height: 1.13636%;">years or more.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.4771%; height: 2.65152%;">Incubation period: Usually 14–84 days for acute schistoso-
miasis (Katayama syndrome); chronic schistosomiasis can be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 28.1046%; height: 1.38889%;">asymptomatic for a long period, months to years.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">Clinical findings: Katayama syndrome is an acute form of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.3137%; height: 4.0404%;">schistosomiasis, caused by the host immune response to devel-
oping larvae and early egg production and presents with noctur-
nal fever, cough, myalgia, headache, and abdominal pain.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 2.77778%;">Katayama syndrome is more common among infected non-
immune individuals (e.g. travelers) and relatively rare among
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">local residentswith exposure since childhood. S. japonicumcauses
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">intestinal schistosomiasis with: diarrhea, abdominal pain, blood
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.4771%; height: 1.38889%;">in the stool, hepatosplenomegaly. Chronic infection leads to liver
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 34.4771%; height: 1.38889%;">fibrosis and portal hypertension, anemia, and altered growth and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.4771%; height: 1.38889%;">cognitive development in infected children; seizures due to egg
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 34.4771%; height: 1.26263%;">granulomas in brain or spinal cord. Infection does not produce
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">full immunity, so reinfection occurs. S.mekongi causes similar, but
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 4.0404%;">milder, disease compared to S. japonicum. Diagnostic tests: Microscopy for eggs in stool samples;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 28.7582%; height: 1.38889%;">quantification of eggs by Kato–Katz method; PCR.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 28.9216%; height: 1.38889%;">Therapy: Praziquantel is the drug of choice for all.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 27.5253%; width: 34.3137%; height: 1.38889%;">Prevention: Access to clean water and sanitation; protective
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">clothing (rubber boots and gloves) for those with occupational
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">exposure; after accidental exposure, dry the skin and apply
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 2.77778%;">70% alcohol; mollusciciding. Replace water buffaloes by trac-
tors, and livestock management like fencing off water
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 5.88235%; height: 1.0101%;">buffaloes.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 36.995%; width: 34.3137%; height: 1.38889%;">Epidemiology: Approximately 1 million people are infected
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">with Schistosoma spp. in Cambodia, China, Lao PDR, and the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">Philippines. Schistosomiasis has been eliminated from Japan
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">and the burden has been greatly reduced in China through
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.13636%;">extensive control efforts. Schistosomiasis is a water-based
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 44.9346%; height: 1.38889%;">disease, that mainly affects rural agricultural and fishing
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">communities. Higher disease prevalence rates in endemic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.3137%; height: 1.38889%;">regions are found close to large irrigation projects or dams.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">S. japonicum is found in China, Philippines, and Indonesia. In
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.3137%; height: 1.26263%;">Indonesia, schistosomiasis is confined to two endemic areas in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">Central Sulawesi. S. mekongi is found in the Mekong River area
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.3137%; height: 1.26263%;">of Cambodia and Laos, and has also been detected in Thailand.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.3137%; height: 1.38889%;">S. malayensis has only been reported from Malaysia and is a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 16.6667%; height: 1.13636%;">rare cause of human disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 57.0707%; width: 34.3137%; height: 1.38889%;">Map sources: The Schistosomiasis map is modified from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 34.3137%; height: 1.38889%;">WHO (1987) Global Schistosomiasis Atlas, at: www.who.int/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 21.5686%; height: 1.38889%;">wormcontrol/documents/maps/en/.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 62.6263%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">ChitsuloL, et al. (2000) The global status of schistosomiasis and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 65.1515%; width: 24.3464%; height: 1.38889%;">its control. Acta Trop 77:41–51.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.5404%; width: 33.9869%; height: 2.65152%;">Ross AGP, et al. (2001) Schistosomiasis in the People’s Repub-
lic of China. Clin Microbiol Rev 14(2):270–295.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">Ross AGP, et al. (2007) Katayama syndrome. Lancet Infect Dis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.5808%; width: 6.04575%; height: 1.13636%;">7:218–224.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 71.9697%; width: 34.4771%; height: 1.26263%;">Steinman P, et al. (2006) Schistosomiasis and water
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.2323%; width: 32.5163%; height: 1.38889%;">resources development. Lancet Infect Dis 6:411–425.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 74.6212%; width: 35.4575%; height: 1.38889%;">World Health Organization (2011) Schistosomiasis. Factsheet
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 76.0101%; width: 13.5621%; height: 1.26263%;">Nr 115 (www.who.int).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">179
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/f429fdb1-b27b-49e1-88d2-00adeadd3413" class="aLF-aPX-aPF-aPE-J3" alt="Page 67 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 68 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 38.7255%; height: 2.39899%;">Disease: Strongyloidiasis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 23.2026%; height: 1.26263%;">Classification: ICD-9 127.2; ICD-10 B78
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.5707%; width: 25.1634%; height: 1.13636%;">Syndromes and synonyms: Larva currens.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 34.4771%; height: 2.65152%;">Agent: Strongyloides stercoralis, a minute nematode round-
worm (up to2.2 mmlong).S.fuelleborni(notshownonthemap)is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">a less common agent and can causehuman diseasein Africa and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 32.3529%; height: 1.38889%;">Papua New Guinea (‘swollen belly syndrome’ in infants).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 39.3791%; height: 2.65152%;">Reservoir: For S. stercoralis: mainly humans, although infec-
tions in non-human primates and dogs have been described. S.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 14.8693%; top: 31.5657%; width: 34.4771%; height: 2.77778%;">fuelleborni is mainly found in in monkeys, but human-to-
human transmission may occur in some geographical regions.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">Transmission: Mainly skin contact with fecally contaminated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 26.4706%; height: 1.26263%;">soil, but oral transmission cannot be excluded.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.3137%; height: 1.38889%;">Cycle: S. stercoralis has a free-living (asexual) and parasitic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">(sexual) lifecycle. Free-living filariform (L3) larvae in the soil
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.3137%; height: 1.38889%;">penetrate the skin, enter the bloodstream, reach the lungs,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">travel up to the throat, and are swallowed. In the duododenal
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">wall they mature into adult female worms, produce eggs
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.3137%; height: 1.38889%;">that hatch immediately, thus only larvae (L1) are excreted.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.3137%; height: 1.38889%;">These non-infectious (L1) larvae develop further in the soil into
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.4771%; height: 2.65152%;">either adult worms or infectious (L3) larvae. Some non-infec-
tious L1 larvae may develop faster into infectious L3 larvae in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">the human intestine and penetrate the perianal skin or colon
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">wall. This process of auto-infection may lead to hyperinfection
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 21.2418%; height: 1.38889%;">in immunocompromised individuals.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">Incubation period: Indefinite and variable; from skin
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 28.4314%; height: 1.38889%;">penetration to larvae in the stool takes 2–4 weeks.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.1111%; width: 46.0784%; height: 2.77778%;">Clinical findings: Most infections with S. stercoralis are asymptomatic. Symptoms may include: upper abdominal
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">pain; cough; diarrhea; a red and painful, creeping urticarial
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">eruption on the skin; and vomiting. Pulmonary symptoms
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">(including Loeffler syndrome) can occur. Disseminated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">strongyloidiasis occurs in immunocompromised patients
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 2.77778%;">and presents with abdominal pain, distension, shock, pulmo-
nary and neurologic complications, and septicemia. High
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.4771%; height: 1.38889%;">mortality rates (15–87%) have been described in patients
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 15.3595%; height: 1.13636%;">with disseminated disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 75.8838%; width: 38.2353%; height: 1.38889%;">Diagnostic tests: Demonstration of Strongyloides larvae on
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.2727%; width: 34.4771%; height: 1.38889%;">repeated stool specimens by microscopy after concentration
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 78.6616%; width: 34.4771%; height: 1.38889%;">(coproculture or Baermann). Stool examination has poor
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">sensitivity, particularly in chronic cases. Serological tests
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">vary in sensitivity and specificity, and perform better in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">chronic cases and are therefore used for screening patients
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.4771%; height: 1.38889%;">at risk for hyperinfection. PCR has higher sensitivity than
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">microscopy. Hyperinfection: larvae or parasite DNA can be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 22.2222%; height: 1.38889%;">found in sputum and other specimens.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 34.3137%; height: 1.38889%;">Therapy: Ivermectin; alternative: albendazole or thiabendazole.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 28.9141%; width: 34.3137%; height: 1.38889%;">Prevention: Access to clean water and sanitation; regular
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 4.16667%;">deworming; use of closed footwear. Infection control in im-
munocompromised patients with hyperinfection. Immuno-
compromised patients who have been in endemic areas
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 24.183%; height: 1.26263%;">should be screened and treated if positive.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 36.995%; width: 34.1503%; height: 1.38889%;">Epidemiology: The estimated prevalence of strongyloidiasis is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.13636%;">between 30 and 100 million infections in 70 countries world
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">wide; however, the accuracy of these estimates is uncertain due
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">to poor performance of screening methods. Most cases are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">found in tropical and subtropical areas (warm, moist). Rarely,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">it is found in foci in North America and Europe. It is of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">significance in developed nations as it can cause hyperinfection
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">in immunocompromised patients that have been infected years
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">before in an endemic region. The most important risk factor for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.3137%; height: 1.38889%;">hyperinfection is corticosteroid therapy; other risk factors are:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.3137%; height: 1.38889%;">hematologic malignancies, malnutrition, alcoholism, HTLV-1
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">infection, and immunosuppressive medication (e.g. for organ
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">transplantation). Interestingly, hyperinfection is not commonly
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 30.3922%; height: 1.13636%;">seen in HIV-infected individuals in endemic countries.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 57.0707%; width: 34.3137%; height: 1.38889%;">Map sources: The Strongyloidiasis map is modified from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">M. Farthing et al. (2004) and updated with data from the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 10.6209%; height: 1.13636%;">medical literature.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 62.6263%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 34.6405%; height: 1.38889%;">Farthing M, et al. (2004)WGO Practice Guideline; Management of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 65.1515%; width: 30.8824%; height: 1.38889%;">Strongyloidiasis. World Gastroenterology Organization.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.5404%; width: 37.7451%; height: 2.77778%;">Keiser PB, et al. (2004) Strongyloides stercoralis in the immuno-
compromised population. Clin Microb Rev 17(1):208–217.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.1919%; width: 34.4771%; height: 2.77778%;">Marcos LA, et al. (2008) Strongyloides hyperinfection syn-
drome: an emerging global infectious disease. Trans R Soc
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 20.5882%; height: 1.38889%;">Trop Med Hyg 102:314–318.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 73.2323%; width: 37.2549%; height: 2.77778%;">Montesa M, Sawhney C, Barrosa N (2010) Strongyloides ster-
coralis: there but not seen. Curr Opin Infect Dis 23:500–504.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 76.0101%; width: 34.6405%; height: 1.26263%;">Olsen A, et al. (2009) Strongyloidiasis – the most neglected of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 77.2727%; width: 33.1699%; height: 1.38889%;">the neglected tropical diseases? Trans R Soc Trop Med Hyg
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 78.6616%; width: 7.35294%; height: 1.13636%;">103:967–972.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">181
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/afdb0350-9726-4668-918f-ee27a66e5f25" class="aLF-aPX-aPF-aPE-J3" alt="Page 68 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.fao.org/ag/againfo/programmes/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.fao.org/ag/againfo/programmes/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.fao.org/ag/againfo/programmes/&amp;ust=1666162860000000&amp;usg=AOvVaw028X2GAxpfbyMph0StT_ys&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 64.0523%; top: 54.0404%; width: 22.7124%; height: 1.38889%;"></a><a href="http://www.who.int/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.who.int/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.who.int/&amp;ust=1666162860000000&amp;usg=AOvVaw0Tifat_sRQaV_yADiVUjyq&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 77.9412%; top: 77.2727%; width: 8.82353%; height: 1.26263%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 69 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 52.6144%; height: 2.39899%;">Disease: Trypanosomiasis, African
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 31.0458%; height: 1.26263%;">Classification: ICD-9 086.3-086.4; ICD-10 B56.0, B56.1
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.3182%; width: 34.4771%; height: 1.38889%;">Syndromes and synonyms: Sleeping sickness, Gambian
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.5808%; width: 34.4771%; height: 1.38889%;">trypanosomiasis, Rhodesian trypanosomiasis, West African
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 21.9697%; width: 27.7778%; height: 1.38889%;">sleeping sickness, East African sleeping sickness.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.3687%; width: 38.8889%; height: 1.38889%;">Agent: Extracellular, unicellular hemoflagellate Trypanosoma
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 25.7576%; width: 34.4771%; height: 1.38889%;">brucei, with two subspecies: T. b. gambiensein West and Central
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.1465%; width: 34.4771%; height: 1.38889%;">Africa (tropical forest), T. b. rhodesiense in East and Southern
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.4091%; width: 10.6209%; height: 1.38889%;">Africa (savannah).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.8081%; width: 34.4771%; height: 1.38889%;">Reservoir: Humans for T. b. gambiense; livestock and wildlife
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.197%; width: 34.4771%; height: 3.78788%;">for T. b. rhodesiense. Vector: Tsetse fly (Glossina). The main human vectors belong
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.9848%; width: 36.6013%; height: 1.38889%;">to the palpalis (riverine flies) and morsitans (forest and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 37.2475%; width: 34.3137%; height: 1.38889%;">savannah flies) complex. The palpalis complex (G. fuscipes,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.6364%; width: 34.3137%; height: 1.38889%;">G. palpalis, G. tachinoides) mainly transmit T. b. gambiense
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 40.0253%; width: 38.7255%; height: 1.38889%;">and the morsitans complex (G. morsitans, G. pallidipes, G.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.2879%; width: 41.5033%; height: 1.38889%;">swynnertoni) mainly transmit T. b. rhodesiense. G. fuscipes and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.6768%; width: 24.183%; height: 1.38889%;">G. tachinoides can transmit both subspecies.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.202%; width: 33.9869%; height: 2.65152%;">Transmission: By tsetse fly bite (day biters); blood transfu-
sion, and congenital.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 48.9899%; width: 34.4771%; height: 1.38889%;">Cycle:The parasite isingested by a tsetse fly during feeding on
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.2525%; width: 34.4771%; height: 1.38889%;">an infected host, and enters the salivary glands after 12–30
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.6414%; width: 34.4771%; height: 1.38889%;">days, and can be transmitted to new susceptible hosts during
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.0303%; width: 34.4771%; height: 1.38889%;">the life of the fly (3 months). There is no vertical transmission in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.2929%; width: 13.8889%; height: 1.38889%;">the fly.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 56.6919%; width: 40.6863%; height: 5.17677%;">Incubation period: 3 days to a few weeks for T. b. rhodesiense, several months to years for T. b. gambiense. Clinical findings: A papule at the bite site develops into a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.8687%; width: 34.3137%; height: 1.38889%;">painful chancre (mainly T.b. rhodesiense), with fever, severe
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.2576%; width: 34.3137%; height: 2.65152%;">headache, lympadenopathy, insomnia and progresses to vari-
able neurological symptoms including a disrupted sleep cycle,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.9091%; width: 33.1699%; height: 1.38889%;">confusion, seizures, and, if left untreated, eventually death.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 68.1818%; width: 34.3137%; height: 1.38889%;">Diagnostic tests: Detection of trypanosomes in blood, lymph,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.5707%; width: 34.4771%; height: 1.38889%;">or CSF after concentration; IgM ELISA, IFA, PCR. A card
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.9596%; width: 42.4837%; height: 1.38889%;">agglutination trypanosomiasis test (CATT) is available for T.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 72.2222%; width: 40.6863%; height: 5.17677%;">b. gambiense but not T. b. rhodesiense. Therapy: Early stage disease: suramin for T. b. rhodesiense, pentamidine forT. b. gambiense; Late stage disease: melarsoprol
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.399%; width: 34.4771%; height: 1.26263%;">for both forms; eflornithine with or without nifurtimox
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 78.7879%; width: 25%; height: 1.38889%;">for gambiense. These drugs can cause SAEs.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 42.4837%; height: 2.65152%;">Prevention: Treat patients to reduce the T. b. gambiense reser- voir, and cattle to reduce the T. b. rhodesiense reservoir; screen
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.3137%; height: 1.38889%;">blood donations; vector control: fly traps, insecticide-treated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.4771%; height: 1.38889%;">screens, ground and aerial spraying, release of sterile male
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 15.1961%; height: 1.13636%;">tsetse flies.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 25.2525%; width: 34.3137%; height: 1.38889%;">Epidemiology: WHO estimates that 50,000 to 70,000 people
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.6414%; width: 34.4771%; height: 1.38889%;">are infected each year, with about 60 million people at risk in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.0303%; width: 34.4771%; height: 1.38889%;">36 countries. The disease distribution is limited by the range
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 29.2929%; width: 37.5817%; height: 1.38889%;">of the tsetse fly vector. Cases outside the tsetse fly distribution
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.6818%; width: 34.4771%; height: 1.38889%;">are likely imported. The disease distribution is patchy, with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.0707%; width: 34.4771%; height: 1.13636%;">discrete foci and little to no disease between these foci. It is a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 33.3333%; width: 34.3137%; height: 1.38889%;">disease of poverty and mainly occurs in remote rural areas.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.7222%; width: 34.4771%; height: 1.38889%;">African trypanosomiasis was close to eradication through a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.1111%; width: 34.4771%; height: 1.26263%;">variety of control programs, a loosening of these control
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 37.3737%; width: 34.3137%; height: 1.38889%;">programs caused the disease to reemerge in the 1980s.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.7626%; width: 34.4771%; height: 1.38889%;">However, recent disease control programs are reversing this
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 40.1515%; width: 34.4771%; height: 1.26263%;">trend. The chronic gambiense form in West and Central Africa
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.4141%; width: 48.5294%; height: 1.38889%;">accounts for 95% of cases and is seperated from rhodesiense by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.803%; width: 34.4771%; height: 1.38889%;">the Great Rift Valley. Uganda is the sole country reporting both
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 44.1919%; width: 39.8693%; height: 1.38889%;">forms, with rhodesiense in the south and gambiense in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.4545%; width: 6.37255%; height: 1.13636%;">northwest.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 48.6111%; width: 34.1503%; height: 1.38889%;">Map sources: The African Trypanosomiasis map was made
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50%; width: 34.4771%; height: 1.26263%;">with data obtained from P.P. Simarro et al. (2010). The tstetse
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.2626%; width: 34.4771%; height: 1.38889%;">fly distribution data is based on statistical distribution
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 52.6515%; width: 34.4771%; height: 1.38889%;">models produced by the Environmental Research Group
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.0404%; width: 34.3137%; height: 1.38889%;">Oxford, available at: www.fao.org/ag/againfo/programmes/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.303%; width: 11.6013%; height: 1.38889%;">en/paat/maps.html.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 58.5859%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">Aksoy S (2011) Sleeping sickness elimination in sight.PloS Negl
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 61.2374%; width: 14.7059%; height: 1.26263%;">Trop Dis 5(2):e1008.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 62.5%; width: 34.4771%; height: 1.38889%;">Food and Agriculture Organization (2000) Consultant’s Report;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 63.8889%; width: 31.6993%; height: 1.38889%;">Predicted Distributions of Tsetse Fly in Africa. Rome, Italy.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 34.4771%; height: 2.52525%;">Simarro PP, et al. (2008) Eliminating human African trypano-
somiasis: where do we start andwhat comes next?PLoS Med
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 67.9293%; width: 5.06536%; height: 1.26263%;">5(2):e55.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.1919%; width: 33.9869%; height: 2.77778%;">Simarro PP, et al. (2010) The Atlas of Human African Try-
panosomiasis. Int J Health Geogr 9:57.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 71.9697%; width: 34.4771%; height: 1.38889%;">Simarro PP, et al. (2011) The human African trypanosomiasis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.2323%; width: 33.1699%; height: 1.38889%;">control and surveillance program of the World Health
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 74.6212%; width: 34.8039%; height: 1.38889%;">Organization 2000–2009. PLoS Negl Trop Dis 5(2):e1007.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 76.0101%; width: 34.3137%; height: 2.65152%;">World Health Organization (2011) African trypanoso-
miasis (sleeping sickness) fact sheet: www.who.int/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 78.6616%; width: 17.1569%; height: 1.38889%;">trypanosomiasis_african/en/.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">183
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/2a5cb885-bdd3-4383-9dd1-8fa0c36b4e76" class="aLF-aPX-aPF-aPE-J3" alt="Page 69 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 70 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 56.0458%; height: 2.39899%;">Disease: Trypanosomiasis, American
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 23.2026%; height: 1.26263%;">Classification: ICD-9 086.2; ICD-10 B57
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 16.3399%; height: 1.38889%;">Synonyms: Chagas disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 41.1765%; height: 1.38889%;">Agent: Trypanosoma cruzi, a protozoan, with a flagellate
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 1.13636%;">form in the bloodstream and an intracellular form without
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 6.04575%; height: 1.38889%;">flagellum.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">Reservoir: Humans and a wide variety of domestic and wild
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">mammals, especially dogs, cats, guinea-pigs, rodents, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.5556%; width: 6.37255%; height: 1.0101%;">opossums.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 41.5033%; height: 1.38889%;">Vector: Blood feeding reduviid bugs of the genera Triatoma,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.2172%; width: 34.4771%; height: 1.38889%;">Rhodnius, and Panstrongylus. The most common vector in south
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 33.4967%; height: 1.38889%;">America is Triatoma infestans. The vector lives up to 2 years.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">Transmission: The vector defecates during feeding, and the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.3137%; height: 1.38889%;">infected feces are rubbed into the bite wound or conjunctivae,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">mucousmembranes, or abraded skin; blood transfusion, organ
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.4771%; height: 1.38889%;">transplant and shared needles. Congenital infection occurs in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">2–8% of infected pregnancies. Oral transmission occurs by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 26.7974%; height: 1.38889%;">eating or drinking contaminated food or drink.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">Cycle: 10–30 days in the vector after first infected meal, then
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 17.9739%; height: 1.38889%;">5–42 days in the reservior host.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">Incubation period: 5–14 days after infected bite, 30–40 days
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 18.3007%; height: 1.13636%;">after infected blood transfusion.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.4771%; height: 4.0404%;">Clinical findings: Most infections produce few or no symp-
toms. Acute symptoms include variable fever, lymphadeno-
pathy,malaise, and hepatosplenomegaly. The entry site may be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 2.65152%;">inflamed for up to 8 weeks, and a diagnostic unilateral bipal-
pebral edema (Romana’s sign) appears in a few cases. After a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.4771%; height: 1.38889%;">latent period which may last 10–30 years, chronic irreversible
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">sequelae occur in 20–30% of cases: myocardial lesions with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">arrhythmia, often fatal, andlesions of the esophagus, colon, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.3137%; height: 1.38889%;">peripheral nervous system. Variations in clinical presentations
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">can be related to the strain involved. Group I T. cruzi, rare north
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">of the Amazon region, produce cardiac but not digestive tract
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">lesions. Group IIT. cruzi can produce both cardiac and digestive
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.4771%; height: 2.65152%;">tract lesions. AIDS patients may develop meningoencephalo-
pathy. CFR from encephalomyelitis or cardiac failure among
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 23.366%; height: 1.38889%;">untreated symptomatic patients is 5–10%.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.2727%; width: 34.3137%; height: 1.38889%;">Diagnostic tests: Direct examination of blood smear (low
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 78.6616%; width: 34.4771%; height: 1.38889%;">sensitivity), PCR, serology (indirect immunofluorescence,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">indirect hemagglutination). Serology can give false positive
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 16.5033%; height: 1.13636%;">results. Culture takes weeks.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.4771%; height: 2.65152%;">Therapy: Benznidazole, pentamidine, melarsoprol, eflorni-
thine, suramin, and nifurtimox are effective in acute cases;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">melarprosol and eflornithine can have SAEs. Patients need to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 16.8301%; height: 1.38889%;">be followed up for 1–2 years.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 2.77778%;">Prevention: Application of residual insecticides or insecti-
cidal paint inside dwellings, use ofinsecticide-treated bed nets,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.3137%; height: 1.38889%;">screening of blood and organ donors from infected areas.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">Application of these methods has eradicated intradomiciliary
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">transmission from Uruguay (1997), Chile (1999), Guatemala
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 34.3434%; width: 34.3137%; height: 1.26263%;">(2005), Brazil (2006), the eastern region of Paraguay, andfive of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">the endemic provinces of Argentina. Honduras and Nicaragua
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">are awaiting certification of eradication. Only the food-borne
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 15.6863%; height: 1.13636%;">risk remains in those areas.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 41.0354%; width: 34.3137%; height: 1.38889%;">Epidemiology: An estimated 7.6 million people are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.26263%;">infected with T. cruzi and 75 million are at risk in Mexico,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">Central and South America, determined by the range of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">the vector. Originally American trypanosomiasis was a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">disease of agricultural workers (mainly adult men) living
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">in rural areas in poor housing conditions. In urban areas
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 2.65152%;">transmission is mainly via blood transfusion, and occa-
sionally via ingestion of contaminated sugarcane juice or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">palm fruit juice. Control programs between 1990 and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.13636%;">2006 resulted in the estimated annual number of deaths
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">falling from more than 45,000 to 12,500, and the incidence
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 34.3137%; height: 1.26263%;">of new cases from an estimated 700,000 to 41,200.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">Chronic cases are diagnosed in non-endemic countries
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 36.4379%; height: 1.38889%;">in immigrants. In the USA 300,000 immigrants have
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">Chagas disease, and an estimated 30,000 cases of Chagas
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.2374%; width: 16.0131%; height: 1.26263%;">cardiomyopathy annually.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 34.3137%; height: 2.65152%;">Map sources: The American Trypanosomiasis map was mod-
ified from P.D. Marsden (1997) and updated with data from A.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.5404%; width: 25.4902%; height: 1.38889%;">Moncayo et al. (2009) and medical literature.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 69.3182%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.5808%; width: 33.9869%; height: 2.77778%;">Marsden PD (1997) The control of Latin American trypanoso-
miasis. Rev Soc Brasil Med Trop 30(6):521–527.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 73.2323%; width: 34.4771%; height: 1.38889%;">Moncayo A, et al. (2009) Current epidemiological trends for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 74.6212%; width: 41.9935%; height: 1.38889%;">Chagas disease in Latin America. Mem Inst Oswaldo Cruz 104
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 76.0101%; width: 9.47712%; height: 1.26263%;">(Suppl. I):17–30.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 77.2727%; width: 34.4771%; height: 1.38889%;">Prata A (2001) Clinical and epidemiological aspects of Chagas
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 78.6616%; width: 22.2222%; height: 1.38889%;">disease. Lancet Inf Dis 1(2):92–100.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">185
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/09837fb9-fed1-4810-8a02-6f1acbc5de41" class="aLF-aPX-aPF-aPE-J3" alt="Page 70 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://gamapserver.who.int/mapLi-brary/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://gamapserver.who.int/mapLi-brary/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://gamapserver.who.int/mapLi-brary/&amp;ust=1666162860000000&amp;usg=AOvVaw14PH2plq4hN6AWKpTHC8wM&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 52.451%; top: 55.8081%; width: 34.4771%; height: 2.65152%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 71 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.7424%; width: 51.7974%; height: 2.39899%;">Disease: Avian Influenza (A/H5N1)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.3464%; height: 1.26263%;">Classification: ICD-9 488.01; ICD-10 J09.0
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">Synonyms: Bird flu, avian influenza, highly pathogenic avian
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 9.96732%; height: 1.26263%;">influenza, H5N1.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">Agent: Influenza A subtype H5N1, a RNA virus, family
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">Orthomyxoviridae. Avian influenza H5N1 occurs in two
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">forms, a virulent form known as highly pathogenic avian
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">influenza H5N1 (HPAI H5N1) and a milder form known as
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">‘low pathogenic’ (LPAI H5N1). H5N1 viruses have diverged
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 29.085%; height: 1.38889%;">into geographically distinct strains (genetic clades).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.3137%; height: 1.38889%;">Reservoir: LPAI viruses naturally circulate in wild birds,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">principally waterfowl and gulls, in which they generally
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">cause no symptoms. LPAI viruses are transmitted to terrestrial
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.4771%; height: 1.38889%;">poultry (chickens, turkeys). LPAI most likely evolved to HPAI
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">in aquatic birds (ducks and geese). Transmission of HPAI into
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 24.5098%; height: 1.38889%;">migratory birds can result in large die-offs.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.4771%; height: 1.38889%;">Transmission: Direct contact with sick or dead poultry (most
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">common) infected with HPAI, and possibly via inhalation of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">virus-laden particles or contact of contaminated material with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 2.65152%;">the eyes or respiratory mucosa. Other postulated routes: inges-
tion of water contaminated with the feces of infected birds,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.3137%; height: 1.38889%;">consumption of undercooked products from infected birds.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">Often, however, the route of exposure is not clear. Limited
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 33.9869%; height: 2.77778%;">person-to-person transmission of HPAI H5N1 is possible fol-
lowing prolonged close contact with an infected patient.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 25.4902%; height: 1.38889%;">Incubation period: 3 days (range 2–9 days).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">Clinical findings: Sudden onset fever and cough. Other early
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.3137%; height: 1.38889%;">symptoms include: myalgia, headache, vomiting, diarrhea,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.3137%; height: 1.26263%;">nausea, and epigastric pain. The disease rapidly progresses
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 33.9869%; height: 2.77778%;">to severe viral pneumonia. Patients may present with enceph-
alitis or gastroenteritis. The CFR is around 60%.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Virus detection by RT-PCR of respiratory
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">specimens is recommended; virus culture requires a BSL-3
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">facility. Microneutralization assay is recommended to detect
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.1503%; height: 2.77778%;">antibodies to A/H5N1. Rapid antigen tests are not recom-
mended due to lack of sensitivity.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.4771%; height: 1.38889%;">Therapy: Oseltamivir may improve survival, if given early
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 26.4706%; height: 1.26263%;">after onset. Otherwise treatment is supportive.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 16.7929%; width: 34.3137%; height: 1.38889%;">Prevention: Prevention of exposure to the wild aquatic bird
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 45.915%; height: 2.65152%;">reservoir and domestic poultry (farm biosecurity). Surveil-
lance for infected poultry flocks and culling of infected flocks
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.4771%; height: 2.77778%;">(stamping out). Poultry workers and cullers must wear pro-
tective clothing. Education of poultry farmers and the general
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">public to reduce high-risk exposures. Human cases must be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 34.4771%; height: 1.26263%;">isolated, close contacts monitored, and healthcare workers
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 24.183%; height: 1.38889%;">must wear personal protective equipment.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 28.9141%; width: 34.3137%; height: 1.26263%;">Epidemiology: Since the end of 2003 the A/H5N1 virus has
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">spread globally, infecting poultry in over 60 countries and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">causing the loss of over 250 million poultry. In 2010 HPAI
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">H5N1 remained entrenched in poultry in several Asian
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">countries and Egypt. While migratory waterfowl plays a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">role in the long-distance spread of H5N1 (see Bird Migration
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">map), the intensification of poultry farming and poorly
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">regulated movement and trade in poultry is probably the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">most important factor in sustaining the current epizootic.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">HPAI H5N1 is highly contagious between birds and has a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 2.77778%;">high fatality in most poultry species, making it an economi-
cally important disease. However, it is the risk to humans
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.0101%;">that has driven most of the control activities. Over
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.13636%;">500 human cases have been detected in 15 countries. The
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">concern remains that H5N1 may evolve or reassort with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 2.65152%;">another influenza A virus to become either more transmissi-
ble from poultry to humans or transmissible from person to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 52.0202%; width: 4.57516%; height: 1.13636%;">person.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 54.4192%; width: 34.3137%; height: 1.38889%;">Map sources: The Avian Influenza map was reproduced from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 33.9869%; height: 2.65152%;">WHO, available at: http://gamapserver.who.int/mapLi-
brary/ (accessed dec. 2010).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 59.8485%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.2374%; width: 42.4837%; height: 2.65152%;">Abdel-Ghafar AN, et al. (2008) Virus update on avian influ- enza A (H5N1) virus infection in humans. N Engl J Med
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 63.8889%; width: 8.82353%; height: 1.26263%;">358(3):261–273.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 33.9869%; height: 2.77778%;">Gambotto A, et al. (2008) Human infection with highly patho-
genic H5N1 influenza virus. Lancet 371(9622):1464–1475.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">Food and Agriculture Organization (revised in 2007)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.1919%; width: 33.0065%; height: 1.38889%;">The Global Strategy for the Prevention and Control of H5N1
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.5808%; width: 33.1699%; height: 1.38889%;">Highly Pathogenic Avian Influenza. FAO/OIE Strategy
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 6.20915%; height: 1.13636%;">document.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 73.2323%; width: 34.4771%; height: 1.38889%;">Peiris JSM, et al. (2007) Avian influenza võrus (H5N1): a threat
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 74.6212%; width: 31.5359%; height: 1.13636%;">to human health. Clin Microb Rev 20:243–267.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">189
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/ae05749a-5fa7-4640-bfa3-a46bdb972a74" class="aLF-aPX-aPF-aPE-J3" alt="Page 71 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www9.health.gov.au/cda/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www9.health.gov.au/cda/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www9.health.gov.au/cda/&amp;ust=1666162860000000&amp;usg=AOvVaw2njPzzCE2TN4s1Azezbvxl&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 66.8301%; top: 52.904%; width: 19.9346%; height: 1.38889%;"></a><a href="http://www.health.gov.au/internet/main/publishing.nsf/Con-tent/cdi3202" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.health.gov.au/internet/main/publishing.nsf/Con-tent/cdi3202" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.health.gov.au/internet/main/publishing.nsf/Con-tent/cdi3202&amp;ust=1666162860000000&amp;usg=AOvVaw0RyD2rp0qN44h_qAWehVMd&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 52.451%; top: 60.9848%; width: 32.3529%; height: 2.52525%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 72 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 65.0327%; height: 2.0202%;">Disease: Barmah Forest &amp; Ross River Virus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 28.9216%; top: 14.2677%; width: 11.7647%; height: 2.14646%;">Disease
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.3182%; width: 34.3137%; height: 1.26263%;">Classification: ICD-9 066.3; ICD-10 R50.9 (Barmah Forest)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.5808%; width: 13.0719%; height: 1.38889%;">and B33.1 (Ross River)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.2323%; width: 34.4771%; height: 1.38889%;">Syndromes and synonyms: Polyarthritis and rash, epidemic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.6212%; width: 34.4771%; height: 1.38889%;">polyarthritis, Barmah Forest virus disease, and Ross River
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.0101%; width: 21.0784%; height: 1.26263%;">virus disease, Murweh virus disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.6616%; width: 34.3137%; height: 1.38889%;">Agent: Barmah Forest virus (BFV) and Ross River virus (RRV),
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.0505%; width: 34.4771%; height: 2.65152%;">enveloped RNA viruses, genus Alphavirus in the family Toga-
viridae. An early isolate of BF from Queensland was initially
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.702%; width: 34.4771%; height: 1.38889%;">named Murweh virus. There are two topotypes of Ross River
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.0909%; width: 33.9869%; height: 2.52525%;">virus, from eastern and western Australia; a third, in north-
eastern Australia, has not been found since the mid-1970s.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.1313%; width: 34.3137%; height: 1.38889%;">Reservoir: Large marsupials, particularly kangaroos and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.3939%; width: 5.88235%; height: 1.13636%;">wallabies.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.1717%; width: 40.6863%; height: 2.65152%;">Vector: Mainly Ochlerotatus vigilax and Culex annulirostris. Aedes camptorhynchus, A. normanensis, A. notoscriptus, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 44.8232%; width: 31.0458%; height: 1.38889%;">Coquillettidia linealis are vectors in some circumstances.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.4747%; width: 34.4771%; height: 1.38889%;">Transmission: Mosquito bite; transovarial transmission has
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 48.8636%; width: 33.9869%; height: 2.77778%;">been demonstrated in Aedes vigilax. There is no direct person-
to-person transmission.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 52.904%; width: 34.4771%; height: 1.38889%;">Cycle: Viremic reservoir host to mosquito during feeding,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.1667%; width: 33.9869%; height: 2.77778%;">then after an extrinsic cycle of a few days, the virus is trans-
mitted to a new reservoir host during feeding.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.2071%; width: 25.3268%; height: 1.38889%;">Incubation period: 3–12 days (usually 7–9).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 60.9848%; width: 34.4771%; height: 1.38889%;">Clinical findings: Self-limiting disease. Sudden onset of joint
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.2475%; width: 34.4771%; height: 1.38889%;">pain; fatigue, marked arthralgia and myalgia in more than
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.6364%; width: 34.4771%; height: 1.38889%;">40%, stiff and swollen joints in 60–85% of cases; anorexia,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.0253%; width: 34.3137%; height: 1.38889%;">headache, back pain, photophobia, sore throat, lethargy, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.2879%; width: 34.4771%; height: 1.38889%;">lymphadenopathy also occur, with fever and a maculopapular
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.6768%; width: 34.4771%; height: 1.38889%;">rash, usually on the trunk and limbs but also on palms and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.0657%; width: 34.4771%; height: 1.38889%;">soles, in 50% of cases. Relapses occur; joint pains and swelling
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.3283%; width: 34.4771%; height: 1.38889%;">may relapse for as long as 6 years. Patients eventually recover
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.7172%; width: 6.86275%; height: 1.38889%;">completely.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.3687%; width: 34.3137%; height: 1.38889%;">Diagnostic tests: Viral RNA dection in blood by RT-PCR;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 75.7576%; width: 34.4771%; height: 1.38889%;">serology (IgM ELISA; four-fold increasein IgG); virus isolation
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.1465%; width: 7.84314%; height: 1.0101%;">is insensitive.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.3182%; width: 29.2484%; height: 1.38889%;">Therapy: Supportive, there is no specific treatment
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 21.9697%; width: 34.4771%; height: 2.65152%;">Prevention: Anti-mosquito measures: light-colored cloth-
ing with long sleeves mosquito repellents containing DEET
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.6212%; width: 34.4771%; height: 2.77778%;">on exposed skin, avoid as much as possible outdoor activi-
ties at dawn and dusk, when mosquitoes are most active,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.2727%; width: 34.4771%; height: 1.38889%;">and removal of mosquito-breeding sites from around the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.6616%; width: 3.92157%; height: 1.13636%;">home.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 31.3131%; width: 34.1503%; height: 1.38889%;">Epidemiology: There are only about 5,000 cases of RRV and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.702%; width: 34.4771%; height: 1.38889%;">usually only a few hundred cases of BFV annually. Peak
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.0909%; width: 34.4771%; height: 1.38889%;">incidence is in the 30–40 year age group, the disease is rare in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.3535%; width: 34.4771%; height: 1.13636%;">children. RRV disease is the most common arboviral disease
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.7424%; width: 34.4771%; height: 2.77778%;">in Aus tralia, accounting for about 90% of cases, often occur-
ring in mixed epidemics with BFV disease on mainland
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.3939%; width: 34.4771%; height: 1.38889%;">Australia (to which BFV is restricted). Most BFV cases
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 40.7828%; width: 34.4771%; height: 1.38889%;">occur in Queensland and are only sporadic. RRV cases
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.1717%; width: 34.4771%; height: 1.26263%;">have been reported from the island of New Guinea and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.4343%; width: 34.4771%; height: 2.77778%;">caused epidemics in Pacific islands in 1979–1980. Transmis-
sion occurs year-round, especially in coastal northern and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.2121%; width: 34.4771%; height: 2.65152%;">northeastern Australia, but is more intense during the mos-
quito season in most of the country. Birds are presumed to be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 48.8636%; width: 34.4771%; height: 1.38889%;">involved in spread around Australia; a viremic tourist from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.2525%; width: 34.4771%; height: 1.26263%;">Australia is believed to have introduced the eastern topotype
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.5152%; width: 34.4771%; height: 1.38889%;">of RRV to the Pacific islands. Detailed epidemiological data
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 52.904%; width: 34.3137%; height: 1.38889%;">is available on line at: http://www9.health.gov.au/cda/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.1667%; width: 13.2353%; height: 1.26263%;">source/cda-index.cfm.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 56.9444%; width: 34.3137%; height: 1.26263%;">Map sources: The Barmah Forest and Ross River Virus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.2071%; width: 34.4771%; height: 1.38889%;">disease map was made with data obtained from the Australian
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.596%; width: 34.3137%; height: 1.38889%;">Government, Department of Health and Ageing, available at:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 60.9848%; width: 32.0261%; height: 2.52525%;">www.health.gov.au/internet/main/publishing.nsf/Con-
tent/cdi3202.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 65.0253%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.2879%; width: 34.4771%; height: 1.38889%;">Harley D, et al. (2001) Ross River virus transmission, infection,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 67.6768%; width: 33.1699%; height: 1.38889%;">and disease: a cross-disciplinary review. Clin Microbiol Rev
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.0657%; width: 8.16994%; height: 1.26263%;">14(4):909–932.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.3283%; width: 34.3137%; height: 1.38889%;">Mackenzie JS (2001) in Service MW (ed.) The Encyclopedia
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.7172%; width: 33.1699%; height: 1.38889%;">of Arthropod-Transmitted Infections. CAB International,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.1061%; width: 6.04575%; height: 1.26263%;">pp. 67–69.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">191
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/c33c6632-b077-47f7-b723-71db7537c1d1" class="aLF-aPX-aPF-aPE-J3" alt="Page 72 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://wwwn.cdc.gov/arbocat/index.asp" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://wwwn.cdc.gov/arbocat/index.asp" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://wwwn.cdc.gov/arbocat/index.asp&amp;ust=1666162860000000&amp;usg=AOvVaw0bO-Tdc1U3YkRHNk-7U-vg&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 52.451%; top: 49.1162%; width: 24.0196%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 73 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 50.9804%; height: 2.39899%;">Disease: Bunyamwera Viral Fever
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.3464%; height: 1.26263%;">Classification: ICD-9 066.3; ICD-10 A92.8
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.3137%; height: 1.38889%;">Syndromes and synonyms: Bunyamwera encephalitis,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 30.5556%; height: 1.38889%;">Bunyamwera viral disease, Cache Valley encephalitis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 36.2745%; height: 2.77778%;">Agent: Bunyamwera group viruses are enveloped, single-
stranded, RNA viruses genus Orthobunyavirus of the family
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.3137%; height: 2.77778%;">Bunyaviridae (see also Bunyavirus Group C map). Bunyam-
wera group viruses that can cause human disease in Africa are:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.3137%; height: 1.38889%;">Bunyamwera virus (BUNV), Germiston virus (GERV), Ilesha
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">virus (ILEV), Ngari virus (NRIV), and Shokwe virus. Cache
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">Valley complex viruses (CVV) have been isolated from human
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 31.3726%; height: 1.38889%;">cases in North America, but are not shown on this map.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.3137%; height: 1.38889%;">Reservoir: Not completely understood; most Bunyamwera
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.3137%; height: 2.65152%;">viruses are likely maintained in nature involving a transmis-
sion cycle with various small mammals (mainly wild rodents)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">as amplifying hosts and mosquitoes. African rodents replicate
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.3137%; height: 1.38889%;">BUNV and develop viremia. Livestock (goats, sheep, cattle),
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.4771%; height: 2.77778%;">horses and rodents are hosts for GERV as shown by seroprev-
alence studies. Amplifying hosts for CVV are mainly large
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 22.8758%; height: 1.38889%;">mammals (caribou, deer, horses, sheep).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 42.9739%; height: 1.38889%;">Vector: Many species of mosquitoes of the genera Aedes,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 27.1242%; height: 4.0404%;">Mansonia, Culex, and Anopheles. Transmission: By mosquito bite.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.3137%; height: 1.38889%;">Cycle: The mosquito becomes infected when feeding on a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">viremic vertebrate host. The virus crosses the mosquito gut
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">wall and replicates in the organs of the mosquito. After several
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.3137%; height: 1.38889%;">days, the virus reaches the salivary glands and is injected into
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 16.6667%; height: 1.38889%;">the next host during feeding.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 29.4118%; height: 1.26263%;">Incubation period: Estimated at less than 2 weeks.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.3137%; height: 2.77778%;">Clinical findings: Sudden onset fever, frontal headache, back-
ache, diarrhea and a rash; usually resolves without sequelae;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 4.0404%;">fatalities are rare and the result of hemorrhage or meningoen-
cephalitis. ILEV and NRIV can cause hemorrhagic fever out-
breaks. CVV rarely causes encephalitis, with only one fatal
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 19.1176%; height: 1.38889%;">case reported in the USA in 1995.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 16.7929%; width: 34.3137%; height: 1.38889%;">Diagnostic tests: Several serologic tests are available. Virus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 33.9869%; height: 1.38889%;">can be isolated or RNA detected in acute blood by RT-PCR.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 28.268%; height: 1.38889%;">Therapy: Supportive; there is no specific therapy.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 23.4848%; width: 22.8758%; height: 1.38889%;">Prevention: Anti-mosquito precautions.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 26.1364%; width: 34.3137%; height: 1.38889%;">Epidemiology: African Bunyamwera viruses known to cause
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 4.0404%;">human disease circulate in Sub-Saharan Africa. Virus trans-
mission peaks in the rainy season when mosquitoes are abun-
dant. All age groups can be infected, though BUNV mainly
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">affects children. BUNV is particularly active in the riverine
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">forests in Nigeria and CAR. 100% of adults living in tropical
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">rainforest of the DRC are seropositive. Neutralizing antibody
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">rates of over 50% for ILEV have been found in people in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">savannah areas of Nigeria. Lower seroprevalences of ILEV
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.13636%;">are found in rainforests. GERV is endemic in southern African
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 2.77778%;">countries. To date, GERV has not been reported to be respon-
sible for any major human disease outbreaks, and is therefore
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 26.4706%; height: 1.38889%;">considered of minor public health importance.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 45.0758%; width: 34.3137%; height: 1.38889%;">Map source: The Bunyamwera Viral Fever map was made by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">geocoding human cases reported in the medical literature
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.3137%; height: 1.38889%;">up to 2010 and the CDC Arbovirus Catalog, available at:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 24.3464%; height: 1.38889%;">http://wwwn.cdc.gov/arbocat/index.asp.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 51.7677%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 40.1961%; height: 1.38889%;">Bouloy M (2001) Bunyamwera virus. In Service MW (ed.) The
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 54.4192%; width: 32.6797%; height: 2.77778%;">Encyclopedia of Arthropod-transmitted Infections. CAB Inter-
national, pp. 94–97.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">Gavrilovskaya I (2001) Issyk-Kul virus disease. In Service MW
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 58.4596%; width: 33.1699%; height: 1.38889%;">(ed.) Encyclopedia of Arthropod-Transmitted Infections. CAB
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 59.8485%; width: 15.1961%; height: 1.38889%;">International, pp. 231–234.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.2374%; width: 33.9869%; height: 4.0404%;">Gerrard SR (2004) Ngari virus is a Bunyamwera virus reas-
sortant that can be associated with large outbreaks of hem-
orrhagic fever in Africa. J Virol 78(16):8922–8926.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">Grimstad PR (2001) Cache Valley virus. In Service MW (ed.)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 66.5404%; width: 33.1699%; height: 1.38889%;">The Encyclopedia of Arthropod-transmitted Infections. CAB
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 67.9293%; width: 15.1961%; height: 1.38889%;">International, pp. 101–104.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">Morvan JM (1994) Ilesha virus: a new aetiological agent of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.5808%; width: 33.1699%; height: 1.38889%;">haemorrhagic fever in Madagascar. Trans R Soc Trop Med
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 15.1961%; height: 1.38889%;">Hyg 88:205.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">193
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/7dc03418-1887-4c96-b361-9803e4d2aaf0" class="aLF-aPX-aPF-aPE-J3" alt="Page 73 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 74 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 57.0261%; height: 2.39899%;">Disease: Bunyavirus Group C Disease
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.3464%; height: 1.26263%;">Classification: ICD-9 066.3; ICD-10 A92.8
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.5707%; width: 15.1961%; height: 1.13636%;">Synonyms: None.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 34.4771%; height: 4.0404%;">Agent: Spherical, enveloped orthobunyaviruses with single-
stranded, negative-sense, tripartite RNA genomes, with con-
siderable recognized reassortment. The name derives from the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">original classification of arthropod-borne viruses in to A, B and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.3137%; height: 1.38889%;">C groups. Group C viruses can be divided into four complexes:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">(1) Caraparu complex [Apeu virus (APEUV), Bruconha virus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">(BRCV), Caraparu virus (CARV), Ossa virus (OSSAV), and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">Vinces virus (VINV)]; (2) Madrid virus (MADV); (3) Marituba
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">complex viruses [Gumbo Limbo virus (GLV), Marituba virus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">(MTBV), Murutucu virus (MURV), Nepuyo virus (NEPV),
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">Restan virus (RESV)], and (4) Oriboca complex viruses [Itaqui
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 18.9542%; height: 1.26263%;">(ITQV), Oriboca viruses (ORIV)].
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 27.6144%; height: 1.38889%;">Reservoir: Forest rodents, marsupials, and bats.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 33.8235%; height: 1.38889%;">Vector: Mosquitoes (Aedes and Culex spp.).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 33.9869%; height: 2.65152%;">Transmission: By mosquito bite. There is no direct person-to-
person transmission.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.3137%; height: 1.38889%;">Cycle: Mosquito-host-mosquito. The mosquito becomes
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">infected when feeding on a viremic reservoir host. Depending
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">on ambient temperature, the virus reaches the salivary glands
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.3137%; height: 1.38889%;">and is transmitted by feeding on the next host in several days.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 19.7712%; height: 1.38889%;">Incubation period: 3–12 days.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.3137%; height: 1.38889%;">Clinical findings: Dengue-like fever with headache, malaise,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">arthralgia or myalgia for about 2 to 5 days; occasionally
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.3137%; height: 1.26263%;">nausea and vomiting, lower limb weakness, conjunctivitis,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">photophobia and a rash. The fever resolves in a few days; the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 11.4379%; height: 1.13636%;">disease is non-fatal.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.4771%; height: 2.77778%;">Diagnostic tests: IgM capture or IgG ELISAs is most com-
monly used on paired acute and convalescent sera. Virus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">isolation in suckling mice or cell culture and identified by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 5.22876%; height: 1.13636%;">RT-PCR.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 17.6471%; height: 1.38889%;">Therapy: Self-limiting disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 30.1768%; width: 34.3137%; height: 1.38889%;">Prevention: Standard anti-mosquito precautions. There is no
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 10.2941%; height: 1.13636%;">vaccine available.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 34.3434%; width: 34.3137%; height: 1.26263%;">Epidemiology: There is little known about the epidemiology
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">of these viruses. Group C viruses are geograpically limited to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">the tropical and subtropical areas of the Americas, and were
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.13636%;">first described in the Brazilian Amazon in the 1950s. Studies
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">show that these viruses circulate in a compact ecosystem in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">which co-infection with more than one virus is possible in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 2.77778%;">reservoir hosts, leading to genetic reassortment. Genetic anal-
ysis shows evidence of intense traffic of these viruses in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.3137%; height: 1.38889%;">Americas. Nepuyo virus has the widest distribution reported,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">from Mexico to Brazil. There is no sex or age preference for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">infection. Inapparent and mild infections are common, overt
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.1503%; height: 1.38889%;">disease is mostly seen in children residing in endemic areas.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 51.7677%; width: 34.3137%; height: 1.38889%;">Map source: The Bunyavirus Group C Disease map was made
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">by showing which bunyavirus group C virus is reported by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 31.0458%; height: 1.38889%;">country, according to the medical literature up to 2010.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 57.197%; width: 8.66013%; height: 1.26263%;">Key reference
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">Nunes MRT, et al. (2005) Molecular epidemiology of group C
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 59.8485%; width: 33.1699%; height: 1.38889%;">viruses (Bunyaviridae: Orthobunyavirus) isolated in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 61.1111%; width: 21.0784%; height: 1.38889%;">Americas. J Virol 79(16):10561–10570.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">195
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/f6fb850c-8c1d-4e67-81d3-54a1c46e3d1d" class="aLF-aPX-aPF-aPE-J3" alt="Page 74 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.cdc.gov/lac/tech/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.cdc.gov/lac/tech/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.cdc.gov/lac/tech/&amp;ust=1666162860000000&amp;usg=AOvVaw3sRyv_SWv1Dn1SKLu6awAA&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 72.549%; top: 61.2374%; width: 14.2157%; height: 1.26263%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 75 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 60.6209%; height: 2.39899%;">Disease: California Group Virus Disease
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.3464%; height: 1.26263%;">Classification: ICD-9 062.5; ICD-10 A83.5
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 33.9869%; height: 2.77778%;">Syndromes and synonyms: California encephalitis, James-
town Canyon encephalitis, La Crosse encephalitis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">Agents: Spherical, enveloped, negative sense RNA viruses
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">forming a subgroup of the Bunyaviridae family. In the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">Americas, human pathogens belonging to the group are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.3137%; height: 1.38889%;">Guaroa virus (GROV), Jamestown Canyon virus (JCV),
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.3137%; height: 1.26263%;">LaCrosse virus (LACV), and snowshoe hare virus (SSHV).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 34.3137%; height: 1.38889%;">Those reported to cause human disease in Europe or Asia are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 31.2092%; height: 1.38889%;">Inkoo virus (INKV), Tahyna virus (TAHV), and SSHV.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 34.4771%; height: 1.13636%;">Reservoir: Small wild mammals such as rodents, snowshoe
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">hares, deer and vector mosquitoes (venereal and transovarian
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.4771%; height: 1.38889%;">transmission occur). Dayfeeding chipmunks and squirrels
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">are the principal amplifying hosts of LACV, as the main vector
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.4771%; height: 2.77778%;">(Aedes triseriatus) only bites in daytime. For this reason, night-
feeding small mammals are rarely infected with LACV. The
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.4771%; height: 1.38889%;">white-tailed deer is the main amplifying host for JCV (horses
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">can also be an amplifying host). Snowshoe hares and the arctic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 28.268%; height: 1.38889%;">ground squirrel are the amplifying hosts of SSHV.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 40.8497%; height: 1.38889%;">Vector: Mosquitoes, primarily Aedes and Ochlerotatus spp.,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">secondarily Anopheles spp. Ae. triseriatus (eastern treehole
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">mosquito) is the most important vector of LACV in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.4771%; height: 1.26263%;">USA. LACV is abundant in forests with oak trees (basal
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.3137%; height: 1.38889%;">holes are important breeding sites) and hickory hardwoods
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">drained by rapid streams. Different species of cold-tolerant
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 27.1242%; height: 1.38889%;">mosquitoes serve as vectors for JCV and SSHV.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 19.1176%; height: 1.38889%;">Transmission: By mosquito bite.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">Cycle: Mosquito–reservoir host–mosquito. The mosquito
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.4771%; height: 1.38889%;">becomes infected during feeding on a viremic reservoir
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.3137%; height: 1.38889%;">host; once the virus reaches the salivary glands it can be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 30.2288%; height: 1.38889%;">transmitted during feeding to the next reservoir host.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 22.549%; height: 1.38889%;">Incubation period: Usually 5–15 days.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">Clinical findings: Fever, headache, vomiting, sometimes
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.3137%; height: 1.38889%;">progressing to acute CNS and respiratory involvement,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 34.4771%; height: 2.77778%;">with recurrent seizures in 25% of CNS cases. INKV is associ-
ated with severe illness and chronic neurologic disease in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 4.41176%; height: 1.0101%;">Russia.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 78.6616%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Serology (IgM and IgG ELISA) on acute and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 80.0505%; width: 34.4771%; height: 1.26263%;">convalescent sera; cross-reactivity exists leading to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.13636%;">misidentification. RT-PCR has been used to test human brain
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 8.82353%; height: 1.38889%;">tissue samples.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.4771%; height: 1.38889%;">Therapy: Supportive, there is no specific treatment. Ribavirin
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">may limit the severity and improve the prognosis of LACV
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.3137%; height: 1.13636%;">infections. Anticonvulsant medication in those with seizures.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 26.1364%; width: 34.3137%; height: 1.38889%;">Prevention: As mosquito vectors and wildlife reservoirs are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">widespread, control is not feasible; personal anti-mosquito
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">measures; eliminating potential breeding sites (e.g. old tires)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 24.8366%; height: 1.38889%;">and filling of basal tree-holes with concrete.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 2.65152%;">Epidemiology: The California group viruses are widely dis-
tributed over all types of terrain. Each has its preferred vector
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">mosquito species and host, for instance snowshoe hare for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">SSHV. LACV is the primary cause of arboviral encephalitis in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.13636%;">children in the USA. Most LACV infections occur in those
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">residing close to woodland breeding sites of Ae. triseriatusfrom
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">July to September. Boys are more often affected with LACV, as
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">they more often play in the woods. JCV is most commonly
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.26263%;">found around the Great Lakes in USA and Canada. The JCV
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">vectors prefer hilly woodlands where they breed in ponds
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">from April to June. SSHV, has a different ecosystem: (sub)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.13636%;">arctic forests and tundras in Canada and Siberia. SSHV has
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">been detected in China. SSHV transmission occurs during the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 2.77778%;">arctic summer from May to August, and mainly affects chil-
dren (&lt;10 years), especially boys. Lumbo virus is a strain of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">TAHV isolated from mosquitoes in Mozambique (Africa), but
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 25.1634%; height: 1.38889%;">no human cases have been diagnosed there.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 57.0707%; width: 34.3137%; height: 1.38889%;">Map sources: The California Group Virus Disease map was
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">made by geolocating human outbreaks reported in the medical
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">literature up to 2010. La Crosse virus epidemiology data was
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.2374%; width: 34.3137%; height: 1.26263%;">obtained from the CDC, available at: www.cdc.gov/lac/tech/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 62.5%; width: 16.8301%; height: 1.38889%;">epi.html (accessed Dec 2010).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 65.2778%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.5404%; width: 39.8693%; height: 1.38889%;">Beaty BJ (2001) La Crosse virus. In Service MW (ed.) The
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 67.9293%; width: 32.6797%; height: 2.65152%;">Encyclopedia of Arthropod-transmitted Infections. CAB Inter-
national, pp. 261–265.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">Grimstad PR (2001) Jamestown Canyon virus. In Service MW
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 39.3791%; height: 2.65152%;">(ed.) The Encyclopedia of Arthropod-transmitted Infections. CAB International, pp. 235–239.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 74.6212%; width: 39.8693%; height: 1.38889%;">Labuda M (2001) Tahyna virus. In Service MW (ed.) The
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 75.8838%; width: 32.6797%; height: 2.77778%;">Encyclopedia of Arthropod-transmitted Infections. CAB Inter-
national, pp. 482–483.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 78.6616%; width: 34.4771%; height: 1.38889%;">Rust RS, et al. (1999) La Crosse and other forms of California
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 80.0505%; width: 22.0588%; height: 1.26263%;">encephalitis. J Child Neurol 14(1):1–14.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 54.5752%; height: 1.26263%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 84.2172%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">197
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/cb1e60fa-7649-4582-9567-b4746809d09b" class="aLF-aPX-aPF-aPE-J3" alt="Page 75 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.cdc.gov/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.cdc.gov/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.cdc.gov/&amp;ust=1666162860000000&amp;usg=AOvVaw1pEBx1miTd_wdBj23rt0lN&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 77.9412%; top: 57.0707%; width: 8.82353%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 76 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 43.3007%; height: 2.39899%;">Disease: Chikungunya Fever
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.3464%; height: 1.26263%;">Classification: ICD-9 066.3; ICD-10 A92.0
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 41.3399%; height: 1.38889%;">Syndromes and synonyms: Chikungunya means ‘that
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 34.3137%; height: 1.38889%;">which bends up’ in Makonde language, to describe the pain.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.3137%; height: 1.38889%;">Agent: Chikungunya virus (CHIKV), an enveloped RNA
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">virus, genus Alphavirus in the family Togaviridae. CHIKV
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">belongs to the same antigenic complex as Mayaro, Ross
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.4771%; height: 2.77778%;">River, and o’nyong-nyong viruses. Phylogenetic analysis sug-
gests an African origin about 500 years ago, with spread to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 16.3399%; height: 1.38889%;">Asia within the last century.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.3137%; height: 1.38889%;">Reservoir: Non-human primates in Africa and humansin Asia;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">Asianmonkeys can be infected, but do not seem to constitute an
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">important reservoir. During intra-epidemic periods, several
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 31.0458%; height: 1.38889%;">vertebrates have been implicated as potential reservoirs.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.3137%; height: 2.77778%;">Vector: In Africa, the principal vectors are the sylvan mosqui-
toes Ae. furcifer and Ae. africanus, Ae. luteocephalus, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.4771%; height: 1.38889%;">Ae. taylori; in Asia, urban Ae. aegypti, Ae. albopictus, and various
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 15.8497%; height: 1.38889%;">Culex species.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">Transmission: By mosquito bite. Transmission from mother
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">to neonate can occur in the intrapartum period; blood-borne
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 13.8889%; height: 1.38889%;">transmission is possible.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">Cycle: Humans are viremic at a titer high enough to infect
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">mosquitoes for 3 to 7 days post illness onset. The virus travels
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">from the mosquito gut to the salivary glands in 5–7 days, after
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 24.183%; height: 1.38889%;">which it can infect another human by bite.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 27.451%; height: 1.38889%;">Incubation period: 3–7 days (range 1–12 days).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">Clinical findings: Sudden onset fever, chills, fatigue, transient
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.4771%; height: 1.38889%;">maculopapular rash constant polyarthralgia/arthritis of small
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 2.65152%;">joints (hands, wrists, ankles, feet); leucopenia and mild throm-
bocytopenia. Neurological, cardiac, and hepatic complications
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">rare . The acute stage in infants and young children can be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">atypical (epidermolysis, myocarditis, or encephalitis), but is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">rarely fatal. Infected neonates (mother-to-child transmission)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">are at a high risk of severe encephalopathy and death. Chronic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.3137%; height: 1.38889%;">inflammatory joint symptoms were observed in up to 50%
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 31.3726%; height: 1.38889%;">of adult cases, and after 2 years in some outbreaks.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 34.3137%; height: 1.26263%;">Diagnostic tests: Within 5 days of disease onset: RT-PCR on
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.2727%; width: 34.4771%; height: 1.38889%;">whole blood, virus isolation; After 5 days: IgM ELISA on
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 78.6616%; width: 22.2222%; height: 1.38889%;">serum; serological tests can cross-react.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 25.9804%; height: 1.38889%;">Therapy: Supportive with pain management.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 19.4444%; width: 28.1046%; height: 1.38889%;">Prevention: Standard anti-mosquito precautions.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 22.2222%; width: 34.3137%; height: 1.26263%;">Epidemiology: Before 2004, CHIKV was considered a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">minor arboviral disease, but since then has spread globally,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 34.3137%; height: 1.38889%;">infecting millions of people. Most cases are symptomatic.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">CHIKV has been endemic in Africa for centuries, typically
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">causing small epidemics in rural areas. CHIKV spread to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">Asia within the last 60 years producing urban outbreaks,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.8039%; height: 1.38889%;">similar to dengue fever, involving Ae. egypti. The global
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 4.0404%;">epidemic started since a mutation in the CHIKV E1 glyco-
protein gene (A226V) occurred, that enhanced its infectiv-
ity and transmission by Ae. albopictus. The mutated CHIKV
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">is succesful in spreading in tropical and temperate regions
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.3137%; height: 1.38889%;">where Ae. albopictus is present. In 2005–2006 CHIKV spread
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">from East Africa to virgin soil in the Indian Ocean Islands
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">to produce epidemics affecting up to three-quarters of the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">population. Since 2006, CHIKV outbreaks with are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">reported from several (sub)tropical countries in the new
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">world. CHIKV virus was imported into several European
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 4.0404%;">countries and caused a small outbreak with autochtho-
nous transmission in northern Italy. CHIKV-viremic tra-
velers can cause autochthonous transmission in previous
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">CHIKV-free areas if Ae. albopictus or other competent
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.505%; width: 14.3791%; height: 1.26263%;">mosquitoes are present.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 53.1566%; width: 34.1503%; height: 1.38889%;">Map sources: The Chikungunya Virus Disease map is made
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">by showing regions with reported outbreaks reported to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 34.3137%; height: 1.38889%;">WHO, ProMED-mail, and the medical literature up to 2010.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 34.3137%; height: 1.38889%;">Datawas also used from the CDC, available at: www.cdc.gov/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">ncidod/dvbid/Chikungunya/CH_GlobalMap.html, and De
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 14.0523%; height: 1.26263%;">Lamballerie et al. (2008).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 62.6263%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 34.3137%; height: 1.38889%;">De Lamballerie X, et al. (2008) Chikungunya virus adapts to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 65.1515%; width: 33.1699%; height: 1.38889%;">tiger mosquito via evolutionary convergence: a sign of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 66.5404%; width: 21.0784%; height: 1.38889%;">things to come? Virol J 5:33.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 67.9293%; width: 34.8039%; height: 1.38889%;">Simon F, et al. (2011) Chikungunya virus infection. Curr Infect
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.1919%; width: 13.0719%; height: 1.38889%;">Dis Rep. 13(3):218–228.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">Volk SM, et al. (2010) Genome-scale phylogenetic analyses
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 33.1699%; height: 1.38889%;">of chikungunya virus reveal independent emergences of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.2323%; width: 38.2353%; height: 1.38889%;">recent epidemics and various evolutionary rates. J Virol 84
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 74.6212%; width: 8.82353%; height: 1.26263%;">(13):6497–6504.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 54.5752%; height: 1.26263%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 84.2172%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">199
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/db7c795d-30e1-480e-a892-96785119e86f" class="aLF-aPX-aPF-aPE-J3" alt="Page 76 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 77 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 44.4444%; height: 2.0202%;">Disease: Colorado Tick Fever
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.3464%; height: 1.26263%;">Classification: ICD-9 066.1; ICD-10 A93.2
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.5707%; width: 24.8366%; height: 1.13636%;">Syndromes and synonyms: None.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 34.3137%; height: 1.38889%;">Agent: Colorado Tick Fever Virus (CTFV), a prototype virus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.3137%; height: 1.38889%;">of the genus Coltivirus of the family Reoviridae; a spherical,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">enveloped virus with a double-stranded RNA genome of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.2626%; width: 7.51634%; height: 1.26263%;">12 segments.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.3137%; height: 1.38889%;">Reservoir: High altitude rodents, including ground squirrels
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">and porcupines; ticks by trans-stadial transmission; possibly
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 25%; height: 1.38889%;">transovarial, but this is considered unlikely.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.2172%; width: 34.6405%; height: 4.16667%;">Vector: Ixodid wood tick (Dermacentor andersoni). Transmission: By tick bite, blood transfusion; bone marrow
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 33.0065%; height: 1.38889%;">for transplantation is routinely screened in endemic areas.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">Cycle:The tick feeds on an infected host, the virusmultipliesin
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.4771%; height: 1.38889%;">the tick’s midgut and spreads to the salivary glands, to be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.3137%; height: 1.38889%;">injected into another host at the next feed, where it infects
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">erythrocytes. As the virus infects erythrocytes, it is partially
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 2.77778%;">protected from immune clearance, leading to prolonged vire-
mia in both humans (up to 4 months) and rodents, favoring
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 4.57516%; height: 1.38889%;">spread.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">Incubation period: &lt;1–19 days, average about 3–4 days,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">depending on the infecting dose. Viremia in humans may
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 15.0327%; height: 1.13636%;">last for 4 months or more.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">Clinical findings: Sudden onset of high fever (biphasic), chills,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.4771%; height: 2.77778%;">myalgia, arthralgia, severe headache, ocular pain, conjuncti-
vitis, anorexia, nausea, and sometimes vomiting. Spleen and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">liver can be palpable, and pericarditis or myocarditis may be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.3137%; height: 1.38889%;">found. A few cases have a petechial or maculopapular rash.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">Prolonged convalescence may follow. Children may have a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">more severe syndrome with hemorrhagic manifestations,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.3137%; height: 1.38889%;">including a more pronounced rash, DIC, and GI bleeding;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.3137%; height: 1.38889%;">or CNS involvement including meningitis and encephalitis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 10.4575%; height: 1.13636%;">Fatalities are rare.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.3137%; height: 1.38889%;">Diagnostic tests: Serology (IgM ELISA, IFA of erythrocytes).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 38.8889%; height: 1.38889%;">Diagnosis is confirmed by a significant ( &gt; 4-fold) change in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">antibody titer between acute and convalescent sera. Virus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.3137%; height: 1.38889%;">isolation or RNA detection by RT-PCR from the blood or CSF.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 13.8889%; height: 1.38889%;">Therapy: Supportive.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 2.77778%;">Prevention: Personal anti-tick precautions (appropriate cloth-
ing, acaricide, repellent). Vaccine production ceased in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 26.1364%; width: 34.3137%; height: 1.38889%;">1970s and there is no possibility of vector control due to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 45.2614%; height: 5.42929%;">the habitat. Screening of bone marrow donors in endemic areas. Epidemiology: Colorado tick fever is only present in North
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.26263%;">America (USA and Canada). In the USA, besides the states
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">with human cases shown on the map, the virus has been
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">isolated from ticks within the range of D. andersoni. The typical
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">habitat of the tick and its rodent hosts is a south-facing slope
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">above 1,500 meters with Ponderosa pine and shrubs on dry,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">rocky surfaces. Infection is seasonal, coinciding with the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">period of greatest tick activity in early summer. Human
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">cases can be detected from March to September in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">Rocky Mountain region, USA. Most human cases are males,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">aged 20–29 years, probably reflecting the frequency of outdoor
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 14.7059%; height: 1.38889%;">activity in the mountains.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 49.1162%; width: 34.3137%; height: 1.38889%;">Map sources: The Colorado Tick Fever map was made with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">geolocating reported cases in the medical literature up to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 3.26797%; height: 1.13636%;">2010.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 54.5455%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 34.4771%; height: 1.26263%;">Attoui H, et al. (2005) Coltiviruses and Seadornaviruses in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 57.0707%; width: 33.1699%; height: 1.38889%;">North America, Europe, and Asia. Emerg Infect Dis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 58.4596%; width: 10.1307%; height: 1.38889%;">11(11):1673–1679.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">Brackney MM, et al. (2010) Epidemiology of Colorado tick
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 61.2374%; width: 35.6209%; height: 1.26263%;">fever in Montana, Utah, and Wyoming, 1995–2003. Vector
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 62.5%; width: 20.098%; height: 1.38889%;">Borne Zoonotic Dis 10(4):381–385.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">Calisher CH (1994) Medically important arboviruses of the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 65.1515%; width: 38.0719%; height: 1.38889%;">United States and Canada. Clin Microbiol Rev 7(1):89–116.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.5404%; width: 34.4771%; height: 1.26263%;">Calisher CH (2001) Colorado tick fever. In Service MW (ed.)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 67.9293%; width: 33.1699%; height: 1.38889%;">The Encyclopedia of Arthropod-Transmitted Infections. CAB
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.1919%; width: 15.1961%; height: 1.38889%;">International, pp. 121–126.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.5808%; width: 34.4771%; height: 1.26263%;">Klasco R (2002) Colorado tick fever. Med Clin North Am
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 8.16994%; height: 1.26263%;">86(2):435–440.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">201
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/bbd3d0be-2975-4ba7-9d70-eaf1156603b8" class="aLF-aPX-aPF-aPE-J3" alt="Page 77 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.who.int/csr/disease/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.who.int/csr/disease/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.who.int/csr/disease/&amp;ust=1666162860000000&amp;usg=AOvVaw2_FFL-4bsnWB-S0c6QWxA_&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 63.5621%; top: 59.8485%; width: 16.0131%; height: 1.26263%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 78 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 67.8105%; height: 2.39899%;">Disease: Crimean–Congo Hemorrhagic Fever
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.3464%; height: 1.26263%;">Classification: ICD-9 065.0; ICD-10 A98.0
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.3137%; height: 1.38889%;">Synonyms: Congo fever, Congo–Crimean hemorrhagic fever,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 18.7909%; height: 1.38889%;">Central Asian hemorrhagic fever
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.3137%; height: 1.38889%;">Agent: Crimean-Congo hemorrhagic fever virus (CCHFV) is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 2.65152%;">an enveloped, spherical virus with a tripartite, single-
stranded, negative sense RNA genome, belonging to the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.3137%; height: 1.38889%;">genus Nairovirusin the family Bunyaviridae. It has 7 genotypes
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 29.2484%; height: 1.38889%;">distinguished by the small (S) segment of the RNA.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.3137%; height: 1.38889%;">Reservoir: Hares, hedgehogs, wild mice, livestock, ostriches.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 33.9869%; height: 2.65152%;">Since hard ticks overwinter and can pass the virus transova-
rially, ticks also serve as reservoirs.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 42.6471%; height: 1.38889%;">Vector: Hard ticks, principally Hyalomma spp., also Boophilus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 22.3856%; height: 1.38889%;">spp. and Rhipicephalus spp.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 2.65152%;">Transmission: By tick bite; larval ticks are carried on migrat-
ing birds, which are refractory to the virus. The virus is also
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.3137%; height: 1.38889%;">spread among veterinarians, farmers, shepherds, butchers,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">and slaughter-house workers by contact with the blood of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">infected livestock. Person-to-person spread is by contact with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 22.8758%; height: 1.38889%;">infectious body fluids of patients.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.3137%; height: 1.38889%;">Cycle: Tick–vertebrate–tick, with humans as incidental hosts.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 24.8366%; height: 1.38889%;">Incubation period: 1–12 days, usually 3–7.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">Clinical findings: Sudden onset of fever (which may be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">biphasic), malaise, weakness, irritability, headache, severe
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">pain in limbs and loins and marked anorexia; occasionally
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 4.0404%;">vomiting, abdominal pain, and diarrhea. Hemorrhage in oro-
pharynx, nose, lungs, uterus, intestines; hematomas, echymo-
sis, and petechiae; hematuria and albuminuria. In Russia,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">estimates are that only 1 in 6 cases is hemorrhagic. The CFR
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 24.8366%; height: 1.38889%;">ranges from 2 to 80% in different countries.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.26263%;">Diagnostic tests: Virus isolation in cell culture; RT-PCR;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">antigen detection; serology by IgM ELISA. The virus is a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 7.35294%; height: 1.38889%;">BSL-4 agent.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 34.4771%; height: 1.38889%;">Therapy: Supportive; intravenous ribavirin and convalescent
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 18.9542%; height: 1.13636%;">human serum are recommended.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 16.7929%; width: 34.3137%; height: 1.38889%;">Prevention: Personal anti-tick precautions. An inactivated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">mouse-brain vaccine is in use in Russia and eastern Europe.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">Healthcare workers caring for CCHF patients are at risk and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 22.7124%; height: 1.38889%;">need to take proper barrier precautions.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 23.4848%; width: 34.3137%; height: 1.38889%;">Epidemiology: The disease is limited geographically to the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">range of the vector tick. Hyalomma spp. do not occur in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">Americas and Oceania. Historically the tick does not appear
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">above 50 N latitude, but possibly due to changes in climate
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.13636%;">and environment the tick and CCHFV outbreaks have
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 39.0523%; height: 1.38889%;">occurred above this latitude. In the northern hemisphere, H.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">marginatum becomes more active by increasing temperatures
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">during spring (April–May) and immature stages are active
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">from May to September. The potential roles of migratory birds
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">and the movement of livestock carrying ticks in the spread of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">the virus are unclear. CCHFV outbreaks mainly occur in those
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">working in agricultural areas. About 90% of the cases in a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">recent outbreak in Turkey were farmers. Cases regularly had
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.13636%;">skin contact with livestock or other animals. Also outdoor
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.3137%; height: 1.38889%;">activities (hiking, camping) in endemic areas are a risk factor.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">Countries on the map marked as having no data (western
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">Sahara, Palestine, parts of the Arabian peninsula, Kashmir) are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">within the range of the vector tick and likely at risk for CCHFV
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">outbreaks. CCHFV genotypes cluster geographically, with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 2.65152%;">exceptions: the Asia 1 genotype has been found in Madagas-
car, where it was possibly introduced by migrating birds, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">Africa 1 in the Middle East, which may have been introduced
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 13.3987%; height: 1.13636%;">with infected livestock.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 55.8081%; width: 34.3137%; height: 1.38889%;">Map sources: The Crimean–Congo Hemorrhagic Fever map
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 34.4771%; height: 1.13636%;">was made with data on CCHF outbreaks between 1943 and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 34.4771%; height: 1.26263%;">2010 obtained from ProMED mail, the medical literature and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 27.451%; height: 1.26263%;">WHO, available at: www.who.int/csr/disease/.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 62.6263%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 34.3137%; height: 1.38889%;">Ergonul O, et al. (2006) Crimean–Congo haemorrhagic fever.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 65.1515%; width: 18.7909%; height: 1.38889%;">Lancet Infect Dis 6:203–214.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">Leblebicioglu H, et al. (2010) Crimean–Congo haemorrhagic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">fever in Eurasia. Int J Antimicrob Agents 36(Suppl. 1):
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.3182%; width: 5.22876%; height: 1.0101%;">S43–S46.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.5808%; width: 34.3137%; height: 1.38889%;">World Health Organization (2004) The Vector-Borne Human
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 33.1699%; height: 1.38889%;">Infections of Europe, their Distribution and Burden on Public
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.2323%; width: 33.1699%; height: 1.38889%;">Health. Publication from the WHO Regional Office for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 74.6212%; width: 4.73856%; height: 1.38889%;">Europe.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">203
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/c2a437b3-94dd-4232-94db-5e4860df2834" class="aLF-aPX-aPF-aPE-J3" alt="Page 78 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 79 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 25.4902%; height: 2.39899%;">Disease: Dengue
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 34.3137%; height: 1.38889%;">Classification: Dengue fever (DF): ICD-9 061, ICD-10 A90;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 18.1818%; width: 34.3137%; height: 1.38889%;">Dengue hemorrhagic fever/Dengue shock syndrome (DHF/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 17.9739%; height: 1.38889%;">DSS): ICD-9 065.4; ICD-10 A91.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.3485%; width: 16.8301%; height: 1.26263%;">Synonyms: Breakbone fever.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 25.2525%; width: 34.3137%; height: 1.38889%;">Agent: Dengue virus (DENV) is an enveloped RNA virus,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.5152%; width: 34.4771%; height: 1.38889%;">genus Flavivirus in the family Flaviviridae. There are four
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.904%; width: 34.4771%; height: 1.38889%;">antigenically related, but distinct, dengue virus serotypes
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 29.1667%; width: 34.4771%; height: 1.38889%;">(DEN-1, DEN-2, DEN-3, and DEN-4), all of which can cause
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.5556%; width: 5.88235%; height: 1.26263%;">DF/DHF.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 33.2071%; width: 34.3137%; height: 1.38889%;">Reservoir: Humans; forest monkeys in West Africa and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.596%; width: 8.98693%; height: 1.13636%;">Southeast Asia.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 37.5%; width: 34.8039%; height: 2.65152%;">Vector: Most commonly, the urban container-breeding, day-
bitingmosquitoesAedes aegypti and Ae. albopictus; in Polynesia,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 40.1515%; width: 38.8889%; height: 1.38889%;">Ae. scutellaris complex spp.; in Malaysia, Ae. nivaeus complex
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.5404%; width: 34.4771%; height: 1.38889%;">spp., in West Africa, Ae. furcifer-taylori complex spp., and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.803%; width: 35.6209%; height: 1.38889%;">recently in Europe by Ae. albopictus (see Aedes map).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.7071%; width: 19.1176%; height: 1.38889%;">Transmission: By mosquito bite.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 48.6111%; width: 42.4837%; height: 4.0404%;">Cycle: Human–mosquito–human around housing; monkey–- mosquito–monkey and monkey–mosquito–human in the for-
ests of West Africa and Malaysia. Human viremia lasts 3–5
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 52.6515%; width: 34.4771%; height: 1.38889%;">days since onset of symptoms; the mosquito can transmit 8–12
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.9141%; width: 34.4771%; height: 1.38889%;">days after taking a viremic blood meal, depending on the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.303%; width: 12.4183%; height: 1.38889%;">ambient temperature.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.2071%; width: 28.268%; height: 1.26263%;">Incubation period: 3–14 days (usually 4–7 days).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.1111%; width: 34.3137%; height: 1.26263%;">Clinical findings: Sudden onset of fever lasting 2–7 days,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.3737%; width: 34.3137%; height: 1.38889%;">sometimes biphasic, severe headache, myalgia, arthralgia,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.7626%; width: 34.3137%; height: 2.77778%;">retro-orbital pain, anorexia, nausea, vomiting and a maculo-
papular rash (not easily seen on dark skin). Most cases recover.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.4141%; width: 34.4771%; height: 1.38889%;">Minor occurrence of petechiae, epistaxis, or gingival bleeding
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.803%; width: 34.4771%; height: 1.38889%;">may be seen. Serious hemorrhagic manifestations, like a severe
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">drop in blood platelets, indicate dengue hemorrhagic fever
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.4545%; width: 34.4771%; height: 1.38889%;">(DHF), that can progress to dengue shock syndrome (DSS) and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.8434%; width: 34.3137%; height: 2.65152%;">death. Infection with any serotype results in lasting homolo-
gous immunity, but little cross-immunity to other serotypes.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.495%; width: 34.4771%; height: 1.38889%;">Cross-immunity may exacerbate, rather than diminish, disease
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 75.8838%; width: 34.4771%; height: 1.38889%;">severity when infected with a new serotype; DHF leading
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.1465%; width: 34.4771%; height: 1.38889%;">to DSS can occur as a secondary infection with a different
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">serotype, but DHF/DSS has also been reported in primary
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">infections. CFR for DHF is up to 20%, for untreated DSS up to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 19.9346%; height: 1.38889%;">50%, and 1–2% if correctly treated.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 2.65152%;">Diagnostic tests: IgM capture ELISA; NS1 antigen test; RT-
PCR of blood or tissue; virus isolation in mosquitoes or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 27.451%; height: 1.38889%;">mosquito cell culture with identification by IFA.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">Therapy: Supportive, including rehydration. Avoid aspirin
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 18.9542%; height: 1.38889%;">because of potential hemorrhage.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 2.77778%;">Prevention: Removal of breeding sites in any type of con-
tainer that holds water (e.g. vase, tire). Larviciding standing
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">water, adulticiding with non-persistent insecticides. Personal
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">protection with suitable clothing, mosquito repellents, nets,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 7.35294%; height: 1.13636%;">and screens.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.3137%; height: 4.0404%;">Epidemiology: The global dengue distribution follows vec-
tor presence and introduction of the virus, and occurs basi-
cally between the 10 C isotherms. Autochthonous dengue
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">fever cases appeared in Europe for the first time in 2010, north
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 41.5033%; height: 1.38889%;">of 10 C isotherm and likely transmitted by Ae. albopictus (see
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 2.77778%;">Aedes agypti and Aedes albopictus map). There is strong sea-
sonality, correlated with the rainy season, which produces a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">marked increase in vectors because more mosquito-breeding
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">sites become available then. Two, 3 or all 4 serotypes may
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">occur concurrently. DHF/DSS in many countries is most
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">often seen in children suffering a secondary infection with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">a different serotype. Incidence rates of up to 3% have been
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">seen in dengue naõve populations such as are found in some
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 8.82353%; height: 1.13636%;">Pacific islands.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 33.9869%; height: 2.65152%;">Map sources: The Dengue map was reproduced from Sim-
mons CP (2012), with permission.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 63.8889%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 34.3137%; height: 1.38889%;">Guzman A, et al. (2010) Update on the global spread of dengue.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 66.5404%; width: 25.1634%; height: 1.38889%;">Int J Antimicrob Agents 36(Suppl. 1):S40–S42.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">Jelinek T (2009) Trends in the epidemiology of dengue fever
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.1919%; width: 33.1699%; height: 1.38889%;">and their relevance for importation to Europe. Euro Surveill
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.5808%; width: 7.51634%; height: 1.26263%;">14(25):19250.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 71.9697%; width: 34.3137%; height: 1.38889%;">Kyle JL, et al. (2008) Global spread and persistence of dengue.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.2323%; width: 17.1569%; height: 1.13636%;">Ann Rev Microbiol 62:71–92.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 74.6212%; width: 34.3137%; height: 1.38889%;">Simmons CP, et al. (2012) Dengue. N Engl J Med.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 76.0101%; width: 8.66013%; height: 1.0101%;">366:1423–1432.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">205
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/33872290-ea94-4088-888c-dff53f5bbdfa" class="aLF-aPX-aPF-aPE-J3" alt="Page 79 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.cdc.gov/EasternEquineEncephalitis/tech/epi" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.cdc.gov/EasternEquineEncephalitis/tech/epi" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.cdc.gov/EasternEquineEncephalitis/tech/epi&amp;ust=1666162860000000&amp;usg=AOvVaw2jA4CjaR-_-ml4Q5FAkXTL&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 57.5163%; top: 54.4192%; width: 29.085%; height: 1.38889%;"></a><a href="http://www.ciesin.org/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.ciesin.org/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.ciesin.org/&amp;ust=1666162860000000&amp;usg=AOvVaw0PdQedt3Lkt4vBbetknolV&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 76.9608%; top: 57.0707%; width: 9.80392%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 80 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 56.2092%; height: 2.39899%;">Disease: Eastern Equine Encephalitis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 23.366%; height: 1.26263%;">Classification: ICD-9 062; ICD-10 A83.2
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.5707%; width: 15.1961%; height: 1.13636%;">Synonyms: None.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 34.4771%; height: 2.65152%;">Agent: Eastern equine encephalitis virus (EEEV) is an envel-
oped, single-stranded positive-sense RNA alphavirus, genus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.3137%; height: 1.38889%;">Alphavirus in the family Togaviridae, with four lineages:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">Group I is endemic in North America and the Caribbean
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">and causes most human disease cases; the other three groups
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">(IIA, IIB, and III) infrequently cause equine or human illness in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 16.0131%; height: 1.13636%;">Central and South America.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">Reservoir: Principally wild birds in North America. Wild
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 34.3137%; height: 1.26263%;">rodents, bats, reptiles, or amphibians may also be involved.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.3137%; height: 1.38889%;">Pheasants may serve as sentinels as they develop fatal disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.4771%; height: 1.38889%;">Chickens are more typically used as sentinels by detection of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.3838%; width: 9.15033%; height: 1.0101%;">seroconversion.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 42.3203%; height: 4.0404%;">Vector: Mosquitoes. In North America,Culiseta melanura bird-
to-bird; Aedes or Coquillettidia spp. from bird to other verte-
brates (including horses and humans). In South America,Culex
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.3283%; width: 2.77778%; height: 1.13636%;">spp.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 33.9869%; height: 2.77778%;">Transmission: By mosquito bite. There is no direct person-to-
person transmission.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 36.6013%; height: 1.38889%;">Cycle: Culiseta melanura: bird to bird; Aedes or Coquillettidia
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">spp.: from bird to other vertebrates (including horses and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">humans). Viremia lasts 2–5 days in birds, and the extrinsic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">cycle in mosquitoes lasts 2–3 days. Horses and humans are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">dead-end hosts because their viremia is generally not high
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 16.5033%; height: 1.38889%;">enough to infect mosquitoes.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 19.7712%; height: 1.26263%;">Incubation period: 4–10 days.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">Clinical findings: Sudden onset of high fever, headache,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.3137%; height: 1.38889%;">chills, vomiting, myalgias, photophobia and dysthesias;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.3137%; height: 1.38889%;">50–90% of apparent cases develop encephalitis. In the USA,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 33.9869%; height: 2.65152%;">one-third of encephalitis cases die and one-third of the survi-
vors are moderately to severely disabled.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: IgM antibody detection in CSF (in serum
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 34.4771%; height: 1.38889%;">may not be from the current infection), neutralization test on
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.4771%; height: 1.38889%;">paired acute and convalescent sera; RT-PCR. Virus isolation
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 29.902%; height: 1.26263%;">takes time. IFA in necropsy brain tissue is definitive.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 78.6616%; width: 29.4118%; height: 1.38889%;">Therapy: Supportive, there is no specific treatment.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 16.7929%; width: 34.3137%; height: 1.38889%;">Prevention: Personal anti-mosquito precautions. Adulticide
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">spraying is practiced in areas where horse cases appear. A
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">human vaccine against only the North American strain is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 19.7712%; height: 1.38889%;">available for laboratory personnel.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 2.77778%;">Epidemiology: In the USA, an average of only 6 neuroinva-
sive cases of EEE are reported annually. The annual number of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">cases has declined in recent years. Incidence is similar among
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">different age groups and ethnicities, but it is twice as high
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">among men. Persons aged over 50 and under 15 are at greatest
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 2.77778%;">risk for developing severe disease. In North America, out-
breaks occur during the mosquito season. In tropical South
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">America transmission to horses is year-round, but human
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.2172%; width: 34.4771%; height: 1.38889%;">cases are rare. Culiseta breeds in swampy areas in woodland,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">transmitting the virus from marsh-nesting birds to horses kept
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.26263%;">in such areas; unvaccinated horses often die. Outbreaks in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.13636%;">Mexico and islands of the Caribbean have all been due to the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">North American subtype, indicating spread by migratory
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.13636%;">birds. South American strains are distinct and of three different
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">lineages, probably determined by the range of different rodent
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">hosts. Only a single human case has been reported from Brazil,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.26263%;">and none from Guatemala, Belize, Colombia, Ecuador Peru,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">Cuba, or Trinidad and Tobago in spite of detection of the virus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">in mosquitoes or horses in those countries. The virus has also
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 25.6536%; height: 1.13636%;">been isolated from horses in eastern Canada.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 51.7677%; width: 34.1503%; height: 1.38889%;">Map sources: The Eastern Equine Encephalitis map was made
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.13636%;">with distribution data obtained from themedical literature and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.3137%; height: 1.38889%;">CDC (www.cdc.gov/EasternEquineEncephalitis/tech/epi.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 44.7712%; height: 2.65152%;">html). The distribution of the vector Culiseta melanura was obtained from CIESIN, available at: www.ciesin.org/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 16.0131%; height: 1.26263%;">docs/001-613/001-613.html.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 61.2374%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 62.5%; width: 33.9869%; height: 2.65152%;">Davis LE, et al. (2008) North American encephalitic arbo-
viruses. Neurol Clin 26(3):727–757.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">Reimann CA, et al. (2008) Epidemiology of neuroinvasive
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 66.5404%; width: 35.7843%; height: 1.26263%;">arboviral disease in the United States, 1999–2007. Am J
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 67.9293%; width: 20.5882%; height: 1.38889%;">Trop Med Hyg 79:974–979.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.1919%; width: 43.9542%; height: 2.77778%;">Smith DW (2009) Arbovirus infections. Chapter 40 inManson’s Tropical Diseases, 22nd edn.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 71.9697%; width: 34.4771%; height: 1.38889%;">Weaver SC (2001) Eastern equine encephalitis. In Service MW
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.2323%; width: 39.3791%; height: 2.77778%;">(ed.) The Encyclopedia of Arthropod-transmitted Infections. CAB International, pp. 151–159.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">207
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/643008d6-9f3c-4e1d-a98c-0dd060bc8547" class="aLF-aPX-aPF-aPE-J3" alt="Page 80 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.cdc" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.cdc" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.cdc&amp;ust=1666162860000000&amp;usg=AOvVaw0kjlhtRyqo6UyyOH-BKeVU&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 80.719%; top: 62.5%; width: 5.88235%; height: 1.13636%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 81 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 64.2157%; height: 2.39899%;">Disease: Ebola and Marburg Virus Disease
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 34.4771%; height: 1.26263%;">Classification: ICD-9 065.8 and 078.89; ICD-10 A98.4 and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 18.1818%; width: 3.75817%; height: 1.13636%;">A98.3
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 34.4771%; height: 1.38889%;">Syndromes and synonyms: Ebola or Marburg hemorrhagic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 3.59477%; height: 1.13636%;">fever.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">Agent: Ebola viruses (genus Ebolavirus), marburg viruses
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.3137%; height: 1.38889%;">(genus Marburgvirus), and ‘cueva viruses’, family Filoviridae,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.3137%; height: 1.38889%;">order Mononegavirales; enveloped, single-stranded,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.8039%; height: 1.38889%;">negative-sense RNA viruses. There are five ebola viruses:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">Bundibugyo virus (BDBV), Ebola virus (EBOV), Reston
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 37.9085%; height: 1.38889%;">virus (RESTV), Sudan virus (SUDV), and Taõ Forest virus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">(TAFV); two marburg viruses: Marburg virus (MARV) and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">Ravn virus (RAVV); and one ‘cuevavirus’: Lloviu virus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 4.90196%; height: 1.26263%;">(LLOV).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">Reservoir: Ebola viruses: possibly fruit bats, unknown for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">BDBV, SUDV, and TAFV; Marburg viruses: infectious MARV
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 37.4183%; height: 2.65152%;">and RAVV have been isolated from Egyptian fruit bats; ‘Cue-
vaviruses’: Schreiber’s long-fingered bats.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.0101%;">Transmission: Ebola viruses: unknown route. Bats have not
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 2.77778%;">yet been implicated in the initiation of ebola outbreaks. How-
ever, most outbreaks are associated with the consumption or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">contact with diverse non-human primates, suggesting that
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">transmission could occur from bats to monkeys to humans;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.4771%; height: 2.77778%;">exposure to contaminated body fluids; by direct person-to-
person contact; via injection with re-used syringes; preparing
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">bodies of cases for burial. Marburg viruses: most outbreaks are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.3137%; height: 1.38889%;">associated with index cases visiting caves or working in mines.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">As Egyptian fruit bats are cave animals, transmission may
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">occur directly from bats to humans or via contact with their
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 1.26263%;">excreta and secreta; transmission between humans is similar as
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">for ebola virus. ‘Cuevaviruses’ are probably apathogenic for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 5.22876%; height: 1.13636%;">humans.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.1503%; height: 1.38889%;">Cycle: Not completely understood (see ‘Transmission’).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 19.7712%; height: 1.38889%;">Incubation period: 2–21 days.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 1.26263%;">Clinical findings: Sudden onset of fever, chills, malaise,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.4771%; height: 1.38889%;">myalgia, and headache, followed by pharyngitis, vomiting,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 34.4771%; height: 1.38889%;">diarrhea, and a maculopapular rash. Severe cases have internal
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.4771%; height: 1.38889%;">and external hemorrhages, CNS involvement and multi-organ
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 34.4771%; height: 1.26263%;">failure leading to terminal shock. The case fatality rate (CFR)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.2727%; width: 34.4771%; height: 1.38889%;">varies, depending on location, virus involved, and clinical
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 78.6616%; width: 34.4771%; height: 1.26263%;">care: 0% for RESTV and TAFV, 34% for BDBV; 78% for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">EBOV, 53% for SUDV, 82% for MARV. Recovery may be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 2.65152%;">prolonged and accompanied by long term sequelae, particu-
larly hearing loss. Filoviruses can persist for months and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 10.7843%; height: 1.38889%;">disease may recur.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 23.4848%; width: 34.3137%; height: 1.26263%;">Diagnostic Tests: Must be done in BSL-4 facilities if
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">samples contain infectious virus. IgM ELISA, RT-PCR and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 33.9869%; height: 4.16667%;">virus isolation can be used on acute specimens; in convales-
cence, antibody tests; on autopsy specimens, electron micros-
copy and immunohistochemistry.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 29.4118%; height: 1.38889%;">Therapy: Supportive, there is no specific treatment.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 34.3434%; width: 34.3137%; height: 1.26263%;">Prevention: Isolation and barrier nursing of cases; discourage
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">butchering of wildlife that died from unknown causes and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">burial practices of cases involving ritual embalming. Avoid
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 25.817%; height: 1.13636%;">bat-infested caves or mines in endemic areas.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 41.0354%; width: 34.3137%; height: 1.38889%;">Epidemiology: Ebola viruses, except RESTV, are endemic in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">the tropical rain forests of equatorial Africa. Most outbreaks
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">started from a single case admitted to a hospital that had
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">inadequate infection control, resulting in rapid nosocomial
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.1503%; height: 3.91414%;">transmission. Cases have been imported from endemic coun-
tries into South Africa and Switzerland, and laboratory infec-
tions have occurred in the UK and Russia.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 2.77778%;">Marburg viruses are endemic in arid woodlands of equato-
rial Africa. Outbreaks are usually limited to a few cases, with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">the exception of one outbreak in the DRC and Angola. Cases
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">have been imported into South Africa, the Netherlands, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">possibly the USA. A laboratory outbreak in 1967 in Germany
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">and in Yugoslavia, led to the discovery of the disease (not
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 11.7647%; height: 1.38889%;">shown on the map).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 61.2374%; width: 34.1503%; height: 1.26263%;">Map sources: The Ebola and Marburg Virus Disease map was
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 62.5%; width: 34.3137%; height: 1.26263%;">made with data obtained from CDC, available at: www.cdc.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 26.634%; height: 1.38889%;">gov/ncidod/dvrd/spb/mnpages/disinfo.htm.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 66.6667%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 67.9293%; width: 34.3137%; height: 1.38889%;">Klenk H-D, Feldmann H (2004) Ebola and Marburg viruses:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.1919%; width: 33.0065%; height: 1.38889%;">Molecular and Cellular Biology. Wymondham, Norfolk, UK:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.5808%; width: 11.4379%; height: 1.13636%;">Horizon Bioscience.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 71.9697%; width: 34.6405%; height: 1.38889%;">Kuhn JH (2008) Filo viruses – A Compendium of 40 Years of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.2323%; width: 33.3333%; height: 1.38889%;">Epidemiological, Clinical, and Laboratory Studies. Archives of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 74.6212%; width: 33.1699%; height: 1.38889%;">Virology Supplement, Vol. 20. Vienna, Austria: Springer,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 76.0101%; width: 10.1307%; height: 1.13636%;">Wien, New York.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 77.2727%; width: 34.4771%; height: 1.38889%;">Kuhn JH, et al. (2010) Proposal for a revised taxonomy of the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 78.6616%; width: 27.6144%; height: 1.38889%;">family Filoviridae. Arch. Virol 155(12):2083–2103.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">209
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/1fa60774-b9a6-4dbd-b9aa-c7f35d975a82" class="aLF-aPX-aPF-aPE-J3" alt="Page 81 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.cdc.gov/ncidod/diseases/hanta/hps/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.cdc.gov/ncidod/diseases/hanta/hps/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.cdc.gov/ncidod/diseases/hanta/hps/&amp;ust=1666162860000000&amp;usg=AOvVaw0h7pA9US2Po2lAMNxR2ymE&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 57.0261%; top: 64.5202%; width: 25.4902%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 82 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 60.4575%; height: 2.27273%;">Disease: Hantaviral Disease, New World
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.183%; height: 1.26263%;">Classification: ICD-9 480.8; ICD-10 B33.4
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.4771%; height: 2.77778%;">Syndromes and synonyms: Hantavirus pulmonary syn-
drome (HPS), Hantavirus cardiopulmonary syndrome, Four
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 9.47712%; height: 1.13636%;">Corners disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.3137%; height: 1.38889%;">Agents: Hantaviruses, a large group of different, enveloped,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">single-stranded, negative-sense viruses with a tripartite RNA
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">genome, that belong to the Bunyaviridae family. Hantaviruses
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.4771%; height: 1.26263%;">that cause HPS were discovered in 1993; more than 30 new
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 34.3137%; height: 1.26263%;">hantaviruses have been detected since then, but not all cause
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.4771%; height: 1.13636%;">HPS.There at least 14 hantaviruses that cause HPS in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">Americas: Sin Nombre virus (SNV), Monongahela virus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">(MGLV), New York virus (NYV), Bayou virus (BAYV),
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.3137%; height: 1.26263%;">Black Creek Canal virus (BCCV), Choclo virus, Andes virus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.4771%; height: 1.38889%;">(ANDV), Bermejo virus (BMJV), Lechiguanas virus (LECV),
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">Maciel virus (MCLV), Oran virus (ORNV), Laguna Negra
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">virus (LANV), Araraquara virus, Hu39694, and Juquitiba
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">virus. Old World and New World hantaviruses share high
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.3137%; height: 1.38889%;">similarity in their genome and have comparable lifecycles.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">Currently, there is no consensus on the classification of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 7.84314%; height: 1.0101%;">hantaviruses.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.3137%; height: 1.38889%;">Reservoir: Each hantavirus has its specific rodent host. HPS is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.3137%; height: 1.38889%;">generally caused by the sigmodontine-borne hantaviruses.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">Phylogenetic analysis reveals that hantaviruses have a long
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 22.3856%; height: 1.38889%;">co-evolutionary history with their host.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">Transmission: By inhalation of aerosols from dried rodent
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">excreta (this is unlike other Bunyaviruses that are generally
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">arthropod-borne). Person-to-person transmission has been
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 11.7647%; height: 1.38889%;">reported for ANDV.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">Cycle: Rodent-to-rodent though saliva, excreta and bite, with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 23.2026%; height: 1.26263%;">humans as an accidental, dead-end host.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 32.5163%; height: 1.38889%;">Incubation period: Typically 2 weeks (days to 6 weeks).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.3137%; height: 1.38889%;">Clinical findings: Typically a cardiopulmonary infection as
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">opposed to the primarily renal infection produced by Old
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">World hantaviruses; renal involvement and hemorrhage are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.4771%; height: 1.38889%;">rare in NewWorld cases. Symptoms are fever, myalgia, and GI
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 34.4771%; height: 1.38889%;">pain, followed by sudden onset of respiratory distress and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.3137%; height: 1.38889%;">hypotension, with rapid progression to respiratory failure and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 29.2484%; height: 1.26263%;">shock. Convalescence is prolonged. CFR is 35–60%.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 16.7929%; width: 34.3137%; height: 1.38889%;">Diagnostic tests: Serology (IgM ELISA, Western blot, strip
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 26.634%; height: 1.38889%;">immunoblot, IFA); RT-PCR of biopsy material.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 29.4118%; height: 1.38889%;">Therapy: Supportive, there is no specific treatment.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 23.4848%; width: 34.3137%; height: 1.38889%;">Prevention: Domestic and peridomestic rodent control,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 24.0196%; height: 1.13636%;">disinfection of rodent-contaminated areas.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 27.5253%; width: 34.3137%; height: 1.26263%;">Epidemiology: The first hantavirus found in the New World
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.26263%;">was Sin Nombre virus in the ‘Four Corners’ area (USA) in 1993,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">where an outbreak occurred of severe pulmonary disease in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">previously healthy adults. Since then, sporadic outbreaks have
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">been detected throughout the Americas, with new strains and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">reservoir hosts. Approximately 200 cases of HPS per year are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">reported in the Americas. There is no HPS in the Caribbean,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 36.6013%; height: 1.38889%;">probably because the rodent host Sigmodontinae is infrequent
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.13636%;">there. The number of cases is much smaller than that of HFRS
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">in the Old World, but the CFR is higher. Cases confirmed by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">serology have been reported in Colombia and Venezuela but
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">the identity of the hantavirus unknown. Seoul virus (see
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">Hantavirus Disease, OldWorld map) seropositives in humans
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">and Rattus norvegicus are found in many port cities in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 2.77778%;">Americas, spread by shipping, but without evidence of dis-
ease. Risk of exposure to hantavirus is correlated with outdoor
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">occupations such as agriculture, in which a person might
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">encounter rodents or their excreta; the greatest risk is entering
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">rodent-infested closed buildings. Epidemiology differs by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">country and virus. In household contacts of index patients
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">with HPS in Chile, the risk of secondary cases was 17.6%
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 34.4771%; height: 2.52525%;">among sex partners and 1.2% among other household mem-
bers. Infection is more common in males, with most cases
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 21.732%; height: 1.38889%;">occurring within the 20–40 age group.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 61.2374%; width: 34.1503%; height: 1.26263%;">Map sources: The New World Hantavirus map was made
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 62.5%; width: 12.2549%; height: 1.13636%;">with various sources:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 64.5202%; width: 34.4771%; height: 1.38889%;">CDC (www.cdc.gov/ncidod/diseases/hanta/hps/), and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 54.2484%; top: 65.9091%; width: 14.5425%; height: 1.26263%;">C.B. Jonsson et al. (2010).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 68.6869%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.9495%; width: 34.4771%; height: 1.38889%;">Bi Z, et al. (2008) Hantavirus infection: a review and global
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.2121%; width: 24.183%; height: 1.38889%;">update. J Infect Dev Ctries 2(1):3–23.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 72.601%; width: 34.4771%; height: 1.38889%;">Jonsson CB, et al. (2010) A global perspective on hantavirus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.9899%; width: 33.1699%; height: 1.38889%;">ecology, epidemiology, and disease. Clin Microbiol Rev
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 75.3788%; width: 8.16994%; height: 1.26263%;">23(2):412–441.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 76.6414%; width: 34.4771%; height: 1.38889%;">Padula PJ, et al. (2000) Genetic diversity, distribution, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 78.0303%; width: 39.5425%; height: 1.38889%;">serological features of hantavirus infection in five countries
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 79.2929%; width: 27.2876%; height: 1.38889%;">in South America. J Clin Microbiol 38:3029–3035.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.4495%; width: 54.5752%; height: 1.26263%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.4596%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">211
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/d5f11021-db82-442c-89c9-ec01860aa555" class="aLF-aPX-aPF-aPE-J3" alt="Page 82 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 83 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.7424%; width: 58.8235%; height: 2.39899%;">Disease: Hantaviral Disease, Old World
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.3464%; height: 1.26263%;">Classification: ICD-9 078.6; ICD-10 A98.5
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">Syndromes and synonyms: Hemorrhagic fever with renal
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 34.4771%; height: 1.38889%;">syndrome (HFRS), Korean Hemorrhagic Fever, Hemorrhagic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 25.4902%; height: 1.38889%;">Nephrosonephritis, Nephropathia epidemica
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">Agent: Hantaviruses, a large group of different, enveloped,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">single-stranded, negative-sense viruses with a tripartite
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.4771%; height: 2.52525%;">RNA genome, that belong to the Bunyaviridae family. Han-
taviruses are named after the Hantan River area in South
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">Korea, where the first hantavirus (Hantaan) was isolated in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.4771%; height: 1.13636%;">the 1970s. Old World and New World hantaviruses share
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">high similarity in their genome and have comparable life
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">cycles. Currently, there is no consensus on the classification
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.3137%; height: 1.38889%;">of hantaviruses. Old World hantaviruses shown on the map
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.4771%; height: 1.38889%;">are: Dobrava–Belgrade virus (DOBV), Hantaan virus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">(HTNV), Puumula virus (PUUV), and Saaremaa virus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">(SAAV). Seoul virus (SEOV) is not shown, it is world wide
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 11.6013%; height: 1.38889%;">in major port cities.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 43.4641%; height: 4.0404%;">Reservoir: HFRS is caused by Myodes-, Rattus-, and Apodemus- borne hantaviruses. Each virus has its particular host: Apode- mus spp. (striped field mouse) for HTNV, DOBV and SAAV
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 41.0131%; height: 1.38889%;">and Myodes ( Clethrionomys) for PUUV. SEOV infects Rattus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 28.7582%; height: 1.38889%;">norvegicus and can therefore be found world wide.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">Transmission: By inhalation of aerosols from dried rodent
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.3137%; height: 1.38889%;">excreta. Person-to-person transmission has not been reported.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">Cycle: Rodent-to-rodent though saliva, excreta and bite, with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 23.2026%; height: 1.26263%;">humans as an accidental, dead-end host.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 33.4967%; height: 1.38889%;">Incubation period: Usually 2–4 weeks (days to 2 months).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.4771%; height: 1.26263%;">Clinical findings: Sudden onset fever, headache, malaise,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">anorexia, severe abdominal or lower back pain, often with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">nausea and vomiting, followed by hypotension which may
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">progress to shock, hemorrhages and renal involvement, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.3137%; height: 1.38889%;">death. Convalescence is prolonged. PUUV virus causes less
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.26263%;">severe disease. The CFR is 5–15% for HFRS; for PUUV and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.3137%; height: 1.26263%;">SAAV infection the CFR is 1%; for DOBV the CFR is 9–12%.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 32.3529%; height: 1.38889%;">The differential diagnosis is leptospirosis or rickettsioses.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Serology (IgM ELISA, IFA); RT-PCR. Virus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 11.4379%; height: 1.0101%;">isolation is difficult.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">Therapy: Supportive; ribavirin is effective if given within the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 18.6275%; height: 1.38889%;">first 6 days; dialysis if indicated.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.4771%; height: 2.65152%;">Prevention: Domestic and peridomestic rodent control; dis-
infection of rodent-contaminated areas; formalin-inactivated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 30.3922%; height: 1.26263%;">HTNV vaccines are used in Russia, China and Korea.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 26.1364%; width: 34.1503%; height: 1.38889%;">Epidemiology: Approximately 150,000 to 200,000 patients
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">with HFRS are hospitalized each year throughout the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">world, more than half of them in China. The main agent of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">HFRS in Asia is HTNV. SEOV is also an important cause, but
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 2.77778%;">has a wider distribution. The most prevalent hantaviral dis-
ease in western and central Europe is caused by PUUV, with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.7778%; top: 34.3434%; width: 33.9869%; height: 1.26263%;">&gt; 9,000 cases per year. DOBV is restricted to the Balkans.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">Hantaviral disease is seasonal, linked to the activity of the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 3.91414%;">rodent host. HFRS epidemics are associated with rodent abun-
dance, caused by various seasonal factors. During the agricul-
tural season, infection is linked to outdoor activities, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 2.65152%;">during the winter, rodents seek shelter in and around build-
ings and infection is contracted indoors. There have been
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">reports of clinical hantaviral infections in the UK and there
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">is serological evidence of human infection in Israel, Kuwait,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">Laos, Malaysia, Philippines, Thailand, and Vietnam and in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 13.7255%; height: 1.13636%;">several African nations.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 50.3788%; width: 34.3137%; height: 1.38889%;">Map sources: The Old World Hantavirus map is made
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.13636%;">with various sources from the medical literature and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 8.49673%; height: 1.13636%;">ProMED-mail.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 55.8081%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">Bi Z, et al. (2008) Hantavirus infection: a review and global
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 58.4596%; width: 24.183%; height: 1.38889%;">update. J Infect Dev Ctries 2(1):3–23.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 38.2353%; height: 1.38889%;">Heyman P, et al. (2009) Hantavirus infections in Europe. Exp
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 61.1111%; width: 20.2614%; height: 1.38889%;">Rev Anti Infec Ther 7(2):205–217.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 62.5%; width: 34.4771%; height: 1.38889%;">Jonsson CB, et al. (2010) A global perspective on hantavirus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 63.8889%; width: 33.1699%; height: 1.38889%;">ecology, epidemiology, and disease. Clin Microbiol Rev
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 65.1515%; width: 8.16994%; height: 1.38889%;">23(2):412–441.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">Makary P, et al. (2010) Disease burden of Puumala virus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 67.9293%; width: 31.8627%; height: 1.38889%;">infections, 1995–2008. Epidemiol Infect 138(10):1484–1492.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">Tersago K, et al. (2010) Hantavirus outbreak in Western
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.5808%; width: 22.2222%; height: 1.38889%;">Europe. Epidemiol Infect 139(3):381–390.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 71.9697%; width: 34.4771%; height: 1.38889%;">Vapalahti O, et al. (2003) Hantavirus infections in Europe.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.2323%; width: 18.9542%; height: 1.38889%;">Lancet Infect Dis 3(10):653–661.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">213
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/c6632c0f-3e79-467e-845e-7f770e016088" class="aLF-aPX-aPF-aPE-J3" alt="Page 83 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.who.int/csr/disease/nipah/en/index.html" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.who.int/csr/disease/nipah/en/index.html" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.who.int/csr/disease/nipah/en/index.html&amp;ust=1666162860000000&amp;usg=AOvVaw2kbLhEiCqX5gQeVKYvSzFc&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 52.451%; top: 65.1515%; width: 28.1046%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 84 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 49.8366%; height: 2.39899%;">Disease: Hendra and Nipah Virus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.0196%; height: 1.26263%;">Classification: ICD-9 078.8; ICD-10 B33.8
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 31.5359%; height: 1.38889%;">Synonyms: Hendra virus disease, Nipah virus disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 34.3137%; height: 1.38889%;">Agent: Hendra virus and Nipah virus are negative-stranded
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">RNA viruses, and comprise the Henipavirus genus within the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">family Paramyxoviridae. Hendra virus was discovered in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">horses and stable staff in Australia in 1994, Nipah virus in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 33.6601%; height: 1.38889%;">pigs and pig farmers in the town Nipah, Malaysia, in 1999.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">Reservoir: Primarily Old World fruit-eating bats, mainly in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 14.3791%; height: 1.38889%;">the family Pteropodidae.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">Transmission: Hendra virus: through contact with infectious
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">body fluids, including urine, saliva, and nasal discharge, or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.4771%; height: 2.65152%;">during autopsy of infected horses. Nipah virus: through con-
tact with infectious body fluids, including bat saliva (on fallen
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">fruit and in date palm sap), or droplets from coughing infected
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">pigs. In Bangladesh, half of reported cases between 2001 and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 28.1046%; height: 1.13636%;">2008 were due to human-to-human transmission.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.26263%;">Cycle: Bat to bat via unknown route. Humans and domestic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 16.3399%; height: 1.13636%;">animals are incidental hosts.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 26.9608%; height: 1.38889%;">Incubation period: Varying from 4 to 45 days.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.3137%; height: 1.38889%;">Clinical findings: Hendra virus: encephalitis and pneumonia,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">with a rapid progression to death (few survive). One case
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">recovered from encephalitis but relapsed 14 months later and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.4771%; height: 2.65152%;">died with neurologic signs, suggesting latency and recrudes-
cence. Nipah virus: encephalitis and pneumonia. There has
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">been a case of relapse encephalitis more than 4 years after
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">infection. The CFR can vary from 10 to 75%, but is generally
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 3.26797%; height: 1.26263%;">high.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Virus isolation, RT-PCR, serology. Both
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.2778%; width: 14.3791%; height: 1.26263%;">viruses are BSL-4 agents.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 2.65152%;">Therapy: Supportive measures such as mechanical ventila-
tion. There is no specific treatment, but ribavirin may have
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 33.9869%; height: 2.77778%;">some effect. Monoclonal antibodies as post-exposure prophy-
laxis before onset of clinical signs.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.4771%; height: 1.38889%;">Prevention: Hendra virus: manage contact between fruit
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 34.4771%; height: 1.26263%;">bats and horse by basic husbandry measures such as placing
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.2727%; width: 34.4771%; height: 1.38889%;">food and water points under cover, regulate movement of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">horses from areas where the disease is occurring, regulate
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">import of horses from Australia during outbreaks. Nipah
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">virus: avoid contact with fruit bats and their discharges;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 33.9869%; height: 2.77778%;">wash and peel fruit, and wash hands before and after prepar-
ing fruit; regulate importation of pigs from outbreak areas.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 24.8737%; width: 34.3137%; height: 1.38889%;">Epidemiology: Hendra virus: pteropid bats are the primary
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">reservoir of Hendra virus and are asymptomatic. The viruses
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">can be isolated from their reproductive tracts and urine. The
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">epidemiological reasons for the emergence of Hendra virus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.13636%;">infection in horses are not clear. All human cases had close
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 16.5033%; height: 1.13636%;">contact with infected horses.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 32.9545%; width: 33.0065%; height: 1.38889%;">Nipah virus outbreaks have occurred only in South Asia
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">and may be associated with the bat-breeding season. In
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">Malaysia, it was hypothesized that the bats fed on fruit
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">trees in pig farms, and that fallen fruit contaminated with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">bat saliva containing Nipah virus was eaten by pigs, who
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">became infected. Nipah viruses have been isolated from bats
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">in Cambodia and Thailand, and a high seroprevalence has
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.26263%;">been found in fruit bats in NW India, in the absence of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">reported pig or human disease. In Bangladesh, there is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">epidemiologic evidence of bat–human transmission without
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 2.77778%;">an intermediate livestock host, and of human–human trans-
mission. Young boys who gather fruit from the trees are at
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">higher risk of disease. Also drinking palm sap from trees is a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">potential risk factor. Antibodies to henipaviruses have been
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 45.7516%; height: 1.38889%;">found in fruit bats in Madagascar (Pteropus and Eidolon sp.)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 2.65152%;">and in Ghana (Eidolon sp.), but in the absence of virus isola-
tion or RNA detection, it is not possible to know which virus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">is involved. No human or animal cases have been reported in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 14.7059%; height: 1.38889%;">Madagascar or in Africa.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 59.8485%; width: 34.3137%; height: 1.38889%;">Map sources: The Hendra and Nipah Virus mapwas made by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">geocoding reported human cases or outbreaks in the medical
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 62.5%; width: 34.4771%; height: 1.38889%;">literature or reported to WHO up to 2011. The fruit bat
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 34.3137%; height: 1.38889%;">distribution was obtained from WHO, available at: http://
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 28.4314%; height: 1.38889%;">www.who.int/csr/disease/nipah/en/index.html.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 67.9293%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">Field H, et al. (2001) The natural history of Hendra and Nipah
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.5808%; width: 21.0784%; height: 1.38889%;">viruses. Microbes Infect 3(4):307–314.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 71.9697%; width: 34.4771%; height: 1.38889%;">Hayman D, et al. (2008) Evidence of henipavirus infection in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.2323%; width: 34.8039%; height: 1.38889%;">West African fruit bats. PLoS ONE 3(7):e2739.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 74.6212%; width: 34.4771%; height: 1.38889%;">Montgomery JM, et al. (2008) Risk factors for Nipah virus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 75.8838%; width: 34.9673%; height: 1.38889%;">encephalitis in Bangladesh. Emerg Infect Dis doi 10.3201/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 77.2727%; width: 9.15033%; height: 1.13636%;">eid1410.060507.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">215
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/08fbcba1-f6ca-4b9f-9048-102f1c3d95a5" class="aLF-aPX-aPF-aPE-J3" alt="Page 84 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 85 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 30.8824%; height: 2.39899%;">Disease: Hepatitis A
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 23.5294%; height: 1.26263%;">Classification: ICD-9 070.1; ICD-10 B15.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">Synonyms: Epidemic hepatitis, infectious hepatitis, infectious
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 16.1765%; height: 1.38889%;">jaundice, catarrhal jaundice.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">Agent: Hepatitis A virus (HAV), a single stranded RNA virus,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 26.634%; height: 1.38889%;">genus Hepatovirus in the family Picornaviridae.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 33.9869%; height: 2.77778%;">Reservoir: Humans are the main reservoir; non-human pri-
mates can be infected, rarely.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">Transmission: Person-to-person transmission via fecal–oral
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 24.0196%; height: 1.26263%;">route (hands, food, water, sexual contact).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">Cycle: After ingestion, the virus infects hepatocytes, resulting
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.4771%; height: 1.38889%;">in periportal necrosis. The virus is shed via bile into the stool
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">and contaminates the environment, leading to new infections
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 19.9346%; height: 1.38889%;">in susceptible exposed individuals.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.3137%; height: 1.38889%;">Incubation period: Commonly 28–30 days, ranging from 15
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 6.53595%; height: 1.38889%;">to 50 days.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 2.77778%;">Clinical findings: Fever, fatigue, anorexia, abdominal dis-
comfort, nausea, vomiting, myalgia, jaundice, dark urine, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">light stools. Arthritis and rash may occur. Disease may be mild
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">and short-lived (several weeks) to severe and prolonged
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 16.6667%; height: 1.26263%;">(months), with a CFR &lt;0.3%.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Serology to detect specific IgM antibodies;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 26.3072%; height: 1.13636%;">RT-PCR to detect viral RNA in blood or stool.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 13.8889%; height: 1.38889%;">Therapy: Supportive.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.3137%; height: 1.26263%;">Prevention: Hygiene, access to clean water, and sanitation.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.4771%; height: 1.26263%;">An effective vaccine is available; vaccination should be offered
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">to high-risk groups (MSM, liver disease, travelers to endemic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.3137%; height: 4.16667%;">areas, IVDUs, outbreaks); passive immunization with immu-
noglobulins can be given as PEP within 2 weeks of the expo-
sure. The virus remains viable for weeks at room temperature.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 16.7929%; width: 34.3137%; height: 1.38889%;">Epidemiology: Globally, there exist four patterns of HAV
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">infection, based on age-specific HAV seroprevalence rates.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">High-endemic areas generally have low disease rates as
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.4771%; height: 1.38889%;">most infections occur in young children, who are usually
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">asymptomatic. Adults are immune and epidemics in these
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">high-endemic areas are uncommon. High-endemic areas is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">defined as a region where &gt; 90% of the children &lt;10 years are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 34.4771%; height: 5.42929%;">already infected and most cases are asymptomatic. The high-
endemic areas are generally in poor regions with poor sanita-
tion and lack of access to clean water (see Human Develop-
ment Index map and Sanitation map). Improving living
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">conditions leads to intermediate endemicity, which causes
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">high disease rates because more infections now occur in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 2.65152%;">older people (as disease averted in children), who are symp-
tomatic. HAV epidemiology in high-endemic areas is shifting
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">to intermediate endemicity, which results in an increase in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">disease burden. Large variations exist within countries in HAV
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">incidence. In (very) low-endemic areas, children will not
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">acquire the disease and the adult population will remain
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">susceptible, leading to localized outbreaks. In areas of low
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">endemicity, the overall prevalence is &lt;25%. In developed
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">countries with low endemicity, outbreaks are often caused
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">by contaminated food products, like shellfish, which can
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 33.9869%; height: 2.77778%;">concentrate virus, and other food products that are contami-
nated by an infected food handler.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 51.7677%; width: 34.1503%; height: 1.38889%;">Map sources: The Hepatitis A map is modified from K.H.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 12.4183%; height: 1.26263%;">Jacobsen et al. (2010).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 55.8081%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 34.4771%; height: 2.77778%;">Beth BP (2002) Global epidemiology of hepatitis A: implica-
tions for control. Proc. 10th International Symposium on Viral
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 34.4771%; height: 2.65152%;">Hepatitis and Liver Disease. Jacobsen KH, et al. (2010) Hepatitis A virus seroprevalence by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 62.5%; width: 34.8039%; height: 1.38889%;">age and world region, 1990 and 2005. Vaccine 28:6653–6657.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">Melnick JL (1995) History and epidemiology of hepatitis A
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 65.1515%; width: 19.4444%; height: 1.38889%;">virus. J Infect Dis 171:S2–S8.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">217
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/ec66b95c-7540-46b5-b361-e2fd0e002efd" class="aLF-aPX-aPF-aPE-J3" alt="Page 85 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 86 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 30.3922%; height: 2.39899%;">Disease: Hepatitis B
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 28.4314%; height: 1.26263%;">Classification: ICD-9 070.3; ICD-10 B16 and B18.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 33.9869%; height: 2.77778%;">Syndromes and synonyms: Type B hepatitis, serum hepati-
tis, homologous serum jaundice, long-incubation hepatitis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.3137%; height: 1.38889%;">Agent: Hepatitis B virus (HBV), a DNA virus belonging to the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">family of Hepadnaviridae. There are 8 genotypes (A to H) with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.4771%; height: 3.91414%;">marked differences in disease severity. Genotypes are classi-
fied by comparing complete HBV genomes. The map illus-
trates the distribution of chronic HBV infection. Co-infection
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">with hepatitis D virus (HDV) may occur resulting in severe
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.4771%; height: 1.13636%;">chronic liver disease. HDV is a defective RNA virus that
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 16.6667%; height: 1.38889%;">requires HBV for replication.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 14.5425%; height: 1.13636%;">Reservoir: Humans.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">Transmission: Percutaneous or mucosal exposure to blood or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">body fluids (e.g. semen, vaginal fluid, saliva) of an infected
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.3137%; height: 1.38889%;">individual. Person-to-person transmission via sexual contact,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.4771%; height: 1.38889%;">needle sharing in IVDUs, sharing toothbrushes or razors, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.3137%; height: 1.38889%;">blood transfusion. Transmission does not occur via kissing,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">coughing, or sneezing. Mother to child transmission occurs
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.1503%; height: 2.77778%;">mainly during birth or transplacentally (not via breast-
feeding).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 19.7712%; height: 1.38889%;">Incubation period: 2–3 months.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.4771%; height: 1.26263%;">Clinical findings: HBV disease has an acute and chronic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">form. 10% of children and 30–50% of adults present with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">symptoms of acute HBV infection similar to hepatitis A and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 2.77778%;">last several weeks: fatigue, abdominal pain, nausea, vomit-
ing, myalgia, jaundice, dark urine, and light stools. Fever is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">often absent and arthritis and rash may be present. Chronic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">disease evolves to cirrhosis or hepatocellular carcinoma and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 41.5033%; height: 1.38889%;">eventually death. 90% of infants who are infected in their first
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.3137%; height: 1.38889%;">year develop chronic infection. Only 10% of adults who
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">acquire infection develop chronic disease, as the majority
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 1.13636%;">is able to clear HBV within 6 months. Differences in disease
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 2.65152%;">severity, risk of liver cirrhosis and development of hepato-
cellular carcinoma are seen by age of infection, level of viral
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.3137%; height: 1.38889%;">replication, level of inflammation, region and HBV genotype.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.4771%; height: 1.13636%;">Also co-infection with HDV leads to more severe chronic liver
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 4.73856%; height: 1.13636%;">disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 34.3137%; height: 1.26263%;">Diagnostic tests: Serologic tests to assess active infection:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.2727%; width: 34.3137%; height: 1.38889%;">HBsAg, HBeAg; HBV DNA can be detected in blood by PCR;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 78.6616%; width: 22.3856%; height: 1.38889%;">quantitative PCR to monitor treatment.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">Therapy: Supportive for acute hepatitis B. Interferon-alpha
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">and reverse transcriptase inhibitors for chronic hepatitis B.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.3137%; height: 1.38889%;">Treatment response, particularly interferon treatment, differs
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.4771%; height: 1.38889%;">by HBV genotype. Treatment is expensive and often not
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">available in developing countries. In SoutheastAsia,medicinal
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">herbs are widely used to treat chronic HBV disease, of which
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">the efficacy is yet unclear. Liver transplant is possible for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 14.5425%; height: 1.38889%;">decompensated cirrhosis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 28.9141%; width: 34.1503%; height: 1.13636%;">Prevention: WHO recommends vaccination of all newborns.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">In countries where prevalence is low: HBV vaccination of risk
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">groups and those living in endemic communities; safe sexual
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">practices; screening of blood products; universal precautions
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 33.9869%; height: 2.65152%;">when caring for patients; infection control. Vaccine and immu-
noglobulins as PEP within 24 hours of exposure.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 38.2576%; width: 34.3137%; height: 1.38889%;">Epidemiology: Hepatitis B is a common disease world wide,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">despite the existence of a vaccine. The WHO estimates that
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">globally 2 billion individuals have been infected, of which
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">about 360 million have chronic disease. Yearly, it is estimated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.26263%;">that there are 500,000 to 700,000 HBV associated deaths world
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">wide. In high-endemic regions like Southeast Asia, Africa, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">the Amazon basin, most individuals become infected during
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">childhood (mother-to-child, or child-to-child). In developed
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 4.0404%;">regions, the prevalence is low and important routes of trans-
mission are different, consisting mostly of unsafe sexual prac-
tices, IVDU, and occupational transmission in healthcare
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 2.65152%;">workers. Chronic HBV associated liver cirrhosis is more com-
mon in developed nations than in Southeast Asia, but the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">incidence of hepatocellular carcinoma is lower compared to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">Southeast Asia. It is not yet fully clear whether this is due to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 27.451%; height: 1.38889%;">differences in HBV genotype or age of infection.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 61.2374%; width: 34.3137%; height: 1.26263%;">Map sources: The Hepatitis B Virus map is redrawn from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 62.5%; width: 34.4771%; height: 1.38889%;">World Health Organization report (2001) and A. Kramvis et al
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 63.8889%; width: 3.92157%; height: 1.26263%;">(2005).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 66.6667%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 67.9293%; width: 36.2745%; height: 1.38889%;">Kramvis A, et al. (2005) Hepatitis B virus genotypes. Vaccine
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.3182%; width: 8.00654%; height: 1.0101%;">23:2409–2423.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">Liaw YF, et al. (2010) The natural history of chronic HBV
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 33.1699%; height: 1.38889%;">infection and geographical differences. Antivir Ther
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.2323%; width: 7.51634%; height: 1.38889%;">15(S3):25–33.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 74.6212%; width: 34.4771%; height: 1.38889%;">Palumbo E (2007) Hepatitis B genotypes and response to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 75.8838%; width: 35.1307%; height: 1.38889%;">antiviral therapy: a review. Am J Therap 14:306–309.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 77.2727%; width: 34.4771%; height: 1.38889%;">World Health Organization (2001) Introduction of Hepatitis B
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 78.6616%; width: 33.0065%; height: 1.38889%;">Vaccine into Childhood Immunization Services. Report WHO/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 80.0505%; width: 11.9281%; height: 1.13636%;">V&amp;B/01.31. Geneva.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 54.5752%; height: 1.26263%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 84.2172%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">219
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/e8e379de-0c07-46b7-a54e-c5e402c2b48a" class="aLF-aPX-aPF-aPE-J3" alt="Page 86 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.who.int/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.who.int/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.who.int/&amp;ust=1666162860000000&amp;usg=AOvVaw0Tifat_sRQaV_yADiVUjyq&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 78.1046%; top: 55.8081%; width: 8.66013%; height: 1.26263%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 87 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 30.5556%; height: 2.39899%;">Disease: Hepatitis C
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 30.2288%; height: 1.26263%;">Classification: ICD-9 070.5; ICD-10 B17.1 and B18.2.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">Syndromes and synonyms: Non-A non-B hepatitis, HCV
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 5.55556%; height: 1.13636%;">infection.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">Agent: Hepatitis C virus (HCV) is an enveloped RNA virus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">(hepacavirus) and belongs to theflaviviruses. The HCV genome
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">is highly mutable. There are at least six HCV genotypes and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.3137%; height: 1.38889%;">several subtypes with differences in clinical presentation,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">geographic distribution and treatment response. HCV was
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 34.4771%; height: 1.13636%;">discovered in 1989 as another cause of transfusion associated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 19.1176%; height: 1.38889%;">hepatitis (non-A non-B hepatitis).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 14.5425%; height: 1.0101%;">Reservoir: Humans.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.4771%; height: 3.78788%;">Transmission: Person-to-person transmission occurs paren-
tally (blood to blood). Mother to child transmission or trans-
mission via sexual contact is rare. Mother to child transmission
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 26.7974%; height: 1.13636%;">increases if the mother is co-infected with HIV.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">Incubation period: Usually 6 to 9 weeks; range from 2 weeks
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 7.35294%; height: 1.0101%;">to 6 months.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">Clinical findings: Majority will be asymptomatic in the acute
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.3137%; height: 1.38889%;">phase, but approximately 80% develops chronic HCV disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">Acute disease: insidious onset with right upper quadrant pain,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.3137%; height: 2.77778%;">fatigue, nausea, malaise and vomiting; some progress to jaun-
dice and dark urine. Most infected cases (approx. 80%) develop
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 2.77778%;">chronic disease with fatigue as main symptom; 20–30% even-
tually develop severe liver disease: cirrhosis and liver cancer
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">(may take 20 years and is dependent on the presence of other
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">risk factors). HCV infection is an important cause for liver
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">transplantation in developed countries. There is accelerated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.4771%; height: 2.65152%;">progression of hepatic fibrosis and increased risk of hepato-
cellular carcinoma in: men, elderly, obese, alcoholics, those
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 21.8954%; height: 1.38889%;">infected with HIV or hepatitis B virus.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Serology (EIA, recombinant immunoblot
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">assay (RIBA)); RT-PCR on plasma; quanititative RT-PCR to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">monitor treatment; genotyping; liver biopsy for histology to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 18.7909%; height: 1.38889%;">assess disease stage and activity.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 34.3137%; height: 1.38889%;">Therapy: Ribavirin in combination with peg-interferon.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.4771%; height: 1.38889%;">Response to interferon differs by HCV genotype: there is a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">more sustained virological response in HCV genotype 2 and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 2.65152%;">3 infections, as compared to HCV genotype1 and 4. The peg-
interferon and ribavarin response can be improved by the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.4771%; height: 1.38889%;">combination with oral DNA-polymerase and protease
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 6.04575%; height: 1.13636%;">inhibitors.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 34.4771%; height: 2.65152%;">Prevention: Infection control hospitals; safe injection prac-
tices by healthcare providers; screening of blood products;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.3137%; height: 1.38889%;">clean needle programs. HCV immunoglobulin is not effective.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 11.4379%; height: 1.13636%;">There is no vaccine.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 31.5657%; width: 34.3137%; height: 1.38889%;">Epidemiology: HCV infection has a worldwide prevalence of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.3137%; height: 1.38889%;">2% and an estimated 130 to 170 million chronic cases globally.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">The highest prevalences are found in Africa and Asia. Egypt
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">has the highest HCV prevalence rate (22%), likely due to a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">national schistosomiasis treatment campaign since the 1960s
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 2.77778%;">that re-used needles. In developing countries the high preva-
lence is likely due to poor infection control practices in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.3137%; height: 1.38889%;">healthcare system (therapeutic injections, blood transfusion,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 2.77778%;">surgery). Also local practices in the community, like acupunc-
ture and cutting of the skin with unsterile knives, are other
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">important routes of transmission. In Asia it is common to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">receive injections for various illnesses outside the hospital
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">setting. In developed countries HCV is mainly transmitted
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 29.7386%; height: 1.38889%;">by IVDU, accounting for 70–80% of HCV infections.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 51.7677%; width: 34.3137%; height: 1.38889%;">Map sources: The Hepatitis C Virus map was made with data
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">obtained from WHO: the prevalence map was redrawn from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">a map by the World Health Organization (2002); and the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 34.3137%; height: 1.38889%;">genotype datawas obtained fromWHO (2009) (www.who.int/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 26.7974%; height: 1.38889%;">vaccine_research/documents/ViralCancer7.pdf)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 59.8485%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">Khattab MA, et al. (2010) Management of hepatitis C virus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 62.5%; width: 33.1699%; height: 1.38889%;">genotype 4: Recommendations of an international expert
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 63.8889%; width: 18.3007%; height: 1.38889%;">panel. J Hepatol 54(6):1250–1262.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">Munir S, et al. (2010) Hepatitis C treatment: current and future
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 66.5404%; width: 19.4444%; height: 1.38889%;">perspectives. Virol J 7:296.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">Shepard CW, et al. (2005) Global epidemiology of Hepatitis C
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.1919%; width: 27.6144%; height: 1.38889%;">virus infection. Lancet Infect Dis 5:558–567.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.5808%; width: 34.6405%; height: 1.38889%;">World Health Organization (2002) Hepatitis C. Guide WHO/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 16.6667%; height: 1.26263%;">CDS/CSR/LYO/2003. Geneva.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 73.2323%; width: 34.3137%; height: 1.38889%;">World Health Organization (2002) Map: Hepatitis C, 2001.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 74.6212%; width: 21.732%; height: 1.38889%;">Weekly Epid Rep 6(77):47.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">221
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/77a19033-14cb-4b3e-bc96-a300ec8185dd" class="aLF-aPX-aPF-aPE-J3" alt="Page 87 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.cdc" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.cdc" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.cdc&amp;ust=1666162860000000&amp;usg=AOvVaw0kjlhtRyqo6UyyOH-BKeVU&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 80.5556%; top: 55.8081%; width: 6.04575%; height: 1.13636%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 88 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 30.2288%; height: 2.39899%;">Disease: Hepatitis E
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.3464%; height: 1.26263%;">Classification: ICD-9 070.5; ICD-10 B17.2.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">Syndromes and synonyms: Epidemic non-A non-B hepatitis,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 33.9869%; height: 2.77778%;">fecal–oral non-A non-B hepatitis, enterically transmitted non-
A non-B hepatitis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 2.65152%;">Agent: Hepatitis E virus (HEV), a non-enveloped single-
stranded RNA virus, genus Hepevirus, the single member in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">the Hepeviridae family. The virus can be classified into four
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.4771%; height: 2.65152%;">genotypes (genotype HEV-1 to HEV-4), and &gt; 24 subgeno-
types (1a–1e, 2a–2b, 3a–3j, and 4a–4g). Avian isolates of HEV
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.4771%; height: 2.77778%;">are now considered to be a separate genus. HEV was discov-
ered in the 1980s as a result of a large water-borne non-A non-B
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 28.9216%; height: 1.26263%;">hepatitis outbreak in India between 1978 and 1979.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.4771%; height: 1.13636%;">Reservoir: Humans are the natural host. Numerous mammals
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">have serologic evidence of HEV disease, including but not
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.3137%; height: 1.38889%;">limited to: pigs, cattle, sheep, goats, horses, macaques, cats,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">dogs, rabbits, mongoose, deer, wild boar, rats, and mice. HEV
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.4771%; height: 1.38889%;">in pigs is asymptomatic, but there is transient viremia and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 22.7124%; height: 1.13636%;">excretion of virus into the environment.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 2.65152%;">Transmission: Fecal–oral route, mainly via fecally contami-
nated water, but also via: food, materno-fetal, and transfusion
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 44.7712%; height: 5.42929%;">of blood products. Direct person-to-person transmission is uncommon. Cycle: Human to human and occasionally animal to human.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 1.13636%;">HEV is excreted from the liver into the stool via the bile and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">eventually into the environment. The amount of infectious
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">virus in the stool is relatively low and explains a lower rate of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">transmission as compared to hepatitis A (see Hepatitis A
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 3.75817%; height: 1.38889%;">map).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.3137%; height: 1.38889%;">Incubation period: On average 40 days (range: 2 to 10 weeks).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.4771%; height: 2.77778%;">Clinical findings: The disease is self-limiting and acute symp-
toms are similar to acute hepatitis A disease. Children are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">generally asymptomatic or have mild disease. Clinical evident
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">disease is more common in age group 15–44 years, with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 2.77778%;">following symptoms: fatigue, fever, nausea, vomiting, abdom-
inal pain, jaundice, dark urine, and light stool. Pregnant
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 34.4771%; height: 1.38889%;">women are at risk for severe disease, including fulminant
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.3137%; height: 1.38889%;">hepatitis and death. In immunocompromised persons (e.g.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">transplant recipients or users of immune-modulating therapy)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 20.4248%; height: 1.38889%;">chronic infection has been reported.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 22.2222%; width: 34.3137%; height: 1.38889%;">Diagnostic tests: Serology (HEV IgM, IgG); HEV RNA
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 23.0392%; height: 1.38889%;">detection in blood and stool by RT-PCR.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.2626%; width: 13.8889%; height: 1.26263%;">Therapy: Supportive.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 28.9141%; width: 34.3137%; height: 1.38889%;">Prevention: Hygiene; access to clean water; sanitation (see
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">Water and Sanitation map). A vaccine has been developed and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 23.2026%; height: 1.38889%;">proven effective, but is not yet available.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 34.3434%; width: 34.1503%; height: 1.26263%;">Epidemiology: HEV is more prevalent in areas with hot
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">climates and poor sanitation. Outbreaks are more common
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 2.65152%;">during heavy rainfall and flooding, which leads to fecal con-
tamination of the drinking water. Food-borne outbreaks also
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">occur, especially with contaminated shellfish. HEV genotypes
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">have their own geographic distribution. HEV-1 is common in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">high endemic areas of Asia and Africa. HEV-2 can be found in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.13636%;">Mexico andWest Africa. HEV-3 has been found in rare cases in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">the USA and several developed countries in Europe, Japan,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">Australia, New Zealand, Korea, and Argentina. HEV-4 causes
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">sporadic human cases in Southeast Asia and Japan. HEV-3 and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">HEV-4 are also reported in pigs on all continents, causing
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 16.1765%; height: 1.38889%;">sporadic disease in humans.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 53.1566%; width: 34.1503%; height: 1.38889%;">Map sources: The Hepatitis E map is redrawn from R.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.3137%; height: 2.77778%;">Aggarwal et al. (2009). The data on levels of HEV endemic-
ity was obtained from CDC (2009), available at: www.cdc.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 12.2549%; height: 1.38889%;">gov/hepatitis/HEV.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 59.8485%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">Aggarwal R, et al. (2009) Epidemiology of Hepatitis E: current
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 62.5%; width: 25.817%; height: 1.38889%;">status. J Gastroenterol Hepatol 24(9):1484–1493.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">Aggarwal R (2011) Hepatitis E: Historical, contemporary
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 65.1515%; width: 37.2549%; height: 1.38889%;">and future perspective. J Gastroenterol Hepatol 26
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 66.5404%; width: 9.96732%; height: 1.38889%;">(Suppl. 1): 72–82.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">Mushahwar IK (2008) Hepatitis E virus: molecular virology,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.1919%; width: 33.1699%; height: 1.38889%;">clinical features, diagnosis, transmission, epidemiology,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.5808%; width: 24.0196%; height: 1.38889%;">and prevention. J Med Virol 80(4):646–658.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 71.9697%; width: 34.6405%; height: 1.38889%;">World Health Organization (2001) Hepatitis E. Guide WHO/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.2323%; width: 17.9739%; height: 1.26263%;">CDSCSR/EDC/2001.12. Geneva.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">223
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/2861ac50-380d-4290-820c-d45e7e488a0a" class="aLF-aPX-aPF-aPE-J3" alt="Page 88 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 89 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 62.4183%; height: 2.39899%;">Disease: Human Immunodeficiency Virus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 26.1438%; height: 1.26263%;">Classification: ICD-9 042-044; ICD-10 B20-24
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.4771%; height: 1.26263%;">Syndromes and synonyms: VIH, SIDA, slim disease,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 26.7974%; height: 1.38889%;">acquired immune deficiency syndrome (AIDS).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">Agent: Human Immunodeficiency Virus (HIV), an enveloped
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 2.65152%;">single-stranded RNA virus of the Lentivirus genus and Retro-
viridae family, is divided into two main species HIV-1 and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.4771%; height: 1.13636%;">HIV-2. HIV-1 is more infectious and more virulent than HIV-2
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">and predominates globally, with HIV-2 transmission
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 27.9412%; height: 1.38889%;">restricted to parts of Western and Central Africa.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 14.5425%; height: 1.13636%;">Reservoir: Humans.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.3137%; height: 2.77778%;">Transmission: HIV is transmitted through contact with HIV-
infected body fluids (blood, semen, and vaginal secretions)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">and is predominantly a sexually transmitted infection. Other
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">routes are: sharing contaminated needles; mother-to-child
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">transmission during pregnancy, childbirth and breastfeeding;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.4771%; height: 1.38889%;">blood or blood product transfusion; and organ or tissue
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 9.15033%; height: 1.38889%;">transplantation.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 1.26263%;">Incubation period: Around 50–70% of infected individuals
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">develop a self-limiting ‘primary’ HIV illness 1–12 weeks after
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">infection. Time from infection to development of clinically
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.3137%; height: 1.38889%;">apparent immunodeficiency ranges from less than 1 year to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 8.16994%; height: 1.38889%;">over 15 years.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 2.77778%;">Clinical findings: Primary HIV infection is usually a non-
specific illness with fever, headache, myalgia, fatigue, and a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 2.77778%;">sore throat. Generalized lymphadenopathy and a maculopap-
ular rash may occur. Following primary infection there is a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">prolonged asymptomatic period before the appearance of the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.4771%; height: 4.0404%;">clinical manifestations of a loss of immune control over infec-
tious pathogens and cancers. Common presenting AIDS-
defining illnesses are tuberculosis, atypical mycobacterial
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.3137%; height: 1.38889%;">infections, recurrent bacterial infections, Pneumocystis jirovecii
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 33.9869%; height: 2.77778%;">pneumonia, candidiasis, Kaposi sarcoma, lymphoma, crypto-
coccal meningitis, and CMV disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 4.0404%;">Diagnostic tests: Enzyme immunoassay to detect anti-
HIV antibodies with confirmation by Western blot. Fourth-
generation HIV serology tests that consist of antibody
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.4771%; height: 1.38889%;">detection and p24 antigen detection in combination are now
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 37.0915%; height: 1.26263%;">commonly used. Also rapid tests are available for field testing.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.2727%; width: 34.4771%; height: 1.38889%;">Viral load and HIV-1 p24 antigen may be used in some
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 78.6616%; width: 34.4771%; height: 1.13636%;">circumstances. CD4 cell counts and HIV viral load are used
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 80.0505%; width: 34.4771%; height: 1.26263%;">to monitor progression of infection. Genotypic and phenotypic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 81.3131%; width: 25.6536%; height: 1.38889%;">tests are used for HIVdrug-resistance testing.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.26263%;">Therapy: A combination of several ARVs is recommended,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.3137%; height: 1.38889%;">known as Highly Active Antiretroviral Therapy (HAART).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">Additional strategies include prophylaxis and vaccination
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.4771%; height: 1.38889%;">against opportunistic infections, general measures to maintain
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">nutrition and health, and treatment of specific infections or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 14.8693%; height: 1.13636%;">HIV-associated disorders.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 25.8838%; width: 34.4771%; height: 2.77778%;">Prevention: Reducing sexual transmission through the pro-
motion ofmonogamy, condom use, male circumcision, and the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.5354%; width: 34.4771%; height: 2.77778%;">detection and treatment of STIs; raising awareness of individ-
ual HIV status through voluntary counseling and testing;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.3131%; width: 34.4771%; height: 1.38889%;">protecting IVDUs through needle/syringe exchange and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.5758%; width: 34.4771%; height: 1.38889%;">methadone replacement programs; reducing mother to child
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 33.9646%; width: 34.4771%; height: 1.38889%;">transmission through voluntary counseling and testing and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.2273%; width: 13.2353%; height: 1.38889%;">the provision of ARVs.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 37.6263%; width: 34.3137%; height: 1.38889%;">Epidemiology: HIV was first recognized clinically in 1981. As
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.0152%; width: 34.4771%; height: 1.38889%;">of 2009, over 25 million people are estimated to have died from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 40.2778%; width: 31.5359%; height: 1.38889%;">HIV and around 33 million people are living with HIV.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.6667%; width: 34.8039%; height: 2.77778%;">HIV epidemics are categorized into ‘low-level’ (HIV preva-
lence &lt;1% in the general population and &lt;5% in vulnerable
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 44.3182%; width: 42.4837%; height: 2.77778%;">group such as MSM, injecting drug users, sex workers); ‘con- centrated’ (HIV prevalence &lt;1% in the general population but
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.7778%; top: 47.096%; width: 38.7255%; height: 1.38889%;">&gt; 5% in at least one vulnerable group); and ‘generalized’ (HIV
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 48.3586%; width: 34.4771%; height: 1.38889%;">prevalence &gt; 1% in the general population). The greatest
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.7475%; width: 34.4771%; height: 1.26263%;">burden of HIV continues to fall on Sub-Saharan Africa, with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.0101%; width: 34.4771%; height: 1.38889%;">68% of all people living with HIV and 72% of all HIV-related
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 52.399%; width: 34.4771%; height: 4.0404%;">deaths in 2009. The epidemic in Africa is, however, heteroge-
neous, with high-prevalence generalized epidemics in South-
ern African countries; generalized but moderate prevalence
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 56.4394%; width: 34.4771%; height: 1.38889%;">epidemics in Central, East and West Africa, and low-level
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.8283%; width: 33.9869%; height: 2.65152%;">epidemics in North Africa. No countries in Asia have a gener-
alized epidemic.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 60.4798%; width: 33.1699%; height: 1.38889%;">HIV-1 can be divided in four groups (M, O, N, and P). Over
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.8687%; width: 34.4771%; height: 1.38889%;">90% of HIV-1 infections are group M and the map opposite
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.2576%; width: 33.9869%; height: 2.65152%;">shows the distribution of the 9 subtypes (clades) and recom-
binants of the M group HIV-1 viruses.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.9192%; width: 34.3137%; height: 2.65152%;">Map sources: The Human Immunodeficiency Virus preva-
lence map was made with UNAIDS (2009) data. The HIV-1
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.5707%; width: 33.9869%; height: 2.65152%;">subtypes and recombinants map is reproduced from J. Heme-
laar et al. (2006).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 73.3586%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 74.6212%; width: 34.3137%; height: 1.38889%;">Joint United Nations Programme on HIV/AIDS (UNAIDS).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 75.8838%; width: 39.3791%; height: 2.52525%;">(2010) UNAIDS Report on the Global AIDS Epidemic 2010. ISBN 978-92-9173-871-7.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 78.6616%; width: 34.4771%; height: 1.38889%;">Hemelaar J, et al. (2006) Global and regional distribution of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 80.0505%; width: 35.7843%; height: 1.26263%;">HIV-1 genetic subtypes and recombinants in 2004. AIDS
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 81.3131%; width: 10.1307%; height: 1.38889%;">20(16):W13–W23.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 84.596%; width: 54.5752%; height: 1.26263%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 85.6061%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">225
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/5e2f20fa-49f9-4833-8436-212a2a6bf383" class="aLF-aPX-aPF-aPE-J3" alt="Page 89 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 90 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 59.8039%; height: 2.39899%;">Disease: Human T-Lymphotropic Virus 1
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 34.3137%; height: 1.26263%;">Classification: ICD-9 202; ICD-10 B97.33 (virus), C84.1
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 18.1818%; width: 33.9869%; height: 2.65152%;">Sezary disease, C84.5 Other and unspecified T-cell lympho-
mas, C91.4 Hairy cell leukemia, C91.5 ATL.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 34.3137%; height: 4.0404%;">Syndromes and synonyms: Adult T-cell leukemia/lym-
phoma (ATL), T-cell lymphosarcoma, peripheral T-cell lym-
phoma (Sezary disease), hairy cell leukemia, HTLV-associated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 33.9869%; height: 2.52525%;">myelopathy/tropical spastic paraparesis (HAM/TSP), HTLV-
associated uveitis and infective dermatitis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 34.3137%; height: 1.38889%;">Agent: Human T-lymphotropic virus 1 (HTLV-1), a type C
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">retrovirus with at least 6 subtypes. The virus was isolated for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.4771%; height: 2.65152%;">the first time in the USA in 1980, before HIV-1 (also a retrovi-
rus) was discovered in 1983. Genomically, simian
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">T-lymphotropic virus (STLV) isolates cluster closely with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.4771%; height: 1.38889%;">HTLV-1 in the same region, suggesting simian-to-human
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 19.9346%; height: 1.38889%;">transmission at multiple occasions.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 14.5425%; height: 1.13636%;">Reservoir: Human.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.3137%; height: 1.13636%;">Transmission: The virus can be transmitted from mother to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 2.65152%;">child through breast-milk; also through sexual contact, con-
taminated blood products, organ transplants, and shared
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 16.3399%; height: 1.38889%;">syringes during iv drug use.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.505%; width: 19.7712%; height: 1.26263%;">Incubation period: 20–30 years.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.4771%; height: 2.39899%;">Clinical findings: The most prevalent HTLV-1 clinical man-
ifestations can be divided into those associated with ATL
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.3137%; height: 4.0404%;">(immunosuppression) or associated with HAM/TSP (immu-
noactivation). The HTLV-1-infected individual who immuno-
logically tends to immunosuppression can develop
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 40.0327%; height: 2.52525%;">opportunistic infections such as Strongyloides stercoralis hyper-
infection, recurrent skin infections and ATL. The HTLV-1-
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.4771%; height: 1.13636%;">infected individual who tends to immunoactivation can
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">develop HTLV-associated uveitis, polymyositis, inclusion
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">body myositis, arthritis, pulmonary infiltrative pneumonitis,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 19.9346%; height: 1.38889%;">Sjogren syndrome and HAM/TSP.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.3137%; height: 1.38889%;">Diagnostic tests: Serological tests cross-react with HTLV-2,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.3137%; height: 1.38889%;">requiring positive ELISA to be confirmed by Western blot, IFA,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 26.4706%; height: 1.38889%;">or radioimmunoprecipitation (RIPA); RT-PCR.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.3137%; height: 1.38889%;">Therapy: Chemotherapy is ineffective for treating aggressive
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 34.3137%; height: 1.26263%;">forms of ATL. There is no satisfactory treatment for HAM/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.2727%; width: 34.4771%; height: 1.38889%;">TSP. Access to adequate counseling and correct information
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 78.6616%; width: 33.9869%; height: 2.65152%;">about HTLV is of fundamental importance for HTLV-1 sero-
positive individuals.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 16.7929%; width: 34.3137%; height: 1.38889%;">Prevention: Screening blood and blood products before use,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">bottle-feeding (20% of breast-fed infants of infected mothers
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">become infected), using condoms. Counseling and education
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 28.1046%; height: 1.38889%;">of IVDUs to implement harm reduction practices.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 2.52525%;">Epidemiology: Approximately 15 to 20 million people world-
wide are believed to be infected. In Africa all HTLV and STLV
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">subtypes are found, and phylogenetic research suggest that
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.3137%; height: 1.38889%;">HTLV-1 originated in Africa about 27,000 years ago. HTLV-1
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">infection is more common in women and the prevalence
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.3137%; height: 1.38889%;">increases with age, with a peak incidence around age 50.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">Among HTLV-1 carriers, the lifetime risk of developing
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">HAM/TSP ranges from between 0.3% and 4%. For ATL,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.0101%;">this risk is estimated to be 1% to 5% and for HTLV-1-associated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 2.77778%;">diseases in general, including ATL, HAM/TSP, uveitis, poly-
myositis and arthropathy, the lifetime risk may be close to 10%.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">Japan, Africa, Caribbean islands and South America are the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">areas of highest prevalence, but the reasons for this are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">unknown. Most infections world wide are due to subtype
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">HTLV-1a. Distribution of the infection is focal, e.g. Brazil,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">Japan, and Iran, where HTLV-1 is limited to certain areas of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">each country. On several Japanese islands the prevalence can
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">reach 37%. Socioeconomic or genetic factors may contribute to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">the development of HTLV-associated infective dermatitis,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">since the disease has not been reported in HTLV-1 epidemic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">Japan. For non-endemic areas such as Europe and North
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">America, HTLV-1 infection is mainly found in immigrants
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">from endemic areas, their offspring and sexual contacts,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 18.4641%; height: 1.38889%;">among sex workers and IVDUs.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 57.0707%; width: 34.1503%; height: 1.38889%;">Map source(s): The HTLV-1 map was made with data from D.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 34.3137%; height: 1.38889%;">U. Goncalves et al. (2010), S.A. Cooper et al. (2009), and F.A.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 11.6013%; height: 1.26263%;">Proietti et al. (2005).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 62.6263%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 34.3137%; height: 1.38889%;">Cooper SA, et al. (2009) The neurology of HTLV-1 infection.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 65.1515%; width: 13.8889%; height: 1.13636%;">Pract Neurol 9:16–26.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">Goncalves DU, et al. (2010) Epidemiology, treatment, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 67.9293%; width: 33.1699%; height: 1.38889%;">prevention of human T-cellleukemia virus type 1-associated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.1919%; width: 27.9412%; height: 1.38889%;">diseases. Clin Microbiol Rev 23(3):577–589.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">Proietti FA, et al. (2005) Global epidemiology of HTLV-I
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 34.6405%; height: 1.38889%;">infection and associated diseases. Oncogene 24:6058–6068.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 73.2323%; width: 34.4771%; height: 1.38889%;">Verdonck K, et al. (2007) Human T-lymphotropic virus 1:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 74.6212%; width: 33.3333%; height: 1.38889%;">recent knowledge about an ancient infection. Lancet Inf
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 76.0101%; width: 11.7647%; height: 1.0101%;">Dis 7:266–281.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 54.5752%; height: 1.26263%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 84.2172%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">227
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/d71cdccd-40c9-476c-b317-dd147ac997ef" class="aLF-aPX-aPF-aPE-J3" alt="Page 90 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.cdc.gov/mmwr/preview/mmwrhtml/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.cdc.gov/mmwr/preview/mmwrhtml/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.cdc.gov/mmwr/preview/mmwrhtml/&amp;ust=1666162860000000&amp;usg=AOvVaw0A9Trb-XMWzWckPEBAg1aD&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 55.3922%; top: 51.0101%; width: 31.3726%; height: 1.38889%;"></a><a href="http://www.cdc.gov/ncidod/dvbid/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.cdc.gov/ncidod/dvbid/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.cdc.gov/ncidod/dvbid/&amp;ust=1666162860000000&amp;usg=AOvVaw0yrTd0vg584PRvaR5bLWNl&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 65.3595%; top: 55.1768%; width: 21.4052%; height: 1.26263%;"></a><a href="http://gamapserver.who.int/mapLibrary/Files/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://gamapserver.who.int/mapLibrary/Files/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://gamapserver.who.int/mapLibrary/Files/&amp;ust=1666162860000000&amp;usg=AOvVaw1DkH20nc_aDlaBBqEUMqRU&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 58.9869%; top: 57.8283%; width: 27.7778%; height: 1.38889%;"></a><a href="http://wwwnc.cdc.gov/travel/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://wwwnc.cdc.gov/travel/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://wwwnc.cdc.gov/travel/&amp;ust=1666162860000000&amp;usg=AOvVaw3m_nCXCrJ-naKzN0qyT4kG&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 68.4641%; top: 69.9495%; width: 18.3007%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 91 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 47.7124%; height: 2.39899%;">Disease: Japanese Encephalitis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.3464%; height: 1.26263%;">Classification: ICD-9 062.0; ICD-10 A83.0
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 30.3922%; height: 1.38889%;">Syndromes and synonyms: Japanese B encephalitis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 38.2353%; height: 2.65152%;">Agent: Japanese encephalitis virus (JEV), an enveloped, sin-
gle-stranded, positive sense RNA flavivirus. It is divided into
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">five antigenic groups and four genotypes, whichmay belinked
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 15.1961%; height: 1.13636%;">to differences in virulence.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">Reservoir: Wading birds (Ardeidae) and domestic pigs which
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 33.9869%; height: 2.77778%;">amplify the virus asymptomatically; mosquitoes by transovar-
ial transmission and possibly overwintering adults.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 35.4575%; height: 1.26263%;">Vector: Mosquito species that breedin rice fields and marshes,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 48.0392%; height: 1.38889%;">principally Culex tritaenorhynchus group; also C. gelidus and C.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 19.1176%; height: 4.0404%;">vishnui. Transmission: By mosquito bite.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.5505%; width: 34.4771%; height: 1.38889%;">Cycle: Only ardeid birds and pigs have a sufficient viremia
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.9394%; width: 34.4771%; height: 1.38889%;">to infect mosquitoes. The mosquito picks up the virus from the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.202%; width: 34.4771%; height: 1.38889%;">blood of a viremic host. After a few days, the virus reaches the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.5909%; width: 34.3137%; height: 1.38889%;">salivary glands and is injected into the next host when bitten.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.9798%; width: 34.4771%; height: 1.13636%;">Humans are incidental and dead-end hosts as viremia does not
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.2424%; width: 24.3464%; height: 1.38889%;">reach sufficient levels to infect mosquitoes.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 52.0202%; width: 19.7712%; height: 1.38889%;">Incubation period: 6–16 days.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.9242%; width: 34.4771%; height: 1.38889%;">Clinical findings: High fever with headache, chills, neck
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 56.3131%; width: 34.4771%; height: 1.26263%;">stiffness, anorexia, nausea, and vomiting developing into
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.5758%; width: 34.4771%; height: 1.38889%;">aseptic meningitis or encephalitis with disorientation, coma,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.9646%; width: 34.4771%; height: 1.38889%;">seizures, spastic paralysis, drowsiness, and stupor. Death
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 60.2273%; width: 34.4771%; height: 1.38889%;">occurs from respiratory complications or seizures. The case
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.6162%; width: 34.4771%; height: 1.38889%;">fatality rate is around 20%, but can be as high as 60%; 30% of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.005%; width: 34.4771%; height: 1.38889%;">those who survive suffer lasting damage to the central nervous
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 64.3939%; width: 4.57516%; height: 1.26263%;">system.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.1717%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Serology: IgM capture ELISA on serum or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 68.5606%; width: 34.4771%; height: 1.38889%;">CSF; antibodies can be detected in CSF after 4 days of disease
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.9495%; width: 34.4771%; height: 1.38889%;">onset, and in serum after 7 days. Virus isolation or viral RNA
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.2121%; width: 20.915%; height: 1.38889%;">detection by RT-PCR are insensitive.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.9899%; width: 29.4118%; height: 1.38889%;">Therapy: Supportive, there is no specific treatment.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.6414%; width: 42.4837%; height: 2.77778%;">Prevention: Various vaccines are available; personal anti-
mosquito precautions; intermittent irrigation of rice fields
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">disrupts vector breeding; vaccination of pigs reduces
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 8.00654%; height: 1.38889%;">amplification.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 20.8333%; width: 34.3137%; height: 1.38889%;">Epidemiology: JEV is the leading cause of viral encephalitis in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.3137%; height: 1.38889%;">Asia: 35,000 to 50,000 cases are reported annually but this
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">believed to be a significant underestimate of the true disease
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">burden. 20–30% die and 30–50% of survivors have neurologic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">or psychiatric sequelae. It is epidemic in temperate parts
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">of Asia, linked to the seasonal occurrence of mosquitoes,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 2.65152%;">and endemic in tropical regions of Asia due to the year-
round mosquito activity. Intensification and expansion of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">irrigated rice production systems in South and Southeast
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">Asia over the past 20 years have had an important impact
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">on the disease burden caused by Japanese encephalitis, since
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">the vectors breed in rice fields. The vectors prefer non-human
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">hosts, but do feed on humans in periods of peak activity. The
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">disease is mainly seen in children under the age of 15 and the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">elderly, since most adults are immune from earlier infection;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">peak age is 3–5 years. The range of JE virus has recently
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">expanded into the Torres Strait of northern Australia, but
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 25.1634%; height: 1.13636%;">the disease is rare in western Pacific islands.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 46.3384%; width: 34.3137%; height: 1.38889%;">Map sources: The Japanese Encephalitis map was made with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 3.40909%;">the following sources: • CDC Approximate geographic range of Japanese encephalitis,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.5948%; top: 51.0101%; width: 33.1699%; height: 1.38889%;">at http://www.cdc.gov/mmwr/preview/mmwrhtml/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 52.399%; width: 34.4771%; height: 2.77778%;">rr5901a1.htm#fig2 (accessed on 30/10/2010). • CDC (2010) Risk of Japanese Encephalitis by country, region
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.5948%; top: 55.1768%; width: 33.1699%; height: 1.26263%;">and season, at http://www.cdc.gov/ncidod/dvbid/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 56.4394%; width: 37.2549%; height: 2.77778%;">jencephalitis/risk-table.htm (accessed on 02/1/2010). • WHO at http://gamapserver.who.int/mapLibrary/Files/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.5948%; top: 59.2172%; width: 33.1699%; height: 1.26263%;">Maps/Global_JE_ITHRiskMap.png (accessed on 26/08/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.5948%; top: 60.4798%; width: 3.59477%; height: 1.38889%;">2010).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 63.2576%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 64.5202%; width: 34.3137%; height: 1.38889%;">Barrett ADT (2001) Japanese encephalitis. In Service MW (ed.),
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 65.9091%; width: 33.1699%; height: 1.38889%;">The Encyclopedia of Arthropod-transmitted Infections, CAB
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 67.1717%; width: 15.1961%; height: 1.38889%;">International, pp. 239–246.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 68.5606%; width: 37.5817%; height: 1.38889%;">Center for Disease Control and Prevention (2012) Japanese
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.9495%; width: 33.0065%; height: 1.38889%;">Encephalitis. Yellow Book. http://wwwnc.cdc.gov/travel/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.2121%; width: 10.9477%; height: 1.38889%;">yellowbook/2012/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 72.601%; width: 34.8039%; height: 1.38889%;">Mackenzie JS, et al. (2004) Emerging flaviviruses: the spread
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.9899%; width: 33.1699%; height: 1.38889%;">and resurgence of Japanese encephalitis, West Nile and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 75.2525%; width: 26.634%; height: 1.38889%;">dengue viruses. Nat Med 10:S98–S109.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 14.8693%; top: 83.8384%; width: 54.7386%; height: 1.26263%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 84.8485%; width: 40.5229%; height: 1.38889%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">229
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/22c26d60-2775-4db2-9e9a-93dbe1d2cecc" class="aLF-aPX-aPF-aPE-J3" alt="Page 91 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 92 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 31.3726%; height: 2.0202%;">Disease: Lassa Fever
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.3464%; height: 1.26263%;">Classification: ICD-9 078.8; ICD-10 A96.2
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.5707%; width: 15.1961%; height: 1.13636%;">Synonyms: None.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 38.7255%; height: 2.65152%;">Agent: Lassa fever virus (LFV), a spherical, enveloped, bi-
segmented negative strand RNA virus of the genus Arenavirus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 15.5229%; height: 1.38889%;">in the family Arenaviridae.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 40.6863%; height: 2.77778%;">Reservoir: The multi-mammate rat (Mastomys natalensis), which lives in houses and surrounding fields. Previous studies
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 35.6209%; height: 1.38889%;">that identified M. erythroleucus and M. huberti as reservoirs
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 36.6013%; height: 1.38889%;">may have confused the species. M. natalensis is generally
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 16.9935%; height: 1.13636%;">absent in coastal West Africa.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 12.9085%; height: 1.13636%;">Vector: None.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.3137%; height: 1.38889%;">Transmission: By inhalation of aerosolized excreta of the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.4771%; height: 2.77778%;">rodent host, or contact with food or household items contami-
nated with rodent excreta. Nosocomial transmission is regular
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 18.4641%; height: 1.38889%;">in resource-constrained settings.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.26263%;">Cycle: Rodent–rodent, with humans as accidental dead-end
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.3137%; height: 1.38889%;">hosts. Infected reservoir hosts are asymptomatic and excrete
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 16.1765%; height: 1.13636%;">infectious virus in the urine.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 28.4314%; height: 1.38889%;">Incubation period: 6–21 days, usually 7–12 days.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.3137%; height: 1.26263%;">Clinical findings: Gradual onset, malaise, fever, headache,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.3137%; height: 1.38889%;">sore throat, cough, nausea, vomiting, diarrhea, myalgia, chest,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">and abdominal pain; inflammation and exudation of the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 2.77778%;">pharynx and conjunctivae are common. Progression to multi-
system disease occurs in 20% of infections, with hypotension
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 2.65152%;">or shock, hemorrhage, pleural effusion, seizures, encephalop-
athy and edema of the face and neck. Transient alopecia,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.4771%; height: 1.38889%;">ataxia, and eighth cranial nerve deafness may follow; deafness
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">may be permanent. In third-trimester pregnant patients, 80%
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.4771%; height: 1.13636%;">have a fatal outcome and 95% of the fetuses abort. The overall
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.3137%; height: 1.38889%;">CFR is 1%, but 15–20% in more severe, hospitalized patients.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: IgM ELISA, RT-PCR, virus isolation from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">blood, urine, or throat washing, seroconversion to IgG
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 5.06536%; height: 1.38889%;">positive.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.4771%; height: 1.38889%;">Therapy: Supportive care; ribavirin iv is effective if given
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 32.6797%; height: 1.26263%;">within the first 6 days after infection. There is no vaccine.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 2.77778%;">Prevention: Rodent control in and around dwellings; infec-
tion control in hospitals, with barrier nursing and precautions
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 29.4118%; height: 1.38889%;">to avoid contact with body fluids.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 22.2222%; width: 34.3137%; height: 1.38889%;">Epidemiology: LFV was isolated from a missionary nurse
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">living in Lassa, Nigeria, in 1969. It is estimated there are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">200,000 to 300,000 symptomatic Lassa fever cases in West
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 34.3137%; height: 1.38889%;">Africa each year, with an associated mortality of 5,000 to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 27.5253%; width: 34.3137%; height: 1.38889%;">10,000. Lassa fever occurs in two geographically distinct
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">regions: the Mano River region (Guinea, Sierra Leone, Liberia)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">in the West, and Nigeria in the East. In the dry season, the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">multi-mammate rat gathers in houses, and in the rainy season,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">the rat forages in the surrounding fields. Villages with Lassa
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.0101%;">fever are all located in rain forest areas or transition zones of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.26263%;">rainforest to savannah, where the mean annual rainfall is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.26263%;">above 1,500 mm and below 3,000 mm. LFV can be transmitted
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.3137%; height: 1.38889%;">from rodents to humans both in the rainy and the dry season.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">However, in the dry season there may be an increased risk for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 30.8824%; height: 1.38889%;">humans due to aggregation of the rats in their houses.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 2.77778%;">Map Source: The Lassa Fever map is modified from Fichet-
Calvet and Rogers (2009), with permission. Positive localities
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">recorded from 1965 to 2007, corresponds to confirmed Lassa
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">cases or studies demonstrating a seroprevalence superior to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 49.1162%; width: 2.94118%; height: 1.13636%;">10%.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 51.7677%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.26263%;">Fichet-Calvet E, et al. (2007) Fluctuation of abundance and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 54.4192%; width: 36.2745%; height: 1.38889%;">Lassa virus prevalence in Mastomys natalensis in Guinea,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 55.8081%; width: 31.2092%; height: 1.26263%;">West Africa. Vector Borne Zoonotic Dis 7(2):119–128.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">Fichet-Calvet E and Rogers D (2009) Risk maps of Lassa fever
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 58.4596%; width: 29.4118%; height: 1.38889%;">in West Africa. PLoS Negl Trop Dis 3(3):e388.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 34.4771%; height: 1.26263%;">Frame JD, et al. (1970) Lassa fever, a new virus disease of man
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 61.1111%; width: 34.1503%; height: 1.38889%;">from West Africa. Am J Trop Med Hyg 19:670–676.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 62.5%; width: 34.4771%; height: 1.38889%;">Gunther S, et al. (2004) Lassa virus. Crit Rev Clin Lab Sci
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 63.8889%; width: 6.69935%; height: 1.13636%;">41:339–390.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 34.6405%; height: 1.38889%;">Lecompte E, et al. (2006) Mastomys natalensis and Lassa fever,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 66.5404%; width: 26.634%; height: 1.38889%;">West Africa. Emerg Infect Dis 12(12):1971–1974.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 67.9293%; width: 34.4771%; height: 1.26263%;">McCormick JB (1999) Lassa fever. In Saluzzo JF and Dodet B
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.1919%; width: 39.3791%; height: 2.77778%;">(eds.), Emergence and Control of Rodent-Borne Viral Diseases. Elsevier, pp. 177–195.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 71.9697%; width: 50.4902%; height: 1.38889%;">Monath TP, et al. (1974) Lassa virus isolation from Mastomys
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.2323%; width: 33.0065%; height: 1.38889%;">natalensis rodents during an epidemic in Sierra Leone.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 74.6212%; width: 13.8889%; height: 1.13636%;">Science 185:263–265.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">231
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/3497ab2a-f9b1-466c-bc1e-ea11899ef5a2" class="aLF-aPX-aPF-aPE-J3" alt="Page 92 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 93 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 34.3137%; height: 2.39899%;">Disease: Mayaro Fever
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.3464%; height: 1.26263%;">Classification: ICD-9 066.3; ICD-10 A92.8
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 24.8366%; height: 1.26263%;">Syndromes and synonyms: Uruma fever.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">Agent: Mayaro virus (MAYV), an enveloped, single-stranded,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 35.7843%; height: 1.38889%;">positive sense RNA virus, genus Alphavirus in the family
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 33.8235%; height: 1.38889%;">Togaviridae, belonging to the Semliki Forest virus complex.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">Reservoir: Probably non-human primates; the virus has been
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">isolated from monkeys in Panama and French Guiana, also in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">the USA from a north-bound migratory bird. Antibody has
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 31.0458%; height: 1.13636%;">been found in domestic animals and other vertebrates.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 42.4837%; height: 2.65152%;">Vector: Mosquitoes, principally canopy-dwelling Haemago-
gus and Sabethes spp. The virus has also been isolated from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 30.3922%; height: 1.38889%;">Psorophora, Mansonia and Culex spp.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.3137%; height: 1.38889%;">Transmission: By mosquito bite. Airborne transmission has
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 24.8366%; height: 1.38889%;">been reported among laboratory personnel.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">Cycle: The mosquito becomes infected with MAYV during
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">feeding on a viremic host. The virus crosses the gut wall and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">multiplies in the organs of the mosquito. After a few days,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">depending on the ambient temperature, the virus reaches the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">salivary glands and is injected into the next host during
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 4.90196%; height: 1.38889%;">feeding.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 21.2418%; height: 1.38889%;">Incubation period: Approx. 1 week.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.3137%; height: 1.38889%;">Clinical findings: Dengue-like acute febrile illness with chills,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">headache, retro-orbital pain, myalgia and severe arthralgia of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">the small joints of the hands and feet, sometimes nausea,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">vomiting and diarrhea, painful lymphadenopathies and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">often a maculopapular rash. Arthralgias may persist for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 25.817%; height: 1.26263%;">months, but no fatalities have been recorded.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 16.7929%; width: 34.3137%; height: 1.38889%;">Diagnostic tests: IgM ELISA; IgG cross-reacts with other
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">alphaviruses. Confirmation needed by neutralization test,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">virus isolation, or a significant rise in specific antibody
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 32.6797%; height: 1.38889%;">between acute and convalescent serum samples; RT-PCR.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 13.8889%; height: 1.38889%;">Therapy: Supportive.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 26.1364%; width: 34.3137%; height: 1.38889%;">Prevention: Since the virus has a jungle cycle, environmental
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 33.9869%; height: 2.77778%;">insecticide spraying is not feasible; routine personal anti-mos-
quito measures are indicated.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 2.77778%;">Epidemiology: MAYV is enzootic in the humid tropical rain-
forests of South America. Infections peak in the rainy season
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">when the mosquito vectors are most abundant. Most human
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">cases occur sporadically and involve persons who work or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">reside in humid tropical forest; several small outbreaks of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 2.77778%;">Mayaro fever have been described in residents of rural com-
munities of the Amazon region of Brazil, Bolivia, and Peru.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 2.39899%;">Travelers have imported MAYV from Surinam to the Nether-
lands and from Brazil into France. The virus has been detected
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 10.9477%; height: 1.38889%;">in migratory birds.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 33.9869%; height: 2.77778%;">Map sources: The Mayaro Fever map was made with multi-
ple sources mentioned under key references.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 50.505%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">Tesh RB, et al. (1999) Mayaro virus disease: an emerging
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 53.1566%; width: 36.6013%; height: 1.38889%;">mosquito-borne zoonosis in tropical South America. Clin
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 54.4192%; width: 15.1961%; height: 1.38889%;">Infect Dis 28(1):67–73.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">Powers AM (2006) Genetic relationships among Mayaro and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 57.0707%; width: 36.2745%; height: 1.38889%;">Una viruses suggest distinct patterns of transmission. Am J
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 58.4596%; width: 20.5882%; height: 1.38889%;">Trop Med Hyg 75(3):461–469.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 34.3137%; height: 1.38889%;">Torres JR (2004) Family cluster of Mayaro fever, Venezuela.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 61.1111%; width: 18.7909%; height: 1.38889%;">Emerg Infect Dis 10(7):1304–1306.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 62.5%; width: 40.0327%; height: 1.38889%;">Calisher CH (2001) Mayaro virus. In Service MW (ed.) The
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 63.8889%; width: 32.6797%; height: 2.65152%;">Encyclopedia of Arthropod-transmitted Infections, CAB Inter-
national, pp. 335–339.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">233
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/bb14c967-eb83-4a8c-8315-b4d4e60cf1a1" class="aLF-aPX-aPF-aPE-J3" alt="Page 93 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.who.int/immunization_mo-nitoring/en/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.who.int/immunization_mo-nitoring/en/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.who.int/immunization_mo-nitoring/en/&amp;ust=1666162860000000&amp;usg=AOvVaw3irOojXmWitOHOiqGxSozo&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 2.65152%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 94 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 26.1438%; height: 2.0202%;">Disease: Measles
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 23.8562%; height: 1.26263%;">Classification: ICD-9 9055.0; ICD-10 B05
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 17.4837%; height: 1.26263%;">Synonyms: Rubeola, morbilli.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 34.3137%; height: 1.38889%;">Agent: Measles virus, a single-stranded RNA negative-sense
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 22.2222%; height: 1.38889%;">morbillivirus, family Paramyxoviridae.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.2626%; width: 14.5425%; height: 1.0101%;">Reservoir: Humans.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.3137%; height: 1.38889%;">Transmission:By airborne droplets from or contact with nose
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">and throat secretions of infected persons, very high from 4
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.3137%; height: 1.38889%;">days before to 4 days after rash appears, or with fomites
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 33.9869%; height: 4.0404%;">contaminated with those secretions. Droplets remain infec-
tious for several hours, longer under conditions of low humid-
ity. Measles virus is highly contagious.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 32.0261%; height: 1.38889%;">Incubation period: Median 12.5 days, range 1–3 weeks.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.3137%; height: 1.38889%;">Clinical findings: High fever, conjunctivitis, coryza, cough,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.4771%; height: 2.52525%;">maculopapular rash beginning on the face, spreading down-
wards to reach the hands and feet. Characteristic small white
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">spots (Koplik spots) on the buccal mucosa. Complications may
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">consist of otitis media, pneumonia, laryngotracheal bronchitis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">(croup), blindness, severe skin infections, severe diarrhea and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.4771%; height: 2.65152%;">encephalitis, sometimes fatal. Complications are more com-
mon and more severe in people with malnutrition, vitamin A
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 33.9869%; height: 2.77778%;">deficiency, and chronic diseases. Very rarely, subacute scle-
rosing panencephalitis may appear years later.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Detection by RT-PCR on blood or swabs of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">nasopharyngeal mucosa; virus isolation from swabs, blood, or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">urine; detection of measles specific IgM or significant rise in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 18.6275%; height: 1.38889%;">antibody titer in paired samples.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 33.9869%; height: 4.0404%;">Therapy: Supportive; vitamin A supplementation is impor-
tant to avoid the complications of vitamin A deficiency result-
ing from the infection. Efficacy of ribavirin is unproven.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.13636%;">Prevention: Vaccination with live attenuated virus vaccine
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">should be routine for children (minimum age: 12 months),
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">preferably with the combined measles, mumps, and rubella
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.4771%; height: 1.38889%;">vaccine (MMR), with a booster at age 4 to 6 years. Infected
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 34.4771%; height: 1.38889%;">children should be kept out of school and away from other
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">child contacts. Displaced persons (e.g. refugees) should be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 2.65152%;">vaccinated within a week of their arrival in a camp. For post-
exposure prophylaxis, vaccination is recommended within 72
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.4771%; height: 1.38889%;">hours of exposure, with a booster in 5–6 weeks; human
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">immunoglobulin for immunocompromised persons and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 24.5098%; height: 1.13636%;">those for whom vaccine is contraindicated.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 26.1364%; width: 34.3137%; height: 1.38889%;">Epidemiology: Measles has a worldwide distribution, but is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.3137%; height: 1.38889%;">eliminated from the western hemisphere through vaccination.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">Measles deaths world wide fell by 78% from an estimated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">733,000 in 2000 to 164,000 in 2008; all regions but one have
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 49.8366%; height: 5.42929%;">achieved the United Nations goal of reducing measles mortal-
ity by 90%, however, it remains the leading cause of vaccine-
preventable deaths in children and there are fears of a resur-
gence if vaccination falters for lack of resources. WHO figures
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">for 2008 were 282,000 reported cases, with many thousands
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">more unreported. Some 58% of countries have 90% or more
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">vaccine coverage, adequate to stop transmission, but endemic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">countries have case fatality rates of up to 30% in places. Most
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">measles deaths ( &gt; 95%) occur in countries with a per capita
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.26263%;">income of &lt;US$ 1,000. Measles-free countries still have
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">imported cases and limited outbreaks in subpopulations
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 2.77778%;">with low or no vaccination coverage (e.g. religious communi-
ties). Measles is being considered for global elimination or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 9.96732%; height: 1.13636%;">even eradication.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 51.7677%; width: 34.1503%; height: 1.38889%;">Map sources: The Measles map was made with data obtained
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 33.9869%; height: 2.65152%;">from WHO, available at: www.who.int/immunization_mo-
nitoring/en/.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 57.197%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 34.3137%; height: 1.38889%;">De Quadros CA (2004) Can measles be eradicated globally?
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 59.8485%; width: 27.451%; height: 1.38889%;">Bull World Health Organ 82(2):134–138.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">Kelly H, et al. (2009) WHO criteria for measles elimination: a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 62.5%; width: 36.6013%; height: 1.38889%;">critique with reference to criteria for polio elimination. Euro
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 63.8889%; width: 11.9281%; height: 1.26263%;">Surveill 14(50):19445.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">Strebel P, et al. (2003) The unfinished measles immunization
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 66.5404%; width: 22.549%; height: 1.38889%;">agenda. J Infect Dis 187(Suppl. 1):S1–S7.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">World Health Organization (2009) State of the World’s Vaccines
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.1919%; width: 33.1699%; height: 1.26263%;">and Immunization, 3rd edn. WHO, UNICEF, World Bank.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.5808%; width: 4.90196%; height: 1.13636%;">Geneva.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">235
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/5a14cb2e-d91d-4574-b926-4cfaa5439605" class="aLF-aPX-aPF-aPE-J3" alt="Page 94 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 95 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 31.6993%; height: 2.39899%;">Disease: Monkeypox
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 23.2026%; height: 1.26263%;">Classification: ICD-9 051.9; ICD-10 B04
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 25.4902%; height: 1.26263%;">Syndromes and synonyms: Simian variola.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">Agent: Monkeypox virus (MPV), a double-stranded DNA
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">virus of the genus Orthopoxvirus, family Poxviridae. Two
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">clades of monkeypox viruses are known: the West African
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">virus and the Congo Basin virus. The Congo Basin strain is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">more virulent than the West African strain. The MPV genome
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">is &gt; 96% identical to the variola virus genome. However, MPV
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 30.5556%; height: 1.13636%;">is not a direct ancestor or descendent of variola virus.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">Reservoir: Undetermined. Thought to be forest rodents
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">(squirrels, rats, mice, dormice), shrews and monkeys in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 22.0588%; height: 1.13636%;">rainforests of West and Central Africa.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.3838%; width: 12.9085%; height: 1.0101%;">Vector: None.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 2.65152%;">Transmission: By bite or direct percutaneous contact, muco-
sal or respiratory exposure to blood, tissues, fluids or lesions of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">infected animals. In Africa, transmission mainly occurs
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 2.65152%;">through butchering infected wildlife for food. Person-to-per-
son transmission probably occurs through direct contact with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">infected tissue/fluid, respiratory droplet spread, and indirect
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 14.5425%; height: 1.38889%;">via contaminated objects.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.3137%; height: 1.38889%;">Cycle:Animal to animal, with occasional spill over to humans.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.4771%; height: 1.13636%;">Sustained human-to-human transmission has not been
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 7.67974%; height: 1.13636%;">documented.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 26.7974%; height: 1.38889%;">Incubation period: 7–21 days (mean 12 days).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">Clinical findings: Symptoms are similar to smallpox, but
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.3137%; height: 4.0404%;">milder: fever, headache, myalgia, backache, lymphadenopa-
thy (not seen in smallpox), malaise, sore throat, cough, short-
ness of breath, followed by a vesicular-pustular rash on the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">face and body; the lesions eventually crust and fall off. The
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 20.2614%; height: 1.26263%;">outcome can be fatal (CFR: 1–10%).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: The detection of virus by culture or PCR in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 2.77778%;">characteristic skin lesions. Histopathology and immunohis-
tochemistry also support the diagnosis. Laboratory testing
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 27.451%; height: 1.38889%;">should be performed in specialized laboratories.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 34.4771%; height: 1.26263%;">Therapy: Supportive. Cidofovir has proven anti-monkeypox
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.2727%; width: 34.4771%; height: 1.38889%;">viral activity in vitro and in animal studies, but its efficacy in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">patients is unknown, neither is any benefit from treatment
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 22.549%; height: 1.38889%;">with vaccinia immune globulin known.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 20.8333%; width: 34.3137%; height: 1.38889%;">Prevention: Smallpox vaccine is protective, but not a feasible
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">solution in the remote forest habitat where monkeypox is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">endemic. Hospital personnel should isolate patients and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 19.4444%; height: 1.38889%;">take infection control precautions.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 27.5253%; width: 34.3137%; height: 1.38889%;">Epidemiology: MPV is endemic in heavily forested areas of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">Africa, primarily of low altitude and high humidity. The
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">outlier in shrub country in the Sudan is anomalous ecologically
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">and might have been initiated by an infected traveler from the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">Congo Basin region. Males and females are equally affected,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">children under 15 more than adults. Comparison of active
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 2.77778%;">surveillance data in one health zone in the Democratic Repub-
lic of the Congo from the 1980s (0.72 per 10,000) and 2006–2007
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 2.77778%;">(14.5 per 10,000) suggests a 20-fold increase in human mon-
keypox incidence 30 years after mass smallpox vaccination
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 13.0719%; height: 1.38889%;">ceased in that country.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 42.298%; width: 33.1699%; height: 1.38889%;">In 2003, multiple cases of monkeypox occurred across the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">USA among persons who had contact with the excretions of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">sick prairie dogs (native ground squirrels) either at a child-care
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">center or from pet stores. The animals had been exposed to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">imported, infected West African rodents on the premises of a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">distributor of exotic pets. There were more than 70 cases but no
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 5.39216%; height: 1.13636%;">fatalities.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 2.65152%;">Map sources: The Monkeypox map is modified with permis-
sion from R.S. Levine et al. (2007) with updates from the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 16.8301%; height: 1.38889%;">medical literature up to 2010.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 58.5859%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 34.3137%; height: 1.38889%;">Center for Food Security and Public Health (2009)Monkeypox.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.1111%; width: 34.3137%; height: 2.77778%;">Factsheet MNKY_2009. Damon IK, et al. (2006) Discovery of monkeypox in Sudan.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 63.8889%; width: 20.2614%; height: 1.38889%;">N Engl J Med 355(9):962–963.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">Hutson CL, et al. (2010) Comparison of West African and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 66.5404%; width: 33.0065%; height: 1.38889%;">Congo Basin monkeypox viruses in BALB/c and C57BL/6
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 67.9293%; width: 24.6732%; height: 1.26263%;">mice. PLoS ONE 5(1):e8912.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">Levine RS, et al. (2007). Ecological niche and geographic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.5808%; width: 33.1699%; height: 1.38889%;">distribution of human monkeypox in Africa. PloS ONE
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 5.55556%; height: 1.26263%;">2(1):e176.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 73.2323%; width: 37.7451%; height: 4.0404%;">Rimoina AW, et al. (2010) Major increase in human monkey-
pox incidence 30 years after smallpox vaccination cam-
paigns cease in the Democratic Republic of Congo. Proc
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 77.2727%; width: 19.6078%; height: 1.38889%;">Natl Acad Sci 107(37):16262–16267.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">237
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/5628ab5b-19c9-4d25-9e10-e90ebc2869ec" class="aLF-aPX-aPF-aPE-J3" alt="Page 95 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.who.int/immunization_mo-nitoring/en/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.who.int/immunization_mo-nitoring/en/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.who.int/immunization_mo-nitoring/en/&amp;ust=1666162860000000&amp;usg=AOvVaw3irOojXmWitOHOiqGxSozo&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 52.451%; top: 61.2374%; width: 34.4771%; height: 2.65152%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 96 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 25%; height: 2.39899%;">Disease: Mumps
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 22.2222%; height: 1.26263%;">Classification: ICD-9 072; ICD-10 B26
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 27.6144%; height: 1.38889%;">Syndromes and synonyms: Infectious parotitis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">Agent: Mumps virus, an enveloped RNA virus of the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">family Paromyxoviridae. Twelve genotypes are currently
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 7.02614%; height: 1.38889%;">recognized.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.6515%; width: 14.5425%; height: 1.0101%;">Reservoir: Humans
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.303%; width: 12.9085%; height: 1.0101%;">Vector: None
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.3137%; height: 1.38889%;">Transmission: Through contact with infectious respiratory
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 10.4575%; height: 1.26263%;">droplets or saliva.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 31.5359%; height: 1.38889%;">Incubation period: Median 19 days, range 15–24 days.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.3137%; height: 1.38889%;">Clinical findings: Up to one-third of cases are subclinical. The
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">illness begins with a prodrome of fever, malaise, and headache
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.4771%; height: 1.38889%;">followed by unilateral or, more commonly, bilateral tender
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.3137%; height: 1.38889%;">swelling of the parotid (parotitis) or other salivary glands.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">Parotitis is present in 95% of clinical cases. Infection and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.3137%; height: 1.38889%;">inflammation of the testicles (orchitis) occurs in up to 30%
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">of adult males but is rare before puberty. Orchitis results in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.3137%; height: 1.38889%;">testicular atrophy in 50% of cases but rarely causes sterility.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">Adult women may rarely suffer inflammation of the ovaries
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">(oophoritis). The commonest nervous system manifestation of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">mumps infection is meningitis, which is seen in up to 10% of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">cases but is self-limiting and does not result in death of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">disability. Other rarer clinical complications include hearing
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">loss, encephalitis, and pancreatitis. Mumps infection in early
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 33.9869%; height: 2.52525%;">pregnancy may be associated with an increased risk of spon-
taneous abortion.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.3137%; height: 4.0404%;">Diagnostic tests: The detection of virus in saliva, cerebrospi-
nal fluid, urine, or seminal fluid by culture or RT-PCR. Detec-
tion of mumps specific IgM or significant rise in antibody titer
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 10.6209%; height: 1.38889%;">in paired samples.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 25%; height: 1.38889%;">Therapy: No specific treatment is available.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.4771%; height: 4.0404%;">Prevention: Mumps is preventable by the use of live attenu-
ated mumps virus vaccines. Various vaccine strains are avail-
able and may vary in immunogenicity and the incidence of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 33.4967%; height: 1.26263%;">adverse effects, such as fever, rash, parotitis, or meningitis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 16.7929%; width: 34.3137%; height: 1.38889%;">Epidemiology: Studies of unvaccinated populations in some
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">western countries indicate that almost everyone will be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 4.16667%;">infected with mumps by adulthood; however the epidemiol-
ogy of mumps is less well characterized in developing coun-
tries. The true number of mumps cases is not known, since it is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">often a mild disease and reported cases probably represent
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">fewer than 10% of all infections. There is geographic variation
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">in circulating mumps virus genotypes, and there can be several
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">genotypes circulating simultaneously in one area and shifts
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">over time in predominant genotypes. Mumps vaccination is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">recommended at age 12–18 months and is included in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">standardimmunization program ofmost developed countries,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">usually in a trivalent vaccine with measles and rubella (MMR
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.3137%; height: 2.65152%;">vaccine). A booster dose in later childhood is also recom-
mended for countries with a good immunization program.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">Several developed countries with a well-established mumps
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">vaccination program have experienced significant outbreaks
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">in young adults, who were too old to be included in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">childhood immunization schedule and had not been exposed
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 2.77778%;">to natural infection due to an overall reduction in the trans-
mission of mumps in the population. Other possible reasons
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">for mumps outbreaks in vaccinated populations include a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">waning of vaccine-induced immunity and genotype mismatch
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.13636%;">between the vaccine strain and the wild virus. Since the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">complications of mumps are more common in affected adults
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">compared to affected children, a shift in the average age of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.13636%;">infection can lead to an increase in the number of observed
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.26263%;">complications. However, despite these issues, it must be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.4771%; height: 2.77778%;">remembered that comprehensive mumps vaccination pro-
grams are associated with a massive overall decrease in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 16.8301%; height: 1.38889%;">burden of mumps morbidity.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 59.8485%; width: 34.1503%; height: 1.38889%;">Map sources: The Mumps map was made with data obtained
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.2374%; width: 33.9869%; height: 2.65152%;">from WHO, available at: www.who.int/immunization_mo-
nitoring/en/.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 65.2778%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">Galazka AM, et al. (1999) Mumps and mumps vaccine: a global
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 67.9293%; width: 29.4118%; height: 1.38889%;">review. Bull World Health Org 77:3–14.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.1919%; width: 29.085%; height: 1.38889%;">Hiivd A, et al. (2008) Mumps. Lancet 371:932–944.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">World Health Organization (2009) State of the World’s Vaccines
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 33.1699%; height: 1.26263%;">and Immunization, 3rd edn. WHO, UNICEF, World Bank.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.2323%; width: 4.90196%; height: 1.13636%;">Geneva.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">239
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/323bb086-0e1e-4241-b91a-06bf6155c792" class="aLF-aPX-aPF-aPE-J3" alt="Page 96 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 97 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.7424%; width: 58.4967%; height: 2.52525%;">Disease: O’nyong-nyong Virus Disease
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.3464%; height: 1.26263%;">Classification: ICD-9 066.3; ICD-10 A92.1
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 41.1765%; height: 2.77778%;">Syndromes and synonyms: The name means ‘joint-breaker’ in the Acholi language of Africa.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">Agent: O’nyong-nyong virus (ONNV), an enveloped RNA
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">virus, genus Alphavirus in the family Togaviridae, closely
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">related to chikungunya virus (CHIKV, see Chikungunya
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">Fever map). Strains bear the names Gulu, Igbo-Ora, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 8.66013%; height: 1.13636%;">SG650 viruses.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 14.5425%; height: 1.13636%;">Reservoir: Unknown.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">Vector: ONNV is transmitted by the African malaria vectors
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.1503%; height: 2.77778%;">Anopheles funestus and An. gambiae, and probably other mem-
bers of the complex.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 33.9869%; height: 3.78788%;">Transmission: By mosquito bite. There is no direct person-to-
person transmission documented, and no evidence of congen-
ital transmission.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">Cycle: Humans are viremic at a titer high enough to infect
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">mosquitoes for up to 5 days after infection. The virus travels
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.3137%; height: 1.38889%;">from the mosquito gut to the salivary glands in 5–7 days,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">depending on the ambient temperature (extrinsic incubation
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">period), after which it can infect another human during
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 4.90196%; height: 1.38889%;">feeding.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 29.2484%; height: 1.38889%;">Incubation period: Estimated to be at least 8 days.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.3137%; height: 2.77778%;">Clinical findings: Dengue-like acute febrile illness with sud-
den onset fever, severe chills, severe headache, eye pain,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">symmetrical polyarthralgia of all joints (as opposed to dengue,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.3137%; height: 1.26263%;">which attacks mainly elbows and knees), generalized myalgia,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.4771%; height: 1.38889%;">sometimes dry cough and coryza, leucopenia and often an
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">itching, descending morbilliform rash. Marked cervical
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.3137%; height: 1.38889%;">lymphadenitis distinguishes it from chikungunya infection.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.3137%; height: 1.38889%;">Hemorrhagic signs have not been seen. Recovery is complete,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 10.2941%; height: 1.38889%;">without sequelae.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 1.26263%;">Diagnostic tests: RT-PCR on whole blood or serum; virus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 33.9869%; height: 2.65152%;">isolation; plaque reduction neutralization test (there is cross-
reactivity with related viruses, including CHIKV).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 29.4118%; height: 1.26263%;">Therapy: Supportive, there is no specific treatment.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 33.9869%; height: 2.52525%;">Prevention: Standard anti-mosquito and anti-malarial pre-
cautions. There is no vaccine.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 20.8333%; width: 34.3137%; height: 1.38889%;">Epidemiology:ONNV is a mutant of CHIKV that appeared in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 22.2222%; width: 34.3137%; height: 1.38889%;">1959 in Uganda and was spread by anopheline mosquitoes
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 2.77778%;">across the malaria belt of Africa, leading to a large mosquito-
borne virus epidemic. This large epidemic was remarkable
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">because, in spite of the occurrence of millions of cases, no
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 2.77778%;">deaths were reported. It ended without a trace in 1962, reap-
pearing as sporadic cases in Africa at rare intervals. In Nigeria
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 2.77778%;">in 1966 and 1969, cases were described as a new virus, Igbo-
Ora, later recognized as ONNV. There was a small outbreak in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">Côte d’Ivoire in 1984–1985 and again in 2003, also described as
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.3137%; height: 1.26263%;">Igbo-Ora virus and a small recurrence in Uganda in 1996.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">Serological evidence suggested its presence in humans in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">Kenya in 1994–1995 and in horses in Nigeria, but serological
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">tests are subject to cross-reactions with CHIKV antibody. It is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 2.77778%;">not known how or where the virus survives between out-
breaks, but sequence data show very little variation between
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">ONNV strains isolated in Uganda in 1959 and 1996–1997,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">suggesting that the virus persists, rather than undergoing
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">repeated mutations from CHIKV (which has a non-human
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 10.7843%; height: 1.38889%;">primate reservoir).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 49.1162%; width: 34.1503%; height: 1.38889%;">Map sources: The O’nyong-nyong Virus Disease map was
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">made by visualizing countries with reported human cases
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">reported in the medical literature up to 2010. In case the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 33.1699%; height: 1.26263%;">location of human cases is known, this is shown (red dot).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 55.8081%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 34.3137%; height: 2.77778%;">Lanciotti RS, et al. (1998) Emergence of epidemic O’nyong-
nyong fever in Uganda after a 35-year absence: genetic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 59.8485%; width: 33.8235%; height: 1.38889%;">characterization of the virus. Virology 252:258–226.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">Moore DL, et al. (1975) Arthropod-borne viral infections of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 62.5%; width: 34.4771%; height: 1.38889%;">man in Nigeria, 1964–1970. Ann Trop Med Parasitol 69:49–64.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">Powers AM, et al. (2000) Re-emergence of Chikungunya and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 65.1515%; width: 33.1699%; height: 1.38889%;">O’nyong-nyong viruses: evidence for distinct geographical
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 66.5404%; width: 33.1699%; height: 1.38889%;">lineages and distant evolutionary relationships. J Gen Virol
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 67.9293%; width: 6.69935%; height: 1.13636%;">81:471–479.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.1919%; width: 40.1961%; height: 1.38889%;">Woodall J (2001) O’nyong-nyong virus. In Service M (ed.) The
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.5808%; width: 32.6797%; height: 2.77778%;">Encyclopedia of Arthropod-transmitted Infections. CAB Inter-
national, pp. 388–390.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">241
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/635f3fb8-b0cc-4118-a884-f2935d0bfb92" class="aLF-aPX-aPF-aPE-J3" alt="Page 97 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.cdc.gov/EID/content/15/12/2063.htm" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.cdc.gov/EID/content/15/12/2063.htm" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.cdc.gov/EID/content/15/12/2063.htm&amp;ust=1666162860000000&amp;usg=AOvVaw1L9Uo0gv3hOqRn12OBcNk5&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 57.0261%; top: 61.2374%; width: 28.9216%; height: 1.26263%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 98 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.7424%; width: 52.1242%; height: 2.52525%;">Disease: Oropouche Virus Disease
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 23.366%; height: 1.26263%;">Classification: ICD-9 065; ICD-10 A93.0
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">Syndromes and synonyms: Oropouche fever, fevre de
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 4.08497%; height: 1.38889%;">Mojui.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">Agent: Oropouche virus (OROV), a spherical enveloped,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">single-stranded, negative-sense RNA virus, belonging to the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.3137%; height: 1.38889%;">Orthobunyavirus group of the Bunyaviridae family, with 3
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.6515%; width: 6.37255%; height: 1.26263%;">genotypes.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 40.6863%; height: 2.77778%;">Reservoir: Monkeys, three-toed sloths (Bradypus tridactylus), marsupials, and forest birds.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.2172%; width: 38.5621%; height: 1.38889%;">Vector: During urban epidemics, biting midges (Culicoides
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 38.5621%; height: 1.38889%;">paraensis); also mosquitoes of Aedes and Culex genera.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 16.9935%; height: 1.38889%;">Transmission: By insect bite.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">Cycle: The vector becomes infected with OROV by feeding on
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.4771%; height: 1.38889%;">a viremic host. The virus crosses the gut wall and multiplies in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">the organs of the insect. After a few days, depending on the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">ambient temperature, the virus reaches the salivary glands and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.3137%; height: 1.38889%;">is injected into the next host during feeding. Jungle cycle:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.3137%; height: 1.38889%;">OROV is transmitted among sloths, marsupials, primates,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 14.8693%; top: 49.1162%; width: 41.5033%; height: 2.65152%;">and birds by the mosquitoes Aedes serratus and Culex quinque-
fasciatus. Urban cycle: OROV is transmitted to humans by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 16.3399%; height: 1.38889%;">midges (Culicoides paraensis).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 19.7712%; height: 1.38889%;">Incubation period: 2–14 days.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">Clinical findings: Sudden onset fever (may be diphasic),
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.3137%; height: 1.38889%;">headache, myalgia, arthralgia, anorexia, dizziness, chills,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">and photophobia. Also nausea, vomiting, diarrhea, epigastric
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">and eye pain, conjunctivitis, and meningitis have been
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.4771%; height: 1.38889%;">reported. Recently, spontaneous hemorrhagic phenomena
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.3137%; height: 1.38889%;">were reported in human cases. The disease is self-limiting,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 25.6536%; height: 1.38889%;">there are no reports of OROV related deaths.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Serology (IgM ELISA, IFA) or by detection
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 20.915%; height: 1.38889%;">of OROV RNA in blood by RT-PCR.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 29.4118%; height: 1.38889%;">Therapy: Supportive, there is no specific treatment.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.4771%; height: 2.65152%;">Prevention: Personal anti-insect measures; there is no vac-
cine. Removal of culicoides breeding sites in cacao husks and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.2727%; width: 12.2549%; height: 1.13636%;">felled banana trunks.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 16.7929%; width: 34.1503%; height: 1.26263%;">Epidemiology: OROV was first isolated in Trinidiad in 1955.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.26263%;">In South America, cases are limited to Trinidad, Panama, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">the Amazon basin. Oropouche fever is, after dengue fever, the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.4771%; height: 1.13636%;">most common arboviral infection in Brazil. The virus has
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">periodically caused large urban epidemics in Brazil and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">Peru, during which up to 60% of the population has been
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 34.3137%; height: 1.38889%;">affected. There also outbreaks in villages and sporadic cases.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">Approximately 500,000 cases have occurred in Brazil since the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 27.5253%; width: 34.1503%; height: 1.38889%;">1960s. There are three OROV genotypes circulating in Brazil:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">genotypes I and II in the Amazon Basin and genotype III in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">Southeast Region. Genotype III has been isolated from a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">marmoset (Callithrix species) in southeastern Brazil, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">also occurs in Panama. Outbreaks coincide with periods of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">highest rainfall, when biting midge density is greatest. OROV
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">infections are likely underdiagnosed in South America as was
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">seen during a concurrent outbreak of dengue virus and OROV
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">in Manus (Brazil), where OROV infections were missed by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 25.1634%; height: 1.38889%;">physicians and the Public Health Authority.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 42.298%; width: 34.3137%; height: 1.38889%;">Map sources: The Oropouche Virus Disease map was made
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">by geocoding human outbreaks that were reported between
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 45.0758%; width: 33.0065%; height: 1.0101%;">1955 and 2010 in the medical literature and ProMED mail.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 47.7273%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">Azevedo RSS, et al. (2007) Reemergence of Oropouche Fever,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 50.3788%; width: 28.4314%; height: 1.38889%;">Northern Brazil. Emerg Infect Dis 13(6):912–915.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">Bernardes-Terzian AC, et al. (2009) Sporadic oropouche virus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 53.1566%; width: 31.2092%; height: 1.38889%;">infection, acre, Brazil. Emerg Infect Dis 15(2):348–350.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 40.1961%; height: 1.38889%;">Mellor PS. (2001) Oropouche virus. In Service MW (ed.) The
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 55.8081%; width: 32.6797%; height: 2.65152%;">Encyclopedia of Arthropod-transmitted Infections, CAB Inter-
national, pp. 391–399.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">Mourao MPG, et al. (2009) Oropouche fever outbreak,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 59.8485%; width: 33.1699%; height: 1.38889%;">Manaus, Brazil, 2007–2008. Emerg Infect Dis. Available
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 61.2374%; width: 32.3529%; height: 1.26263%;">from: http://www.cdc.gov/EID/content/15/12/2063.htm.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 62.5%; width: 34.4771%; height: 1.38889%;">Nunes MR, et al. (2005) Oropouche virus isolation, southeast
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 63.8889%; width: 23.2026%; height: 1.38889%;">Brazil. Emerg Infect Dis 11(10):1610–1613.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">Saeed MF (2000) Nucleotide sequences and phylogeny of the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 66.5404%; width: 33.1699%; height: 1.38889%;">nucleocapsid gene of Oropouche virus. J Gen Virol
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 67.9293%; width: 6.69935%; height: 1.13636%;">81:473–478.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">Vasconcelos HB (2009) Oropouche fever epidemic in Northern
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.5808%; width: 33.1699%; height: 1.38889%;">Brazil: Epidemiology and molecular characterization of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 18.1373%; height: 1.26263%;">isolates. J Clin Virol 44:129–133.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">243
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/f059b781-8371-4bc0-a9ba-b50e77fedae6" class="aLF-aPX-aPF-aPE-J3" alt="Page 98 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.polioeradication.org" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.polioeradication.org" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.polioeradication.org&amp;ust=1666162860000000&amp;usg=AOvVaw0G24eEox4gcOvbJCgHpSm0&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 54.2484%; top: 65.1515%; width: 15.0327%; height: 1.38889%;"></a><a href="http://www.who.int" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.who.int" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.who.int&amp;ust=1666162860000000&amp;usg=AOvVaw0W9UExHTZLQL7zArFgSjZi&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 58.3333%; top: 70.5808%; width: 8.16994%; height: 1.13636%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 99 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 33.8235%; height: 2.39899%;">Disease: Poliomyelitis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 22.3856%; height: 1.26263%;">Classification: ICD-9 045; ICD-10 A80
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 33.9869%; height: 2.77778%;">Syndromes and synonyms: Polioviral fever, infantile paraly-
sis, acute flaccid paralysis (AFP), bulbar polio.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">Agent: Poliovirus, an RNA enterovirus with three types; type
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">1 cases are most common, followed by type 3; wild type 2
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">disappeared in 1999. Rare cases of all three types occur in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.4771%; height: 1.13636%;">unimmunized contacts of children vaccinated with the Sabin
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 13.5621%; height: 1.13636%;">live attenuated vaccine.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">Reservoir: Humans, generally children with inapparent
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 6.04575%; height: 1.13636%;">infections.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">Transmission: Oro-fecal. 100% of susceptible contacts
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.4771%; height: 1.38889%;">become infected. Virus appears in the throat &lt; 36 hours
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.4771%; height: 1.26263%;">after infection, for a week, and in the feces after 72 hours
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">for 3–6 weeks. Transmission through contaminated water and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 17.3203%; height: 1.38889%;">food has been reported rarely.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 31.5359%; height: 1.38889%;">Incubation period: 3–35 days; 6–20 for paralytic cases.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.3137%; height: 1.38889%;">Clinical findings: Less than 1% of infections result in acute
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.3137%; height: 2.77778%;">flaccid paralysis, with around 90% of infections being subclin-
ical. In 10% symptoms may include fever, malaise, headache,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 2.77778%;">neck stiffness, pain in the limbs, nausea, and vomiting. Paral-
ysis persists in 0.1–1.0% depending on the virulence of the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">strain. The flaccid paralysis is usually asymmetric and in one
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 4.0404%;">leg. The risk of paralysis is increased by intramuscular injec-
tions, immune-compromised state, trauma or surgery (tonsil-
lectomy), and intense physical activity during the incubation
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">period. Also adults are at greater risk of developing paralysis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">than young children. Aseptic meningitis occurs in around 1%
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">of infections. More severe paralysis with quadriplegia and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 25.9804%; height: 1.38889%;">breathing problems (bulbar polio) may occur.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.4771%; height: 2.77778%;">Diagnostic tests: Virus isolation from stool, CSF or oropha-
ryngeal secretion, followed by typing (to determine if the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">virus is ‘wild type’ or a vaccine strain). Alternatively, the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 29.4118%; height: 1.38889%;">diagnosis can be established by serological testing.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 32.6797%; height: 1.38889%;">Therapy: Supportive, there is no specific polio treatment.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.4771%; height: 1.26263%;">Prevention: In 1988, the WHO launched the Global Polio
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 34.4771%; height: 1.26263%;">Eradication Initiative (GPEI). The Americas were certified
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.2727%; width: 34.3137%; height: 1.38889%;">polio-free in 1994, the WHO Western Pacific Region in 2000
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 78.6616%; width: 34.4771%; height: 1.38889%;">and Europe in 2002 (in 2010, there was importation of polio
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">into Europe). The GPEI has four main strategies to stop
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 2.65152%;">transmission of the wild poliovirus: (1) high infant immuniza-
tion coverage with four doses of oral poliovirus vaccine (OPV)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.4771%; height: 1.38889%;">in the first year of life; (2) supplementary doses of OPV to all
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">children under 5 years of age during SIAs; (3) surveillance for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">wild poliovirus through reporting and laboratory testing of all
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">acute flaccid paralysis (AFP) cases among children under 15
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">years of age; (4) targeted campaigns once wild poliovirus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">transmission is limited to a specific focal area. To be certified
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">polio-free, three conditions must be met: (1) there are at least 3
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">years of zero polio cases due to wild poliovirus; (2) disease
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.26263%;">surveillance efforts in countries meet international standards;
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">and (3) each country must illustrate the capacity to detect,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 4.0404%;">report, and respond to ‘imported’ polio cases. Oral live atten-
uated polio vaccines can give rise to circulation of vaccine-
derived polioviruses and rare cases of vaccine-associated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">paralytic poliomyelitis. For this reason, efforts are underway
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">to develop affordable options for inactivated polio
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 7.02614%; height: 1.13636%;">vaccination.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 43.6869%; width: 34.3137%; height: 1.26263%;">Epidemiology: Since the Global Polio Eradication Initiative,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">cases have decreased significantly. There were 1,292 reported
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">cases in 2010, of which only 232 were in the endemic countries
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 2.77778%;">Afghanistan, India, Nigeria, and Pakistan. In endemic coun-
tries most cases are children aged &lt;3 years. In 2009–2010, 23
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.3137%; height: 2.77778%;">previously polio-free countries were re-infected due to impor-
tation of the virus, notably hundreds of cases in Tajikistan.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 35.4575%; height: 5.30303%;">Most reported polio cases in 2010 (n 1,060) were in non-
endemic countries. Polio transmission seems to have been re-
established in Chad, Angola, Sudan, and the DRC. This illus-
trates the difficulties of the global polio eradication program.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">Risk is seasonal in the temperate climates, with highest risks
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 16.0131%; height: 1.38889%;">during the warmer months.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 62.5%; width: 34.3137%; height: 1.38889%;">Map sources: The Poliomyelitis map was made with data
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 34.4771%; height: 1.26263%;">obtained from the Global Polio Eradication Initiative, available
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 16.9935%; height: 1.38889%;">at: www.polioeradication.org.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 67.9293%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.1919%; width: 35.2941%; height: 1.38889%;">World Health Organization (2010) Poliomyelitis. Factsheet
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.5808%; width: 13.5621%; height: 1.26263%;">Nr 114 (www.who.int).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 71.9697%; width: 39.7059%; height: 1.38889%;">Dutta A (2008) Epidemiology of poliomyelitis – options and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.2323%; width: 19.1176%; height: 1.38889%;">update. Vaccine 26(45):5767–5773.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 74.6212%; width: 34.4771%; height: 1.38889%;">Nathanson N, et al. (2010) From emergence to eradication: the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 75.8838%; width: 32.6797%; height: 2.77778%;">epidemiology of poliomyelitis deconstructed. Am J Epide-
miol 172(11):1213–1229.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">245
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/de8d3a78-0c0e-4816-94b0-b30b3cf0a26a" class="aLF-aPX-aPF-aPE-J3" alt="Page 99 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.who.int/rabies" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.who.int/rabies" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.who.int/rabies&amp;ust=1666162860000000&amp;usg=AOvVaw2ajW2sjy5bKaFFbrLHtx3_&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 71.2418%; top: 58.4596%; width: 12.4183%; height: 1.26263%;"></a><a href="http://www.who.int" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.who.int" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.who.int&amp;ust=1666162860000000&amp;usg=AOvVaw0W9UExHTZLQL7zArFgSjZi&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 60.9477%; top: 77.2727%; width: 8.16994%; height: 1.13636%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 100 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 23.8562%; height: 2.0202%;">Disease: Rabies
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 22.3856%; height: 1.26263%;">Classification: ICD-9 071; ICD-10 A82
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">Syndromes and synonyms: Hydrophobia, furious rabies,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 31.8627%; height: 1.38889%;">paralytic (dumb) rabies, classic rabies, non-classic rabies
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 40.6863%; height: 2.77778%;">Agent: Rabies virus, a rhabdovirus of the genus Lyssavirus, with a nonsegmented, negative-stranded RNA genome. At
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">least 11 different genotypes exist, with genotype 1, rabies virus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.3137%; height: 1.38889%;">(RABV) causing classic rabies world wide. Genotypes 2–11
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.3137%; height: 1.38889%;">have a more limited host-range and geographic distribution:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 34.3137%; height: 1.38889%;">Lagos bat virus (LBV), Mokola virus (MOKV), Duvenhage
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.3137%; height: 1.38889%;">virus (DUVV), European bat lyssa virus 1 and 2 (EBLV-1/2),
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">Australian bat lyssa virus (ABLV), Aravan virus (ARAV), Irkut
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">virus (IRKV), Khujand virus (KHUV), and West Caucasian bat
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 8.66013%; height: 1.26263%;">virus (WCBV).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.4771%; height: 1.26263%;">Reservoir: Wild and domestic canines, also skunks, raccoons,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 32.5163%; height: 1.38889%;">mongooses; vampire, frugivorous and insectivorous bats.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.4242%; width: 12.9085%; height: 1.0101%;">Vector: None.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">Transmission: By animal bite through saliva commonly or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">scratch (rarely). Infected livestock do not bite typically, but
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">may infect a person through their saliva. Very rare: licks upon
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.3137%; height: 2.65152%;">mucosal surfaces; aerosols in bat-infested caves; person-to-
person transmission via organ/tissue transplantation. Rabies
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">can be transmitted via slaughtering of infected reservoir
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">species, for instance dogs in countries where dogs are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 6.53595%; height: 1.13636%;">consumed.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">Incubation period: Usually 1–3 months (rarely &lt;1 week and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.3595%; top: 58.4596%; width: 34.1503%; height: 1.38889%;">&gt; 1 year) depending on virus variant, dose, wound severity
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 22.0588%; height: 1.13636%;">and distance of wound from the brain.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.4771%; height: 1.38889%;">Clinical findings: Rabies can manifest itself in two general
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">forms: classic encephalitic (furious) rabies and paralytic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">(dumb) rabies. Both forms are progressive and generally
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">lead to death. The majority of the cases present as encephalitic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">rabies, with hydrophobia and hyperexcitability. Paralytic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">rabies presents with flaccid muscle weakness or as febrile
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">encephalopathy. In some papers, a third form, non-classic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 16.1765%; height: 1.38889%;">atypical rabies, is described.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: FA staining of frozen skin sections taken
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 34.4771%; height: 1.26263%;">from the nape of the neck, or postmortem brain tissue; RT-PCR
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.2727%; width: 34.4771%; height: 1.38889%;">on saliva, skin or brain biopsy or buccal swab; serology; cell
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 78.6616%; width: 31.6993%; height: 1.26263%;">culture or mouse inoculation from saliva, skin, or brain.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 2.77778%;">Therapy: Supportive and palliative as rabies is almost invari-
ably fatal. Heavy sedation with supportive management needs
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">further study (Milwaukee protocol). Vaccination after onset of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 14.0523%; height: 1.13636%;">rabies confers no benefit.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 2.77778%;">Prevention: Thorough cleansing of wounds and postexpo-
sure prophylaxis (PEP): rabies-immune globulin and a series of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 34.4771%; height: 2.77778%;">rabies vaccinations. Vaccination of people at high risk (veter-
inarians, animal rescue personnel, laboratory staff, etc.), avoid
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">contact with stray dogs or cats, sick or dead wildlife; vaccinate
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">all dogs and cats; distribute baits containing oral vaccine in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 2.77778%;">wildlife habitat; quarantine dogs arriving from infected coun-
tries. Culling of stray dogs is ineffective; sterilization prevents
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 12.9085%; height: 1.26263%;">replacement breeding.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 36.995%; width: 34.1503%; height: 1.26263%;">Epidemiology: Rabies occurs in more than 150 countries and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">territories; world wide, more than 55,000 people die of rabies
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">every year; 40% of people who are bitten by suspect rabid
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">animals are children under 15 years of age. Dogs are the source
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">of 99% of human rabies deaths, which is largely due to low
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.3137%; height: 1.38889%;">rabies vaccination coverage of dogs in developing countries.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.0101%;">Most cases of rabies in North America and Australia have been
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">acquired from bats, often with no documented record of a bite.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.13636%;">The USA was declared free of canine rabies transmission in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">2007. In the Americas, dog rabies control reduced human cases
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">to 16 by 2009. Every year, more than 15 million people world
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 45.098%; height: 1.38889%;">wide receive a preventive PEP regimen to avert the disease –
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">this is estimated to prevent more than 327,000 rabies deaths
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 5.71895%; height: 1.38889%;">annually.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 57.0707%; width: 34.3137%; height: 1.38889%;">Map sources: The Rabies map is made with data obtained
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 31.3726%; height: 1.26263%;">from WHO RabNet, available at: www.who.int/rabies.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 61.2374%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 62.5%; width: 34.4771%; height: 1.38889%;">Hemachudha T, et al. (2006) Rabies. Curr Neurol Neurosci Rep
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 63.8889%; width: 7.51634%; height: 1.26263%;">6(6):460–468.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">Jackson AC. (2002) Update on rabies. Curr Opin Neurol
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 66.5404%; width: 33.0065%; height: 1.38889%;">15(3):327–331. Milwaukee protocol, available at: www.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 67.9293%; width: 9.64052%; height: 1.13636%;">mcw.edu/rabies
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">Rupprecht CE, et al. (2006) Current and future trends in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.5808%; width: 33.1699%; height: 1.38889%;">prevention, treatment and controlof rabies. Expert Rev Anti
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 15.6863%; height: 1.38889%;">Infect Ther 4(6):1021–1038.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 73.2323%; width: 34.4771%; height: 1.38889%;">Wertheim HF, et al. (2009) Furious rabies after an atypical
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 74.6212%; width: 23.6928%; height: 1.38889%;">exposure. PloS Med 6(3):e44.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 75.8838%; width: 34.4771%; height: 1.38889%;">WHO (2005) Expert Consultation on Rabies. WHO Technical
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 77.2727%; width: 16.0131%; height: 1.38889%;">Report 931. (www.who.int).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">247
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/73d269ab-b028-426f-a244-059a3c9cb73b" class="aLF-aPX-aPF-aPE-J3" alt="Page 100 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 101 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 38.8889%; height: 2.39899%;">Disease: Rift Valley Fever
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.3464%; height: 1.26263%;">Classification: ICD-9 066.3; ICD-10 A92.4
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.5707%; width: 24.8366%; height: 1.13636%;">Syndromes and synonyms: None.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 40.6863%; height: 4.0404%;">Agent: Rift Valley fever virus (RVFV), an enveloped, single-
stranded tripartite RNA virus, belonging to the genus Phlebo-
virus of the family Bunyaviridae. There are three lineages:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.3137%; height: 1.38889%;">Egyptian, West African, and East-Central African. Zinga virus,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">isolated in 1982 inMadagascar, was later found to be a strain of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 4.08497%; height: 1.13636%;">RVFV.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.1503%; height: 2.65152%;">Reservoir: Livestock (cattle, camels, goats, sheep), wild buf-
falo, waterbuck, some rodents.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 42.8105%; height: 1.38889%;">Vector: Mosquitoes of the genera Aedes, Culex, Mansonia and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.4771%; height: 2.65152%;">others. There is transovarian transmission of RVFV in mos-
quitoes. Dried mosquito eggs can remain viable and infected
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">for years. Originally, the eggs are laid in the damp soil above
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 31.8627%; height: 1.13636%;">the water line and hatch when flooded.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 2.77778%;">Transmission: Human infections occur via two main trans-
mission routes: (1) mosquito bite, and (2) direct or indirect
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.3137%; height: 1.38889%;">contact with the blood or organs of infected animals (e.g.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">slaughtering, butchering, veterinary procedures, animal
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">births, disposing of carcasses or fetuses) by percutaneous
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">inoculation or inhaling aerosols. Transmissionmay be possible
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.3137%; height: 2.77778%;">via consumption of raw milk of an infected animal. Person-to-
person transmission has not been described. However,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">humans develop high viral loads in the blood, and may
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 15.0327%; height: 1.13636%;">transmit virus to contacts.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">Cycle: Animal–mosquito–animal with spillover to humans in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">epidemics via direct/indirect contact to infected animal tissue
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 9.96732%; height: 1.26263%;">or mosquito bite.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 19.7712%; height: 1.38889%;">Incubation period: 2–6 days.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">Clinical findings: A self-limiting disease that lasts for about
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">4 to 7 days. Patients usually experience dengue-like illness
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">with fever, muscle pain, headache, and joint pain. The disease
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">may progress in some cases to one or more of three
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.3137%; height: 1.38889%;">distinct syndromes: ocular (eye) disease (0.5–2% of patients)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 34.3137%; height: 1.38889%;">with retinitis and possible blindness; meningoencephalitis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.4771%; height: 1.38889%;">(about 1%), patients usually recover; or acute hepatitis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 34.4771%; height: 1.26263%;">and hemorrhagic fever (about 1%) with a CFR of 50%. Some
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.2727%; width: 23.2026%; height: 1.38889%;">patients are misdiagnosed as meningitis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 16.7929%; width: 34.3137%; height: 1.38889%;">Diagnostic tests: Serology (IgM ELISA or EIA); RT-PCR on
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">blood in early phase of disease; virus isolation in specialized
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 7.35294%; height: 1.13636%;">laboratories.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.3485%; width: 29.4118%; height: 1.38889%;">Therapy: Supportive, there is no specific treatment.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 25.2525%; width: 34.3137%; height: 1.38889%;">Prevention: An inactivated virus vaccine (not licenced) is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.6414%; width: 34.4771%; height: 1.38889%;">limited available to protect laboratory workers, veterinarians
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.0303%; width: 34.4771%; height: 1.26263%;">and others ‘at risk.’ Livestock vaccines are available, but are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 29.2929%; width: 34.4771%; height: 1.38889%;">not licenced in Europe or the USA. Animal movement should
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.6818%; width: 34.4771%; height: 1.38889%;">be banned during outbreaks. Protective clothing worn by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.0707%; width: 34.4771%; height: 1.38889%;">those exposed to infected animals/tissue. All animal products
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 33.3333%; width: 34.3137%; height: 1.38889%;">(blood, meat and milk) should be thoroughly cooked before
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.7222%; width: 34.4771%; height: 1.38889%;">eating. Infection control for those taking care of severe human
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.1111%; width: 34.4771%; height: 2.65152%;">cases. Personal anti-mosquito precautions. Larviciding at mos-
quito-breeding sites. Early warning systems for RVF are in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.7626%; width: 33.9869%; height: 2.77778%;">place that use satellite images and weather/climate forecast-
ing data.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 43.0556%; width: 34.3137%; height: 1.38889%;">Epidemiology: RVFV primarily causes disease in animals in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 44.3182%; width: 34.4771%; height: 1.38889%;">Africa and Middle East, with human cases occurring during
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.7071%; width: 34.4771%; height: 1.38889%;">animal epidemics. Humans that regularly work with animals
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 47.096%; width: 34.3137%; height: 1.38889%;">(farmers, herders, veterinarians, slaughterhouse workers) are at
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 48.3586%; width: 34.4771%; height: 1.38889%;">increased risk of infection. Epidemics in animals occur when
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.7475%; width: 34.4771%; height: 1.38889%;">mosquito populations dramatically increase after periods of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.0101%; width: 34.4771%; height: 1.38889%;">heavy rainfall or the production of wetlands behind man-made
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 52.399%; width: 34.4771%; height: 1.38889%;">dams. RVF was initially confined to Sub-Saharan Africa, but
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.7879%; width: 34.4771%; height: 1.38889%;">appeared in Egypt in 1977 and was discovered on the Arabian
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.1768%; width: 34.4771%; height: 1.26263%;">Peninsula (Saudi Arabia and Yemen) in 2000 and later also on
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 56.4394%; width: 34.4771%; height: 1.38889%;">the Comoros Islands. As RVFV epidemics are closely associated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.8283%; width: 34.4771%; height: 1.38889%;">with above-average rainfall, outbreaks can be forecasted upon
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.2172%; width: 27.451%; height: 1.26263%;">which preventive measures can be implemented.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 62.1212%; width: 34.1503%; height: 1.38889%;">Map source(s): The Rift Valley Fever map is modified from A.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.3838%; width: 34.4771%; height: 1.38889%;">Clements et al. (2007), with permission, and updated with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 64.7727%; width: 16.8301%; height: 1.38889%;">medical literature up to 2010.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 67.5505%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 68.8131%; width: 34.3137%; height: 1.38889%;">Bouloy M (2001) In Service MW (ed.) Rift Valley fever virus.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.0758%; width: 33.1699%; height: 1.38889%;">The Encyclopedia of Arthropod-transmitted Infections. CAB
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.4646%; width: 15.1961%; height: 1.38889%;">International, pp. 151–159.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 72.8535%; width: 34.3137%; height: 1.38889%;">Clements ACA, et al. (2007) A Rift Valley fever atlas for Africa.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 74.1162%; width: 21.732%; height: 1.13636%;">Prevent Vet Med 8B2:72–82.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 75.5051%; width: 35.6209%; height: 1.38889%;">World Health Organization (2010) Rift Valley Fever. Factsheet
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 76.8939%; width: 9.47712%; height: 1.13636%;">Nr 207. Geneva.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">249
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/e1e64d2f-191a-4b31-9f8a-09b2c021a3db" class="aLF-aPX-aPF-aPE-J3" alt="Page 101 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.who.int/immunization_monitoring/burden/rotavirus_" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.who.int/immunization_monitoring/burden/rotavirus_" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.who.int/immunization_monitoring/burden/rotavirus_&amp;ust=1666162860000000&amp;usg=AOvVaw2_y1xz6N0BSQBEP9P7nGu-&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 52.451%; top: 55.8081%; width: 34.1503%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 102 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 41.3399%; height: 2.0202%;">Disease: Rotaviral Enteritis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 25%; height: 1.26263%;">Classification: ICD-9 008.61; ICD-10 A08.0
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">Synonyms: Rotavirus diarrhea, acute viral gastroenteritis,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 15.5229%; height: 1.38889%;">severe viral gastroenteritis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">Agent: Rotavirus, a non-enveloped double-stranded RNA
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">virus within the Reoviridae family, is classified into 7 rotavirus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.3137%; height: 1.38889%;">groups (A–G) as determined by the antigenic properties of the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">VP6 capsid protein. Group A is most common in human
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.3137%; height: 1.38889%;">disease, with B and C to a lesser extent. Subgroups and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 34.4771%; height: 2.77778%;">serotypes are determined by sero- and genotyping the epi-
topes P and G, of the VP4 and VP7 outer capsid proteins,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.3137%; height: 1.38889%;">respectively. These proteins are relevant for vaccine efficacy.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.4771%; height: 1.13636%;">Reservoir: Humans. Rotaviruses in animals are distinct from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 18.9542%; height: 1.38889%;">those causing disease in humans.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 12.9085%; height: 1.13636%;">Vector: None
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.4771%; height: 2.77778%;">Transmission:Direct fecal–oral transmission and via contam-
inated surfaces. Rotavirus has also been detected in repiratory
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 6.20915%; height: 1.0101%;">secretions.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 19.7712%; height: 1.38889%;">Incubation period: 1 to 3 days.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">Clinical findings: Fever, vomiting, and watery diarrhea, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.4771%; height: 2.77778%;">signs of dehydration in severe cases (mainly in young chil-
dren). In adults the disease is often subclinical. Symptoms last
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 11.6013%; height: 1.13636%;">for about one week.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Rotavirus antigen detection by EIA and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 21.5686%; height: 1.38889%;">other serological techniques; RT-PCR.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 25.4902%; height: 1.26263%;">Therapy: Supportive, including rehydration.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 1.13636%;">Prevention: Two licensed oral live attenuated rotavirus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.4771%; height: 1.13636%;">vaccines are available. Surveillance is needed to collect
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">data on the burden of rotaviral disease and the circulating
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.3137%; height: 1.38889%;">strains to assess the potential impact of vaccine introduction.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.13636%;">Virus is shedded before and until 1 week after onset of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">illness and can survive for a prolonged period of time on hard
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">surfaces, hands, and in water. Improved sanitation, access to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">clean water, and hygiene have not yet shown to reduce
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 16.1765%; height: 1.13636%;">rotavirus disease incidence.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 23.4848%; width: 34.3137%; height: 1.38889%;">Epidemiology: Group A rotaviruses have been established as
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">the single most important cause of severe acute gastroenteritis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 34.3137%; height: 1.38889%;">in young children in developed and developing nations.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">Rotavirus is estimated to cause 138 million diarrheal episodes
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">per year with 2 million requiring hospitalization and 440,000
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.3137%; height: 1.38889%;">deaths in children of &lt;5 years. The incidence of rotavirus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.3137%; height: 1.38889%;">disease is similar in developed and developing countries,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">but deaths mainly occur in poverty stricken nations due to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">poor health infrastructure. Control is likely not achieved by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.3137%; height: 1.38889%;">improvements in clean water access, hygiene, and sanitation.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">Rotavirus vaccines are recommended to prevent severe and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">fatal rotavirus disease. For vaccine introduction, knowledge of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">the regional circulating rotavirus serotypes is needed. The
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">epidemiology of rotavirus serotypes has substantial temporal
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 2.77778%;">and geographic variability and multiple serotypes may cocir-
culate within the same region and fluctuates each year within
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">the same region. The 5 most common rotavirus serotypes
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 46.3384%; width: 34.3137%; height: 1.38889%;">(G1–G4 and G9) were responsible for approximately 95% of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">infections world wide with G1[P8] responsible for more than
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">70% of infections in North America, Australia, and Europe but
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 33.1699%; height: 1.38889%;">only 30% of infections in South America, Asia, and Africa.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 53.1566%; width: 34.3137%; height: 1.38889%;">Map sources: The Rotavirus Enteritis map was made with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.3137%; height: 1.38889%;">data obtained from M. O’Ryan (2009) and WHO, available at:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 34.1503%; height: 1.38889%;">www.who.int/immunization_monitoring/burden/rotavirus_
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 8.82353%; height: 1.26263%;">estimates/en/.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 59.8485%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">O’Ryan M (2009) The ever-changing landscape of rotavirus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 62.5%; width: 22.7124%; height: 1.38889%;">serotypes. Ped Infect Dis J 28(3):S60–S62.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 34.4771%; height: 1.26263%;">Parashar UD, et al. (2006) Rotavirus and severe childhood
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 65.1515%; width: 24.183%; height: 1.38889%;">diarrhea. Emerg Infect Dis 12(2):304–306.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.5404%; width: 35.9477%; height: 1.26263%;">MMWR (2008) Rotavirus surveillance – Worldwide, 2001–
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 67.9293%; width: 24.6732%; height: 1.26263%;">2008. MMWR 57(46):1255–1257.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">251
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/8f581e12-161e-4f1a-86d2-0a54c7dc2ff4" class="aLF-aPX-aPF-aPE-J3" alt="Page 102 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.who.int/immunization_" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.who.int/immunization_" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.who.int/immunization_&amp;ust=1666162860000000&amp;usg=AOvVaw0Z00rN-2EIlGRJTM036cz3&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 69.4444%; top: 51.7677%; width: 17.4837%; height: 1.26263%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 103 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 25.1634%; height: 2.0202%;">Disease: Rubella
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 22.2222%; height: 1.26263%;">Classification: ICD-9 056; ICD-10 B06
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 16.8301%; height: 1.26263%;">Synonyms: German measles
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">Agent: Rubella virus, a single-stranded RNA positive-sense
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 20.4248%; height: 1.38889%;">rubivirus of the family Togaviridae.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.2626%; width: 14.5425%; height: 1.0101%;">Reservoir: Humans.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 12.9085%; height: 1.13636%;">Vector: None.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.4771%; height: 4.0404%;">Transmission: By airborne droplets from respiratory secre-
tions of infected persons. Subclinical cases can transmit infec-
tion. Rubella virusmay be transmitted to the fetus if the mother
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 16.8301%; height: 1.38889%;">is infected during pregnancy.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 29.085%; height: 1.38889%;">Incubation period: 16–18 days (range 12–24 days)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">Clinical findings: A generally mild and short-lived illness
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.4771%; height: 1.38889%;">with fever, coryza, conjunctivitis, lymphadenopathy, and a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">fine maculopapular rash beginning on the face later spreading
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">to the trunks and limbs. Postauricular, occipital or posterior
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.3137%; height: 1.38889%;">cervical lymphadenopathy may precede the rash by 5–10 days.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.4771%; height: 2.77778%;">Around half of rubella infections are subclinical and constitu-
tional symptoms may be minimal in children. Arthropathy
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">may occur, especially in young women. The most important
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">clinical consequence of rubella is congenital rubella syndrome
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">(CRS), which may result from intra-uterine infection in thefirst
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">16 weeks of pregnancy. CRS is a severe disease characterized
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">by deafness, cataract, cardiac abnormalities, and a range of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 15.0327%; height: 1.38889%;">neurological impairments.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Rubella specific IgM or significant rise in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">antibody titer in paired samples; RT-PCR or virus isolation
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 25.9804%; height: 1.38889%;">from throat swab, or other specimens in CRS.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">Therapy: Supportive only. Human immunoglobulin has been
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">given to pregnantwomen exposed to rubella and infected with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">rubella in an attempt to prevent infection or CRS, but its
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 12.7451%; height: 1.38889%;">efficacy is not proven.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.4771%; height: 2.65152%;">Prevention: Live attenuated virus vaccine, usually in combi-
nation with measles and mumps virus vaccine, at 12–18
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 19.6078%; height: 1.38889%;">months with a pre-school booster.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 16.7929%; width: 34.3137%; height: 1.26263%;">Epidemiology: World wide, but close to elimination in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.3137%; height: 1.38889%;">Americas and targeted for elimination in Europe by 2015.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 2.77778%;">In the absence of vaccination the prevalence of rubella infec-
tion by the age of 13 years ranges from 20 to 95%, but is most
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">often over 50%. Reported data on clinical rubella are a vast
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">underestimate since it is a mild disease with a clinical picture
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 34.4771%; height: 2.65152%;">similar to several other infections. CRS is also grossly under-
reported. For example, it is estimated that over 45,000 CRS
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">cases occur annually in Southeast Asia yet only an average of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 28.9141%; width: 34.3137%; height: 1.38889%;">13 CRS cases per year were reported to WHO between 2000
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">and 2009. Rubella is a public health concern because of CRS
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.26263%;">and in 1996 it was estimated that 110,000 CRS cases occurred
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">annually in developing countries. Paradoxically, a poor
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">rubella immunization program may actually increase the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">incidence of CRS if the burden of illness is shifted to young
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 4.0404%;">adults, where pregnancy is common. Therefore rubella immu-
nization programs must achieve and maintain high immuni-
zation rates ( &gt; 80%) or be supplemented by the immunization
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">of women of childbearing age. In 2009 two-thirds of countries
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 2.77778%;">included a rubella containing vaccine in their national immu-
nization schedule yet in many developing countries rubella
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.0101%;">vaccine has not been included because of lack of information
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">on the burden of CRS, costs, and concerns about causing a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 19.6078%; height: 1.38889%;">paradoxical increase in CRS cases.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 50.3788%; width: 34.1503%; height: 1.38889%;">Map source: The Rubella map was made with data obtained
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.26263%;">from WHO, available at: www.who.int/immunization_
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 9.80392%; height: 1.38889%;">monitoring/en/.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 55.8081%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 34.3137%; height: 1.38889%;">Brown DW, et al. (2004) Rubella. Lancet 363(9415):1127–1137.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">Centers for Disease Control and Prevention (2010) Progress
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 59.8485%; width: 33.1699%; height: 1.38889%;">toward control of rubella and prevention of congenital
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 61.2374%; width: 45.098%; height: 1.26263%;">rubella syndrome - Worldwide, 2009. MMWR 59(40):
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 62.5%; width: 6.37255%; height: 1.13636%;">1307–1310.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">Cutts FT, et al. (1999) Modelling the incidence of congenital
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 65.1515%; width: 33.1699%; height: 1.38889%;">rubella syndrome in developing countries. Int J Epidemiol
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 66.5404%; width: 9.47712%; height: 1.26263%;">28(6):1176–1184.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">World Health Organization (2009) State of the World’s Vaccines
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.1919%; width: 33.1699%; height: 1.26263%;">and Immunization, 3rd edn. WHO, UNICEF, World Bank.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 70.5808%; width: 4.90196%; height: 1.13636%;">Geneva.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">253
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/9d07cee7-7200-4974-b201-ef9b7347859f" class="aLF-aPX-aPF-aPE-J3" alt="Page 103 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.who.int/csr/dis-ease/en/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.who.int/csr/dis-ease/en/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.who.int/csr/dis-ease/en/&amp;ust=1666162860000000&amp;usg=AOvVaw3K11oRqg6w9OsnQcpNSJ4S&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 52.451%; top: 54.4192%; width: 34.4771%; height: 2.65152%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 104 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 69.1176%; height: 2.39899%;">Disease: Severe Acute Respiratory Syndrome
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 17.1569%; height: 1.26263%;">Classification: ICD-10 J12.81
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.5707%; width: 15.1961%; height: 1.13636%;">Synonyms: SARS
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">Agent: SARS coronavirus (SARS-CoV) is a positive-sense,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.3137%; height: 2.65152%;">single-stranded, enveloped RNA virus of the family Corona-
viridae. The viral membrane contains a transmembrane (M)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.3137%; height: 1.38889%;">glycoprotein, spike (S) glycoprotein, and envelope (E) protein.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 33.9869%; height: 2.77778%;">Coronaviruses derive their name from the crown-like (corona-
like) morphology on electron microscopy.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">Reservoir: Although SARS-like coronaviruses with very high
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">genetic homology to SARS-CoV have been identified in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">masked palm civets, civets are thought to be a non-reservoir,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">spillover species. Horseshoe bats are thought to be the natural
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 25.817%; height: 1.38889%;">reservoir of the progenitor of the SARS virus.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 12.9085%; height: 1.13636%;">Vector: None.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.4771%; height: 1.38889%;">Transmission: Direct person-to-person transmission, usually
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 4.0404%;">following close contact with a symptomatic case or the respi-
ratory secretions or body fluids of a symptomatic case. Health-
care facilities were key in amplifying the transmission of SARS
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">in 2003. Respiratory droplets or contaminated surfaces are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">thought to be the principal routes of transmission, although
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 33.9869%; height: 2.77778%;">one outbreak in a residential block in Hong Kong was attrib-
uted to aerosol spread.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 19.7712%; height: 1.38889%;">Incubation period: 4–5 days.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 2.77778%;">Clinical findings: SARS presents initially with fever, head-
ache, myalgia, and a non-productive cough that may progress
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.3137%; height: 1.38889%;">to dyspnoea with pulmonary infiltrations on chest x-ray.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">Gastrointestinal symptoms may also be present in early
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.4771%; height: 1.38889%;">SARS illness. Case fatality is around 10%, and is higher in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 27.1242%; height: 1.38889%;">older adults than in children and young adults.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.3137%; height: 1.38889%;">Diagnostic tests: Detection of virus in respiratory specimens,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">stool or blood by RT-PCR; virus isolation; serology by IFA or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.3137%; height: 1.38889%;">ELISA. Specimen processing and testing should be performed
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 22.549%; height: 1.38889%;">under strict biosafety measures (BSL-3).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 31.5359%; height: 1.38889%;">Therapy: Supportive, no specific treatment is available.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 19.4444%; width: 34.3137%; height: 1.13636%;">Prevention: The control of wildlife farms and markets to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.4771%; height: 1.38889%;">reduce the risk of transmission from bats to humans through
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">an intermediate species. Rapid case detection and isolation,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 33.9869%; height: 2.77778%;">contact tracing and quarantine, and stringent hospital infec-
tion control effectively controlled the SARS outbreak.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.3137%; height: 2.77778%;">Epidemiology: SARS is thought to have emerged in Guang-
dong Province, China, in November 2002 and within 6 months
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.26263%;">cases were detected in 26 countries, with local transmission
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">occurring in 6. In total over 8,000 cases and almost 800 deaths
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 41.1765%; height: 5.42929%;">were recorded and, remarkably, much of the global transmis-
sion of SARS can be traced to a single individual who dissemi-
nated infection at a hotel in Hong Kong. ‘Super spreading’ events (where one person infects an unusually large number of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">people), such as occurred at the Hong Kong Hotel, appear to be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">an important feature of SARS epidemiology. The precise
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">circumstances and timing of the interspecies transfer of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">SARS-CoV remains unknown. Many of the early cases in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">Guangdong had epidemiological links to the wild animal
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">trade but later the transmission of SARS was exclusively
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 2.77778%;">person-to-person with a large nosocomial element. Labora-
tory-accident associated cases in late 2003 and April 2004, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">a cluster linked to the wild animal trade in January 2004,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 30.2288%; height: 1.38889%;">highlight the potential for the re-emergence of SARS.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 53.1566%; width: 34.3137%; height: 1.38889%;">Map sources: The Severe Acute Respiratory Syndrome map is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 33.9869%; height: 2.65152%;">reproduced from WHO, available at: www.who.int/csr/dis-
ease/en/.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 58.5859%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">Anderson RM, et al. (2004) Epidemiology, transmission
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 61.2374%; width: 33.0065%; height: 1.26263%;">dynamics and control of SARS: the 2002–2003 epidemic.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 62.5%; width: 30.719%; height: 1.38889%;">Philos Trans R Soc Lond B Biol Sci 359(1447):1091–1105.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">Poon LL, et al. (2004) The aetiology, origins, and diagnosis of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 65.1515%; width: 33.1699%; height: 1.38889%;">severe acute respiratory syndrome. Lancet Infect Dis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 66.5404%; width: 8.16994%; height: 1.26263%;">4(11):663–671.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">Wanh LG, et al. (2006) Review of bats and SARS. Emerg Infect
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.1919%; width: 12.2549%; height: 1.38889%;">Dis 12(12):1834–1840.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">255
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/709b4f0c-4a75-4b8b-a450-ecee4266c5b3" class="aLF-aPX-aPF-aPE-J3" alt="Page 104 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 105 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 34.4771%; height: 2.0202%;">Disease: Sindbis Fever
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.3464%; height: 1.26263%;">Classification: ICD-9 066.3; ICD-10 A92.8
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 33.9869%; height: 2.65152%;">Syndromes and synonyms: Ockelbo disease, Pogosta dis-
ease, Karelian fever
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">Agent: Sindbis virus (SINV), a single-stranded, positive sense,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 2.65152%;">enveloped RNA alphavirus, with 5 genotypes: SIN I (Euro-
pean/African), SIN II and III (Asian/Australian), SIN IV
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 43.1373%; height: 1.38889%;">(Azerbaijan/China), and SIN V (New Zealand). The first
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">Sindbis virus isolated was cultured in 1952 from a mosquito
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 34.3137%; height: 1.38889%;">near Sindbis village in the Nile Delta (Egypt). Almost 10 years
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">later the first human case was detected in Uganda in 1961 and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 10.6209%; height: 1.38889%;">in Europe in 1971.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">Reservoir: Wild, migratory birds of the order Passeriformes
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.3137%; height: 1.38889%;">(mainlyfieldfare, redwing, and songthrush) and Anseriformes
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">(ducks, geese and swans). Tetraonid birds (grouse) population
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">size changes coincide with SINV epidemics in Finland. Larger
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">passerine species have higher prevalences of infection as
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 16.5033%; height: 1.38889%;">compared to smaller species.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">Vector: Mosquitoes: Culex and Culiseta spp. between birds,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 18.1373%; height: 1.38889%;">Aedes spp. from bird to human.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 19.1176%; height: 1.38889%;">Transmission: By mosquito bite.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.3137%; height: 1.38889%;">Cycle: Probably bird–mosquito–bird. Mosquitoes become
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">infected when feeding on viremic reservoir birds. This is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">followed by an extrinsic cycle of a few days in the mosquito,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.3137%; height: 1.38889%;">with subsequent transmission to birds or humans by bite.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.13636%;">Humans are a dead-end host. There is evidence for vertical
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 23.8562%; height: 1.38889%;">(transovarial) transmission in mosquitoes.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">Incubation period: Varies from a few days to just over a week,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 17.1569%; height: 1.38889%;">depending on infectious dose.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">Clinical findings: The majority of infections are subclinical
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">( 95%). Those with disease have mild fever, maculopapular
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">rash often involving the palms and soles, which may be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.3137%; height: 1.38889%;">hemorrhagic and may recur, polyarthritis of both large and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">small joints, occasionally swollen extremities, anorexia, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.4771%; height: 1.38889%;">lymphadenopathy. The disease is more severe in Scandinavia
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 34.4771%; height: 1.26263%;">and South Africa than elsewhere. The disease is non-fatal, but
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.4771%; height: 1.38889%;">moderate residual pain and stiffness in the joints may persist
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 5.71895%; height: 1.26263%;">for years.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 33.9869%; height: 2.77778%;">Diagnostic tests: Detection of viral RNA in blood by RT-
PCR; serology (IgM ELISA); virus culture.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 30.5556%; height: 1.38889%;">Therapy: Symptomatic, there is no specific treatment.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 23.4848%; width: 34.3137%; height: 1.38889%;">Prevention: Anti-mosquito precautions; there is no vaccine
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 5.71895%; height: 1.13636%;">available.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 27.5253%; width: 34.3137%; height: 1.26263%;">Epidemiology: SINV has been isolated from Africa, Eurasia,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">and Australia. The highest disease burden is in northern
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 38.2353%; height: 1.38889%;">Europe (approximately between 60 and 64 N) and South
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">Africa. Evolutionary studies show that SINV likely originated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 2.65152%;">from South America, with subsequent spread to North Amer-
ica, Asia, and Australia, with later spread to Europe and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">Africa. Intererestingly, there are high levels of gene sequence
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.26263%;">similarities of SINV isolates within the same north–south axis,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">which correlates with major bird migration patterns (see Bird
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">Migration map). Preferred habitat is a wetland ecosystem. The
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.3137%; height: 1.38889%;">disease is seasonal, coinciding with the period of mosquito
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">abundance and reservoir presence. Overwintering in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">northern hemisphere may be by vertical transmission in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">vectors. In Scandinavia, most cases occur in July through
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.3137%; height: 2.77778%;">September, when there is plenty of vector species. Peak inci-
dence in Karelia is about one month after the peak in Finland.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">Highest attack rates in Finland are in the eastern parts, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">mainly in the age group 45 to 65 years. Epidemics tend to occur
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">every 7 years in Finland, with the last epidemic in 2002. No
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">epidemic occurred in 2009, probably due to a decline in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 10.9477%; height: 1.38889%;">grouse population.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 57.0707%; width: 34.3137%; height: 1.38889%;">Map source: The Sindbis Fever map was made with data on
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 34.4771%; height: 1.13636%;">human Sindbis virus isolations obtained from S. Kurkela
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 7.18954%; height: 1.26263%;">et al. (2004).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 62.6263%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 35.7843%; height: 1.38889%;">Hubalek Z (2008) Mosquito-borne viruses in Europe. Parasitol
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 65.1515%; width: 14.7059%; height: 1.38889%;">Res 103(Suppl 1):S29–S43.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">Kurkela S, et al. (2004) Causative agent of Pogosta disease
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 67.9293%; width: 33.1699%; height: 1.38889%;">isolated from blood and skin lesions. Emerg Infect Dis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.1919%; width: 8.16994%; height: 1.38889%;">10(5):889–894.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">Lundstrom JO, et al. (2010) Phylogeographic structure and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 33.1699%; height: 1.38889%;">evolutionary history of Sindbis virus. Vector Borne Zoonotic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 73.2323%; width: 11.7647%; height: 1.38889%;">Dis 10(9):899–907.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 74.6212%; width: 38.0719%; height: 2.65152%;">Sane J, et al. (2010) Epidemiological analysis of mosquito-
borne Pogosta disease in Finland, 2009. Euro Surveill 15(2)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 77.399%; width: 5.71895%; height: 1.26263%;">pii:19462.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">257
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/6c7406e7-a2be-4e50-98da-c0e56fd27198" class="aLF-aPX-aPF-aPE-J3" alt="Page 105 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 106 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 62.9085%; height: 2.39899%;">Disease: Tacaribe Complex Virus Disease
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 23.366%; height: 1.26263%;">Classification: ICD-9 078.7; ICD-10 A96
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.4771%; height: 2.77778%;">Syndromes and synonyms: Argentinian (Junin virus), Boli-
vian (Machupo virus), Brazilian (Sabia virus), and Venezuelan
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 21.5686%; height: 1.38889%;">(Guanarito virus) hemorrhagic fevers.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 2.65152%;">Agent: Tacaribe complex viruses are spherical or pleomor-
phic, enveloped arenaviruses containing two single-stranded
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">RNA molecules, with four distinct lineages (A, B, C, and a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.4771%; height: 1.26263%;">recombinant RecA). Out of more than 20 known arenaviruses,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 34.3137%; height: 1.38889%;">only the following have been associated with human disease:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">Chapare, Guanarito, Junin, Machupo, Sabia, and Whitewater
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">Arroyo viruses. All South American hemorrhagic fever
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">viruses, except Whitewater Arroyo virus, are classified as
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">high-priority bioterrorism pathogens. Other Tacaribe complex
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.4771%; height: 1.38889%;">arenaviruses are capable of infecting humans and possibly
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 8.16994%; height: 1.13636%;">cause disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.3137%; height: 1.13636%;">Reservoir: Each virus is associated with either one or a few
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 44.7712%; height: 2.77778%;">closely related species of rodents, which constitute the virus’s natural reservoir. Tacaribe complex viruses in the New World
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">are generally associated with rats and mice (family Muridae,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 2.77778%;">subfamily Sigmodontinae). The reservoir rodents are chroni-
cally infected, and the virus is transmitted among them,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">leading to lifelong viremia and virus excretion, and they do
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 41.6667%; height: 1.38889%;">not die. The reservoir for Junin virus is Calomys musculinus and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">C. laucha, for Machupo virus, C. callosus, for Guanarito virus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">Zygodontomys brevicauda, and for Whitewater Arroyo virus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">Neotoma albigula. For Sabia and Chapare viruses the reservoir
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 10.1307%; height: 1.13636%;">host is unknown.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 12.9085%; height: 1.13636%;">Vector: None.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.3137%; height: 1.26263%;">Transmission: By contact with the excretions, or materials
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.4771%; height: 1.26263%;">contaminated with the excretions, of an infected rodent, such
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">as ingestion of contaminated food or by direct contact of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.4771%; height: 1.13636%;">abraded or broken skin with rodent excrement. Infection
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">can also occur by inhalation of minute particles soiled with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">rodent urine or saliva (aerosol transmission). Person-to-person
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 32.1895%; height: 1.38889%;">transmission is rare and known only for Machupo virus.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 28.4314%; height: 1.38889%;">Incubation period: 5–21 days; usually 7–14 days.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.4771%; height: 1.26263%;">Clinical findings: Gradual onset of malaise, headache, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 34.4771%; height: 1.26263%;">retro-orbital pain, conjunctivitis, fever, and sweats, followed by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.2727%; width: 34.4771%; height: 1.38889%;">prostration. Petechiae on the soft palate are frequent, on the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 78.6616%; width: 34.4771%; height: 1.38889%;">body with ecchymoses less frequent. In severe cases: epistaxis,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.3137%; height: 1.38889%;">hematemesis, melena, hematuria, and gingival hemorrhage.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">Enceplalopathy, intention tremors, depressed deep tendon
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 4.16667%;">reflexes, bradycardia, and hypotension with shock are com-
mon. Infection during pregnancy can result in abortion. Con-
valescence may be prolonged. CFR due to these viruses, even
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 31.8627%; height: 1.38889%;">after intensive hospital treatment, can be as high as 33%.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 26.0101%; width: 34.3137%; height: 1.38889%;">Diagnostic tests: Virus detection in blood or tissue by culture
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.2727%; width: 34.4771%; height: 1.38889%;">or RT-PCR; serology (IgM ELISA, IFA). Virus isolation should
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.6616%; width: 17.4837%; height: 1.38889%;">be done in a BSL-4 laboratory.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.1869%; width: 34.4771%; height: 1.38889%;">Therapy: Supportive treatment; ribavirin. Junin convalescent
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.4495%; width: 34.4771%; height: 1.38889%;">serum reduces the CFR of Argentinian hemorrhagic fever to &lt;1%.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.9747%; width: 34.4771%; height: 2.65152%;">Prevention: There is a vaccine against Junin virus only. Tar-
geted rodent control in houses, except for Junin virus, which is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 37.6263%; width: 31.0458%; height: 1.38889%;">spread by rodents in the fields. Barrier nursing of cases.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 40.1515%; width: 34.3137%; height: 1.38889%;">Epidemiology: Junin virus is spread annually around harvest
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.4141%; width: 34.3137%; height: 2.77778%;">time by rodents to farmers. The range of Junin virus is extend-
ing to the north, putting an estimated 5 million people at risk.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 44.1919%; width: 34.4771%; height: 1.38889%;">The other viruses are brought into villages and houses by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.4545%; width: 34.4771%; height: 2.77778%;">peridomestic rodents, causing sporadic outbreaks with inter-
vals of several years. Deforestation and human invasion into
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 48.1061%; width: 34.4771%; height: 2.52525%;">rodent habitat may have resulted in increased human expo-
sure to infected rodents and a concomitant increase in human
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.8838%; width: 34.4771%; height: 1.38889%;">illnesses (see Forest Cover map). Only single cases of an
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 52.1465%; width: 34.3137%; height: 1.38889%;">infection by Sabia and Chapare viruses have been recorded.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.5354%; width: 34.4771%; height: 1.38889%;">Pathogenicity of Whitewater Arroyo virus remains to be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.9242%; width: 33.9869%; height: 2.39899%;">confirmed since there was no virus isolation from the Cali-
fornian cases.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 58.7121%; width: 34.3137%; height: 1.38889%;">Map source(s): The Tacaribe Complex Virus Disease map was
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 60.101%; width: 34.4771%; height: 1.38889%;">made by geolocating reported human outbreaks in the medical
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.3636%; width: 19.281%; height: 1.13636%;">literature between 1960 and 2008.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 63.8889%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 33.9869%; height: 2.77778%;">Bowen MD, et al. (1996) The phylogeny of New World (Tacar-
ibe complex) arenaviruses. Virology 219:285–290.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 67.9293%; width: 33.9869%; height: 2.65152%;">Charrel RN, et al. (2010) Zoonotic aspects of arenavirus infec-
tions. Vet Microbiol 140(3–4):213–220.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.5808%; width: 34.3137%; height: 1.26263%;">Centers for Disease Control and Prevention (2005) Arenavirus.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 71.9697%; width: 34.4771%; height: 2.65152%;">CDC factsheet. Delgado S, et al. (2008) Chapare virus, a newly discovered
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 74.6212%; width: 33.1699%; height: 1.38889%;">arenavirus isolated from a fatal hemorrhagic fever case in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 75.8838%; width: 22.8758%; height: 1.38889%;">Bolivia. PLoS Path 4(4):e1000047.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 77.2727%; width: 42.3203%; height: 1.38889%;">Jay MT, et al. (2005) The arenaviruses. J Am Vet Med Assoc 227
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 78.6616%; width: 6.86275%; height: 1.38889%;">(6):904–915.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">259
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/68495ff7-a38e-47b2-8ea3-b4cc06bf7c1a" class="aLF-aPX-aPF-aPE-J3" alt="Page 106 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.baxter.com/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.baxter.com/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.baxter.com/&amp;ust=1666162860000000&amp;usg=AOvVaw2ho4oS1a2dgSTYhlX-LQGS&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 71.8954%; top: 58.4596%; width: 14.8693%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 107 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 49.8366%; height: 2.39899%;">Disease: Tick-borne Encephalitis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 27.1242%; height: 1.26263%;">Classification: ICD-9 063; ICD-10 A84.0, A84.1
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">Synonyms: TBE, Western, European or Central European
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 34.4771%; height: 1.38889%;">tick-borne encephalitis, Siberian tick-borne encephalitis, Far
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">Eastern tick-borne encephalitis (formerly known as Russian
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">Spring Summer encephalitis), diphasic milk fever, diphasic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 11.9281%; height: 1.38889%;">meningoencephalitis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">Agent: Tick-borne encephalitis (TBE) virus, an enveloped
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">RNA virus with three subtypes: European (EUR), Siberian
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 15.6863%; height: 1.38889%;">(SIB), and Far-Eastern (FE).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.3137%; height: 1.38889%;">Reservoir: The only real reservoir is the tick. Viremia persists
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 34.3137%; height: 1.26263%;">only for a few days in transmission competent vertebrates,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 33.9869%; height: 2.77778%;">rodents (mainly Apodemus spp.). Deer, birds, possibly mar-
mots are not competent to transmit to ticks.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">Vector: Hard ticks, with Ixodes ricinus as the most important
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 36.9281%; height: 1.38889%;">vector of the European subtype and I. persulcatus for the other
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 5.71895%; height: 1.38889%;">subtypes.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">Transmission: Via tick bite. Or consumption of raw milk or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">dairy products from infected animals. For EUR, rarely, by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 19.7712%; height: 1.13636%;">blood transfusion and breast milk.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">Cycle: Wildlife–tick–wildlife. The tick ingests infected blood
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">of reservoir host, virus passes from gut to hemocoele to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">salivary glands and is transmitted to a new host at the next
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">feed. The virus is transmitted from tick to tick trans-stadially
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 33.9869%; height: 2.39899%;">and transovarially. Trans-stadial transmission is key to tick-
borne infections.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 27.2876%; height: 1.38889%;">Incubation period: 4–28 days (median 8 days).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.3137%; height: 1.38889%;">Clinical findings: TBE causes acute meningitis, encephalitis,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">or meningoencephalitis with or without myelitis. Severity of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.1515%; width: 34.3137%; height: 1.38889%;">disease increases with age, with an excess of males and is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.3137%; height: 1.38889%;">highest in adults, of whom half develop encephalitis. It begins
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">with fever (99%), fatigue, and general malaise (62%), headache
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 2.77778%;">and body pain (54%). In diphasic infections (EUR), neurologi-
cal symptoms appear 4–10 days after apparent recovery. FE
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.4771%; height: 1.38889%;">disease is often severe with signs of encephalitis, focal epilepsy
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 34.4771%; height: 1.38889%;">and flaccid paralysis of the shoulder girdle (CFR: 5–40%); EUR
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.4771%; height: 1.38889%;">is a milder disease, with death and severe sequelae less
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 34.4771%; height: 2.65152%;">frequent than in FE. Long-lasting or permanent neuropsychi-
atric sequelae are observed in 10–20% or more of infected
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 1.38889%;">patients. Infections with the European and Siberian subtypes
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 16.0131%; height: 1.26263%;">are less severe (CFR: 1–3%).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.1503%; height: 2.77778%;">Diagnostic tests: IgM serology on paired sera; specific iden-
tification to subtype by virus isolation; RT-PCR.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 29.4118%; height: 1.38889%;">Therapy: Supportive, there is no specific treatment.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 2.77778%;">Prevention: Avoid tick bites, use repellent on skin and repel-
lent or acaricide on clothing, check body daily for ticks after
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">exposure, boil or pasteurize milk from cows, sheep, and goats
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 45.2614%; height: 2.77778%;">in endemic areas. An inactivated vaccine is available. Specific hyperimmune globulin used in the past as prophylaxis after
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 18.9542%; height: 1.26263%;">tick-bite may worsen the disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 36.995%; width: 34.3137%; height: 1.38889%;">Epidemiology: The disease is seasonal, generally coinciding
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">with tick activity; there are peaks of incidence every 5–7 years
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">in China. Europe and Russia have an estimated 12,000 cases
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">per year (2007). In eastern regions the disease coincides with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">tick habitat in cold, moist forest, but tick ranges extend well
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 2.77778%;">beyond reported disease at both eastern and western geo-
graphical extremes. During the past two decades, new
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">endemic foci and an increase in cases have been reported in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">many European countries, in spite of widespread vaccination
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">of at-risk populations. In 1989, FE virus was isolated from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">Ixodes ovatus ticks and the blood of a febrile patient in Yunnan
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">province, southwestern China. The virus may have completely
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.13636%;">different rodent hosts and tick vectors from those in northern
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 4.08497%; height: 1.13636%;">China.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 57.0707%; width: 34.3137%; height: 1.38889%;">Map sources: The Tick-Borne Encephalitis map is modified
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 34.3137%; height: 1.38889%;">from the maps produced by Baxter (http://www.baxter.com/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 32.3529%; height: 1.38889%;">press_room/factsheets/vaccines/tick-borne_encephalitis.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.2374%; width: 34.3137%; height: 1.26263%;">html) and L. Lindquist et al. (2008). Baxter produces a TBE
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 62.5%; width: 34.4771%; height: 1.38889%;">vaccine and for this purpose keeps track of the TBE
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 7.18954%; height: 1.13636%;">distribution.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 66.6667%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 67.9293%; width: 34.3137%; height: 1.38889%;">Dumpis U, et al. (1999) Tick-borne encephalitis. Clin Infect Dis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.1919%; width: 8.16994%; height: 1.38889%;">28(4):882–890.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.5808%; width: 36.4379%; height: 1.38889%;">Lindquist L, et al. (2008) Tick-borne encephalitis. Lancet
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 12.0915%; height: 1.26263%;">371(9627):1861–1871.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 73.2323%; width: 45.7516%; height: 1.38889%;">Mansfield KL, et al. (2009) Tick-borne encephalitis virus – a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 74.6212%; width: 36.1111%; height: 1.38889%;">review of an emerging zoonosis. J Gen Virol 90(Pt
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 76.0101%; width: 7.84314%; height: 1.26263%;">8):1781–1794.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 77.2727%; width: 34.3137%; height: 1.38889%;">Lu Z, et al. (2008) Tick-borne encephalitis in mainland China.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 78.6616%; width: 23.8562%; height: 1.38889%;">Vector Borne Zoonotic Dis 8(5):713–720.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">261
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/e1684e15-349e-4e1e-b74d-00bbafa4c3fc" class="aLF-aPX-aPF-aPE-J3" alt="Page 107 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.eurocjd.ed.ac.uk" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.eurocjd.ed.ac.uk" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.eurocjd.ed.ac.uk&amp;ust=1666162860000000&amp;usg=AOvVaw19Cj_ihNCGoYRIcW9p42g_&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 52.451%; top: 67.9293%; width: 13.0719%; height: 1.38889%;"></a><a href="http://www.oie.int/eng/info/en_" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.oie.int/eng/info/en_" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.oie.int/eng/info/en_&amp;ust=1666162860000000&amp;usg=AOvVaw37ybIsMbwE0jMIDpujyWN_&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 71.0784%; top: 67.9293%; width: 15.8497%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 108 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 66.5033%; height: 2.0202%;">Disease: Variant Creutzfeldt–Jakob Disease
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.3464%; height: 1.26263%;">Classification: ICD-9 046.1; ICD-10 A81.0
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 33.9869%; height: 2.77778%;">Synonyms: vCJD, mad cow disease, transmissible spongi-
form encephalopathy, prion disease.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">Agent: The etiological agent of variant Creutzfeldt–Jakob
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 2.65152%;">Disease (vCJD) is thought to be an abnormal form of a natu-
rally occurring host protein, which is transmissible and can
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">transform normal host protein into the pathogenic form,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.4771%; height: 2.65152%;">known as ‘prions.’ vCJD refers specifically to the neurodegen-
erative prion disease of humans and is associated with Bovine
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.3137%; height: 1.38889%;">Spongiform Encephalopathy (BSE), a prion disease of cows.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.4771%; height: 2.65152%;">vCJD is clinically and neuropathologically distinct from spo-
radic CJD, which is endemic throughout the world and has no
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 16.6667%; height: 1.13636%;">known association with BSE.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 33.9869%; height: 1.38889%;">Reservoir: Cattle with Bovine Spongiform Encephalopathy.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">Transmission route: Thought to be acquired primarily
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.3137%; height: 1.38889%;">through ingestion of infected tissue from cattle with BSE.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 2.65152%;">Iatrogenic transmission has occurred through blood transfu-
sion. To date there have been no known transmissions of vCJD
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">by tissue or organ transplantation from infected people, or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 25%; height: 1.38889%;">through contaminated surgical instruments.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 4.16667%;">Cycle: The protein concentrates in tissues of the central ner-
vous system. Prions are resistant to normal cooking tempera-
tures and humans are thought to be infected by ingesting
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">contaminated food. In contrast to other forms of human prion
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">diseases, in vCJD significant levels of infectivity are found in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">the lymphoreticular system (lymph nodes, spleen, tonsil, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 6.37255%; height: 1.38889%;">appendix).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.4771%; height: 1.26263%;">Incubation period: Uncertain; the mean incubation period is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 62.5%; width: 34.4771%; height: 1.38889%;">likely to be 10 to 20 years, but shorter periods have been
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 23.2026%; height: 1.13636%;">observed in transfusion-associated cases.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.3137%; height: 1.38889%;">Clinical findings: vCJD is characterized by a relatively early
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">age of onset (28 years) and prominent early psychiatric
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">symptoms: anxiety, depression, agitation, delusions, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.3137%; height: 1.38889%;">unpleasant sensory symptoms. Neurological features are:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.3137%; height: 4.0404%;">unsteadiness, difficulty walking, and involuntary move-
ments. Memory loss progresses to severe cognitive im-
pairment and, at the time of death, patients have become
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 34.3137%; height: 1.26263%;">unable to move or speak. The median duration of illness is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.2727%; width: 6.69935%; height: 1.13636%;">14 months.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 16.7929%; width: 34.4771%; height: 2.77778%;">Diagnostic tests: Compatible clinical features, a characteris-
tic MRI (pulvinar sign) and the exclusion of other neurological
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 41.1765%; height: 4.16667%;">diseases, are usually sufficient to diagnose ‘probable vCJD.’ Definitive diagnosis of vCJD is by neuropathological exami-
nation of the brain, usually at postmortem.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 23.6928%; height: 1.38889%;">Therapy: No proven treatment available.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 27.5253%; width: 34.3137%; height: 1.38889%;">Prevention: Prevention is focused on eliminating BSE in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">cattle, preventing infected bovinematerial entering the animal
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">and human food chain, and reducing the risk of secondary
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">transmission to humans in the healthcare setting. To this end
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">many countries have banned bovine meat and bone meal from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">livestock feed, slaughtered infected herds, and taken other
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">precautions to prevent infected cattle from entering the human
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.13636%;">food chain. Measures to reduce the risk of transmission of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">vCJD through blood products include low-risk sourcing and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">leucodepletion. Further precautionary methods to reduce the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">risk of transmission through contaminated surgical
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.4242%; width: 7.35294%; height: 1.0101%;">instruments.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 2.65152%;">Epidemiology: There is strong epidemiological and labora-
tory evidence for a causal relation between vCJD and the BSE
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">agent. In the UK, the primary epidemic has been associated
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">with dietary exposure to BSE-infected bovine material during
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 2.77778%;">the BSE epidemic in the late 1980s to mid-1990s, before effec-
tive controls to prevent the BSE agent entering the human food
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">supply were put into place. Most people who have developed
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.3137%; height: 1.38889%;">vCJD have lived in or visited the UK during this time period.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">The behavior of the vCJD agent under laboratory conditions is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">also very like that of BSE. There is a strong host genetic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">component, with certain variants of the prion protein gene
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 21.732%; height: 1.38889%;">being much more susceptible to vCJD
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 62.5%; width: 34.3137%; height: 1.38889%;">Map sources: The Variant Creutzfeldt–Jakob Disease map
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">was made with data from the European Creutzfeldt–
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 34.4771%; height: 1.38889%;">Jakob Disease Surveillance Network (EUROCJD) and the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.5404%; width: 34.3137%; height: 1.38889%;">World Organization for Animal Health (OIE), available at:
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">www.eurocjd.ed.ac.uk and www.oie.int/eng/info/en_
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.1919%; width: 8.82353%; height: 1.13636%;">esbmonde.htm
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 71.9697%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 73.2323%; width: 34.4771%; height: 1.38889%;">Heath CA, et al. (2010) Validation of diagnostic criteria for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 74.6212%; width: 33.1699%; height: 1.26263%;">variant Creutzfeldt–Jakob disease. Ann Neurol 67(6):761–770.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 76.0101%; width: 34.4771%; height: 1.26263%;">Hilton DA (2006) Pathogenesis and prevalence of variant
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 77.2727%; width: 28.4314%; height: 1.38889%;">Creutzfeldt–Jakob disease. J Pathol 208(2):134–141.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 78.6616%; width: 34.4771%; height: 1.38889%;">Will RG (2003) Acquired prion disease: iatrogenic CJD, variant
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 80.0505%; width: 19.9346%; height: 1.26263%;">CJD, kuru. Br Med Bull 66:255–265.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">263
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/56637bfa-6a7a-46d4-a6e5-8a1e92342c54" class="aLF-aPX-aPF-aPE-J3" alt="Page 108 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.paho.org/english/sha/epibul_95-98/be954out.htm" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.paho.org/english/sha/epibul_95-98/be954out.htm" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.paho.org/english/sha/epibul_95-98/be954out.htm&amp;ust=1666162860000000&amp;usg=AOvVaw3m5rvxss2dVRHUlTEJsNAE&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 52.9412%; top: 55.8081%; width: 32.6797%; height: 1.38889%;"></a><a href="http://www.cdc.gov" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.cdc.gov" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.cdc.gov&amp;ust=1666162860000000&amp;usg=AOvVaw0jbCAwN0S8YcX3HA8IM5YF&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 56.0458%; top: 57.0707%; width: 8.16994%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 109 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 62.2549%; height: 2.39899%;">Disease: Venezuelan Equine Encephalitis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 24.3464%; height: 1.26263%;">Classification: ICD-9 066.2; ICD-10 A92.2
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 33.9869%; height: 2.77778%;">Syndromes and synonyms: Venezuelan equine encephalo-
myelitis, Venezuelan equine fever, Mucambo virus fever.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">Agents: Venezuelan equine encephalitis virus (VEEV), an
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">enveloped, spherical, single-stranded positive-sense RNA
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.3137%; height: 1.38889%;">virus, genus Alphavirus in the family Togaviridae. Epizootic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.3137%; height: 1.38889%;">or epidemic VEE viruses belong to subtypes IAB and IC.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">Enzootic VEE complex viruses belong to subtypes II to VI
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">and ID, IE, and IF.With the exception of IE strains, these do not
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 34.4771%; height: 1.38889%;">cause disease in equids, but can cause sporadic disease in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.9545%; width: 34.3137%; height: 1.38889%;">humans. VEEV is considered a potential biological warfare
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 3.75817%; height: 1.26263%;">agent.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.3137%; height: 1.38889%;">Reservoir: Principally sylvatic rodents; also marsupials, bats,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.3137%; height: 1.38889%;">and shore birds may be involved in the enzootic virus cycle.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">Vector: Mosquitoes. The main vector of enzootic VEEV is the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.4771%; height: 1.38889%;">Culex (Melanoconion) spp. (Spissipes group). During VEEV
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">outbreaks, Ochlerotatus taeniorhynchus is often the main vector
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">in coastal regions. Epizootic/epidemic subtypes of VEEV are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 30.0654%; height: 1.38889%;">transmitted by mosquitoes of many different genera.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 33.9869%; height: 2.39899%;">Transmission: Mosquito bite. Direct person-to-person trans-
mission has not been documented.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">Cycle: Mosquito–reservoir animal–mosquito. Humans are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.3137%; height: 1.38889%;">dead-end hosts. Equines (horses, mules, and donkeys) are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">amplifying hosts for the epidemic subtypes of VEEV, with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">high viremias that can infect a wide range of mosquitoes. Half
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">of infected equids die from VEEV. Viremia lasts 2–5 days in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">birds and 3 days in equids. Extrinsic cycle in the mosquito lasts
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.3137%; height: 1.26263%;">up to 7 days but transmission can occur in as little as 4 days.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 21.732%; height: 1.38889%;">Incubation period: Usually 2–3 days.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 1.26263%;">Clinical findings: Infections are often mild, with more severe
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">neurologic disease in 4–14% of the cases that may progress to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">death. VEEV infection often presents like an influenza-like
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 2.77778%;">illness. Severe encephalitis is less common in adults as com-
pared to children. Absence of a rash distinguishes it from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 73.2323%; width: 34.3137%; height: 1.38889%;">dengue and Mayaro fevers. About 30% of survivors have
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 74.6212%; width: 34.4771%; height: 1.38889%;">neurological sequelae. CFR for VEE is &lt;1%. VEEV infection
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 12.2549%; height: 1.26263%;">may cause stillbirths.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 16.7929%; width: 34.3137%; height: 1.38889%;">Diagnostic tests: Serology or RT-PCR on blood or CSF; virus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 5.55556%; height: 1.13636%;">isolation.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 29.4118%; height: 1.38889%;">Therapy: Supportive, there is no specific treatment.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 23.4848%; width: 34.3137%; height: 1.38889%;">Prevention: Personal anti-mosquito precautions. Inoculation
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">of equids with live, attenuated TC-83 VEE vaccine blocks
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">amplification; this vaccine is available to laboratory personnel
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">but not to the public. VEE isinfectious if airborne and can cause
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 16.5033%; height: 1.38889%;">infections in laboratory staff.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 31.5657%; width: 35.9477%; height: 1.26263%;">Epidemiology: VEEV was isolated for the first time in 1938
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.13636%;">from a diseased horse in Venezuela. The VEEV distribution is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">limited to the Americas, and predominantly in Central and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">South America. In 1995, a large outbreak with approximately
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 36.995%; width: 34.3137%; height: 1.38889%;">100,000 human cases, of which 300 were fatal, happened in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">Colombia and Venezuela. The Guajira peninsula (region in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">northern Colombia and northwest Venezuela) has the highest
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">disease burden, probably due to a large donkey population
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">that serves as an amplifying host. In 2005, human VEE cases
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.3137%; height: 1.38889%;">were detected for the first time in Bolivia, cause by a new
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">Bolivia–Peru ID genotype. Typical VEEV enzootic habitats are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">lowland forests and swamps in (sub)tropical areas of the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 2.77778%;">Americas, from northern Argentina up to southern USA (Flor-
ida and Colorado). Enzootic subtype distribution generally
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 27.6144%; height: 1.38889%;">does not overlap, except in the Amazon regions.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 53.1566%; width: 34.1503%; height: 1.38889%;">Map sources: The Venezuelan Equine Encephalitis map was
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">made with data from the Pan-American Health Organization
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 55.8081%; width: 33.6601%; height: 1.38889%;">(www.paho.org/english/sha/epibul_95-98/be954out.htm),
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 25.1634%; height: 1.38889%;">CDC (www.cdc.gov) and medical literature.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 59.8485%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.2374%; width: 34.3137%; height: 2.65152%;">Aguilar PV, et al. (2009) Genetic characterization of Venezue-
lan equine encephalitis virus from Bolivia, Ecuador and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 63.8889%; width: 35.9477%; height: 1.38889%;">Peru: identification of a new subtype ID lineage. PLoS
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 65.1515%; width: 17.4837%; height: 1.38889%;">Negl Trop Dis 3(9):e514.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.5404%; width: 34.4771%; height: 2.77778%;">Ventura AK, et al. (1974) Human Venezuelan equine enceph-
alitis virus infection in Florida. Am J Trop Med Hyg
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.1919%; width: 8.16994%; height: 1.38889%;">23(3):507–521.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">Weaver SC (2001) Venezuelan equine encephalitis. In Service
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 39.3791%; height: 2.65152%;">MW (ed.) The Encyclopedia of Arthropod-transmitted Infections. CAB International, pp. 539–548.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 74.6212%; width: 34.4771%; height: 1.38889%;">ZacksMA, et al. (2010) Encephalitic alphaviruses. Vet Microbiol
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 76.0101%; width: 10.1307%; height: 1.26263%;">140(3–4):281–286.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">265
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/7f1753a7-d84c-4f82-bc65-4db3450ed03d" class="aLF-aPX-aPF-aPE-J3" alt="Page 109 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.paho.org/english/sha/epibul_95-98/be954out.htm" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.paho.org/english/sha/epibul_95-98/be954out.htm" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.paho.org/english/sha/epibul_95-98/be954out.htm&amp;ust=1666162860000000&amp;usg=AOvVaw3m5rvxss2dVRHUlTEJsNAE&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 52.9412%; top: 58.4596%; width: 32.5163%; height: 1.38889%;"></a><a href="http://www.cdc.gov" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.cdc.gov" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.cdc.gov&amp;ust=1666162860000000&amp;usg=AOvVaw0jbCAwN0S8YcX3HA8IM5YF&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 56.0458%; top: 59.8485%; width: 8.16994%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 110 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 57.1895%; height: 2.39899%;">Disease: Western Equine Encephalitis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 23.366%; height: 1.26263%;">Classification: ICD-9 062; ICD-10 A83.1
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.5707%; width: 24.8366%; height: 1.13636%;">Syndromes and synonyms: None.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">Agents: Western equine encephalitis virus (WEEV), an
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">enveloped, spherical, single-stranded positive-sense RNA
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">virus, genus Alphavirus in the family Togaviridae. WEEV is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.4771%; height: 1.13636%;">believed to have descended from an ancestral recombinant
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">derived from eastern equine encephalitis virus and Sindbis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 3.59477%; height: 1.13636%;">virus.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.5657%; width: 32.6797%; height: 1.38889%;">Reservoir: Principally birds, secondarily rabbits, poultry.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">Vector: Mosquitoes. In North America, the primary vector of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.3137%; height: 2.77778%;">WEEV for the enzootic cycle is Culex tarsalis. WEEV is trans-
mitted to humans and horses by bridging mosquitoes (e.g.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 30.5556%; height: 1.38889%;">Ochlerotatus melanimon and Aedes species).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 33.9869%; height: 2.65152%;">Transmission: Mosquito bite. There is no direct person-to-
person transmission.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">Cycle: Mosquito to reservoir animal to mosquito. There is an
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.3137%; height: 1.38889%;">enzootic cycle, mainly between C. taralsis and passerine birds.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.3137%; height: 1.38889%;">There is a secondary cycle that involves rabbits. Viremia lasts
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">2–5 days in birds. Extrinsic cycle in the mosquito lasts up to 7
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.3137%; height: 1.38889%;">days but transmission can occur in as little as 4 days. Humans
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 51.7677%; width: 34.4771%; height: 1.13636%;">and horses are dead-end hosts for WEEV because their viremia
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 28.4314%; height: 1.38889%;">is generally not high enough to infect mosquitoes.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 21.732%; height: 1.38889%;">Incubation period: Usually 2–7 days.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.4771%; height: 1.38889%;">Clinical findings: Infections are generally asymptomatic to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">mild. WEE can present as an influenza-like illness with sudden
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 34.3137%; height: 2.65152%;">onset fever, severe headache, chills, and myalgia. Other symp-
toms are: retro-orbital pain, nausea, vomiting, and diarrhea.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 34.4771%; height: 2.65152%;">The disease can progress to more severe disease with enceph-
alitis and death. Encephalitis occurs in about 13% of infected
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 1.38889%;">cases. Absence of a rash distinguishes it from dengue and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">Mayaro fevers. Younger children with WEE are more severely
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 1.38889%;">affected neurologically and fatally. About 30% of infants
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">develop serious neurologic sequelae. The overall CFR for
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 8.16994%; height: 1.13636%;">WEE is 3–7%.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 16.7929%; width: 34.3137%; height: 1.38889%;">Diagnostic tests: Serology or RT-PCR on blood or CSF; virus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 5.55556%; height: 1.13636%;">isolation.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 29.4118%; height: 1.38889%;">Therapy: Supportive, there is no specific treatment.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 23.4848%; width: 34.3137%; height: 1.38889%;">Prevention: Personal anti-mosquito precautions; there is no
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 9.96732%; height: 1.13636%;">vaccine for WEE.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 27.5253%; width: 34.3137%; height: 1.38889%;">Epidemiology: WEEV was first isolated during an equine
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">epizootic in California in 1930. Eight years later WEEV was
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.13636%;">isolated from a fatal humanWEE case in California. TheWEEV
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.3137%; height: 1.38889%;">distribution is limited to the Americas with human epidemics
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">occurring in North America west of the Mississippi river and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">Brazil. WEEV does not occur at higher altitudes in the Rocky
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 2.65152%;">Mountains. In the USA it overlaps with eastern equine enceph-
alitis virus (EEEV) in Texas, Indiana, Wisconsin, Tennessee,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">and Michigan. It is absent from Central America (except
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">Veracruz, Mexico). In South America, WEEV epizootics
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">occur periodically in northern Argentina. The WEEV vector,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">Culex tarsalis, is associated with irrigated agriculture and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">stream drainages. The WEEV cycle in warmer regions is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">maintained and in colder areas it can be reintroduced by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">migratory birds or remain in an unknown reservoir host
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">species. Between 1964 and 2005, there were 639 confirmed
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">human WEE cases in the USA. In temperate regions the disease
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">is seasonal with cases appearing during the warmer summer
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">months. The incidence declined to less than 10 cases per year
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 6.53595%; height: 1.13636%;">since 1988.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 55.8081%; width: 34.1503%; height: 1.38889%;">Map sources: The Western Equine Encephalitis map was
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">made with data from the Pan-American Health Organization
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 58.4596%; width: 33.6601%; height: 1.38889%;">(www.paho.org/english/sha/epibul_95-98/be954out.htm),
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 27.2876%; height: 1.38889%;">CDC (www.cdc.gov) and the medical literature.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 62.6263%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">Reisen WK (2001) Western equine encephalitis. In Service MW
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 65.1515%; width: 39.3791%; height: 2.77778%;">(ed.) The Encyclopedia of Arthropod-transmitted Infections. CAB International, pp. 558–563.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 67.9293%; width: 34.3137%; height: 1.26263%;">Weaver SC, et al. (2010) Present and future arboviral threats.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 69.1919%; width: 16.9935%; height: 1.38889%;">Antiviral Res 85(2):328–345.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">ZacksMA, et al. (2010) Encephalitic alphaviruses. VetMicrobiol
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 10.1307%; height: 1.26263%;">140(3–4):281–286.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">267
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/97d8ae72-bd45-4b5a-b162-8544e3283893" class="aLF-aPX-aPF-aPE-J3" alt="Page 110 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://www.cdc.gov/ncidod/dvbid/westnile/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.cdc.gov/ncidod/dvbid/westnile/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.cdc.gov/ncidod/dvbid/westnile/&amp;ust=1666162860000000&amp;usg=AOvVaw2C-p5Byitmb_qn7_wvlIyD&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 63.7255%; top: 62.5%; width: 23.0392%; height: 1.38889%;"></a><a href="http://www.eidgis.com/wnvmonitorca/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://www.eidgis.com/wnvmonitorca/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://www.eidgis.com/wnvmonitorca/&amp;ust=1666162860000000&amp;usg=AOvVaw1MtKmtVhLigXwsvG5q5y9c&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 52.9412%; top: 65.1515%; width: 19.4444%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 111 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 37.4183%; height: 2.0202%;">Disease: West Nile Fever
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 23.2026%; height: 1.26263%;">Classification: ICD-066.3; ICD-10 A92.3
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 18.8131%; width: 24.8366%; height: 1.26263%;">Syndromes and synonyms: None.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 34.4771%; height: 1.38889%;">Agent: West Nile virus (WNV), a flavivirus, with an envelope
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">and RNA plus-strand genome. Sequencing and phylogenetic
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">analysis of full-length genomes has resulted in a division of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">WNV strains into four distinct lineages, with lineage 1 strains
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">further separatedinto three clades (1a, 1b, and 1c). Kunjin virus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">and Murray Valley encephalitis virus are subtypes of WNV
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 21.0784%; height: 1.38889%;">that are endemic in parts of Oceania.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.9343%; width: 34.4771%; height: 1.38889%;">Reservoir: Wild birds. Over 100 bird species can be infected by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 32.3232%; width: 34.4771%; height: 1.26263%;">WNV infection. Many birds get infected and amplify the virus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 33.5859%; width: 34.4771%; height: 1.38889%;">but do not die. The robin is probably the main amplifying host,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.9747%; width: 34.4771%; height: 1.38889%;">and rarely has overt disease. American crows, blue jays, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.2374%; width: 34.3137%; height: 1.38889%;">hawks are susceptible to death. The number WNV bird deaths
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 37.6263%; width: 34.4771%; height: 1.38889%;">can predict subsequent disease severity in humans and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.0152%; width: 4.90196%; height: 1.38889%;">equines.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">Vector: Mosquitoes of more than 40 species, principally of the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 34.4771%; height: 1.38889%;">genus Culex, but also Anopheles, Aedes and others. Some vector
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">species can shift their feeding preference from birds to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">humans, depending on the season (e.g. Culex pipiens). The
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 37.0915%; height: 1.38889%;">main vectors in the USA are: Culex pipiens (Eastern), Culex
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 36.2745%; height: 2.77778%;">tarsalis(Midwest andWest), and Culex quinquefasciatus(South-
east). In Europe two populations of Culex pipiens exist: one that
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 23.2026%; height: 1.13636%;">feeds on birds and the other on humans.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 52.399%; width: 34.4771%; height: 4.0404%;">Transmission: By mosquito bite. Transfused red cells, plate-
lets, and fresh-frozen plasma from infected donors can trans-
mit WNV; transmission has also been reported more rarely
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 56.4394%; width: 34.4771%; height: 1.38889%;">through organ transplantation, blood transfusion, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.8283%; width: 34.4771%; height: 1.38889%;">mother-to-child. Laboratory infections have occurred from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.2172%; width: 21.5686%; height: 1.26263%;">aerosols and percutaneous exposures.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 61.2374%; width: 33.9869%; height: 2.65152%;">Cycle: Bird–mosquito–bird, with accidental dead-end infec-
tions in humans, equines, and other vertebrate animals.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 64.5202%; width: 34.4771%; height: 1.38889%;">Incubation period: Typically from 2 to 14 days, longer in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 65.9091%; width: 17.8105%; height: 1.38889%;">immunocompromised persons.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">Clinical findings: The majority of the cases (70–80%) are
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.4771%; height: 2.77778%;">asymptomatic. Sudden onset of fever, headache, malaise, myal-
gia, arthralgia, abdominal pain and upset, nausea, sore throat,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.4771%; height: 4.0404%;">conjunctivitis, lymphadenopathy, and frequently a maculo-
papular rash. Less than 1% of infected persons develop neu-
roinvasive disease. Neurological disorders are more frequent in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 34.4771%; height: 1.26263%;">the elderly and immunocompromised, and may be fatal, with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 77.2727%; width: 34.4771%; height: 1.38889%;">the exception of the Kunjin strain. After 5 years 60% of patients
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 78.6616%; width: 34.4771%; height: 1.38889%;">who presented with neuroinvasive disease continued to report
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 80.0505%; width: 24.6732%; height: 1.26263%;">weakness, fatigue, memory loss, and ataxia.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 16.7929%; width: 34.3137%; height: 1.38889%;">Diagnostic tests: Serology (IFA,ELISA)or RT-PCR on bloodor
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 34.4771%; height: 1.38889%;">CSF. Serology may cross-react with otherflaviviruses andlead to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">false-positives. Plaque Reduction Neutralization Tests (PRNT)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 32.5163%; height: 1.38889%;">and virus isolation are only done in specialized laboratories.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.8535%; width: 29.4118%; height: 1.38889%;">Therapy: Supportive, there is no specific treatment.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 34.4771%; height: 2.65152%;">Prevention: Personal anti-mosquito precautions; vector con-
trol; screening blood and transplant products. There is no
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">vaccine approved for human use. There are several veterinary
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 5.39216%; height: 1.13636%;">vaccines.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 30.9343%; width: 36.2745%; height: 1.26263%;">Epidemiology: WNV was cultured for the first time from a
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.3232%; width: 34.4771%; height: 1.26263%;">woman with a fever of unknown origin in the West Nile district
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 33.5859%; width: 34.4771%; height: 1.38889%;">of Uganda in 1937. Molecular studies suggest that WNV
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.9747%; width: 34.3137%; height: 1.38889%;">emerged in Africa and spread through migrating waterbirds.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.2374%; width: 34.4771%; height: 1.26263%;">Until the introduction of WNV in New York in 1999, WNV
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 37.6263%; width: 34.4771%; height: 1.38889%;">infections usually caused mild disease outbreaks and episodes
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.0152%; width: 34.4771%; height: 2.65152%;">of neuroinvasive disease in the old world. Since the introduc-
tion to northeast America, the virus has spread to most regions
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.6667%; width: 34.4771%; height: 1.26263%;">in North America, Canada, Mexico, the Caribbean and several
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.0556%; width: 34.4771%; height: 1.38889%;">cases in South America. The national average annual incidence
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 44.3182%; width: 34.4771%; height: 1.38889%;">of neuroinvasive disease in the USA during 1999 to 2008 was
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.7071%; width: 34.4771%; height: 1.38889%;">0.40 per 100,000 population (range: 0.01–1.02). In that time
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.096%; width: 34.4771%; height: 1.38889%;">period in the USA, 28,961 cases were confirmed, including
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 48.3586%; width: 34.4771%; height: 1.38889%;">1,131 deaths. Neuroinvasive disease incidence is higher among
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.7475%; width: 36.6013%; height: 1.38889%;">males, especially among persons aged 60 years. The highest
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.0101%; width: 34.4771%; height: 1.13636%;">incidence of neuroinvasive disease occurredin theWest Central
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 52.399%; width: 42.4837%; height: 2.77778%;">and Mountain regions, probably resulting from the high effi- ciency of Cx. tarsalis as both an epizootic and epidemic WNV
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 55.1768%; width: 34.4771%; height: 1.13636%;">vector in those areas. Most US cases occur in the late summer,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 56.4394%; width: 34.4771%; height: 2.77778%;">when Culex mosquitoes are more active and after WNV ampli-
fication in the bird reservoir. In warm climates year-round
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.2172%; width: 11.7647%; height: 1.0101%;">transmission is seen.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 61.2374%; width: 34.3137%; height: 1.26263%;">Map sources: The West Nile Fever map was made with
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 62.5%; width: 34.3137%; height: 1.38889%;">data from CDC (www.cdc.gov/ncidod/dvbid/westnile/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 63.8889%; width: 34.4771%; height: 1.38889%;">surv&amp;control.htm#maps), the Canadian public health agency
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 65.1515%; width: 34.3137%; height: 1.38889%;">(www.eidgis.com/wnvmonitorca/) and reported outbreaks
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 66.5404%; width: 22.549%; height: 1.13636%;">in ProMED mail and medical literature.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 68.6869%; width: 9.31373%; height: 1.13636%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 69.9495%; width: 34.4771%; height: 1.38889%;">Hayes EB, et al. (2005) Virology, pathology, and clinical
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.2121%; width: 33.0065%; height: 1.38889%;">manifestations of West Nile virus disease. Emerg Infect Dis
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 72.601%; width: 9.47712%; height: 1.26263%;">11(8):1174–1179.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 73.9899%; width: 34.4771%; height: 1.38889%;">Lindsey NP, et al. (2010) Surveillance for Human West Nile
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 75.2525%; width: 33.1699%; height: 1.26263%;">Virus Disease – United States, 1999–2008. CDC/MMWR
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 76.6414%; width: 26.4706%; height: 1.26263%;">Surveill Sum 59(02):1–17.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 78.0303%; width: 34.4771%; height: 1.38889%;">Murray KO, et al. (2011) The virology, epidemiology, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 79.2929%; width: 36.2745%; height: 1.38889%;">clinical impact of West Nile virus. Epidemiol Infect 23:1–11.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">269
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/5f640d5d-87f0-4648-9c41-92029e72a534" class="aLF-aPX-aPF-aPE-J3" alt="Page 111 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"><a href="http://gamapserver.who.int/mapLibrary/" target="_blank" class="aLF-aPX-aPF-aPE-Ke" tabindex="0" role="link" aria-label="http://gamapserver.who.int/mapLibrary/" data-saferedirecturl="https://www.google.com/url?sa=D&amp;q=http://gamapserver.who.int/mapLibrary/&amp;ust=1666162860000000&amp;usg=AOvVaw316ShZsDemlWyXaf1yOcz4&amp;hl=en&amp;source=gmail" data-saferedirectmessageid="183e9db54da6b54c" style="left: 62.2549%; top: 65.1515%; width: 24.5098%; height: 1.38889%;"></a></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 112 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 33.4967%; height: 2.0202%;">Disease: Yellow Fever
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 22.3856%; height: 1.26263%;">Classification: ICD-9 060; ICD-10 A95
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 34.4771%; height: 1.38889%;">Syndromes and synonyms: Hemorrhagic fever, jungle
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 20.8333%; width: 18.9542%; height: 1.38889%;">yellow fever, urban yellow fever.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 34.4771%; height: 2.77778%;">Agent: Yellow fever virus (YFV) is an enveloped single-
stranded positive-sense RNA virus that belongs to the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 34.4771%; height: 1.38889%;">genus Flavivirus. YFV is genetically more heterogeneous in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 27.5253%; width: 32.8431%; height: 1.38889%;">Africa than in America, suggesting it originated in Africa.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">Reservoir: Humans and non-human primates are the main
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 31.6919%; width: 6.20915%; height: 1.0101%;">reservoirs.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.2172%; width: 39.7059%; height: 1.38889%;">Vector: Tree-hole-breeding forest mosquitoes: Aedes spp. in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 35.6061%; width: 34.3137%; height: 1.38889%;">Africa, and Haemagogus and Sabethes spp. in South America.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 36.995%; width: 34.4771%; height: 1.38889%;">Transovarian transmission occurs in the mosquito and may be
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">the way the virus survives in the years between cycles. The
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 33.6601%; height: 4.0404%;">urban vector on both continents is Aedes aegypti. Transmission: By mosquito bite.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">Cycle: There are three transmission cycles: (1) sylvatic or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">jungle, (2) intermediate or savannah, and (3) urban. All
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">three cycles exist in Africa and the sylvatic and urban yellow
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">fever occur in South America. The sylvatic cycle happens in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 50.3788%; width: 34.4771%; height: 2.77778%;">tropical rainforests where monkeys are infected by mosqui-
toes, and pass the virus onto other mosquitoes that feed on
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.4771%; height: 2.65152%;">them; sporadically humans can become infected when enter-
ing the forest for work. The intermediate cycle is present in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 34.4771%; height: 1.38889%;">savannahs of Africa, resulting in small oubreaks in rural
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">settlements. Urban yellow fever can lead to large outbreaks
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 34.4771%; height: 1.13636%;">in humans when infected individualsintroduce the virus to the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 59.8485%; width: 34.4771%; height: 2.65152%;">urban mosquito population (mainly Aedes aegypti), that sub-
sequently can transmit to other humans.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 63.8889%; width: 19.7712%; height: 1.38889%;">Incubation period: 3–6 days.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 66.5404%; width: 34.4771%; height: 1.26263%;">Clinical findings: Sudden onset of fever, chills, headache, and
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 67.9293%; width: 34.4771%; height: 1.38889%;">can progress with signs of myalgia, photophobia, arthralgia,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 69.1919%; width: 34.3137%; height: 1.38889%;">nausea, vomiting, jaundice, and congestion of conjunctivae.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 70.5808%; width: 34.4771%; height: 1.38889%;">After 3–4 days there can be a remission phase leading to either
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 71.9697%; width: 34.4771%; height: 4.0404%;">recovery or more severe disease with hemorrhagic signs (epi-
staxis, gingival bleeding, hematemesis, melena) and hepator-
enal syndrome, multi-organ failure and death. CFR in severe
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 76.0101%; width: 10.6209%; height: 1.0101%;">cases is 15 to 50%.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 16.7929%; width: 34.3137%; height: 1.38889%;">Diagnostic tests: Early phase: RT-PCR on blood; serology
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 18.1818%; width: 40.6863%; height: 4.0404%;">(IgM and IgG), but there is cross-reactivity with other flavi-
viruses; positive serology requires confirmation by more spe-
cific tests, like plaque-reduction assay.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">Therapy: Supportive, there is no specific treatment. Aspirin
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 11.1111%; height: 1.13636%;">should be avoided.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 27.5253%; width: 34.3137%; height: 1.38889%;">Prevention: The 17D live, attenuated vaccine is protective
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.3137%; height: 1.38889%;">after 10 days; revaccination is recommended every 10 years.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.4771%; height: 1.38889%;">Anti-mosquito precautions. Prevent infected individuals from
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 29.085%; height: 1.38889%;">mosquito exposure to break the transmission cycle.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 34.3434%; width: 34.3137%; height: 1.26263%;">Epidemiology: An estimated 200,000 yellow fever cases occur
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">annually with 30,000 deaths. The disease is present in the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">jungles of South America and in the jungles and Savannahs of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 2.77778%;">Sub-Saharan Africa. On both continents it is endemic in vari-
ous species of forest monkey, transmitted among them by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 34.4771%; height: 1.38889%;">mosquito bite. The disease is more common in West Africa as
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 42.298%; width: 34.4771%; height: 1.38889%;">compared to East Africa. In Africa, mainly children acquire
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 43.6869%; width: 34.4771%; height: 1.38889%;">infection as older persons have acquired immunity. In South
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">America, yellow fever is mainly an occupational disease of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 34.4771%; height: 1.38889%;">men who work in forests and can carry the infection back
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 47.7273%; width: 34.4771%; height: 1.38889%;">home, causing urban epidemics. The yellow fever virus is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 49.1162%; width: 34.4771%; height: 1.38889%;">thought to have originated in Africa and to have been carried
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.4771%; height: 1.38889%;">to the Americas in slave ships. Due to the relatively recent
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 51.7677%; width: 34.4771%; height: 1.38889%;">introduction (about 500 years ago) in the Americas, the virus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">has not yet adapted to the reservoir, explaining why South
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.4771%; height: 2.77778%;">American monkeys become diseased, but not African mon-
keys. All countries with urban dengue are at risk of the
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 57.0707%; width: 34.4771%; height: 1.38889%;">introduction of yellow fever, including Asia and Australasia,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 58.4596%; width: 45.915%; height: 1.38889%;">because the vector is the same (see Aedes egypti and Aedes
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 59.8485%; width: 34.4771%; height: 1.38889%;">albopictus map). Why Asia has remained free from yellow fever
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 61.2374%; width: 10.6209%; height: 1.0101%;">is not understood.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 63.8889%; width: 34.3137%; height: 1.38889%;">Map sources: The Yellow Fever map is reproduced
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 65.1515%; width: 34.3137%; height: 1.38889%;">from WHO, at: http://gamapserver.who.int/mapLibrary/
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 66.5404%; width: 11.6013%; height: 1.26263%;">(accessed June 2010)
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 69.3182%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 70.5808%; width: 34.3137%; height: 1.38889%;">Barrett AD, et al. (2007) Yellow fever: a disease that has yet to
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 71.9697%; width: 24.8366%; height: 1.38889%;">be conquered. Ann Rev Entomol 52:209–229.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 73.2323%; width: 34.3137%; height: 1.38889%;">Ellis BR, et al. (2008) The enigma of yellow fever in East Africa.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 74.6212%; width: 16.3399%; height: 1.26263%;">Rev Med Virol 18(5):331–346.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 76.0101%; width: 34.4771%; height: 1.26263%;">Staples JE, et al. (2010) Yellow fever vaccine: recommendations
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 77.2727%; width: 33.1699%; height: 1.38889%;">of the Advisory Committee on Immunization Practices
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 78.6616%; width: 27.9412%; height: 1.38889%;">(ACIP). MMWR Recom Rep 59(RR-7):1–27.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">271
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/8ff27be3-89b3-48b8-abcb-d21dfda5abaf" class="aLF-aPX-aPF-aPE-J3" alt="Page 112 of 113" aria-hidden="true"></div><div class="aLF-aPX-aPF-aPE" style="padding-bottom: 129.375%;"><div class="aLF-aPX-aPF-aPE-aOo"></div><div class="aLF-aPX-aPF-aPE-a1J-Jz-Jw"><h2 class="aLF-aPX-aPF-aPE-a1J-avC" tabindex="0">Page 113 of 113</h2><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.1961%; top: 11.8687%; width: 29.7386%; height: 2.0202%;">Disease: Zika Fever
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 16.7929%; width: 17.1569%; height: 1.13636%;">Classification: ICD-10 A92.9
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 19.4444%; width: 16.6667%; height: 1.26263%;">Synonyms: Zika virus fever.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 22.2222%; width: 42.8105%; height: 1.38889%;">Agent: Zika virus, an enveloped RNA flavivirus; closely
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 23.4848%; width: 16.0131%; height: 1.38889%;">related to Spondweni virus.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 26.1364%; width: 22.2222%; height: 1.38889%;">Reservoir: Monkeys, possibly rodents.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 28.9141%; width: 47.0588%; height: 2.65152%;">Vector: In Africa, isolated from Aedes africanus, Ae. apicoar-
genteus, Ae. luteocephalus, Ae. aegypti, Ae. vittatus, and Ae.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 14.8693%; top: 31.5657%; width: 31.3726%; height: 1.38889%;">furcifer mosquitoes; probably Ae. hensilii on Yap island.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 34.3434%; width: 33.9869%; height: 2.65152%;">Transmission: By mosquito bite. There is no person-to-
person transmission.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">Cycle: Reservoir host to mosquito to reservoir host; 2–5 days
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 39.6465%; width: 33.3333%; height: 1.38889%;">viremia in host, 5–7 days in mosquito, then back into host.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 42.298%; width: 19.7712%; height: 1.38889%;">Incubation period: 3–12 days.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 45.0758%; width: 34.3137%; height: 2.65152%;">Clinical findings: Mild self-limiting dengue-like febrile ill-
ness, with headache, malaise, arthralgia, myalgia, nausea,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 47.7273%; width: 33.9869%; height: 4.0404%;">vomiting, photophobia, maculopapular rash, and conjunctivi-
tis. Other symptoms may include anorexia, diarrhea, consti-
pation, and abdominal pain.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 53.1566%; width: 34.4771%; height: 1.38889%;">Diagnostic tests: Virus detection in the blood by RT-PCR or
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">virus isolation; IgM ELISA is available, cross-reactivity may
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 55.8081%; width: 19.281%; height: 1.13636%;">occur with other flaviviruses.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 58.4596%; width: 13.8889%; height: 1.38889%;">Therapy: Supportive.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 16.7929%; width: 22.8758%; height: 1.38889%;">Prevention: Anti-mosquito precautions.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 19.4444%; width: 34.3137%; height: 1.38889%;">Epidemiology: Zika virus is present in the tropical regions in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 20.8333%; width: 34.4771%; height: 1.38889%;">the Old World and is absent from the Americas (a single case in
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 22.2222%; width: 34.4771%; height: 1.38889%;">the USA was imported from Yap island). The competence of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 23.4848%; width: 34.4771%; height: 1.38889%;">mosquitoes on the American continent for Zika virus is
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 24.8737%; width: 34.4771%; height: 1.38889%;">unknown. The geographic distribution is confirmed by
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 26.1364%; width: 34.3137%; height: 1.38889%;">virus isolation from cases, mosquitoes and sentinel monkeys.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 27.5253%; width: 34.4771%; height: 1.38889%;">Positive results in serosurveys are not conclusive, because of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 28.9141%; width: 34.4771%; height: 1.38889%;">extensive cross-reactions among flaviviruses. In 2007 a virgin
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 30.1768%; width: 34.3137%; height: 1.38889%;">soil epidemic affected 73% of the population of Yap island.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 31.5657%; width: 34.3137%; height: 1.38889%;">There were no hospitalizations or deaths during this outbreak.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 32.9545%; width: 34.4771%; height: 1.38889%;">Due to intense air travel in the Pacific region and presence of
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 34.3434%; width: 34.4771%; height: 1.26263%;">competent vectors, there is concern that the disease will spread
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 35.6061%; width: 34.4771%; height: 1.38889%;">to other islands and even beyond. Adult females have higher
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 36.995%; width: 34.4771%; height: 1.38889%;">attack rates and few cases are found above the age of 60 years.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 38.2576%; width: 34.4771%; height: 1.38889%;">Approximately 18% of individuals infected by the Zika virus
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 39.6465%; width: 34.4771%; height: 1.38889%;">develop symptoms; this is similar to that reported for West
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 41.0354%; width: 11.6013%; height: 1.13636%;">Nile virus infection.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 43.6869%; width: 34.3137%; height: 1.38889%;">Map sources: The Zika Fever map was made with data
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 45.0758%; width: 34.4771%; height: 1.38889%;">obtained from M.R. Duffy et al (2009) and E.B. Hayes
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 46.3384%; width: 6.86275%; height: 1.38889%;">et al (2009).
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.6144%; top: 49.1162%; width: 9.31373%; height: 1.26263%;">Key references
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 50.3788%; width: 34.3137%; height: 1.38889%;">Duffy MR, et al. (2009) Zika virus outbreak on Yap island,
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 51.7677%; width: 33.1699%; height: 1.38889%;">Federated States of Micronesia. New Engl J Med
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 53.1566%; width: 10.7843%; height: 1.26263%;">360(24):2536–2543.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 52.451%; top: 54.4192%; width: 34.4771%; height: 1.38889%;">Hayes EB, et al. (2009) Zika virus outside Africa. Emerg Infect
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 53.7582%; top: 55.8081%; width: 11.7647%; height: 1.26263%;">Dis 15(9):1347–1350.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 82.0707%; width: 54.5752%; height: 1.38889%;">Atlas of Human Infectious Diseases, First Edition. Heiman F.L. Wertheim, Peter Horby and John P. Woodall.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 15.0327%; top: 83.2071%; width: 40.6863%; height: 1.26263%;"> 2012 Blackwell Publishing Ltd. Published 2012 by Blackwell Publishing Ltd.
</p><p class="aLF-aPX-aPF-aPE-a1J-Ji" style="left: 84.4771%; top: 9.21717%; width: 2.45098%; height: 1.0101%;">273
</p></div><div class="aLF-aPX-aPF-wU-JT" style="display: none;"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axQ"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-LD-K0-axL"></div><div class="aLF-aPX-LD-K0-aPv aLF-aPX-aPF-Jf-axQ"></div><img src="blob:https://mail.google.com/f2a663fc-f76b-4476-9137-bc9a7abf46ca" class="aLF-aPX-aPF-aPE-J3" alt="Page 113 of 113" aria-hidden="true"></div></div>